0	Furthermore	O	O
1	such	O	O
2	disruption	O	O
3	in	O	O
4	white	O	O
5	matter	O	O
6	organization	O	O
7	appears	O	O
8	to	O	O
9	be	O	O
10	a	O	O
11	feature	O	O
12	specific	O	O
13	to	O	O
14	Aicardi	BU	O
15	syndrome	IU	O
16	and	O	O
17	not	O	O
18	shared	O	O
19	by	O	O
20	other	O	O
21	neurodevelopmental	BI	O
22	disorders	II	O
23	with	O	O
24	similar	O	O
25	anatomic	O	O
26	manifestations	O	O
27	.	O	O

0	Mandibulofacial	BU	O
1	dysostosis	IU	O
2	Guion-Almeida	IU	O
3	type	IU	O
4	MFDGA	IU	O
5	is	O	O
6	a	O	O
7	recently	O	O
8	delineated	O	O
9	multiple	O	O
10	congenital	O	O
11	anomalies	O	O
12	mental	BI	O
13	retardation	II	O
14	syndrome	II	O
15	characterized	O	O
16	by	O	O
17	the	O	O
18	association	O	O
19	of	O	O
20	mandibulofacial	BU	O
21	dysostosis	IU	O
22	MFD	IU	O
23	with	O	O
24	external	O	O
25	ear	O	O
26	malformations	O	O
27	hearing	BI	O
28	loss	II	O
29	cleft	BU	O
30	palate	IU	O
31	choanal	BU	O
32	atresia	IU	O
33	microcephaly	O	O
34	intellectual	BI	O
35	disability	II	O
36	oesophageal	O	O
37	atresia	O	O
38	OA	O	O
39	congenital	O	O
40	heart	O	O
41	defects	O	O
42	CHDs	O	O
43	and	O	O
44	radial	O	O
45	ray	O	O
46	defects	O	O
47	.	O	O

0	We	O	O
1	show	O	O
2	that	O	O
3	Pex1-G844D	O	O
4	homozygous	O	O
5	mice	O	O
6	recapitulate	O	O
7	many	O	O
8	classic	O	O
9	features	O	O
10	of	O	O
11	mild	O	O
12	ZSD	BU	O
13	cases	O	O
14	including	O	O
15	growth	BI	O
16	retardation	II	O
17	and	O	O
18	fatty	O	O
19	livers	O	O
20	with	O	O
21	cholestasis	O	O
22	.	O	O

0	His	O	O
1	12-Year-old	O	O
2	daughter	O	O
3	also	O	O
4	presented	O	O
5	visual	BI	O
6	loss	II	O
7	with	O	O
8	severe	O	O
9	bilateral	O	O
10	corneal	BU	O
11	dystrophy	IU	O
12	and	O	O
13	total	O	O
14	congenital	O	O
15	cataract	O	O
16	associated	O	O
17	with	O	O
18	aniridia	BU	O
19	.	O	O

0	BACKGROUND	O	O
1	Borjeson-Forssman-Lehmann	BU	O
2	syndrome	IU	O
3	BFLS	IU	O
4	is	O	O
5	an	O	O
6	X-linked	O	O
7	recessive	O	O
8	intellectual	BI	O
9	disability	II	O
10	ID	O	O
11	disorder	O	O
12	caused	O	O
13	by	O	O
14	mutations	O	O
15	in	O	O
16	the	O	O
17	PHF6	O	O
18	gene	O	O
19	and	O	O
20	characterised	O	O
21	by	O	O
22	variable	BI	O
23	cognitive	II	O
24	impairment	II	O
25	a	O	O
26	distinct	O	O
27	facial	O	O
28	gestalt	O	O
29	obesity	O	O
30	and	O	O
31	hypogonadism	O	O
32	.	O	O

0	Hearing	BI	O
1	impairment	II	O
2	is	O	O
3	common	O	O
4	in	O	O
5	individuals	O	O
6	with	O	O
7	branchio-oculo-facial	BU	O
8	BOF	IU	O
9	syndrome	IU	O
10	.	O	O

0	Friedreich	BI	O
1	ataxia	II	O
2	is	O	O
3	an	O	O
4	autosomal	O	O
5	recessive	O	O
6	hereditary	O	O
7	spinocerebellar	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	progressive	O	O
12	limb	O	O
13	and	O	O
14	gait	BI	O
15	ataxia	II	O
16	due	O	O
17	to	O	O
18	proprioceptive	O	O
19	loss	O	O
20	often	O	O
21	complicated	O	O
22	by	O	O
23	cardiomyopathy	BU	O
24	diabetes	O	O
25	and	O	O
26	skeletal	O	O
27	deformities	O	O
28	.	O	O

0	Multiple	BU	O
1	System	IU	O
2	Atrophy	IU	O
3	MSA	O	O
4	is	O	O
5	a	O	O
6	neurodegenerative	O	O
7	disease	O	O
8	which	O	O
9	presents	O	O
10	heterogeneously	O	O
11	with	O	O
12	symptoms	O	O
13	and	O	O
14	signs	O	O
15	of	O	O
16	parkinsonism	O	O
17	ataxia	BI	O
18	and	O	O
19	autonomic	BI	O
20	dysfunction	II	O
21	.	O	O

0	Carbamoyl	BU	O
1	phosphate	IU	O
2	synthetase	IU	O
3	1	IU	O
4	CPS1	IU	O
5	deficiency	IU	O
6	CPS1D	IU	O
7	is	O	O
8	an	O	O
9	inborn	O	O
10	error	O	O
11	of	O	O
12	the	O	O
13	urea	O	O
14	cycle	O	O
15	having	O	O
16	autosomal	O	O
17	2q34	O	O
18	recessive	O	O
19	inheritance	O	O
20	that	O	O
21	can	O	O
22	cause	O	O
23	hyperammonemia	O	O
24	and	O	O
25	neonatal	O	O
26	death	O	O
27	or	O	O
28	mental	BI	O
29	retardation	II	O
30	.	O	O

0	CMTX1	BU	O
1	should	O	O
2	be	O	O
3	included	O	O
4	in	O	O
5	the	O	O
6	differential	O	O
7	diagnosis	O	O
8	of	O	O
9	patients	O	O
10	who	O	O
11	present	O	O
12	with	O	O
13	transient	O	O
14	central	O	O
15	nervous	O	O
16	system	O	O
17	phenomena	O	O
18	including	O	O
19	stroke-like	O	O
20	episodes	O	O
21	tetraparesis	BI	O
22	suggestive	O	O
23	of	O	O
24	periodic	BU	O
25	paralysis	IU	O
26	dysarthria	BI	O
27	ataxia	BI	O
28	or	O	O
29	combinations	O	O
30	of	O	O
31	these	O	O
32	deficits	O	O
33	.	O	O

0	Norrie	BU	O
1	disease	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	X-linked	BI	O
6	recessive	II	O
7	neurodevelopmental	II	O
8	disorder	II	O
9	.	O	O

0	West	BU	O
1	syndrome	IU	O
2	WS	IU	O
3	is	O	O
4	a	O	O
5	severe	O	O
6	age-related	O	O
7	acute	O	O
8	epileptic	O	O
9	encephalopathy	O	O
10	of	O	O
11	infancy	O	O
12	characterized	O	O
13	by	O	O
14	infantile	BU	O
15	spasms	IU	O
16	hypsarrhythmia	O	O
17	and	O	O
18	psychomotor	BI	O
19	delay	II	O
20	.	O	O

0	This	O	O
1	pattern	O	O
2	of	O	O
3	expression	O	O
4	may	O	O
5	be	O	O
6	involved	O	O
7	in	O	O
8	cognitive	BI	O
9	impairment	II	O
10	and	O	O
11	facial	O	O
12	dysmorphisms	O	O
13	found	O	O
14	in	O	O
15	Coffin-Lowry	BU	O
16	Syndrome	IU	O
17	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	genetic	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	juvenile-onset	O	O
10	diabetes	O	O
11	mellitus	O	O
12	diabetes	O	O
13	insipidus	O	O
14	optic	BI	O
15	nerve	II	O
16	atrophy	II	O
17	hearing	BI	O
18	loss	II	O
19	and	O	O
20	neurodegeneration	O	O
21	.	O	O

0	Prader-Willi	O	O
1	syndrome	O	O
2	PWS	O	O
3	is	O	O
4	the	O	O
5	most	O	O
6	frequent	O	O
7	neurodevelopmental	BI	O
8	disorder	II	O
9	with	O	O
10	syndromic	BU	O
11	obesity	IU	O
12	and	O	O
13	has	O	O
14	a	O	O
15	well-established	O	O
16	management	O	O
17	and	O	O
18	treatment	O	O
19	plan	O	O
20	.	O	O

0	Our	O	O
1	aim	O	O
2	was	O	O
3	to	O	O
4	identify	O	O
5	fragile	BU	O
6	X	IU	O
7	syndrome	IU	O
8	among	O	O
9	children	O	O
10	with	O	O
11	intellectual	BI	O
12	disability	II	O
13	in	O	O
14	Saudi	O	O
15	Arabia	O	O
16	.	O	O

0	OBJECTIVES	O	O
1	To	O	O
2	examine	O	O
3	the	O	O
4	risk	O	O
5	of	O	O
6	intellectual	BI	O
7	disability	II	O
8	and	O	O
9	subclinical	BI	O
10	impairments	II	O
11	in	II	O
12	cognitive	II	O
13	ability	II	O
14	in	O	O
15	Darier	BU	O
16	disease	IU	O
17	.	O	O

0	Severe	BU	O
1	deficiency	IU	O
2	of	IU	O
3	methylenetetrahydrofolate	IU	O
4	reductase	IU	O
5	MTHFR	IU	O
6	with	O	O
7	homocystinuria	O	O
8	can	O	O
9	result	O	O
10	in	O	O
11	early	O	O
12	demise	O	O
13	or	O	O
14	later-onset	O	O
15	neurological	O	O
16	impairment	O	O
17	including	O	O
18	developmental	BI	O
19	delay	II	O
20	motor	BI	O
21	dysfunction	II	O
22	and	O	O
23	seizures	O	O
24	.	O	O

0	D-2-Hydroxyglutaric	BU	O
1	aciduria	IU	O
2	was	O	O
3	documented	O	O
4	in	O	O
5	a	O	O
6	newborn	O	O
7	who	O	O
8	presented	O	O
9	with	O	O
10	seizures	O	O
11	hypotonia	O	O
12	cortical	BI	O
13	blindness	II	O
14	a	O	O
15	movement	BI	O
16	disorder	II	O
17	and	O	O
18	developmental	BI	O
19	delay	II	O
20	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	5-year-old	O	O
7	boy	O	O
8	with	O	O
9	SLS	BU	O
10	diagnosed	O	O
11	clinically	O	O
12	based	O	O
13	on	O	O
14	congenital	O	O
15	ichythosis	O	O
16	quadriplegia	BI	O
17	and	O	O
18	mental	BI	O
19	retardation	II	O
20	.	O	O

0	Of	O	O
1	the	O	O
2	30	O	O
3	children	O	O
4	with	O	O
5	DS	BU	O
6	and	O	O
7	without	O	O
8	epilepsy	O	O
9	21	O	O
10	70%	O	O
11	had	O	O
12	mild	BI	O
13	mental	II	O
14	retardation	II	O
15	and	O	O
16	9	O	O
17	30%	O	O
18	had	O	O
19	moderate	BI	O
20	to	II	O
21	severe	II	O
22	cognitive	II	O
23	impairment	II	O
24	.	O	O

0	Mental	BI	O
1	retardation	II	O
2	and	O	O
3	behavioral	BI	O
4	abnormalities	II	O
5	are	O	O
6	prevalent	O	O
7	in	O	O
8	both	O	O
9	infantile	O	O
10	and	O	O
11	late	O	O
12	onset	O	O
13	forms	O	O
14	although	O	O
15	the	O	O
16	phenotype	O	O
17	in	O	O
18	late	O	O
19	onset	O	O
20	atypical	O	O
21	NKH	BU	O
22	is	O	O
23	more	O	O
24	heterogeneous	O	O
25	.	O	O

0	OBJECTIVE	O	O
1	To	O	O
2	illustrate	O	O
3	the	O	O
4	spectrum	O	O
5	of	O	O
6	behavioral	BI	O
7	and	II	O
8	psychiatric	II	O
9	abnormalities	II	O
10	associated	O	O
11	with	O	O
12	del22q11	BU	O
13	and	O	O
14	the	O	O
15	subtle	O	O
16	nature	O	O
17	of	O	O
18	its	O	O
19	associated	O	O
20	physical	O	O
21	findings	O	O
22	.	O	O

0	WS1	BU	O
1	is	O	O
2	a	O	O
3	rare	O	O
4	disorder	O	O
5	characterized	O	O
6	by	O	O
7	the	O	O
8	development	O	O
9	of	O	O
10	insulin-dependent	O	O
11	diabetes	O	O
12	mellitus	O	O
13	at	O	O
14	an	O	O
15	average	O	O
16	age	O	O
17	of	O	O
18	6	O	O
19	years	O	O
20	followed	O	O
21	by	O	O
22	optic	BI	O
23	atrophy	II	O
24	figure	O	O
25	at	O	O
26	an	O	O
27	average	O	O
28	age	O	O
29	of	O	O
30	11	O	O
31	and	O	O
32	partial	O	O
33	central	O	O
34	diabetes	O	O
35	insipidus	O	O
36	and	O	O
37	deafness	BI	O
38	in	O	O
39	adolescence	O	O
40	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	an	O	O
4	autosomal-recessive	O	O
5	variant	O	O
6	of	O	O
7	Ehlers-Danlos	BU	O
8	syndrome	IU	O
9	EDS	IU	O
10	characterized	O	O
11	by	O	O
12	severe	O	O
13	muscle	O	O
14	hypotonia	O	O
15	at	O	O
16	birth	O	O
17	progressive	O	O
18	scoliosis	O	O
19	joint	O	O
20	hypermobility	O	O
21	hyperelastic	O	O
22	skin	O	O
23	myopathy	O	O
24	sensorineural	BI	O
25	hearing	II	O
26	impairment	II	O
27	and	O	O
28	normal	O	O
29	pyridinoline	O	O
30	excretion	O	O
31	in	O	O
32	urine	O	O
33	.	O	O

0	Typical	O	O
1	features	O	O
2	of	O	O
3	CdCs	BU	O
4	that	O	O
5	are	O	O
6	present	O	O
7	in	O	O
8	the	O	O
9	proband	O	O
10	include	O	O
11	moderate	BI	O
12	intellectual	II	O
13	disability	II	O
14	speech	BI	O
15	and	II	O
16	motor	II	O
17	delay	II	O
18	as	O	O
19	well	O	O
20	as	O	O
21	dysmorphic	O	O
22	features	O	O
23	e.g.	O	O
24	broad	O	O
25	and	O	O
26	high	O	O
27	nasal	O	O
28	root	O	O
29	hypertelorism	O	O
30	and	O	O
31	coarse	O	O
32	facies	O	O
33	.	O	O

0	The	O	O
1	first	O	O
2	published	O	O
3	descriptions	O	O
4	of	O	O
5	behavior	O	O
6	in	O	O
7	CS	BU	O
8	children	O	O
9	underlined	O	O
10	the	O	O
11	presence	O	O
12	of	O	O
13	irritability	O	O
14	and	O	O
15	shyness	O	O
16	at	O	O
17	younger	O	O
18	ages	O	O
19	with	O	O
20	sociable	O	O
21	personality	O	O
22	and	O	O
23	good	O	O
24	empathic	O	O
25	skills	O	O
26	after	O	O
27	4-5	O	O
28	years	O	O
29	of	O	O
30	age	O	O
31	however	O	O
32	some	O	O
33	recent	O	O
34	studies	O	O
35	have	O	O
36	reported	O	O
37	autistic	BI	O
38	traits	II	O
39	.	O	O

0	INTRODUCTION	O	O
1	AND	O	O
2	OBJECTIVES	O	O
3	Neurofibromatosis	BU	O
4	type	IU	O
5	2	IU	O
6	NF2	IU	O
7	is	O	O
8	an	O	O
9	infrequent	O	O
10	autosomal	O	O
11	dominant	O	O
12	disease	O	O
13	characterised	O	O
14	by	O	O
15	the	O	O
16	appearance	O	O
17	of	O	O
18	viii	O	O
19	nerve	O	O
20	schwannomas	O	O
21	meningiomas	BU	O
22	and	O	O
23	ocular	BI	O
24	abnormalities	II	O
25	.	O	O

0	RESULTS	O	O
1	All	O	O
2	three	O	O
3	patients	O	O
4	with	O	O
5	cblC	BU	O
6	disease	IU	O
7	exhibited	O	O
8	bilateral	BI	O
9	optic	II	O
10	atrophy	II	O
11	with	O	O
12	decreased	O	O
13	visual	O	O
14	acuity	O	O
15	.	O	O

0	Cerebellar	BI	O
1	ataxia	II	O
2	is	O	O
3	commonly	O	O
4	observed	O	O
5	in	O	O
6	hyperornithinemia-hyperammonemia-homocitrullinuria	BU	O
7	HHH	IU	O
8	syndrome	IU	O
9	an	O	O
10	inherited	O	O
11	metabolic	O	O
12	disorder	O	O
13	biochemically	O	O
14	characterized	O	O
15	by	O	O
16	ornithine	O	O
17	Orn	O	O
18	homocitrulline	O	O
19	Hcit	O	O
20	and	O	O
21	ammonia	O	O
22	accumulation	O	O
23	.	O	O

0	However	O	O
1	severe	BI	O
2	mental	II	O
3	impairment	II	O
4	was	O	O
5	atypical	O	O
6	of	O	O
7	Charcot	BU	O
8	Marie	IU	O
9	Tooth	IU	O
10	disease	IU	O
11	type	IU	O
12	1A	IU	O
13	.	O	O

0	OBJECTIVE	O	O
1	To	O	O
2	describe	O	O
3	the	O	O
4	hearing	BI	O
5	loss	II	O
6	in	O	O
7	facioscapulohumeral	BU	O
8	muscular	IU	O
9	dystrophy	IU	O
10	FSHD	O	O
11	and	O	O
12	examine	O	O
13	the	O	O
14	relationship	O	O
15	to	O	O
16	genotype	O	O
17	.	O	O

0	Alpha-mannosidosis	BU	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	mild	BI	O
5	to	II	O
6	moderate	II	O
7	intellectual	II	O
8	disability	II	O
9	ID	O	O
10	moderate	BI	O
11	to	II	O
12	severe	II	O
13	neurosensory	II	O
14	hearing	II	O
15	loss	II	O
16	frequent	O	O
17	infections	O	O
18	psychomotor	BI	O
19	disturbances	II	O
20	and	O	O
21	skeletal	O	O
22	dysmorphism	O	O
23	.	O	O

0	These	O	O
1	include	O	O
2	neurofibromatosis	O	O
3	tuberous	BU	O
4	sclerosis	IU	O
5	Fragile	BU	O
6	X	IU	O
7	syndrome	IU	O
8	other	O	O
9	inherited	O	O
10	forms	O	O
11	of	O	O
12	mental	BI	O
13	retardation	II	O
14	cretinism	O	O
15	Coffin-Lowry	BU	O
16	syndrome	IU	O
17	lead	BU	O
18	poisoning	IU	O
19	Rett	BU	O
20	syndrome	IU	O
21	epilepsy	O	O
22	hypoxic-ischemic	BU	O
23	encephalopathy	IU	O
24	and	O	O
25	cerebral	O	O
26	palsy	O	O
27	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	10-years-old	O	O
7	male	O	O
8	patient	O	O
9	diagnosed	O	O
10	with	O	O
11	Hurler	BU	O
12	syndrome	IU	O
13	the	O	O
14	severe	O	O
15	presentation	O	O
16	5	O	O
17	years	O	O
18	ago	O	O
19	by	O	O
20	enzyme	O	O
21	a-L-iduronidase	O	O
22	activity	O	O
23	measurement	O	O
24	in	O	O
25	leukocytes	O	O
26	with	O	O
27	a	O	O
28	history	O	O
29	of	O	O
30	recurrent	O	O
31	respiratory	O	O
32	infections	O	O
33	umbilical	O	O
34	hernia	O	O
35	corneal	O	O
36	opacity	O	O
37	coarse	O	O
38	facial	O	O
39	features	O	O
40	macroglossia	BU	O
41	hearing	BI	O
42	loss	II	O
43	stiffness	O	O
44	of	O	O
45	joints	O	O
46	cardiac	O	O
47	compromise	O	O
48	claw	O	O
49	hands	O	O
50	mental	BI	O
51	retardation	II	O
52	and	O	O
53	stunted	O	O
54	growth	O	O
55	.	O	O

0	Alport	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	hereditary	O	O
5	type	O	O
6	IV	O	O
7	collagen	O	O
8	disease	O	O
9	leading	O	O
10	to	O	O
11	progressive	O	O
12	renal	O	O
13	fibrosis	O	O
14	hearing	BI	O
15	loss	II	O
16	and	O	O
17	ocular	O	O
18	changes	O	O
19	.	O	O

0	COMMENT	O	O
1	Choroideremia	BU	O
2	is	O	O
3	a	O	O
4	degenerative	BI	O
5	retinal	II	O
6	disease	II	O
7	recognized	O	O
8	in	O	O
9	the	O	O
10	late	O	O
11	stages	O	O
12	by	O	O
13	a	O	O
14	near	O	O
15	total	O	O
16	absence	O	O
17	of	O	O
18	the	O	O
19	choriocapillaris	O	O
20	retinal	O	O
21	pigment	O	O
22	epithelium	O	O
23	and	O	O
24	neurosensory	O	O
25	retina	O	O
26	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	inherited	O	O
8	form	O	O
9	of	O	O
10	intellectual	BI	O
11	disability	II	O
12	and	O	O
13	the	O	O
14	leading	O	O
15	genetic	O	O
16	cause	O	O
17	of	O	O
18	autism	BI	O
19	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	O	O
6	semi-dominant	O	O
7	condition	O	O
8	with	O	O
9	learning	BI	O
10	difficulties	II	O
11	and	O	O
12	dysmorphism	O	O
13	caused	O	O
14	by	O	O
15	mutations	O	O
16	in	O	O
17	the	O	O
18	gene	O	O
19	RSK2	O	O
20	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	WFS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	diffuse	O	O
7	neurodegenerative	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	diabetes	O	O
12	insipidus	O	O
13	diabetes	O	O
14	mellitus	O	O
15	optic	BI	O
16	atrophy	II	O
17	deafness	BI	O
18	and	O	O
19	a	O	O
20	wide	O	O
21	variety	O	O
22	of	O	O
23	central	O	O
24	nervous	O	O
25	system	O	O
26	abnormalities	O	O
27	.	O	O

0	This	O	O
1	review	O	O
2	addresses	O	O
3	hearing	BI	O
4	loss	II	O
5	as	O	O
6	it	O	O
7	occurs	O	O
8	and	O	O
9	has	O	O
10	been	O	O
11	reported	O	O
12	in	O	O
13	Muenke	O	O
14	syndrome	O	O
15	as	O	O
16	well	O	O
17	as	O	O
18	six	O	O
19	additional	O	O
20	FGFR	O	O
21	related	O	O
22	craniosynostosis	BU	O
23	syndromes	O	O
24	Apert	O	O
25	syndrome	O	O
26	Pfeiffer	O	O
27	syndrome	O	O
28	Crouzon	BU	O
29	syndrome	IU	O
30	Beare-Stevenson	O	O
31	syndrome	O	O
32	Crouzon	O	O
33	syndrome	O	O
34	with	O	O
35	acanthosis	O	O
36	nigricans	O	O
37	and	O	O
38	Jackson-Weiss	O	O
39	syndrome	O	O
40	.	O	O

0	The	O	O
1	juvenile	O	O
2	type	O	O
3	of	O	O
4	dentatorubral-pallidoluysian	BU	O
5	atrophy	IU	O
6	like	O	O
7	Huntingtons	BU	O
8	disease	IU	O
9	is	O	O
10	most	O	O
11	commonly	O	O
12	inherited	O	O
13	via	O	O
14	paternal	O	O
15	transmission	O	O
16	of	O	O
17	the	O	O
18	gene	O	O
19	and	O	O
20	most	O	O
21	frequently	O	O
22	presents	O	O
23	with	O	O
24	early-onset	O	O
25	progressive	BU	O
26	myoclonus	IU	O
27	epilepsy	IU	O
28	with	O	O
29	mental	BI	O
30	retardation	II	O
31	and	O	O
32	ataxia	BI	O
33	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	pantothenate	O	O
4	kinase	O	O
5	2	O	O
6	gene	O	O
7	PANK2	O	O
8	are	O	O
9	the	O	O
10	cause	O	O
11	of	O	O
12	pantothenate	O	O
13	kinase	O	O
14	associated	O	O
15	neurodegeneration	O	O
16	PKAN	O	O
17	an	O	O
18	autosomal	O	O
19	recessive	O	O
20	AR	O	O
21	disorder	O	O
22	characterized	O	O
23	by	O	O
24	motor	O	O
25	symptoms	O	O
26	as	O	O
27	such	O	O
28	as	O	O
29	dystonia	O	O
30	or	O	O
31	parkinsonism	O	O
32	mental	BI	O
33	retardation	II	O
34	retinitis	BU	O
35	pigmentosa	IU	O
36	and	O	O
37	iron	O	O
38	accumulation	O	O
39	in	O	O
40	the	O	O
41	brain	O	O
42	.	O	O

0	Phf6	O	O
1	gene	O	O
2	expression	O	O
3	and	O	O
4	nuclear	O	O
5	localisation	O	O
6	of	O	O
7	Phf6	O	O
8	protein	O	O
9	correlate	O	O
10	with	O	O
11	clinical	O	O
12	symptoms	O	O
13	in	O	O
14	BFLS	BU	O
15	patients	O	O
16	namely	O	O
17	mental	BI	O
18	disability	II	O
19	pan-anterior	O	O
20	pituitary	O	O
21	hormonal	O	O
22	deficiency	O	O
23	and	O	O
24	facial	O	O
25	as	O	O
26	well	O	O
27	digit	O	O
28	abnormalities	O	O
29	.	O	O

0	INTRODUCTION	O	O
1	Mutations	O	O
2	in	O	O
3	PDS	O	O
4	or	O	O
5	SLC26A4	O	O
6	cause	O	O
7	both	O	O
8	Pendred	BU	O
9	syndrome	IU	O
10	PS	O	O
11	and	O	O
12	DFNB4	O	O
13	two	O	O
14	autosomal	O	O
15	recessive	O	O
16	disorders	O	O
17	that	O	O
18	share	O	O
19	hearing	BI	O
20	loss	II	O
21	as	O	O
22	a	O	O
23	common	O	O
24	feature	O	O
25	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	the	O	O
4	clinical	O	O
5	history	O	O
6	and	O	O
7	neuroimaging	O	O
8	studies	O	O
9	of	O	O
10	a	O	O
11	child	O	O
12	with	O	O
13	a	O	O
14	complex	O	O
15	cardiac	O	O
16	malformation	O	O
17	developmental	BI	O
18	delay	II	O
19	and	O	O
20	oculomotor	BI	O
21	anomalies	II	O
22	whose	O	O
23	neuroimaging	O	O
24	findings	O	O
25	were	O	O
26	consistent	O	O
27	with	O	O
28	an	O	O
29	acquired	O	O
30	form	O	O
31	of	O	O
32	DWM	BU	O
33	.	O	O

0	To	O	O
1	present	O	O
2	the	O	O
3	detailed	O	O
4	clinical	O	O
5	findings	O	O
6	of	O	O
7	a	O	O
8	large	O	O
9	family	O	O
10	with	O	O
11	hereditary	BU	O
12	motor	IU	O
13	and	IU	O
14	sensory	IU	O
15	neuropathy	IU	O
16	type	IU	O
17	VI	IU	O
18	HMSN	IU	O
19	VI	IU	O
20	a	O	O
21	syndrome	O	O
22	featuring	O	O
23	optic	BI	O
24	atrophy	II	O
25	.	O	O

0	In	O	O
1	humans	O	O
2	alpha-mannosidosis	BU	O
3	results	O	O
4	in	O	O
5	progressive	O	O
6	facial-	O	O
7	and	O	O
8	skeletal	O	O
9	abnormalities	O	O
10	motor	BI	O
11	impairment	II	O
12	hearing	BI	O
13	impairment	II	O
14	intellectual	BI	O
15	disability	II	O
16	recurrent	O	O
17	infections	O	O
18	and	O	O
19	immune	O	O
20	deficiency	O	O
21	.	O	O

0	The	O	O
1	clinical	O	O
2	features	O	O
3	shared	O	O
4	by	O	O
5	our	O	O
6	patients	O	O
7	were	O	O
8	coloboma	O	O
9	VSD	BU	O
10	digital	O	O
11	abnormalities	O	O
12	congenital	O	O
13	dislocation	O	O
14	of	O	O
15	a	O	O
16	hip	O	O
17	feeding	BI	O
18	problems	II	O
19	psychomotor	BI	O
20	delay	II	O
21	and	O	O
22	convulsions	O	O
23	.	O	O

0	Infants	O	O
1	with	O	O
2	PDs	BU	O
3	are	O	O
4	usually	O	O
5	presented	O	O
6	with	O	O
7	developmental	BI	O
8	delay	II	O
9	visual	BI	O
10	and	II	O
11	hearing	II	O
12	impairment	II	O
13	.	O	O

0	The	O	O
1	duplication	O	O
2	belongs	O	O
3	to	O	O
4	the	O	O
5	15q11q13	BU	O
6	duplication	IU	O
7	syndrome	IU	O
8	OMIM	O	O
9	608636	O	O
10	which	O	O
11	when	O	O
12	maternally	O	O
13	derived	O	O
14	is	O	O
15	characterised	O	O
16	by	O	O
17	neuro-behavioural	O	O
18	disorders	O	O
19	like	O	O
20	autism	BI	O
21	hypotonia	O	O
22	cognitive	BI	O
23	deficit	II	O
24	language	BI	O
25	delay	II	O
26	and	O	O
27	epilepsy	O	O
28	.	O	O

0	BACKGROUND	O	O
1	Cerebral	BU	O
2	autosomal	IU	O
3	dominant	IU	O
4	arteriopathy	IU	O
5	with	IU	O
6	subcortical	IU	O
7	infarcts	IU	O
8	and	IU	O
9	leukoencephalopathy	IU	O
10	CADASIL	IU	O
11	is	O	O
12	an	O	O
13	inherited	O	O
14	cerebral	O	O
15	small	O	O
16	vessel	O	O
17	disease	O	O
18	clinically	O	O
19	characterized	O	O
20	by	O	O
21	migraine	O	O
22	recurrent	O	O
23	transient	O	O
24	ischemic	O	O
25	attacks	O	O
26	or	O	O
27	strokes	O	O
28	psychiatric	BI	O
29	disorders	II	O
30	and	O	O
31	cognitive	BI	O
32	decline	II	O
33	.	O	O

0	The	O	O
1	typical	O	O
2	clinical	O	O
3	manifestations	O	O
4	of	O	O
5	PMD	BU	O
6	include	O	O
7	psychomotor	BI	O
8	retardation	II	O
9	nystagmus	O	O
10	abnormal	O	O
11	muscle	O	O
12	tone	O	O
13	seizures	O	O
14	and	O	O
15	cognitive	BI	O
16	impairment	II	O
17	.	O	O

0	We	O	O
1	find	O	O
2	the	O	O
3	most	O	O
4	frequent	O	O
5	features	O	O
6	in	O	O
7	22q11	O	O
8	distal	O	O
9	deletion	O	O
10	to	O	O
11	be	O	O
12	developmental	BI	O
13	delay	II	O
14	or	O	O
15	learning	BI	O
16	disability	II	O
17	short	O	O
18	stature	O	O
19	microcephalus	O	O
20	premature	O	O
21	birth	O	O
22	with	O	O
23	low	O	O
24	birth	O	O
25	weight	O	O
26	and	O	O
27	congenital	BU	O
28	heart	IU	O
29	malformation	IU	O
30	ranging	O	O
31	from	O	O
32	minor	O	O
33	anomalies	O	O
34	to	O	O
35	complex	O	O
36	malformations	O	O
37	.	O	O

0	In	O	O
1	a	O	O
2	14-year-old	O	O
3	girl	O	O
4	presenting	O	O
5	with	O	O
6	hematuria	O	O
7	proteinuria	O	O
8	mental	BI	O
9	retardation	II	O
10	MR	O	O
11	sensorineural	BI	O
12	hearing	II	O
13	loss	II	O
14	dysmorphisms	O	O
15	and	O	O
16	epilepsy	O	O
17	we	O	O
18	detected	O	O
19	a	O	O
20	microdeletion	BU	O
21	in	IU	O
22	chromosome	IU	O
23	Xq22.3-q23	IU	O
24	.	O	O

0	Clinical	O	O
1	findings	O	O
2	in	O	O
3	alpha-mannosidosis	BU	O
4	include	O	O
5	skeletal	O	O
6	malformations	O	O
7	intellectual	BI	O
8	disabilities	II	O
9	and	O	O
10	hearing	BI	O
11	impairment	II	O
12	.	O	O

0	PURPOSE	O	O
1	Behavioral	BU	O
2	variant	IU	O
3	frontotemporal	IU	O
4	dementia	IU	O
5	bvFTD	IU	O
6	is	O	O
7	a	O	O
8	non-Alzheimer	BI	O
9	dementia	II	O
10	characterized	O	O
11	by	O	O
12	difficulty	O	O
13	in	O	O
14	documenting	O	O
15	social-emotional	O	O
16	changes	O	O
17	.	O	O

0	INTRODUCTION	O	O
1	Langer-Giedion	BU	O
2	syndrome	IU	O
3	trichorhinophalangeal	IU	O
4	syndrome	IU	O
5	type	IU	O
6	II	IU	O
7	is	O	O
8	an	O	O
9	extremely	O	O
10	rare	O	O
11	disorder	O	O
12	characterized	O	O
13	by	O	O
14	dysmorphic	O	O
15	facial	O	O
16	features	O	O
17	multiple	O	O
18	exostoses	O	O
19	mental	BI	O
20	retardation	II	O
21	and	O	O
22	digit	O	O
23	deformities	O	O
24	.	O	O

0	CHARGE	BU	O
1	syndrome	IU	O
2	was	O	O
3	discussed	O	O
4	because	O	O
5	of	O	O
6	ear	O	O
7	anomalies	O	O
8	choanal	BU	O
9	atresia	IU	O
10	and	O	O
11	developmental	BI	O
12	delay	II	O
13	in	O	O
14	our	O	O
15	patients	O	O
16	.	O	O

0	Terminal	O	O
1	deletions	O	O
2	of	O	O
3	the	O	O
4	long	O	O
5	arm	O	O
6	of	O	O
7	chromosome	O	O
8	4	O	O
9	are	O	O
10	associated	O	O
11	with	O	O
12	a	O	O
13	recognizable	O	O
14	phenotype	O	O
15	consisting	O	O
16	of	O	O
17	dysmorphic	O	O
18	facial	O	O
19	features	O	O
20	cleft	BU	O
21	palate	IU	O
22	upper	O	O
23	and	O	O
24	lower	O	O
25	limb	O	O
26	malformations	O	O
27	cardiac	O	O
28	defects	O	O
29	and	O	O
30	growth	BI	O
31	and	II	O
32	mental	II	O
33	retardation	II	O
34	.	O	O

0	Congenital	BU	O
1	rubella	IU	O
2	syndrome	IU	O
3	CRS	IU	O
4	is	O	O
5	a	O	O
6	global	O	O
7	cause	O	O
8	of	O	O
9	preventable	O	O
10	hearing	BI	O
11	impairment	II	O
12	blindness	BI	O
13	and	O	O
14	intellectual	BI	O
15	impairment	II	O
16	.	O	O

0	CHARGE	BU	O
1	association	IU	O
2	with	O	O
3	hearing	BI	O
4	impairment	II	O
5	is	O	O
6	a	O	O
7	challenge	O	O
8	to	O	O
9	ENT	O	O
10	surgeons	O	O
11	.	O	O

0	Patients	O	O
1	with	O	O
2	MERRF	BU	O
3	develop	O	O
4	myoclonus	O	O
5	epileptic	O	O
6	seizures	O	O
7	cerebellar	BI	O
8	ataxia	II	O
9	dementia	BI	O
10	sensorineural	BI	O
11	hearing	II	O
12	disturbance	II	O
13	optic	BI	O
14	atrophy	II	O
15	muscular	O	O
16	wasting	O	O
17	and	O	O
18	foot	O	O
19	deformities	O	O
20	at	O	O
21	the	O	O
22	advanced	O	O
23	stage	O	O
24	.	O	O

0	The	O	O
1	terminal	O	O
2	22q13.3	BU	O
3	deletion	IU	O
4	syndrome	IU	O
5	is	O	O
6	characterized	O	O
7	by	O	O
8	severe	BI	O
9	expressive-language	II	O
10	delay	II	O
11	mild	BI	O
12	mental	II	O
13	retardation	II	O
14	hypotonia	O	O
15	joint	O	O
16	laxity	O	O
17	dolichocephaly	O	O
18	and	O	O
19	minor	O	O
20	facial	O	O
21	dysmorphisms	O	O
22	.	O	O

0	In	O	O
1	cases	O	O
2	of	O	O
3	gouty	O	O
4	arthritis	O	O
5	with	O	O
6	urate	O	O
7	overproduction	O	O
8	a	O	O
9	careful	O	O
10	evaluation	O	O
11	for	O	O
12	motor	BI	O
13	impairments	II	O
14	or	O	O
15	neurocognitive	BI	O
16	abnormalities	II	O
17	may	O	O
18	help	O	O
19	to	O	O
20	identify	O	O
21	attenuated	O	O
22	variants	O	O
23	of	O	O
24	Lesch-Nyhan	BU	O
25	disease	IU	O
26	for	O	O
27	better	O	O
28	management	O	O
29	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	inositol	O	O
4	polyphosphate	O	O
5	5-phosphatase	O	O
6	OCRL1	O	O
7	cause	O	O
8	Lowe	BU	O
9	Syndrome	IU	O
10	leading	O	O
11	to	O	O
12	cataracts	O	O
13	mental	BI	O
14	retardation	II	O
15	and	O	O
16	renal	O	O
17	failure	O	O
18	.	O	O

0	We	O	O
1	report	O	O
2	an	O	O
3	11-year-old	O	O
4	girl	O	O
5	for	O	O
6	whom	O	O
7	the	O	O
8	diagnosis	O	O
9	of	O	O
10	cri	BU	O
11	du	IU	O
12	chat	IU	O
13	syndrome	IU	O
14	CdCS	IU	O
15	was	O	O
16	made	O	O
17	during	O	O
18	a	O	O
19	genetic	O	O
20	investigation	O	O
21	of	O	O
22	childhood	BI	O
23	apraxia	II	O
24	of	II	O
25	speech	II	O
26	.	O	O

0	Compared	O	O
1	to	O	O
2	patients	O	O
3	with	O	O
4	stroke	O	O
5	however	O	O
6	AD	O	O
7	and	O	O
8	bvFTD	BU	O
9	showed	O	O
10	more	O	O
11	bilateral	O	O
12	or	O	O
13	even	O	O
14	right	O	O
15	lateralized	O	O
16	neural	O	O
17	representations	O	O
18	of	O	O
19	limb	BI	O
20	apraxia	II	O
21	proposing	O	O
22	a	O	O
23	greater	O	O
24	influence	O	O
25	of	O	O
26	visuospatial	BI	O
27	impairments	II	O
28	and	O	O
29	spatial	O	O
30	body	O	O
31	representation	O	O
32	deficits	O	O
33	on	O	O
34	praxis	O	O
35	performance	O	O
36	.	O	O

0	This	O	O
1	unique	O	O
2	presentation	O	O
3	suggests	O	O
4	that	O	O
5	facioscapulohumeral	BU	O
6	muscular	IU	O
7	dystrophy	IU	O
8	should	O	O
9	be	O	O
10	considered	O	O
11	in	O	O
12	the	O	O
13	differential	O	O
14	diagnosis	O	O
15	of	O	O
16	children	O	O
17	with	O	O
18	cognitive	BI	O
19	impairment	II	O
20	seizures	O	O
21	and	O	O
22	hearing	BI	O
23	loss	II	O
24	.	O	O

0	The	O	O
1	Coffin-Lowry	BU	O
2	syndrome	IU	O
3	CLS	IU	O
4	is	O	O
5	a	O	O
6	syndromic	O	O
7	form	O	O
8	of	O	O
9	X-linked	BI	O
10	mental	II	O
11	retardation	II	O
12	characterised	O	O
13	in	O	O
14	male	O	O
15	patients	O	O
16	by	O	O
17	psychomotor	BI	O
18	and	II	O
19	growth	II	O
20	retardation	II	O
21	and	O	O
22	various	O	O
23	skeletal	O	O
24	anomalies	O	O
25	.	O	O

0	Forty	O	O
1	percent	O	O
2	of	O	O
3	the	O	O
4	patients	O	O
5	had	O	O
6	autism	BI	O
7	atypical	BU	O
8	autism	IU	O
9	and	O	O
10	82%	O	O
11	had	O	O
12	developmental	BI	O
13	delay	II	O
14	.	O	O

0	We	O	O
1	review	O	O
2	the	O	O
3	current	O	O
4	knowledge	O	O
5	of	O	O
6	the	O	O
7	FTD	BU	O
8	spectrum	O	O
9	and	O	O
10	common	O	O
11	features	O	O
12	shared	O	O
13	by	O	O
14	FTD	BU	O
15	and	O	O
16	some	O	O
17	psychiatric	BI	O
18	diseases	II	O
19	starting	O	O
20	from	O	O
21	Picks	O	O
22	clinical	O	O
23	description	O	O
24	of	O	O
25	the	O	O
26	disease	O	O
27	moving	O	O
28	toward	O	O
29	pathogenic	O	O
30	aspects	O	O
31	of	O	O
32	the	O	O
33	disease	O	O
34	and	O	O
35	genetic	O	O
36	causes	O	O
37	and	O	O
38	associated	O	O
39	phenotypes	O	O
40	and	O	O
41	finishing	O	O
42	with	O	O
43	analysis	O	O
44	of	O	O
45	crossing	O	O
46	borders	O	O
47	between	O	O
48	FTD	BU	O
49	and	O	O
50	psychiatric	BI	O
51	disorders	II	O
52	mainly	O	O
53	represented	O	O
54	by	O	O
55	schizophrenia	O	O
56	and	O	O
57	bipolar	O	O
58	spectrum	O	O
59	disorders	O	O
60	in	O	O
61	clinical	O	O
62	practice	O	O
63	in	O	O
64	terms	O	O
65	of	O	O
66	overlapping	O	O
67	symptoms	O	O
68	differential	O	O
69	diagnosis	O	O
70	comorbidity	O	O
71	and	O	O
72	treatment	O	O
73	issues	O	O
74	.	O	O

0	In	O	O
1	conclusion	O	O
2	we	O	O
3	provide	O	O
4	further	O	O
5	evidences	O	O
6	that	O	O
7	extramuscular	O	O
8	findings	O	O
9	such	O	O
10	as	O	O
11	epilepsy	O	O
12	speech	BI	O
13	delay	II	O
14	and	O	O
15	mental	BI	O
16	retardation	II	O
17	may	O	O
18	occur	O	O
19	in	O	O
20	those	O	O
21	patients	O	O
22	carrying	O	O
23	smaller	O	O
24	4q35	O	O
25	deletions	O	O
26	suggesting	O	O
27	that	O	O
28	a	O	O
29	close	O	O
30	correlation	O	O
31	between	O	O
32	4q35	O	O
33	fragment	O	O
34	size	O	O
35	and	O	O
36	clinical	O	O
37	severity	O	O
38	in	O	O
39	FSHD	BU	O
40	is	O	O
41	therefore	O	O
42	not	O	O
43	constant	O	O
44	.	O	O

0	RESULTS	O	O
1	Majority	O	O
2	of	O	O
3	the	O	O
4	patients	O	O
5	with	O	O
6	MSUD	BU	O
7	had	O	O
8	developmental	BI	O
9	delay	II	O
10	intellectual	BI	O
11	disability	II	O
12	88%	O	O
13	speech	BI	O
14	delay	II	O
15	69%	O	O
16	and	O	O
17	seizures	O	O
18	65%	O	O
19	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	3-year-old	O	O
4	boy	O	O
5	with	O	O
6	complete	O	O
7	agenesis	O	O
8	of	O	O
9	corpus	O	O
10	callosum	O	O
11	developmental	BI	O
12	delay	II	O
13	mental	BI	O
14	retardation	II	O
15	anterior	O	O
16	diaphragmatic	O	O
17	hernia	O	O
18	Morgagni	O	O
19	type	O	O
20	severe	O	O
21	hypermetropia	O	O
22	and	O	O
23	facial	O	O
24	dysmorphism	O	O
25	suggesting	O	O
26	the	O	O
27	diagnosis	O	O
28	of	O	O
29	Donnai-Barrow	BU	O
30	syndrome	IU	O
31	.	O	O

0	In	O	O
1	contrast	O	O
2	LGS	BU	O
3	was	O	O
4	associated	O	O
5	with	O	O
6	mental	BI	O
7	retardation	II	O
8	which	O	O
9	persisted	O	O
10	after	O	O
11	seizure	O	O
12	control	O	O
13	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	MEB	BU	O
4	case	O	O
5	whose	O	O
6	presenting	O	O
7	sign	O	O
8	was	O	O
9	congenital	BI	O
10	blindness	II	O
11	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	is	O	O
3	an	O	O
4	X-linked	BI	O
5	mental	II	O
6	retardation	II	O
7	disorder	II	O
8	with	II	O
9	dysmorphism	II	O
10	caused	O	O
11	by	O	O
12	mutation	O	O
13	of	O	O
14	the	O	O
15	ribosomal	O	O
16	S6	O	O
17	kinase	O	O
18	RSK2	O	O
19	gene	O	O
20	.	O	O

0	Usually	O	O
1	patients	O	O
2	with	O	O
3	Treacher	BU	O
4	Collins	IU	O
5	syndrome	IU	O
6	do	O	O
7	not	O	O
8	present	O	O
9	with	O	O
10	intellectual	BI	O
11	disability	II	O
12	.	O	O

0	Sjögren-Larsson	BU	O
1	syndrome	IU	O
2	SLS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	ichthyosis	BU	O
12	spastic	BI	O
13	di-	II	O
14	or	II	O
15	tetraplegia	II	O
16	and	O	O
17	mental	BI	O
18	retardation	II	O
19	due	O	O
20	a	O	O
21	defect	O	O
22	of	O	O
23	the	O	O
24	fatty	O	O
25	aldehyde	O	O
26	dehydrogenase	O	O
27	FALDH	O	O
28	related	O	O
29	to	O	O
30	mutations	O	O
31	in	O	O
32	the	O	O
33	ALDH3A2	O	O
34	gene	O	O
35	.	O	O

0	Missense	O	O
1	mutations	O	O
2	in	O	O
3	this	O	O
4	gene	O	O
5	result	O	O
6	in	O	O
7	HSD10	BU	O
8	deficiency	IU	O
9	whereas	O	O
10	a	O	O
11	silent	O	O
12	mutation	O	O
13	results	O	O
14	in	O	O
15	mental	BI	O
16	retardation	II	O
17	X-linked	O	O
18	syndromic	O	O
19	10	O	O
20	MRXS10	O	O
21	.	O	O

0	Spinocerebellar	BU	O
1	ataxia	IU	O
2	type	IU	O
3	7	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	autosomal	BI	O
8	dominant	II	O
9	cerebellar	II	O
10	ataxia	II	O
11	ADCA	IU	O
12	.	O	O

0	Why	O	O
1	their	O	O
2	gait	O	O
3	improved	O	O
4	remain	O	O
5	unclear	O	O
6	but	O	O
7	a	O	O
8	defect	O	O
9	in	O	O
10	selenium	O	O
11	metabolism	O	O
12	may	O	O
13	play	O	O
14	a	O	O
15	role	O	O
16	in	O	O
17	the	O	O
18	development	O	O
19	of	O	O
20	congenital	BU	O
21	muscular	IU	O
22	dystrophy	IU	O
23	and	O	O
24	mental	BI	O
25	retardation	II	O
26	.	O	O

0	MAE	BU	O
1	frequently	O	O
2	shows	O	O
3	the	O	O
4	course	O	O
5	of	O	O
6	an	O	O
7	epileptic	O	O
8	encephalopathy	O	O
9	and	O	O
10	may	O	O
11	result	O	O
12	in	O	O
13	permanent	BI	O
14	cognitive	II	O
15	impairment	II	O
16	.	O	O

0	Both	O	O
1	patients	O	O
2	showed	O	O
3	moderate	BI	O
4	intellectual	II	O
5	disability	II	O
6	spastic	BI	O
7	ataxic	II	O
8	syndrome	II	O
9	hypomyelination	O	O
10	and	O	O
11	cerebellar	O	O
12	atrophy	O	O
13	on	O	O
14	magnetic	O	O
15	resonance	O	O
16	imaging	O	O
17	MRI	O	O
18	and	O	O
19	lysosomal	O	O
20	storage	O	O
21	all	O	O
22	typical	O	O
23	of	O	O
24	Salla	BU	O
25	disease	IU	O
26	.	O	O

0	Here	O	O
1	we	O	O
2	present	O	O
3	a	O	O
4	44year	O	O
5	old	O	O
6	patient	O	O
7	who	O	O
8	presented	O	O
9	to	O	O
10	our	O	O
11	hospital	O	O
12	with	O	O
13	central	O	O
14	respiratory	O	O
15	failure	O	O
16	cognitive	BI	O
17	impairment	II	O
18	ataxia	BI	O
19	and	O	O
20	parkinsonism	O	O
21	and	O	O
22	was	O	O
23	first	O	O
24	diagnosed	O	O
25	with	O	O
26	Wolfram	BU	O
27	syndrome	IU	O
28	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	family	O	O
5	affected	O	O
6	by	O	O
7	FSHD	BU	O
8	carrying	O	O
9	a	O	O
10	small	O	O
11	4q35	O	O
12	deletion	O	O
13	and	O	O
14	residual	O	O
15	fragments	O	O
16	length	O	O
17	of	O	O
18	17kb	O	O
19	presenting	O	O
20	with	O	O
21	epilepsy	O	O
22	three	O	O
23	patients	O	O
24	speech	BI	O
25	delay	II	O
26	two	O	O
27	and	O	O
28	mental	BI	O
29	retardation	II	O
30	one	O	O
31	.	O	O

0	Möbius	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	congenital	O	O
5	disorder	O	O
6	with	O	O
7	facial	BI	O
8	and	II	O
9	abducens	II	O
10	palsy	II	O
11	.	O	O

0	The	O	O
1	Cockayne	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	disease	O	O
9	characterized	O	O
10	by	O	O
11	a	O	O
12	general	BI	O
13	developmental	II	O
14	delay	II	O
15	the	O	O
16	unique	O	O
17	face	O	O
18	and	O	O
19	abnormal	O	O
20	skin	O	O
21	sensitivity	O	O
22	to	O	O
23	sunlight	O	O
24	.	O	O

0	Because	O	O
1	it	O	O
2	is	O	O
3	difficult	O	O
4	to	O	O
5	suspect	O	O
6	AHDS	BU	O
7	solely	O	O
8	according	O	O
9	to	O	O
10	neurological	O	O
11	features	O	O
12	thyroid	O	O
13	function	O	O
14	including	O	O
15	the	O	O
16	T3	O	O
17	level	O	O
18	should	O	O
19	be	O	O
20	screened	O	O
21	in	O	O
22	male	O	O
23	patients	O	O
24	with	O	O
25	X-linked	BI	O
26	mental	II	O
27	retardation	II	O
28	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	CS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	congenital	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	severe	O	O
11	failure	O	O
12	to	O	O
13	thrive	O	O
14	coarse	O	O
15	facial	O	O
16	appearance	O	O
17	cardiac	O	O
18	and	O	O
19	skin	O	O
20	abnormalities	O	O
21	developmental	BI	O
22	delay	II	O
23	intellectual	BI	O
24	disability	II	O
25	and	O	O
26	predisposition	O	O
27	to	O	O
28	malignancies	O	O
29	.	O	O

0	Of	O	O
1	the	O	O
2	nine	O	O
3	children	O	O
4	with	O	O
5	DS	BU	O
6	and	O	O
7	epilepsy	O	O
8	two	O	O
9	22%	O	O
10	presented	O	O
11	mild	BI	O
12	mental	II	O
13	retardation	II	O
14	and	O	O
15	seven	O	O
16	78%	O	O
17	had	O	O
18	moderate	BI	O
19	to	II	O
20	severe	II	O
21	cognitive	II	O
22	delay	II	O
23	.	O	O

0	Hearing	BI	O
1	loss	II	O
2	in	O	O
3	Fechtner	BU	O
4	syndrome	IU	O
5	appears	O	O
6	to	O	O
7	be	O	O
8	sensorineural	O	O
9	with	O	O
10	the	O	O
11	higher	O	O
12	frequencies	O	O
13	primarily	O	O
14	affected	O	O
15	.	O	O

0	This	O	O
1	aberrant	O	O
2	ERK1	O	O
3	2	O	O
4	signaling	O	O
5	can	O	O
6	influence	O	O
7	various	O	O
8	neuronal	O	O
9	functions	O	O
10	and	O	O
11	thus	O	O
12	play	O	O
13	a	O	O
14	significant	O	O
15	role	O	O
16	in	O	O
17	cognitive	BI	O
18	dysfunction	II	O
19	in	O	O
20	mrsk2_KO	O	O
21	mice	O	O
22	and	O	O
23	in	O	O
24	the	O	O
25	Coffin-Lowry	BU	O
26	syndrome	IU	O
27	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	refine	O	O
4	the	O	O
5	description	O	O
6	of	O	O
7	the	O	O
8	motor	O	O
9	phenotype	O	O
10	we	O	O
11	prospectively	O	O
12	studied	O	O
13	16	O	O
14	consecutive	O	O
15	pediatric	O	O
16	and	O	O
17	adult	O	O
18	GA1	BU	O
19	patients	O	O
20	focusing	O	O
21	on	O	O
22	the	O	O
23	movement	BI	O
24	disorders	II	O
25	and	O	O
26	their	O	O
27	time	O	O
28	course	O	O
29	.	O	O

0	Leber	BU	O
1	congenital	IU	O
2	amaurosis	IU	O
3	LCA	IU	O
4	is	O	O
5	the	O	O
6	most	O	O
7	severe	BI	O
8	retinal	II	O
9	dystrophy	II	O
10	causing	O	O
11	blindness	BI	O
12	or	O	O
13	severe	BI	O
14	visual	II	O
15	impairment	II	O
16	before	O	O
17	the	O	O
18	age	O	O
19	of	O	O
20	1	O	O
21	year	O	O
22	.	O	O

0	The	O	O
1	same	O	O
2	condition	O	O
3	is	O	O
4	present	O	O
5	in	O	O
6	people	O	O
7	suffering	O	O
8	from	O	O
9	Down	BU	O
10	syndrome	IU	O
11	DS	IU	O
12	even	O	O
13	if	O	O
14	their	O	O
15	clumsy	O	O
16	movements	O	O
17	are	O	O
18	due	O	O
19	to	O	O
20	cerebral	BI	O
21	and	II	O
22	cognitive	II	O
23	impairments	II	O
24	.	O	O

0	We	O	O
1	describe	O	O
2	three	O	O
3	families	O	O
4	with	O	O
5	X-linked	BI	O
6	mental	II	O
7	retardation	II	O
8	two	O	O
9	with	O	O
10	a	O	O
11	deletion	O	O
12	of	O	O
13	a	O	O
14	single	O	O
15	amino	O	O
16	acid	O	O
17	and	O	O
18	one	O	O
19	with	O	O
20	a	O	O
21	missense	O	O
22	mutation	O	O
23	in	O	O
24	the	O	O
25	proximal	O	O
26	domain	O	O
27	of	O	O
28	the	O	O
29	RSK2RPS6KA3	O	O
30	ribosomal	O	O
31	protein	O	O
32	S6	O	O
33	kinase	O	O
34	90	O	O
35	kDa	O	O
36	polypeptide	O	O
37	3	O	O
38	protein	O	O
39	similar	O	O
40	to	O	O
41	mutations	O	O
42	found	O	O
43	in	O	O
44	Coffin-Lowry	BU	O
45	syndrome	IU	O
46	CLS	IU	O
47	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	boy	O	O
7	with	O	O
8	myoclonic	BU	O
9	epilepsy	IU	O
10	with	IU	O
11	ragged-red	IU	O
12	fibers	IU	O
13	MERRF	IU	O
14	who	O	O
15	had	O	O
16	astatic	O	O
17	seizures	O	O
18	since	O	O
19	2years	O	O
20	of	O	O
21	age	O	O
22	and	O	O
23	later	O	O
24	developed	O	O
25	ataxia	BI	O
26	absence	O	O
27	seizures	O	O
28	and	O	O
29	myoclonus	O	O
30	.	O	O

0	The	O	O
1	fourth	O	O
2	family	O	O
3	had	O	O
4	a	O	O
5	boy	O	O
6	that	O	O
7	died	O	O
8	at	O	O
9	3	O	O
10	weeks	O	O
11	of	O	O
12	age	O	O
13	with	O	O
14	microcephaly	O	O
15	dysmorphic	O	O
16	facial	O	O
17	features	O	O
18	congenital	O	O
19	heart	O	O
20	disease	O	O
21	mitral	BU	O
22	atresia	IU	O
23	and	O	O
24	septal	O	O
25	defects	O	O
26	and	O	O
27	Meckel	O	O
28	diverticulum	O	O
29	and	O	O
30	a	O	O
31	girl	O	O
32	5	O	O
33	years	O	O
34	of	O	O
35	age	O	O
36	with	O	O
37	intrauterine	O	O
38	growth	O	O
39	retardation	O	O
40	microcephaly	O	O
41	and	O	O
42	mental	BI	O
43	retardation	II	O
44	.	O	O

0	OBJECTIVE	O	O
1	People	O	O
2	with	O	O
3	velo-cardio-facial	O	O
4	syndrome	O	O
5	or	O	O
6	22q11	BU	O
7	deletion	IU	O
8	syndrome	IU	O
9	22q11DS	IU	O
10	have	O	O
11	behavioral	BI	O
12	cognitive	II	O
13	and	II	O
14	psychiatric	II	O
15	problems	II	O
16	.	O	O

0	In	O	O
1	2000	O	O
2	the	O	O
3	other	O	O
4	blinding	BI	O
5	disorder	II	O
6	dominant	BU	O
7	optic	IU	O
8	atrophy	IU	O
9	DOA	IU	O
10	Kjer	O	O
11	type	O	O
12	was	O	O
13	found	O	O
14	associated	O	O
15	with	O	O
16	mutations	O	O
17	in	O	O
18	the	O	O
19	nuclear	O	O
20	gene	O	O
21	OPA1	O	O
22	that	O	O
23	encodes	O	O
24	a	O	O
25	mitochondrial	O	O
26	protein	O	O
27	.	O	O

0	CONCLUSION	O	O
1	Glutaric	BU	O
2	aciduria	IU	O
3	type	IU	O
4	1	IU	O
5	usually	O	O
6	induced	O	O
7	neurological	O	O
8	deterioration	O	O
9	resulting	O	O
10	in	O	O
11	severe	BI	O
12	psychomotor	II	O
13	retardation	II	O
14	and	O	O
15	dystonia	O	O
16	.	O	O

0	This	O	O
1	review	O	O
2	confirms	O	O
3	that	O	O
4	patients	O	O
5	with	O	O
6	TSC2	BU	O
7	mutations	O	O
8	considered	O	O
9	as	O	O
10	a	O	O
11	group	O	O
12	usually	O	O
13	present	O	O
14	a	O	O
15	more	O	O
16	severe	O	O
17	phenotype	O	O
18	characterized	O	O
19	by	O	O
20	higher	O	O
21	number	O	O
22	of	O	O
23	tubers	O	O
24	earlier	O	O
25	age	O	O
26	at	O	O
27	seizure	O	O
28	onset	O	O
29	and	O	O
30	higher	O	O
31	prevalence	O	O
32	of	O	O
33	intellectual	BI	O
34	disability	II	O
35	.	O	O

0	In	O	O
1	so-called	O	O
2	RASopathies	O	O
3	[e.g.	O	O
4	neurofibromatosis	BU	O
5	1	IU	O
6	NF1]	IU	O
7	neurocognitive	BI	O
8	impairments	II	O
9	are	O	O
10	frequent	O	O
11	and	O	O
12	are	O	O
13	affected	O	O
14	by	O	O
15	components	O	O
16	of	O	O
17	the	O	O
18	RAS	O	O
19	pathway	O	O
20	which	O	O
21	lead	O	O
22	to	O	O
23	impairments	O	O
24	in	O	O
25	synaptic	O	O
26	plasticity	O	O
27	.	O	O

0	α-Thalassemia	BU	O
1	X-linked	IU	O
2	mental	IU	O
3	retardation	IU	O
4	syndrome	IU	O
5	is	O	O
6	a	O	O
7	rare	O	O
8	inherited	BI	O
9	intellectual	II	O
10	disability	II	O
11	disorder	O	O
12	due	O	O
13	to	O	O
14	mutations	O	O
15	in	O	O
16	the	O	O
17	ATRX	O	O
18	gene	O	O
19	.	O	O

0	Cardiac	O	O
1	rhythm	O	O
2	disturbances	O	O
3	have	O	O
4	been	O	O
5	described	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	this	O	O
10	disease	O	O
11	but	O	O
12	it	O	O
13	is	O	O
14	not	O	O
15	known	O	O
16	whether	O	O
17	myotonic	BU	O
18	dystrophy	IU	O
19	type	IU	O
20	2	IU	O
21	proximal	BU	O
22	myotonic	IU	O
23	myopathy	IU	O
24	patients	O	O
25	suffer	O	O
26	from	O	O
27	dysautonomia	O	O
28	and	O	O
29	whether	O	O
30	cardiac	O	O
31	arrhythmias	O	O
32	relate	O	O
33	to	O	O
34	autonomic	BI	O
35	dysfunction	II	O
36	.	O	O

0	The	O	O
1	5p15.2	O	O
2	has	O	O
3	been	O	O
4	defined	O	O
5	as	O	O
6	a	O	O
7	critical	O	O
8	region	O	O
9	for	O	O
10	CdC	BU	O
11	syndrome	IU	O
12	however	O	O
13	genotype-phenotype	O	O
14	studies	O	O
15	allowed	O	O
16	isolation	O	O
17	of	O	O
18	particular	O	O
19	characteristics	O	O
20	such	O	O
21	as	O	O
22	speech	BI	O
23	delay	II	O
24	cat-like	O	O
25	cry	O	O
26	and	O	O
27	mental	O	O
28	retardation	O	O
29	caused	O	O
30	by	O	O
31	distinct	O	O
32	deletions	O	O
33	of	O	O
34	5p	O	O
35	.	O	O

0	Most	O	O
1	PA	BU	O
2	patients	O	O
3	present	O	O
4	in	O	O
5	the	O	O
6	neonatal	O	O
7	period	O	O
8	with	O	O
9	metabolic	O	O
10	acidosis	O	O
11	and	O	O
12	hyperammonemia	O	O
13	developing	O	O
14	different	O	O
15	neurological	O	O
16	symptoms	O	O
17	movement	BI	O
18	disorders	II	O
19	and	O	O
20	cardiac	O	O
21	complications	O	O
22	.	O	O

0	The	O	O
1	most	O	O
2	striking	O	O
3	difference	O	O
4	between	O	O
5	hearing	BI	O
6	loss	II	O
7	in	O	O
8	Fechtner	BU	O
9	syndrome	IU	O
10	and	O	O
11	that	O	O
12	in	O	O
13	Alports	BU	O
14	syndrome	IU	O
15	was	O	O
16	that	O	O
17	the	O	O
18	vast	O	O
19	majority	O	O
20	of	O	O
21	hearing	BI	O
22	disorders	II	O
23	in	O	O
24	the	O	O
25	latter	O	O
26	occur	O	O
27	in	O	O
28	male	O	O
29	patients	O	O
30	which	O	O
31	is	O	O
32	not	O	O
33	the	O	O
34	case	O	O
35	in	O	O
36	Fechtner	BU	O
37	syndrome	IU	O
38	.	O	O

0	In	O	O
1	his	O	O
2	mothers	O	O
3	cousin	O	O
4	who	O	O
5	bears	O	O
6	the	O	O
7	identical	O	O
8	unbalanced	O	O
9	translocation	O	O
10	mild	BI	O
11	mental	II	O
12	retardation	II	O
13	patent	BU	O
14	ductus	IU	O
15	arteriosus	IU	O
16	hypogammaglobulinemia	O	O
17	recurrent	O	O
18	infections	O	O
19	unilateral	O	O
20	kidney	O	O
21	hypoplasia	O	O
22	pes	O	O
23	equinovarus	O	O
24	and	O	O
25	hearing	BI	O
26	deficiencies	II	O
27	were	O	O
28	reported	O	O
29	.	O	O

0	Forty-two	O	O
1	ascertained	O	O
2	Cypriot	O	O
3	sporadic	BI	O
4	ataxia	II	O
5	patients	O	O
6	the	O	O
7	index	O	O
8	case	O	O
9	from	O	O
10	1	O	O
11	ADCA	BU	O
12	and	O	O
13	14	O	O
14	ARCA	O	O
15	families	O	O
16	and	O	O
17	a	O	O
18	cohort	O	O
19	of	O	O
20	normal	O	O
21	population	O	O
22	individuals	O	O
23	were	O	O
24	included	O	O
25	in	O	O
26	the	O	O
27	study	O	O
28	.	O	O

0	Prominent	O	O
1	orofacial	O	O
2	involvement	O	O
3	was	O	O
4	a	O	O
5	consistent	O	O
6	feature	O	O
7	in	O	O
8	GA1	BU	O
9	patients	O	O
10	with	O	O
11	movement	BI	O
12	disorders	II	O
13	resulting	O	O
14	in	O	O
15	speech	BI	O
16	disorders	II	O
17	with	O	O
18	features	O	O
19	of	O	O
20	combined	O	O
21	hyperkinetic	BI	O
22	dysarthria	II	O
23	and	O	O
24	speech	BI	O
25	apraxia	II	O
26	.	O	O

0	BACKGROUND	O	O
1	Cerebro-oculo-facio-skeletal	BU	O
2	COFS	IU	O
3	syndrome	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	autosomal-recessive	O	O
8	disorder	O	O
9	that	O	O
10	includes	O	O
11	microcephaly	O	O
12	severe	BI	O
13	mental	II	O
14	retardation	II	O
15	and	O	O
16	multiple	BI	O
17	congenital	II	O
18	anomalies	II	O
19	.	O	O

0	Progressive	BI	O
1	sensorineural	II	O
2	deafness	II	O
3	is	O	O
4	an	O	O
5	early	O	O
6	feature	O	O
7	of	O	O
8	XP	BU	O
9	and	O	O
10	CS	BU	O
11	.	O	O

0	Sensorineural	BI	O
1	deafness	II	O
2	and	O	O
3	amyloidosis	BU	O
4	are	O	O
5	the	O	O
6	two	O	O
7	major	O	O
8	complications	O	O
9	of	O	O
10	MWS	O	O
11	and	O	O
12	determine	O	O
13	poor	O	O
14	prognosis	O	O
15	of	O	O
16	the	O	O
17	disease	O	O
18	.	O	O

0	Kabuki	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	genetic	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	intellectual	BI	O
10	disability	II	O
11	and	O	O
12	multiple	O	O
13	congenital	O	O
14	anomalies	O	O
15	including	O	O
16	short	O	O
17	stature	O	O
18	peculiar	O	O
19	facial	O	O
20	appearance	O	O
21	skeletal	O	O
22	anomalies	O	O
23	a	O	O
24	variety	O	O
25	of	O	O
26	visceral	O	O
27	malformations	O	O
28	and	O	O
29	abnormal	O	O
30	dermatoglyphic	O	O
31	patterns	O	O
32	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	the	O	O
4	typical	O	O
5	Charcot-Marie-Tooth	BU	O
6	disease	IU	O
7	clinical	O	O
8	phenotype	O	O
9	some	O	O
10	patients	O	O
11	had	O	O
12	delayed	BI	O
13	motor	II	O
14	development	II	O
15	sensorineural	BI	O
16	hearing	II	O
17	loss	II	O
18	tremor	O	O
19	pathologic	O	O
20	fractures	O	O
21	or	O	O
22	transient	O	O
23	CNS	O	O
24	disturbances	O	O
25	.	O	O

0	Propionic	BU	O
1	acidemia	IU	O
2	PA	IU	O
3	is	O	O
4	an	O	O
5	organic	O	O
6	acidemia	O	O
7	which	O	O
8	has	O	O
9	a	O	O
10	broad	O	O
11	range	O	O
12	of	O	O
13	neurological	O	O
14	complications	O	O
15	including	O	O
16	developmental	BI	O
17	delay	II	O
18	intellectual	BI	O
19	disability	II	O
20	structural	O	O
21	abnormalities	O	O
22	metabolic	O	O
23	stroke-like	O	O
24	episodes	O	O
25	seizures	O	O
26	optic	O	O
27	neuropathy	O	O
28	and	O	O
29	cranial	O	O
30	nerve	O	O
31	abnormalities	O	O
32	.	O	O

0	Characteristic	O	O
1	fundus	O	O
2	night	BI	O
3	blindness	II	O
4	peripheral	BI	O
5	visual	II	O
6	field	II	O
7	loss	II	O
8	electroretinography	O	O
9	and	O	O
10	other	O	O
11	manifestations	O	O
12	led	O	O
13	us	O	O
14	to	O	O
15	a	O	O
16	diagnosis	O	O
17	of	O	O
18	choroideremia	BU	O
19	.	O	O

0	Autism	BI	O
1	in	O	O
2	CHARGE	BU	O
3	association	IU	O
4	may	O	O
5	represent	O	O
6	a	O	O
7	neuro-endocrine	O	O
8	dysfunction	O	O
9	.	O	O

0	Familial	BU	O
1	Danish	IU	O
2	dementia	IU	O
3	FDD	IU	O
4	is	O	O
5	an	O	O
6	autosomal	O	O
7	dominant	O	O
8	neurodegenerative	O	O
9	disease	O	O
10	clinically	O	O
11	characterized	O	O
12	by	O	O
13	the	O	O
14	presence	O	O
15	of	O	O
16	cataracts	O	O
17	hearing	BI	O
18	impairment	II	O
19	cerebellar	BI	O
20	ataxia	II	O
21	and	O	O
22	dementia	BI	O
23	.	O	O

0	An	O	O
1	increasing	O	O
2	number	O	O
3	of	O	O
4	studies	O	O
5	implicate	O	O
6	the	O	O
7	GABAAergic	O	O
8	system	O	O
9	in	O	O
10	the	O	O
11	pathophysiology	O	O
12	of	O	O
13	the	O	O
14	fragile	BU	O
15	X	IU	O
16	syndrome	IU	O
17	a	O	O
18	frequent	O	O
19	cause	O	O
20	of	O	O
21	intellectual	BI	O
22	disability	II	O
23	and	O	O
24	autism	BI	O
25	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS0	IU	O
3	is	O	O
4	a	O	O
5	complex	O	O
6	and	O	O
7	rare	O	O
8	genetic	O	O
9	multisystem	O	O
10	disorder	O	O
11	characterized	O	O
12	by	O	O
13	a	O	O
14	variable	O	O
15	pattern	O	O
16	of	O	O
17	cognitive	BI	O
18	deficits	II	O
19	accompanied	O	O
20	by	O	O
21	a1	O	O
22	distinctive	O	O
23	behavioral	O	O
24	phenotype	O	O
25	.	O	O

0	BACKGROUND	O	O
1	Jacobsen	BU	O
2	syndrome	IU	O
3	JBS	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	chromosomal	O	O
8	disorder	O	O
9	leading	O	O
10	to	O	O
11	multiple	BI	O
12	physical	II	O
13	and	II	O
14	mental	II	O
15	impairment	II	O
16	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	SLS	O	O
6	in	O	O
7	an	O	O
8	11-month-old	O	O
9	girl	O	O
10	of	O	O
11	Lebanese	O	O
12	and	O	O
13	Mexican-Syrian	O	O
14	ancestry	O	O
15	who	O	O
16	presented	O	O
17	with	O	O
18	ichthyosis	BU	O
19	developmental	BI	O
20	delay	II	O
21	and	O	O
22	spasticity	O	O
23	.	O	O

0	CONCLUSION	O	O
1	Optic	BI	O
2	atrophy	II	O
3	should	O	O
4	be	O	O
5	included	O	O
6	in	O	O
7	the	O	O
8	clinical	O	O
9	spectrum	O	O
10	of	O	O
11	DRPLA	BU	O
12	.	O	O

0	Social	BI	O
1	deficits	II	O
2	are	O	O
3	prevalent	O	O
4	in	O	O
5	Turner	BU	O
6	syndrome	IU	O
7	TS	IU	O
8	however	O	O
9	the	O	O
10	extent	O	O
11	to	O	O
12	which	O	O
13	these	O	O
14	difficulties	O	O
15	are	O	O
16	secondary	O	O
17	to	O	O
18	characteristic	O	O
19	cognitive	BI	O
20	impairments	II	O
21	is	O	O
22	not	O	O
23	well	O	O
24	known	O	O
25	.	O	O

0	Our	O	O
1	literature	O	O
2	review	O	O
3	revealed	O	O
4	the	O	O
5	following	O	O
6	incidences	O	O
7	of	O	O
8	hearing	BI	O
9	loss	II	O
10	in	O	O
11	FGFR	O	O
12	craniosynostoses	O	O
13	61%	O	O
14	in	O	O
15	Muenke	O	O
16	syndrome	O	O
17	80%	O	O
18	in	O	O
19	Apert	O	O
20	Syndrome	O	O
21	92%	O	O
22	in	O	O
23	Pfeiffer	O	O
24	syndrome	O	O
25	74%	O	O
26	in	O	O
27	Crouzon	BU	O
28	syndrome	IU	O
29	68%	O	O
30	in	O	O
31	Jackson	O	O
32	Weiss	O	O
33	syndrome	O	O
34	4%	O	O
35	in	O	O
36	Beare	O	O
37	Stevenson	O	O
38	syndrome	O	O
39	and	O	O
40	14%	O	O
41	in	O	O
42	Crouzon	O	O
43	syndrome	O	O
44	with	O	O
45	Acanthosis	O	O
46	Nigricans	O	O
47	.	O	O

0	Despite	O	O
1	variation	O	O
2	in	O	O
3	size	O	O
4	of	O	O
5	the	O	O
6	9p	O	O
7	duplications	O	O
8	trisomy	BU	O
9	9p	IU	O
10	syndrome	O	O
11	is	O	O
12	characterized	O	O
13	by	O	O
14	typical	O	O
15	dysmorphic	O	O
16	features	O	O
17	and	O	O
18	a	O	O
19	variable	O	O
20	but	O	O
21	constant	O	O
22	psychomotor	BI	O
23	and	II	O
24	mental	II	O
25	retardation	II	O
26	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	on	O	O
4	an	O	O
5	11½-year-old	O	O
6	child	O	O
7	with	O	O
8	myopia	O	O
9	Duane	BU	O
10	retraction	IU	O
11	syndrome	IU	O
12	bilateral	BI	O
13	mixed	II	O
14	hearing	II	O
15	loss	II	O
16	skeletal	O	O
17	anomalies	O	O
18	including	O	O
19	multiple	BU	O
20	epiphyseal	IU	O
21	dysplasia	IU	O
22	and	O	O
23	global	BI	O
24	developmental	II	O
25	delay	II	O
26	and	O	O
27	a	O	O
28	complex	O	O
29	6p25	O	O
30	genomic	O	O
31	rearrangement	O	O
32	.	O	O

0	Furthermore	O	O
1	we	O	O
2	evaluated	O	O
3	the	O	O
4	similarities	O	O
5	of	O	O
6	SMS	BU	O
7	adult	O	O
8	food-related	O	O
9	behaviors	O	O
10	to	O	O
11	those	O	O
12	with	O	O
13	intellectual	BI	O
14	disability	II	O
15	and	O	O
16	found	O	O
17	that	O	O
18	SMS	BU	O
19	adults	O	O
20	had	O	O
21	more	O	O
22	severe	BI	O
23	behavioral	II	O
24	problems	II	O
25	.	O	O

0	Toddlers	O	O
1	with	O	O
2	triple	BU	O
3	X	IU	O
4	syndrome	IU	O
5	show	O	O
6	delayed	BI	O
7	language	II	O
8	development	II	O
9	.	O	O

0	We	O	O
1	explored	O	O
2	the	O	O
3	clinical	O	O
4	presentation	O	O
5	of	O	O
6	patients	O	O
7	with	O	O
8	a	O	O
9	very	O	O
10	short	O	O
11	4q35	O	O
12	fragment	O	O
13	10-13	O	O
14	kb	O	O
15	focusing	O	O
16	on	O	O
17	hearing	BI	O
18	loss	II	O
19	a	O	O
20	still	O	O
21	debated	O	O
22	FSHD	BU	O
23	extra-muscular	O	O
24	manifestation	O	O
25	.	O	O

0	Two	O	O
1	affected	O	O
2	females	O	O
3	manifest	O	O
4	moderate	BI	O
5	mental	II	O
6	retardation	II	O
7	and	O	O
8	psychotic	O	O
9	symptoms	O	O
10	such	O	O
11	as	O	O
12	delusion	O	O
13	of	O	O
14	persecution	O	O
15	auditory	O	O
16	hallucination	O	O
17	self-talking	O	O
18	and	O	O
19	self-laughing	O	O
20	which	O	O
21	are	O	O
22	rare	O	O
23	in	O	O
24	cri-du-chat	BU	O
25	syndrome	IU	O
26	.	O	O

0	In	O	O
1	addition	O	O
2	gait	BI	O
3	disturbance	II	O
4	low	O	O
5	back	O	O
6	pain	O	O
7	and	O	O
8	alopecia	BU	O
9	are	O	O
10	characteristic	O	O
11	features	O	O
12	.	O	O

0	AGR	O	O
1	syndrome	O	O
2	the	O	O
3	clinical	O	O
4	triad	O	O
5	of	O	O
6	aniridia	BU	O
7	genitourinary	O	O
8	anomalies	O	O
9	and	O	O
10	mental	BI	O
11	retardation	II	O
12	a	O	O
13	subgroup	O	O
14	of	O	O
15	WAGR	BU	O
16	syndrome	IU	O
17	for	O	O
18	Wilms	O	O
19	tumor	O	O
20	aniridia	BU	O
21	genitourinary	O	O
22	anomalies	O	O
23	and	O	O
24	mental	BI	O
25	retardation	II	O
26	is	O	O
27	a	O	O
28	rare	O	O
29	syndrome	O	O
30	caused	O	O
31	by	O	O
32	a	O	O
33	contiguous	O	O
34	gene	O	O
35	deletion	O	O
36	in	O	O
37	the	O	O
38	11p13-14	O	O
39	region	O	O
40	.	O	O

0	The	O	O
1	authors	O	O
2	highlight	O	O
3	the	O	O
4	importance	O	O
5	of	O	O
6	suspecting	O	O
7	HD	BU	O
8	in	O	O
9	the	O	O
10	aetiology	O	O
11	of	O	O
12	spinocerebellar	BI	O
13	ataxias	II	O
14	when	O	O
15	dementia	BI	O
16	is	O	O
17	a	O	O
18	prominent	O	O
19	feature	O	O
20	in	O	O
21	the	O	O
22	proband	O	O
23	or	O	O
24	their	O	O
25	family	O	O
26	.	O	O

0	Based	O	O
1	on	O	O
2	these	O	O
3	data	O	O
4	we	O	O
5	propose	O	O
6	a	O	O
7	phenotype	O	O
8	map	O	O
9	for	O	O
10	several	O	O
11	clinical	O	O
12	features	O	O
13	of	O	O
14	the	O	O
15	18p-	BU	O
16	syndrome	IU	O
17	Round	O	O
18	face	O	O
19	was	O	O
20	tentatively	O	O
21	mapped	O	O
22	to	O	O
23	the	O	O
24	distal	O	O
25	1.6	O	O
26	Mb	O	O
27	of	O	O
28	18p	O	O
29	post-natal	BI	O
30	growth	II	O
31	retardation	II	O
32	and	O	O
33	seizures	O	O
34	to	O	O
35	the	O	O
36	distal	O	O
37	8	O	O
38	Mb	O	O
39	and	O	O
40	ptosis	BU	O
41	and	O	O
42	short	O	O
43	neck	O	O
44	to	O	O
45	the	O	O
46	proximal	O	O
47	half	O	O
48	of	O	O
49	18p	O	O
50	.	O	O

0	The	O	O
1	90	O	O
2	kDa	O	O
3	ribosomal	O	O
4	S6	O	O
5	serine	O	O
6	threonine	O	O
7	kinase	O	O
8	2	O	O
9	gene	O	O
10	RSK2	O	O
11	U08316	O	O
12	has	O	O
13	been	O	O
14	recently	O	O
15	identified	O	O
16	as	O	O
17	a	O	O
18	disease-causing	O	O
19	gene	O	O
20	in	O	O
21	an	O	O
22	X-linked	O	O
23	disorder	O	O
24	the	O	O
25	Coffin-Lowry	BU	O
26	Syndrome	IU	O
27	MIM	O	O
28	303600	O	O
29	characterized	O	O
30	by	O	O
31	severe	BI	O
32	mental	II	O
33	retardation	II	O
34	facial	O	O
35	dysmorphisms	O	O
36	and	O	O
37	progressive	O	O
38	skeletal	O	O
39	malformations	O	O
40	.	O	O

0	SMS	BU	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	subtle	O	O
5	facial	O	O
6	dysmorphology	O	O
7	short	O	O
8	stature	O	O
9	sleep	BI	O
10	disturbances	II	O
11	and	O	O
12	neurobehavioral	O	O
13	abnormalities	O	O
14	.	O	O

0	Greater	O	O
1	monitoring	O	O
2	deficits	O	O
3	were	O	O
4	apparent	O	O
5	in	O	O
6	frontotemporal	BI	O
7	dementia	II	O
8	than	O	O
9	in	O	O
10	Alzheimers	O	O
11	disease	O	O
12	and	O	O
13	participants	O	O
14	with	O	O
15	frontotemporal	BU	O
16	dementia	IU	O
17	were	O	O
18	less	O	O
19	likely	O	O
20	to	O	O
21	utilize	O	O
22	task	O	O
23	experience	O	O
24	to	O	O
25	update	O	O
26	and	O	O
27	improve	O	O
28	the	O	O
29	accuracy	O	O
30	of	O	O
31	subsequent	O	O
32	monitoring	O	O
33	judgments	O	O
34	.	O	O

0	PURPOSE	O	O
1	To	O	O
2	establish	O	O
3	the	O	O
4	zebrafish	O	O
5	platinum	O	O
6	mutant	O	O
7	as	O	O
8	a	O	O
9	model	O	O
10	for	O	O
11	studying	O	O
12	vision	BI	O
13	defects	II	O
14	caused	O	O
15	by	O	O
16	syndromic	O	O
17	albinism	O	O
18	diseases	O	O
19	such	O	O
20	as	O	O
21	Chediak-Higashi	BU	O
22	syndrome	IU	O
23	Griscelli	O	O
24	syndrome	O	O
25	and	O	O
26	Hermansky-Pudlak	BU	O
27	syndrome	IU	O
28	HPS	IU	O
29	.	O	O

0	The	O	O
1	absence	O	O
2	of	O	O
3	dysarthria	BI	O
4	and	O	O
5	ataxia	BI	O
6	retention	O	O
7	of	O	O
8	reflexes	O	O
9	absence	O	O
10	of	O	O
11	diabetes	O	O
12	and	O	O
13	variable	O	O
14	development	O	O
15	of	O	O
16	cardiomyopathy	BU	O
17	support	O	O
18	a	O	O
19	slow	O	O
20	progression	O	O
21	of	O	O
22	disease	O	O
23	with	O	O
24	compound	O	O
25	heterozygous	O	O
26	mutation	O	O
27	at	O	O
28	G130V	O	O
29	.	O	O

0	BACKGROUND	O	O
1	AND	O	O
2	PURPOSE	O	O
3	Recurrent	O	O
4	strokes	O	O
5	and	O	O
6	cognitive	BI	O
7	dysfunction	II	O
8	are	O	O
9	the	O	O
10	major	O	O
11	symptoms	O	O
12	of	O	O
13	cerebral	BU	O
14	autosomal	IU	O
15	dominant	IU	O
16	arteriopathy	IU	O
17	with	IU	O
18	subcortical	IU	O
19	infarcts	IU	O
20	and	IU	O
21	leukoencephalopathy	IU	O
22	CADASIL	IU	O
23	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	is	O	O
3	caused	O	O
4	by	O	O
5	a	O	O
6	deletion	O	O
7	of	O	O
8	the	O	O
9	distal	O	O
10	portion	O	O
11	of	O	O
12	the	O	O
13	short	O	O
14	arm	O	O
15	of	O	O
16	chromosome	O	O
17	4	O	O
18	and	O	O
19	is	O	O
20	characterized	O	O
21	by	O	O
22	psychomotor	BI	O
23	retardation	II	O
24	seizures	O	O
25	congenital	O	O
26	malformations	O	O
27	and	O	O
28	typical	O	O
29	facial	O	O
30	appearance	O	O
31	including	O	O
32	Greek	O	O
33	warrior	O	O
34	helmet	O	O
35	appearance	O	O
36	of	O	O
37	the	O	O
38	nose	O	O
39	.	O	O

0	Cerebral	O	O
1	malformations	O	O
2	ventricular	O	O
3	hypertrophy	O	O
4	increased	O	O
5	subarachnoid	O	O
6	space	O	O
7	morphological	O	O
8	alterations	O	O
9	of	O	O
10	corpus	O	O
11	callosum	O	O
12	cortical	BI	O
13	atrophy	II	O
14	delays	O	O
15	in	O	O
16	myelinisation	O	O
17	periventricular	BU	O
18	leukomalacia	IU	O
19	and	O	O
20	periventricular	O	O
21	heterotopia	O	O
22	.	O	O

0	Six	O	O
1	cases	O	O
2	of	O	O
3	the	O	O
4	CHARGE	BU	O
5	association	IU	O
6	are	O	O
7	described	O	O
8	that	O	O
9	were	O	O
10	encountered	O	O
11	consecutively	O	O
12	at	O	O
13	an	O	O
14	institute	O	O
15	for	O	O
16	the	O	O
17	deaf	BI	O
18	.	O	O

0	BACKGROUND	O	O
1	Dentatorubropallidoluysian	BU	O
2	atrophy	IU	O
3	DRPLA	O	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	autosomal	O	O
8	dominant	O	O
9	neurodegenerative	O	O
10	disease	O	O
11	that	O	O
12	is	O	O
13	associated	O	O
14	with	O	O
15	numerous	O	O
16	movement	BI	O
17	disorders	II	O
18	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	patient	O	O
4	with	O	O
5	non-Down	O	O
6	syndrome	O	O
7	AML	O	O
8	also	O	O
9	known	O	O
10	as	O	O
11	AMKL	BU	O
12	with	O	O
13	monosomy	O	O
14	7	O	O
15	who	O	O
16	was	O	O
17	also	O	O
18	obese	O	O
19	and	O	O
20	had	O	O
21	a	O	O
22	hearing	BI	O
23	impairment	II	O
24	and	O	O
25	mental	BI	O
26	retardation	II	O
27	.	O	O

0	Less	O	O
1	common	O	O
2	clinical	O	O
3	features	O	O
4	include	O	O
5	ocular	BI	O
6	anomalies	II	O
7	craniosynostosis	BU	O
8	mild	BI	O
9	intellectual	II	O
10	disability	II	O
11	and	O	O
12	choanal	BU	O
13	atresia	IU	O
14	.	O	O

0	Developmental	BI	O
1	regression	II	O
2	and	O	O
3	refractory	O	O
4	focal	O	O
5	motor	O	O
6	or	O	O
7	myoclonic	O	O
8	seizures	O	O
9	are	O	O
10	consistent	O	O
11	clinical	O	O
12	features	O	O
13	of	O	O
14	Alpers	BU	O
15	syndrome	IU	O
16	with	O	O
17	polymerase-	O	O
18	mutations	O	O
19	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	a	O	O
5	complex	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	numerous	O	O
10	challenges	O	O
11	including	O	O
12	intellectual	BI	O
13	disability	II	O
14	speech	BI	O
15	delay	II	O
16	decreased	O	O
17	pain	O	O
18	sensitivity	O	O
19	sleep	BI	O
20	disturbances	II	O
21	hyperactivity	BI	O
22	mood	O	O
23	instability	O	O
24	and	O	O
25	self-injury	O	O
26	.	O	O

0	Norrie	BU	O
1	disease	IU	O
2	is	O	O
3	an	O	O
4	X-linked	O	O
5	recessive	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	congenital	BI	O
10	blindness	II	O
11	and	O	O
12	in	O	O
13	some	O	O
14	cases	O	O
15	mental	BI	O
16	retardation	II	O
17	and	O	O
18	deafness	BI	O
19	.	O	O

0	Terminal	O	O
1	or	O	O
2	interstitial	O	O
3	deletion	O	O
4	on	O	O
5	the	O	O
6	short	O	O
7	arm	O	O
8	of	O	O
9	chromosome	O	O
10	5	O	O
11	is	O	O
12	associated	O	O
13	with	O	O
14	a	O	O
15	genetic	O	O
16	disorder	O	O
17	cri-du-chat	BU	O
18	syndrome	IU	O
19	cat	O	O
20	cry	O	O
21	syndrome	O	O
22	which	O	O
23	is	O	O
24	characterized	O	O
25	by	O	O
26	a	O	O
27	cat-like	O	O
28	cry	O	O
29	in	O	O
30	infancy	O	O
31	facial	O	O
32	dysmorphism	O	O
33	microcephaly	O	O
34	and	O	O
35	mental	BI	O
36	retardation	II	O
37	.	O	O

0	Sensorineural	BI	O
1	hearing	II	O
2	loss	II	O
3	is	O	O
4	a	O	O
5	common	O	O
6	symptom	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	myoclonic	BU	O
11	epilepsy	IU	O
12	associated	IU	O
13	with	IU	O
14	ragged-red	IU	O
15	fibres	IU	O
16	MERRF	O	O
17	one	O	O
18	of	O	O
19	the	O	O
20	mitochondrial	O	O
21	encephalomyopathies	O	O
22	although	O	O
23	the	O	O
24	lesion	O	O
25	causing	O	O
26	hearing	O	O
27	loss	O	O
28	in	O	O
29	such	O	O
30	cases	O	O
31	remains	O	O
32	unknown	O	O
33	.	O	O

0	The	O	O
1	Roussy-Lévy	BU	O
2	syndrome	IU	O
3	MIM	O	O
4	#180800	O	O
5	was	O	O
6	described	O	O
7	in	O	O
8	1926	O	O
9	as	O	O
10	a	O	O
11	disorder	O	O
12	presenting	O	O
13	with	O	O
14	pes	O	O
15	cavus	O	O
16	and	O	O
17	tendon	O	O
18	areflexia	O	O
19	distal	O	O
20	limb	O	O
21	weakness	O	O
22	tremor	O	O
23	in	O	O
24	the	O	O
25	upper	O	O
26	limbs	O	O
27	gait	BI	O
28	ataxia	II	O
29	and	O	O
30	distal	BI	O
31	sensory	II	O
32	loss	II	O
33	.	O	O

0	Owing	O	O
1	to	O	O
2	the	O	O
3	unknown	O	O
4	pathogenesis	O	O
5	of	O	O
6	the	O	O
7	progressive	BI	O
8	hearing	II	O
9	loss	II	O
10	seen	II	O
11	in	O	O
12	CINCA	BU	O
13	syndrome	IU	O
14	and	IU	O
15	the	O	O
16	limited	O	O
17	effectiveness	O	O
18	of	O	O
19	anakinra	O	O
20	in	O	O
21	reversing	O	O
22	the	O	O
23	progressive	BI	O
24	hearing	II	O
25	loss	II	O
26	we	O	O
27	suggest	O	O
28	that	O	O
29	cochlear	O	O
30	implantation	O	O
31	is	O	O
32	the	O	O
33	modality	O	O
34	of	O	O
35	choice	O	O
36	in	O	O
37	rehabilitating	O	O
38	severe-to-profound	BI	O
39	hearing	II	O
40	loss	II	O
41	not	II	O
42	responsive	O	O
43	to	O	O
44	anakinra	O	O
45	.	O	O

0	BACKGROUND	O	O
1	The	O	O
2	classic	O	O
3	form	O	O
4	of	O	O
5	Chédiak-Higashi	BU	O
6	syndrome	IU	O
7	CHS	IU	O
8	an	O	O
9	autosomal	O	O
10	recessive	O	O
11	disorder	O	O
12	of	O	O
13	lysosomal	O	O
14	trafficking	O	O
15	with	O	O
16	childhood	O	O
17	onset	O	O
18	caused	O	O
19	by	O	O
20	mutations	O	O
21	in	O	O
22	ITALIC!	O	O
23	LYST	O	O
24	is	O	O
25	typified	O	O
26	ophthalmologically	O	O
27	by	O	O
28	ocular	BU	O
29	albinism	IU	O
30	with	O	O
31	vision	BI	O
32	loss	II	O
33	attributed	O	O
34	to	O	O
35	foveal	O	O
36	hypoplasia	O	O
37	or	O	O
38	nystagmus	O	O
39	.	O	O

0	BACKGROUND	O	O
1	Cognitive	BI	O
2	impairment	II	O
3	has	O	O
4	been	O	O
5	reported	O	O
6	in	O	O
7	a	O	O
8	significant	O	O
9	proportion	O	O
10	of	O	O
11	patients	O	O
12	with	O	O
13	congenital	BU	O
14	muscular	IU	O
15	dystrophies	IU	O
16	CMD	IU	O
17	generally	O	O
18	associated	O	O
19	with	O	O
20	brain	O	O
21	changes	O	O
22	.	O	O

0	Both	O	O
1	disorders	O	O
2	cause	O	O
3	developmental	BI	O
4	delay	II	O
5	and	O	O
6	ISSD	BU	O
7	is	O	O
8	generally	O	O
9	fatal	O	O
10	in	O	O
11	early	O	O
12	childhood	O	O
13	.	O	O

0	All	O	O
1	patients	O	O
2	had	O	O
3	osteopetrosis	BU	O
4	renal	O	O
5	tubular	O	O
6	acidosis	O	O
7	developmental	BI	O
8	delay	II	O
9	short	O	O
10	stature	O	O
11	and	O	O
12	craniofacial	O	O
13	disproportion	O	O
14	with	O	O
15	large	O	O
16	cranial	O	O
17	vault	O	O
18	and	O	O
19	broad	O	O
20	forehead	O	O
21	.	O	O

0	Hearing	BI	O
1	impairment	II	O
2	in	O	O
3	MWS	BU	O
4	is	O	O
5	variable	O	O
6	and	O	O
7	shows	O	O
8	resemblance	O	O
9	to	O	O
10	previously	O	O
11	described	O	O
12	intra-cochlear	BI	O
13	conductive	II	O
14	hearing	II	O
15	impairment	II	O
16	.	O	O

0	Refsums	BU	O
1	disease	IU	O
2	is	O	O
3	a	O	O
4	disorder	O	O
5	of	O	O
6	lipid	O	O
7	metabolism	O	O
8	with	O	O
9	pigmentary	O	O
10	retinopathy	O	O
11	demyelinating	O	O
12	neuropathy	O	O
13	ataxia	BI	O
14	and	O	O
15	hearing	BI	O
16	loss	II	O
17	.	O	O

0	For	O	O
1	conscripted	O	O
2	individuals	O	O
3	with	O	O
4	Darier	BU	O
5	disease	IU	O
6	but	O	O
7	no	O	O
8	diagnosed	O	O
9	intellectual	BI	O
10	disability	II	O
11	mean	O	O
12	cognitive	O	O
13	ability	O	O
14	scores	O	O
15	were	O	O
16	about	O	O
17	half	O	O
18	a	O	O
19	standard	O	O
20	deviation	O	O
21	lower	O	O
22	than	O	O
23	for	O	O
24	comparison	O	O
25	subjects	O	O
26	.	O	O

0	Leber	BU	O
1	hereditary	IU	O
2	optic	IU	O
3	neuropathy	IU	O
4	LHON	IU	O
5	is	O	O
6	caused	O	O
7	by	O	O
8	point	O	O
9	mutations	O	O
10	in	O	O
11	mitochondrial	O	O
12	DNA	O	O
13	mtDNA	O	O
14	and	O	O
15	is	O	O
16	characterized	O	O
17	by	O	O
18	bilateral	BI	O
19	painless	II	O
20	sub-acute	II	O
21	visual	II	O
22	loss	II	O
23	that	O	O
24	develops	O	O
25	during	O	O
26	the	O	O
27	second	O	O
28	decade	O	O
29	of	O	O
30	life	O	O
31	.	O	O

0	A	O	O
1	woman	O	O
2	with	O	O
3	psychomotor	BI	O
4	developmental	II	O
5	delay	II	O
6	congenital	BU	O
7	glaucoma	IU	O
8	and	O	O
9	distinctive	O	O
10	facial	O	O
11	features	O	O
12	and	O	O
13	a	O	O
14	short	O	O
15	neck	O	O
16	was	O	O
17	diagnosed	O	O
18	with	O	O
19	Jacobsen	BU	O
20	syndrome	IU	O
21	JBS	IU	O
22	at	O	O
23	age	O	O
24	40	O	O
25	years	O	O
26	.	O	O

0	Unlike	O	O
1	many	O	O
2	pathogenic	O	O
3	mitochondrial	O	O
4	DNA	O	O
5	mutations	O	O
6	the	O	O
7	T8993G	O	O
8	mutation	O	O
9	associated	O	O
10	with	O	O
11	Leigh	BU	O
12	syndrome	IU	O
13	LS	IU	O
14	and	O	O
15	neurogenic	O	O
16	muscle	O	O
17	weakness	O	O
18	ataxia	BI	O
19	retinitis	BU	O
20	pigmentosa	IU	O
21	NARP	O	O
22	typically	O	O
23	shows	O	O
24	little	O	O
25	variation	O	O
26	in	O	O
27	mutant	O	O
28	load	O	O
29	between	O	O
30	different	O	O
31	tissue	O	O
32	types	O	O
33	.	O	O

0	OBJECTIVES	O	O
1	Autosomal	O	O
2	recessive	O	O
3	long	BU	O
4	QT	IU	O
5	syndrome	IU	O
6	LQTS	O	O
7	or	O	O
8	Jervell	BU	O
9	and	IU	O
10	Lange-Nielsen	IU	O
11	syndrome	IU	O
12	JLNS	IU	O
13	can	O	O
14	be	O	O
15	associated	O	O
16	with	O	O
17	sensorineural	BI	O
18	hearing	II	O
19	loss	II	O
20	.	O	O

0	A	O	O
1	previous	O	O
2	study	O	O
3	in	O	O
4	proximal	O	O
5	myotonic	O	O
6	myopathy	O	O
7	PROMM	O	O
8	DM-2	O	O
9	and	O	O
10	myotonic	BU	O
11	dystrophy	IU	O
12	type	IU	O
13	1	IU	O
14	DM-1	O	O
15	using	O	O
16	brain	O	O
17	positron	O	O
18	emission	O	O
19	tomography	O	O
20	demonstrated	O	O
21	a	O	O
22	reduced	O	O
23	cerebral	O	O
24	blood	O	O
25	flow	O	O
26	in	O	O
27	the	O	O
28	frontal	O	O
29	and	O	O
30	temporal	O	O
31	regions	O	O
32	associated	O	O
33	with	O	O
34	cognitive	BI	O
35	impairment	II	O
36	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	WHS	IU	O
3	is	O	O
4	a	O	O
5	rare	BI	O
6	developmental	II	O
7	disorder	II	O
8	associated	O	O
9	with	O	O
10	hemizygous	O	O
11	deletion	O	O
12	of	O	O
13	short	O	O
14	arm	O	O
15	of	O	O
16	chromosome	O	O
17	4	O	O
18	.	O	O

0	Germline	O	O
1	missense	O	O
2	mutations	O	O
3	of	O	O
4	PTPN11	O	O
5	are	O	O
6	found	O	O
7	in	O	O
8	more	O	O
9	than	O	O
10	half	O	O
11	of	O	O
12	patients	O	O
13	with	O	O
14	Noonan	BU	O
15	syndrome	IU	O
16	NS	IU	O
17	and	O	O
18	LEOPARD	BU	O
19	syndrome	IU	O
20	LS	IU	O
21	both	O	O
22	of	O	O
23	which	O	O
24	are	O	O
25	congenital	BI	O
26	developmental	II	O
27	disorders	II	O
28	with	O	O
29	multiple	O	O
30	common	O	O
31	symptoms	O	O
32	.	O	O

0	Postlingual	BI	O
1	progressive	II	O
2	hearing	II	O
3	loss	II	O
4	is	O	O
5	found	O	O
6	as	O	O
7	an	O	O
8	isolated	O	O
9	feature	O	O
10	in	O	O
11	DFN2	BU	O
12	patients	O	O
13	.	O	O

0	Recently	O	O
1	the	O	O
2	EFTUD2	O	O
3	gene	O	O
4	was	O	O
5	identified	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	mandibulofacial	BU	O
10	dysostosis	IU	O
11	associated	O	O
12	with	O	O
13	microcephaly	O	O
14	intellectual	BI	O
15	disability	II	O
16	and	O	O
17	esophageal	BU	O
18	atresia	IU	O
19	.	O	O

0	Congenital	BU	O
1	hypothyroidism	IU	O
2	is	O	O
3	associated	O	O
4	with	O	O
5	delay	O	O
6	in	O	O
7	cell	O	O
8	migration	O	O
9	and	O	O
10	proliferation	O	O
11	in	O	O
12	brain	O	O
13	tissue	O	O
14	impairment	O	O
15	of	O	O
16	synapse	O	O
17	formation	O	O
18	misregulation	O	O
19	of	O	O
20	neurotransmitters	O	O
21	hypomyelination	O	O
22	and	O	O
23	mental	BI	O
24	retardation	II	O
25	.	O	O

0	Expected	O	O
1	CdCs	O	O
2	features	O	O
3	that	O	O
4	are	O	O
5	not	O	O
6	present	O	O
7	are	O	O
8	growth	BI	O
9	delay	II	O
10	microcephaly	O	O
11	round	O	O
12	facies	O	O
13	micrognathia	O	O
14	epicanthal	BU	O
15	folds	IU	O
16	and	O	O
17	the	O	O
18	signature	O	O
19	high-pitched	O	O
20	cry	O	O
21	.	O	O

0	Manifestations	O	O
1	include	O	O
2	severe	BI	O
3	developmental	II	O
4	delay	II	O
5	rounded	O	O
6	face	O	O
7	sparse	O	O
8	hair	O	O
9	ear	O	O
10	anomalies	O	O
11	hypertelorism	O	O
12	cleft	BU	O
13	soft	IU	O
14	palate	IU	O
15	a	O	O
16	thin	O	O
17	vermilion	O	O
18	border	O	O
19	of	O	O
20	the	O	O
21	upper	O	O
22	lip	O	O
23	and	O	O
24	left	O	O
25	renal	O	O
26	dysgenesis	O	O
27	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	O	O
3	OMIM	O	O
4	303600	O	O
5	is	O	O
6	an	O	O
7	X-linked	O	O
8	inherited	O	O
9	disorder	O	O
10	characterised	O	O
11	in	O	O
12	male	O	O
13	patients	O	O
14	by	O	O
15	growth	BI	O
16	and	II	O
17	psychomotor	II	O
18	retardation	II	O
19	hypotonia	O	O
20	and	O	O
21	progressive	O	O
22	skeletal	O	O
23	changes	O	O
24	.	O	O

0	Frontotemporal	BU	O
1	dementia	IU	O
2	is	O	O
3	an	O	O
4	umbrella	O	O
5	clinical	O	O
6	term	O	O
7	that	O	O
8	encompasses	O	O
9	a	O	O
10	group	O	O
11	of	O	O
12	neurodegenerative	O	O
13	diseases	O	O
14	characterised	O	O
15	by	O	O
16	progressive	BI	O
17	deficits	II	O
18	in	II	O
19	behaviour	II	O
20	executive	II	O
21	function	II	O
22	or	II	O
23	language	II	O
24	.	O	O

0	Lujan	BU	O
1	Lujan-Fryns	IU	O
2	syndrome	IU	O
3	is	O	O
4	characterised	O	O
5	by	O	O
6	tall	O	O
7	stature	O	O
8	with	O	O
9	asthenic	O	O
10	habitus	O	O
11	macrocephaly	O	O
12	a	O	O
13	tall	O	O
14	narrow	O	O
15	face	O	O
16	maxillary	O	O
17	hypoplasia	O	O
18	a	O	O
19	high	O	O
20	narrow	O	O
21	palate	O	O
22	with	O	O
23	dental	O	O
24	crowding	O	O
25	a	O	O
26	small	O	O
27	or	O	O
28	receding	O	O
29	chin	O	O
30	long	O	O
31	hands	O	O
32	with	O	O
33	hyperextensible	O	O
34	digits	O	O
35	hypernasal	O	O
36	speech	O	O
37	hypotonia	O	O
38	mild-to-moderate	BI	O
39	mental	II	O
40	retardation	II	O
41	behavioural	BI	O
42	aberrations	II	O
43	and	O	O
44	dysgenesis	O	O
45	of	O	O
46	the	O	O
47	corpus	O	O
48	callosum	O	O
49	.	O	O

0	Children	O	O
1	with	O	O
2	DD	BU	O
3	experience	O	O
4	both	O	O
5	growth	BI	O
6	and	II	O
7	motor	II	O
8	developmental	II	O
9	delays	II	O
10	.	O	O

0	Although	O	O
1	the	O	O
2	phenotypic	O	O
3	features	O	O
4	of	O	O
5	the	O	O
6	patient	O	O
7	including	O	O
8	psychomotor	BI	O
9	developmental	II	O
10	delay	II	O
11	distinctive	O	O
12	features	O	O
13	and	O	O
14	mild	O	O
15	thrombocytopenia	O	O
16	were	O	O
17	consistent	O	O
18	with	O	O
19	JBS	O	O
20	congenital	BU	O
21	glaucoma	IU	O
22	which	O	O
23	is	O	O
24	an	O	O
25	uncommon	O	O
26	finding	O	O
27	of	O	O
28	JBS	O	O
29	was	O	O
30	the	O	O
31	most	O	O
32	prominent	O	O
33	condition	O	O
34	during	O	O
35	her	O	O
36	natural	O	O
37	history	O	O
38	.	O	O

0	Mitofusin-2	O	O
1	gene	O	O
2	MFN2	O	O
3	mutations	O	O
4	cause	O	O
5	Charcot-Marie-Tooth	BU	O
6	type	IU	O
7	2A	IU	O
8	CMT2A	IU	O
9	sometimes	O	O
10	complicated	O	O
11	by	O	O
12	additional	O	O
13	features	O	O
14	such	O	O
15	as	O	O
16	optic	BI	O
17	atrophy	II	O
18	hearing	BI	O
19	loss	II	O
20	upper	O	O
21	motor	O	O
22	neuron	O	O
23	signs	O	O
24	and	O	O
25	cerebral	O	O
26	white-matter	O	O
27	abnormalities	O	O
28	.	O	O

0	This	O	O
1	report	O	O
2	describes	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	mild	BI	O
7	language	II	O
8	delay	II	O
9	and	O	O
10	mental	BI	O
11	retardation	II	O
12	who	O	O
13	was	O	O
14	found	O	O
15	to	O	O
16	have	O	O
17	nonketotic	BU	O
18	hyperglycinemia	IU	O
19	following	O	O
20	her	O	O
21	presentation	O	O
22	with	O	O
23	acute	O	O
24	encephalopathy	O	O
25	and	O	O
26	chorea	O	O
27	shortly	O	O
28	after	O	O
29	initiation	O	O
30	of	O	O
31	valproate	O	O
32	therapy	O	O
33	.	O	O

0	1p36	BU	O
1	deletion	IU	O
2	syndrome	IU	O
3	is	O	O
4	reported	O	O
5	in	O	O
6	1	O	O
7	in	O	O
8	5000-10000	O	O
9	newborns	O	O
10	and	O	O
11	its	O	O
12	characteristic	O	O
13	clinical	O	O
14	features	O	O
15	include	O	O
16	developmental	BI	O
17	delay	II	O
18	mental	BI	O
19	retardation	II	O
20	hypotonia	O	O
21	congenital	O	O
22	heart	O	O
23	defects	O	O
24	seizure	O	O
25	and	O	O
26	facial	O	O
27	dysmorphism	O	O
28	.	O	O

0	Recently	O	O
1	mutations	O	O
2	in	O	O
3	the	O	O
4	SLC16A2	O	O
5	gene	O	O
6	coding	O	O
7	for	O	O
8	the	O	O
9	monocarboxylate	O	O
10	thyroid	O	O
11	hormone	O	O
12	transporter	O	O
13	8	O	O
14	MCT8	O	O
15	have	O	O
16	been	O	O
17	associated	O	O
18	with	O	O
19	Allan-Herndon-Dudley	BU	O
20	syndrome	IU	O
21	AHDS	IU	O
22	an	O	O
23	X-linked	O	O
24	condition	O	O
25	characterized	O	O
26	by	O	O
27	severe	BI	O
28	mental	II	O
29	retardation	II	O
30	dysarthria	BI	O
31	athetoid	BI	O
32	movements	II	O
33	muscle	O	O
34	hypoplasia	O	O
35	and	O	O
36	spastic	BI	O
37	paraplegia	II	O
38	.	O	O

0	CINCA	BU	O
1	syndrome	IU	O
2	is	O	O
3	also	O	O
4	associated	O	O
5	with	O	O
6	sensory	O	O
7	organ	O	O
8	damage	O	O
9	especially	O	O
10	progressive	BI	O
11	hearing	II	O
12	loss	II	O
13	and	O	O
14	loss	BI	O
15	of	II	O
16	vision	II	O
17	.	O	O

0	We	O	O
1	review	O	O
2	articles	O	O
3	examining	O	O
4	metacognitive	O	O
5	comparisons	O	O
6	between	O	O
7	two	O	O
8	of	O	O
9	the	O	O
10	most	O	O
11	common	O	O
12	dementia	BI	O
13	subtypes	O	O
14	Alzheimers	O	O
15	disease	O	O
16	and	O	O
17	frontotemporal	BU	O
18	dementia	IU	O
19	.	O	O

0	We	O	O
1	hypothesized	O	O
2	that	O	O
3	BDNF+	O	O
4	would	O	O
5	be	O	O
6	associated	O	O
7	with	O	O
8	more	O	O
9	severe	BI	O
10	cognitive	II	O
11	impairment	II	O
12	in	II	O
13	subjects	O	O
14	with	O	O
15	WAGR	BU	O
16	syndrome	IU	O
17	.	IU	O

0	Patients	O	O
1	with	O	O
2	mutations	O	O
3	in	O	O
4	KCNQ1	O	O
5	may	O	O
6	show	O	O
7	only	O	O
8	the	O	O
9	cardiac	O	O
10	defect	O	O
11	Romano-Ward	O	O
12	syndrome	O	O
13	or	O	O
14	RWS	O	O
15	or	O	O
16	may	O	O
17	also	O	O
18	have	O	O
19	severe	BI	O
20	deafness	II	O
21	Jervell	BU	O
22	and	IU	O
23	Lange-Nielsen	IU	O
24	syndrome	IU	O
25	or	O	O
26	JLNS	O	O
27	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	was	O	O
3	delineated	O	O
4	based	O	O
5	on	O	O
6	its	O	O
7	distinctive	O	O
8	phenotype	O	O
9	including	O	O
10	severe	O	O
11	failure-to-thrive	O	O
12	with	O	O
13	macrocephaly	O	O
14	characteristic	O	O
15	facial	O	O
16	features	O	O
17	hypertrophic	BU	O
18	cardiomyopathy	IU	O
19	papillomata	O	O
20	malignant	O	O
21	tumors	O	O
22	and	O	O
23	cognitive	BI	O
24	impairment	II	O
25	.	O	O

0	PURPOSE	O	O
1	To	O	O
2	investigate	O	O
3	severe	BI	O
4	unilateral	II	O
5	vision	II	O
6	loss	II	O
7	in	O	O
8	a	O	O
9	choroideremia	BU	O
10	carrier	O	O
11	.	O	O

0	Cockayne	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	multi-systemic	O	O
5	autosomal	O	O
6	recessive	O	O
7	disease	O	O
8	characterised	O	O
9	by	O	O
10	postnatal	BI	O
11	growth	II	O
12	failure	II	O
13	and	O	O
14	progressive	O	O
15	multi-organ	O	O
16	dysfunction	O	O
17	.	O	O

0	In	O	O
1	this	O	O
2	review	O	O
3	we	O	O
4	discuss	O	O
5	Nf1	O	O
6	fly	O	O
7	and	O	O
8	mouse	O	O
9	systems	O	O
10	that	O	O
11	mimic	O	O
12	many	O	O
13	of	O	O
14	the	O	O
15	cognitive	BI	O
16	abnormalities	II	O
17	seen	O	O
18	in	O	O
19	children	O	O
20	with	O	O
21	NF1	BU	O
22	.	O	O

0	Patients	O	O
1	were	O	O
2	cognitively	O	O
3	classified	O	O
4	as	O	O
5	having	O	O
6	ALS	BU	O
7	with	O	O
8	normal	O	O
9	cognition	O	O
10	ALS	BU	O
11	with	O	O
12	frontotemporal	BU	O
13	dementia	IU	O
14	FTD	IU	O
15	ALS	BU	O
16	with	O	O
17	executive	O	O
18	or	O	O
19	nonexecutive	O	O
20	impairment	O	O
21	and	O	O
22	ALS	BU	O
23	with	O	O
24	behavioral	BI	O
25	impairment	II	O
26	.	O	O

0	Trisomy	BU	O
1	18	IU	O
2	is	O	O
3	frequently	O	O
4	associated	O	O
5	with	O	O
6	neurologic	O	O
7	abnormalities	O	O
8	including	O	O
9	hypotonia	O	O
10	in	O	O
11	infancy	O	O
12	mental	BI	O
13	retardation	II	O
14	central	O	O
15	apnea	O	O
16	and	O	O
17	epilepsy	O	O
18	.	O	O

0	Three	O	O
1	different	O	O
2	genes	O	O
3	of	O	O
4	the	O	O
5	glycosylphosphatidylinositol	O	O
6	anchor	O	O
7	synthesis	O	O
8	pathway	O	O
9	PIGV	O	O
10	PIGO	O	O
11	and	O	O
12	PGAP2	O	O
13	have	O	O
14	recently	O	O
15	been	O	O
16	implicated	O	O
17	in	O	O
18	hyperphosphatasia-mental	BU	O
19	retardation	IU	O
20	syndrome	IU	O
21	HPMRS	IU	O
22	also	O	O
23	known	O	O
24	as	O	O
25	Mabry	BU	O
26	syndrome	IU	O
27	a	O	O
28	rare	O	O
29	autosomal	O	O
30	recessive	O	O
31	form	O	O
32	of	O	O
33	intellectual	BI	O
34	disability	II	O
35	.	O	O

0	Because	O	O
1	Danon	BU	O
2	disease	IU	O
3	is	O	O
4	inherited	O	O
5	in	O	O
6	an	O	O
7	X-linked	O	O
8	dominant	O	O
9	fashion	O	O
10	males	O	O
11	are	O	O
12	more	O	O
13	severely	O	O
14	affected	O	O
15	than	O	O
16	females	O	O
17	who	O	O
18	usually	O	O
19	have	O	O
20	only	O	O
21	cardiomyopathy	BU	O
22	without	O	O
23	myopathy	O	O
24	or	O	O
25	intellectual	BI	O
26	disability	II	O
27	moreover	O	O
28	the	O	O
29	onset	O	O
30	of	O	O
31	symptoms	O	O
32	in	O	O
33	females	O	O
34	is	O	O
35	usually	O	O
36	in	O	O
37	adulthood	O	O
38	.	O	O

0	The	O	O
1	PUBMED	O	O
2	PsycInfo	O	O
3	SCIELO	O	O
4	and	O	O
5	LILACS	O	O
6	electronic	O	O
7	databases	O	O
8	were	O	O
9	used	O	O
10	and	O	O
11	the	O	O
12	following	O	O
13	search	O	O
14	terms	O	O
15	were	O	O
16	employed	O	O
17	CMT	BU	O
18	HMSN	O	O
19	hereditary	BU	O
20	motor	IU	O
21	and	IU	O
22	sensory	IU	O
23	neuropathy	IU	O
24	mental	BI	O
25	disorder	II	O
26	quality	O	O
27	of	O	O
28	life	O	O
29	psychiatry	O	O
30	psychiatric	O	O
31	and	O	O
32	psychological	O	O
33	without	O	O
34	the	O	O
35	use	O	O
36	of	O	O
37	time-limit	O	O
38	filters	O	O
39	.	O	O

0	Shah-Waardenburg	O	O
1	syndrome	O	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	congenital	O	O
6	disorder	O	O
7	with	O	O
8	variable	O	O
9	clinical	O	O
10	expression	O	O
11	characterised	O	O
12	by	O	O
13	aganglionosis	O	O
14	of	O	O
15	the	O	O
16	rectosigmoïd	O	O
17	Hirschsprung	BU	O
18	disease	IU	O
19	and	O	O
20	abnormal	O	O
21	melanocyte	O	O
22	migration	O	O
23	resulting	O	O
24	in	O	O
25	pigmentary	O	O
26	abnormalities	O	O
27	and	O	O
28	sensorineural	BI	O
29	deafness	II	O
30	Waardenburg	BU	O
31	syndrome	IU	O
32	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	a	O	O
5	genetic	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	the	O	O
10	association	O	O
11	of	O	O
12	facial	O	O
13	dysmorphism	O	O
14	oral	BI	O
15	speech	II	O
16	delay	II	O
17	as	O	O
18	well	O	O
19	as	O	O
20	behavioral	BI	O
21	and	II	O
22	sleep	II	O
23	wake	II	O
24	circadian	II	O
25	rhythm	II	O
26	disorders	II	O
27	.	O	O

0	BACKGROUND	O	O
1	Submicroscopic	O	O
2	deletions	O	O
3	in	O	O
4	14q12	O	O
5	spanning	O	O
6	FOXG1	O	O
7	or	O	O
8	intragenic	O	O
9	mutations	O	O
10	have	O	O
11	been	O	O
12	reported	O	O
13	in	O	O
14	patients	O	O
15	with	O	O
16	a	O	O
17	developmental	BI	O
18	disorder	II	O
19	described	O	O
20	as	O	O
21	a	O	O
22	congenital	O	O
23	variant	O	O
24	of	O	O
25	Rett	BU	O
26	syndrome	IU	O
27	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	WHS	IU	O
3	is	O	O
4	a	O	O
5	contiguous	O	O
6	gene	O	O
7	deletion	O	O
8	syndrome	O	O
9	of	O	O
10	the	O	O
11	distal	O	O
12	4p	O	O
13	chromosome	O	O
14	characterized	O	O
15	by	O	O
16	craniofacial	O	O
17	features	O	O
18	growth	BI	O
19	impairment	II	O
20	intellectual	BI	O
21	disability	II	O
22	and	O	O
23	seizures	O	O
24	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	girl	O	O
4	with	O	O
5	motor	BI	O
6	and	II	O
7	mental	II	O
8	retardation	II	O
9	macrocephaly	O	O
10	a	O	O
11	"coarse"	O	O
12	face	O	O
13	choanal	BU	O
14	atresia	IU	O
15	postnatal	O	O
16	feeding	O	O
17	difficulty	O	O
18	redundant	O	O
19	skin	O	O
20	with	O	O
21	deep	O	O
22	palmar	O	O
23	and	O	O
24	plantar	O	O
25	creases	O	O
26	and	O	O
27	histopathological	O	O
28	evidence	O	O
29	of	O	O
30	altered	O	O
31	elastic	O	O
32	fibers	O	O
33	who	O	O
34	died	O	O
35	at	O	O
36	the	O	O
37	age	O	O
38	of	O	O
39	11	O	O
40	months	O	O
41	.	O	O

0	She	O	O
1	presented	O	O
2	with	O	O
3	unilateral	O	O
4	ptosis	O	O
5	and	O	O
6	coloboma	O	O
7	of	O	O
8	the	O	O
9	iris	O	O
10	choroid	O	O
11	and	O	O
12	retina	O	O
13	patent	BU	O
14	ductus	IU	O
15	arteriosus	IU	O
16	growth	BI	O
17	and	II	O
18	mental	II	O
19	retardation	II	O
20	unilateral	O	O
21	ear	O	O
22	deformity	O	O
23	and	O	O
24	a	O	O
25	hearing	BI	O
26	loss	II	O
27	.	O	O

0	Townes-Brocks	BU	O
1	syndrome	IU	O
2	TBS	IU	O
3	is	O	O
4	an	O	O
5	autosomal	O	O
6	dominantly	O	O
7	inherited	O	O
8	malformation	O	O
9	syndrome	O	O
10	characterized	O	O
11	by	O	O
12	imperforate	O	O
13	anus	O	O
14	and	O	O
15	limb	O	O
16	and	O	O
17	ear	O	O
18	malformations	O	O
19	with	O	O
20	sensorineural	BI	O
21	hearing	II	O
22	loss	II	O
23	.	O	O

0	Pitt-Hopkins	BU	O
1	syndrome	IU	O
2	is	O	O
3	characterized	O	O
4	by	O	O
5	marked	BI	O
6	intellectual	II	O
7	impairment	II	O
8	hyperventilation	O	O
9	episodes	O	O
10	and	O	O
11	dysmorphic	O	O
12	facial	O	O
13	features	O	O
14	.	O	O

0	Moreover	O	O
1	accumulating	O	O
2	reports	O	O
3	have	O	O
4	linked	O	O
5	various	O	O
6	genetic	O	O
7	defects	O	O
8	that	O	O
9	either	O	O
10	up-	O	O
11	or	O	O
12	down-regulate	O	O
13	Ras	O	O
14	Rap	O	O
15	signaling	O	O
16	with	O	O
17	several	BI	O
18	mental	II	O
19	disorders	II	O
20	associated	O	O
21	with	O	O
22	learning	BI	O
23	disability	II	O
24	e.g.	O	O
25	Alzheimers	O	O
26	disease	O	O
27	Angelman	O	O
28	syndrome	O	O
29	autism	BI	O
30	cardio-facio-cutaneous	O	O
31	syndrome	O	O
32	Coffin-Lowry	BU	O
33	syndrome	IU	O
34	Costello	BU	O
35	syndrome	IU	O
36	Cowden	O	O
37	and	O	O
38	Bannayan-Riley-Ruvalcaba	O	O
39	syndromes	O	O
40	fragile	BU	O
41	X	IU	O
42	syndrome	IU	O
43	neurofibromatosis	BU	O
44	type	IU	O
45	1	IU	O
46	Noonan	O	O
47	syndrome	O	O
48	schizophrenia	O	O
49	tuberous	BU	O
50	sclerosis	IU	O
51	and	O	O
52	X-linked	BI	O
53	mental	II	O
54	retardation	II	O
55	highlighting	O	O
56	the	O	O
57	necessity	O	O
58	of	O	O
59	happy-medium	O	O
60	dynamic	O	O
61	regulation	O	O
62	of	O	O
63	Ras	O	O
64	Rap	O	O
65	signaling	O	O
66	in	O	O
67	learning	O	O
68	behavior	O	O
69	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	is	O	O
3	one	O	O
4	of	O	O
5	the	O	O
6	rare	O	O
7	autosomal	O	O
8	recessive	O	O
9	progressive	O	O
10	neurodegenerative	O	O
11	disorders	O	O
12	characterized	O	O
13	by	O	O
14	diabetes	O	O
15	mellitus	O	O
16	and	O	O
17	optic	BI	O
18	atrophy	II	O
19	.	O	O

0	BACKGROUND	O	O
1	Choroideremia	BU	O
2	is	O	O
3	an	O	O
4	X-linked	O	O
5	recessive	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	vision	BI	O
10	loss	II	O
11	with	O	O
12	progressive	O	O
13	atrophy	O	O
14	of	O	O
15	the	O	O
16	retinal	O	O
17	photoreceptors	O	O
18	retinal	O	O
19	pigment	O	O
20	epithelium	O	O
21	RPE	O	O
22	and	O	O
23	choriocapillaris	O	O
24	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	on	O	O
4	the	O	O
5	fourth	O	O
6	male	O	O
7	patient	O	O
8	presenting	O	O
9	with	O	O
10	brain	O	O
11	anomaly	O	O
12	intellectual	BI	O
13	disability	II	O
14	growth	BI	O
15	retardation	II	O
16	ectodermal	BU	O
17	dysplasia	IU	O
18	vertebral	O	O
19	skeletal	O	O
20	anomaly	O	O
21	Hirschsprung	BU	O
22	disease	IU	O
23	low-set	O	O
24	and	O	O
25	large	O	O
26	ears	O	O
27	cryptorchidism	O	O
28	and	O	O
29	small	O	O
30	kidneys	O	O
31	.	O	O

0	CONCLUSIONS	O	O
1	More	O	O
2	than	O	O
3	half	O	O
4	the	O	O
5	CADASIL	BU	O
6	patients	O	O
7	had	O	O
8	emotional	BI	O
9	disturbances	II	O
10	either	O	O
11	DED	O	O
12	or	O	O
13	NDED	O	O
14	.	O	O

0	Stimulant	O	O
1	medication	O	O
2	may	O	O
3	be	O	O
4	a	O	O
5	safe	O	O
6	and	O	O
7	effective	O	O
8	intervention	O	O
9	for	O	O
10	Sturge-Weber	BU	O
11	syndrome	IU	O
12	children	O	O
13	with	O	O
14	attention	BI	O
15	issues	II	O
16	attention	BI	O
17	deficit	II	O
18	hyperactivity	BI	O
19	disorder	II	O
20	.	O	O

0	Intellectual	BI	O
1	disability	II	O
2	is	O	O
3	uncommon	O	O
4	in	O	O
5	TRPS	BU	O
6	I	O	O
7	and	O	O
8	if	O	O
9	present	O	O
10	usually	O	O
11	mild	O	O
12	.	O	O

0	Ophthalmologists	O	O
1	should	O	O
2	be	O	O
3	aware	O	O
4	that	O	O
5	progressive	BI	O
6	visual	II	O
7	loss	II	O
8	and	O	O
9	the	O	O
10	constriction	O	O
11	of	O	O
12	visual	O	O
13	field	O	O
14	can	O	O
15	occur	O	O
16	in	O	O
17	patients	O	O
18	with	O	O
19	Chediak-Higashi	BU	O
20	syndrome	IU	O
21	as	O	O
22	they	O	O
23	grow	O	O
24	older	O	O
25	.	O	O

0	Patients	O	O
1	with	O	O
2	22q11.2	BU	O
3	deletion	IU	O
4	exhibited	O	O
5	facial	O	O
6	dysmorphic	O	O
7	features	O	O
8	82%	O	O
9	congenital	O	O
10	heart	O	O
11	defects	O	O
12	70%	O	O
13	immunological	O	O
14	problems	O	O
15	47%	O	O
16	multiple	O	O
17	congenital	O	O
18	anomalies	O	O
19	64%	O	O
20	hypocalcemia	O	O
21	47%	O	O
22	mental	BI	O
23	retardation	II	O
24	learning	BI	O
25	difficulties	II	O
26	35%	O	O
27	cleft	BU	O
28	palate	IU	O
29	velopharyngeal	O	O
30	insufficiency	O	O
31	23.5%	O	O
32	seizures	O	O
33	hypotonia	O	O
34	23%	O	O
35	and	O	O
36	growth	BI	O
37	retardation	II	O
38	12%	O	O
39	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	autosomal	O	O
6	recessive	O	O
7	neurodegenerative	O	O
8	disorder	O	O
9	presenting	O	O
10	with	O	O
11	the	O	O
12	main	O	O
13	clinical	O	O
14	symptoms	O	O
15	of	O	O
16	childhood-onset	O	O
17	diabetes	O	O
18	mellitus	O	O
19	optic	BI	O
20	atrophy	II	O
21	diabetes	O	O
22	insipidus	O	O
23	and	O	O
24	deafness	BI	O
25	DIDMOAD	O	O
26	.	O	O

0	Children	O	O
1	with	O	O
2	severe	O	O
3	form	O	O
4	diagnosed	O	O
5	at	O	O
6	12-36	O	O
7	months	O	O
8	have	O	O
9	coarse	O	O
10	facial	O	O
11	feature	O	O
12	short	O	O
13	stature	O	O
14	joint	O	O
15	stiffness	O	O
16	short	O	O
17	neck	O	O
18	broad	O	O
19	chest	O	O
20	large	O	O
21	head	O	O
22	circumference	O	O
23	watery	O	O
24	diarrhea	O	O
25	skeletal	O	O
26	changes	O	O
27	progressive	BI	O
28	and	II	O
29	profound	II	O
30	mental	II	O
31	retardation	II	O
32	retinal	BI	O
33	degeneration	II	O
34	hearing	BI	O
35	loss	II	O
36	cardiomyopathy	BU	O
37	valvular	O	O
38	involvement	O	O
39	with	O	O
40	progressive	O	O
41	thickening	O	O
42	and	O	O
43	stiffening	O	O
44	of	O	O
45	the	O	O
46	valve	O	O
47	leaflets	O	O
48	leading	O	O
49	to	O	O
50	mitral	O	O
51	and	O	O
52	aortic	O	O
53	regurgitation	O	O
54	and	O	O
55	stenosis	O	O
56	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	FXS	IU	O
4	is	O	O
5	one	O	O
6	of	O	O
7	the	O	O
8	major	O	O
9	causes	O	O
10	for	O	O
11	autism	BI	O
12	and	O	O
13	mental	BI	O
14	retardation	II	O
15	in	O	O
16	humans	O	O
17	.	O	O

0	Autosomal	BU	O
1	dominant	IU	O
2	spinocerebellar	IU	O
3	ataxias	IU	O
4	SCAs	IU	O
5	are	O	O
6	a	O	O
7	clinical	O	O
8	and	O	O
9	genetically	O	O
10	heterogeneous	O	O
11	group	O	O
12	of	O	O
13	debilitating	O	O
14	neurodegenerative	O	O
15	diseases	O	O
16	that	O	O
17	are	O	O
18	related	O	O
19	to	O	O
20	at	O	O
21	least	O	O
22	36	O	O
23	different	O	O
24	genetic	O	O
25	loci	O	O
26	they	O	O
27	are	O	O
28	clinically	O	O
29	characterized	O	O
30	by	O	O
31	progressive	BI	O
32	cerebellar	II	O
33	ataxia	II	O
34	and	O	O
35	are	O	O
36	frequently	O	O
37	accompanied	O	O
38	by	O	O
39	other	O	O
40	neurological	O	O
41	and	O	O
42	non-neurological	O	O
43	manifestations	O	O
44	.	O	O

0	Several	O	O
1	of	O	O
2	these	O	O
3	genes	O	O
4	have	O	O
5	also	O	O
6	been	O	O
7	implicated	O	O
8	in	O	O
9	other	O	O
10	non-syndromic	BI	O
11	or	II	O
12	syndromic	II	O
13	retinal	II	O
14	diseases	II	O
15	such	O	O
16	as	O	O
17	retinitis	BU	O
18	pigmentosa	IU	O
19	and	O	O
20	Joubert	O	O
21	syndrome	O	O
22	respectively	O	O
23	.	O	O

0	Glucose	BU	O
1	transporter	IU	O
2	1	IU	O
3	GLUT1	IU	O
4	deficiency	IU	O
5	syndrome	O	O
6	GLUT1DS	O	O
7	was	O	O
8	initially	O	O
9	described	O	O
10	in	O	O
11	the	O	O
12	early	O	O
13	90s	O	O
14	as	O	O
15	a	O	O
16	sporadic	O	O
17	clinical	O	O
18	condition	O	O
19	characterized	O	O
20	by	O	O
21	seizures	O	O
22	motor	BI	O
23	and	II	O
24	intellectual	II	O
25	impairment	II	O
26	with	O	O
27	variable	O	O
28	clinical	O	O
29	presentation	O	O
30	and	O	O
31	without	O	O
32	a	O	O
33	known	O	O
34	genetic	O	O
35	cause	O	O
36	.	O	O

0	Although	O	O
1	the	O	O
2	patient	O	O
3	groups	O	O
4	showed	O	O
5	distinct	O	O
6	atrophy	O	O
7	patterns	O	O
8	with	O	O
9	significantly	O	O
10	more	O	O
11	severe	O	O
12	frontal	O	O
13	GM	O	O
14	loss	O	O
15	in	O	O
16	bvFTD	BU	O
17	we	O	O
18	found	O	O
19	similar	O	O
20	neural	O	O
21	correlates	O	O
22	of	O	O
23	limb	BI	O
24	apraxia	II	O
25	within	O	O
26	posterior	O	O
27	brain	O	O
28	regions	O	O
29	for	O	O
30	both	O	O
31	dementia	BI	O
32	subtypes	O	O
33	limb-imitation	O	O
34	was	O	O
35	associated	O	O
36	with	O	O
37	bilateral	O	O
38	atrophy	O	O
39	of	O	O
40	superior	O	O
41	inferior	O	O
42	and	O	O
43	medial	O	O
44	parietal	O	O
45	cortex	O	O
46	.	O	O

0	Children	O	O
1	affected	O	O
2	with	O	O
3	infantile	O	O
4	Krabbe	BU	O
5	disease	IU	O
6	present	O	O
7	with	O	O
8	motor	BI	O
9	dysfunction	II	O
10	cognitive	BI	O
11	decline	II	O
12	intractable	O	O
13	seizures	O	O
14	and	O	O
15	premature	O	O
16	death	O	O
17	between	O	O
18	two	O	O
19	to	O	O
20	five	O	O
21	years	O	O
22	of	O	O
23	age	O	O
24	.	O	O

0	Through	O	O
1	exome	O	O
2	sequencing	O	O
3	and	O	O
4	candidate	O	O
5	gene	O	O
6	screening	O	O
7	we	O	O
8	report	O	O
9	two	O	O
10	families	O	O
11	with	O	O
12	autosomal	O	O
13	recessive	O	O
14	transmission	O	O
15	of	O	O
16	ALDH18A1	O	O
17	mutations	O	O
18	and	O	O
19	predominant	O	O
20	complex	O	O
21	hereditary	BU	O
22	spastic	IU	O
23	paraplegia	IU	O
24	with	O	O
25	marked	O	O
26	cognitive	BI	O
27	impairment	II	O
28	without	O	O
29	any	O	O
30	cutaneous	O	O
31	abnormality	O	O
32	.	O	O

0	The	O	O
1	technique	O	O
2	can	O	O
3	be	O	O
4	applied	O	O
5	for	O	O
6	the	O	O
7	rapid	O	O
8	screening	O	O
9	for	O	O
10	fragile	BU	O
11	X	IU	O
12	syndrome	IU	O
13	among	O	O
14	patients	O	O
15	with	O	O
16	intellectual	BI	O
17	disability	II	O
18	.	O	O

0	Danon	BU	O
1	disease	IU	O
2	DD	O	O
3	is	O	O
4	a	O	O
5	monogenic	O	O
6	X-linked	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	cardiomyopathy	BU	O
11	skeletal	O	O
12	myopathy	O	O
13	and	O	O
14	variable	O	O
15	degrees	O	O
16	of	O	O
17	intellectual	BI	O
18	disability	II	O
19	.	O	O

0	According	O	O
1	to	O	O
2	the	O	O
3	survey	O	O
4	conducted	O	O
5	at	O	O
6	special	O	O
7	schools	O	O
8	for	O	O
9	the	O	O
10	deaf	BI	O
11	83	O	O
12	232	O	O
13	77	O	O
14	and	O	O
15	167	O	O
16	children	O	O
17	were	O	O
18	born	O	O
19	with	O	O
20	CRS	BU	O
21	on	O	O
22	the	O	O
23	Japanese	O	O
24	mainland	O	O
25	respectively	O	O
26	after	O	O
27	the	O	O
28	19651969	O	O
29	19751977	O	O
30	1982	O	O
31	and	O	O
32	19871988	O	O
33	nationwide	O	O
34	rubella	O	O
35	epidemics	O	O
36	suggesting	O	O
37	that	O	O
38	the	O	O
39	incidence	O	O
40	of	O	O
41	CRS	BU	O
42	in	O	O
43	Japan	O	O
44	is	O	O
45	in	O	O
46	fact	O	O
47	comparable	O	O
48	to	O	O
49	that	O	O
50	in	O	O
51	the	O	O
52	U.S.	O	O
53	and	O	O
54	Europe	O	O
55	.	O	O

0	Hence	O	O
1	this	O	O
2	study	O	O
3	was	O	O
4	undertaken	O	O
5	to	O	O
6	review	O	O
7	the	O	O
8	details	O	O
9	of	O	O
10	patients	O	O
11	with	O	O
12	TS	BU	O
13	with	O	O
14	respect	O	O
15	to	O	O
16	the	O	O
17	pattern	O	O
18	of	O	O
19	cognitive	BI	O
20	psychiatric	II	O
21	and	II	O
22	motor	II	O
23	dysfunction	II	O
24	.	O	O

0	Therefore	O	O
1	even	O	O
2	without	O	O
3	any	O	O
4	obvious	O	O
5	syndromic	O	O
6	features	O	O
7	MWS	BU	O
8	can	O	O
9	be	O	O
10	the	O	O
11	cause	O	O
12	of	O	O
13	sensorineural	BI	O
14	hearing	II	O
15	impairment	II	O
16	especially	O	O
17	when	O	O
18	combined	O	O
19	with	O	O
20	mild	O	O
21	skin	O	O
22	rash	O	O
23	and	O	O
24	musculoskeletal	O	O
25	symptoms	O	O
26	.	O	O

0	A	O	O
1	review	O	O
2	of	O	O
3	the	O	O
4	current	O	O
5	literature	O	O
6	reveals	O	O
7	only	O	O
8	chronic	O	O
9	otitis	O	O
10	media	O	O
11	and	O	O
12	conductive	BI	O
13	hearing	II	O
14	loss	II	O
15	as	O	O
16	otolaryngologic	O	O
17	manifestations	O	O
18	of	O	O
19	Sotos	BU	O
20	syndrome	IU	O
21	.	O	O

0	RESULTS	O	O
1	AND	O	O
2	CONCLUSIONS	O	O
3	Behavioral	BI	O
4	and	II	O
5	psychiatric	II	O
6	problems	II	O
7	are	O	O
8	common	O	O
9	in	O	O
10	patients	O	O
11	with	O	O
12	del22q11	BU	O
13	syndrome	O	O
14	.	O	O

0	Alpha-mannosidosis	BU	O
1	is	O	O
2	an	O	O
3	inherited	O	O
4	lysosomal	O	O
5	storage	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	immune	O	O
10	deficiency	O	O
11	facial	O	O
12	and	O	O
13	skeletal	O	O
14	abnormalities	O	O
15	hearing	BI	O
16	impairment	II	O
17	and	O	O
18	intellectual	BI	O
19	disability	II	O
20	.	O	O

0	Angelman	BU	O
1	syndrome	IU	O
2	AS	IU	O
3	is	O	O
4	a	O	O
5	neurodevelopmental	BI	O
6	disorder	II	O
7	characterized	O	O
8	by	O	O
9	a	O	O
10	number	O	O
11	of	O	O
12	neurological	O	O
13	problems	O	O
14	including	O	O
15	developmental	BI	O
16	delay	II	O
17	movement	BI	O
18	disorders	II	O
19	and	O	O
20	epilepsy	O	O
21	.	O	O

0	Leber	BU	O
1	described	O	O
2	a	O	O
3	particular	O	O
4	type	O	O
5	of	O	O
6	hereditary	O	O
7	optic	BI	O
8	atrophy	II	O
9	in	O	O
10	1871	O	O
11	.	O	O

0	The	O	O
1	clinical	O	O
2	picture	O	O
3	typically	O	O
4	associated	O	O
5	with	O	O
6	cri	BU	O
7	du	IU	O
8	chat	IU	O
9	syndrome	IU	O
10	is	O	O
11	one	O	O
12	of	O	O
13	profound	BI	O
14	intellectual	II	O
15	impairment	II	O
16	severe	BI	O
17	motor	II	O
18	delay	II	O
19	and	O	O
20	increased	O	O
21	morbidity	O	O
22	.	O	O

0	Leber	BU	O
1	congenital	IU	O
2	amaurosis	IU	O
3	caused	O	O
4	by	O	O
5	mutations	O	O
6	in	O	O
7	RPE65	O	O
8	and	O	O
9	LRAT	O	O
10	is	O	O
11	a	O	O
12	severe	O	O
13	form	O	O
14	of	O	O
15	inherited	BI	O
16	retinal	II	O
17	degeneration	II	O
18	leading	O	O
19	to	O	O
20	blindness	BI	O
21	.	O	O

0	Amyotrophic	BU	O
1	lateral	IU	O
2	sclerosis	IU	O
3	ALS	IU	O
4	is	O	O
5	a	O	O
6	fatal	O	O
7	neurodegenerative	O	O
8	disease	O	O
9	characterized	O	O
10	by	O	O
11	progressive	BI	O
12	motor	II	O
13	dysfunction	II	O
14	and	O	O
15	loss	O	O
16	of	O	O
17	large	O	O
18	motor	O	O
19	neurons	O	O
20	in	O	O
21	the	O	O
22	spinal	O	O
23	cord	O	O
24	and	O	O
25	brain	O	O
26	stem	O	O
27	.	O	O

0	SCA17	BU	O
1	is	O	O
2	clinically	O	O
3	heterogeneous	O	O
4	and	O	O
5	typically	O	O
6	presents	O	O
7	with	O	O
8	slowly	O	O
9	evolving	O	O
10	ataxia	BI	O
11	dysarthria	BI	O
12	dementia	BI	O
13	depression	O	O
14	and	O	O
15	other	O	O
16	movement	BI	O
17	disorders	II	O
18	such	O	O
19	as	O	O
20	chorea	O	O
21	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	2	O	O
4	children	O	O
5	with	O	O
6	Townes-Brocks	BU	O
7	syndrome	IU	O
8	TBS	O	O
9	and	O	O
10	mental	BI	O
11	retardation	II	O
12	.	O	O

0	Main	O	O
1	clinical	O	O
2	features	O	O
3	were	O	O
4	mental	BI	O
5	retardation	II	O
6	peripheral	O	O
7	neuropathy	O	O
8	deafness	BI	O
9	Hirschsprung	BU	O
10	disease	IU	O
11	distal	BU	O
12	arthrogryposis	IU	O
13	white	O	O
14	hairlock	O	O
15	and	O	O
16	growth	BI	O
17	retardation	II	O
18	.	O	O

0	Patient	O	O
1	1	O	O
2	was	O	O
3	a	O	O
4	16-year-old	O	O
5	girl	O	O
6	with	O	O
7	myopathy	O	O
8	cardiomyopathy	BU	O
9	severe	BI	O
10	mental	II	O
11	retardation	II	O
12	and	O	O
13	epilepsy	O	O
14	.	O	O

0	Furthermore	O	O
1	while	O	O
2	growth	BI	O
3	failure	II	O
4	and	O	O
5	mental	BI	O
6	retardation	II	O
7	are	O	O
8	primarily	O	O
9	explained	O	O
10	by	O	O
11	loss	O	O
12	of	O	O
13	IGF1R	O	O
14	the	O	O
15	occurrence	O	O
16	of	O	O
17	VSD	BU	O
18	might	O	O
19	suggest	O	O
20	the	O	O
21	existence	O	O
22	of	O	O
23	a	O	O
24	cardiac	O	O
25	anomaly	O	O
26	gene	O	O
27	other	O	O
28	than	O	O
29	the	O	O
30	candidate	O	O
31	cardiac	O	O
32	anomaly	O	O
33	gene	O	O
34	NR2F2	O	O
35	in	O	O
36	the	O	O
37	deleted	O	O
38	region	O	O
39	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	form	O	O
7	of	O	O
8	X-linked	BI	O
9	mental	II	O
10	retardation	II	O
11	caused	O	O
12	by	O	O
13	mutations	O	O
14	of	O	O
15	the	O	O
16	RSK2	O	O
17	gene	O	O
18	associated	O	O
19	with	O	O
20	cognitive	BI	O
21	impairment	II	O
22	and	O	O
23	skeletal	O	O
24	malformations	O	O
25	.	O	O

0	It	O	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	distinct	O	O
5	craniofacial	O	O
6	abnormalities	O	O
7	including	O	O
8	abnormal	O	O
9	location	O	O
10	of	O	O
11	the	O	O
12	ears	O	O
13	aplastic	O	O
14	cervical	O	O
15	skin	O	O
16	lesions	O	O
17	malformed	O	O
18	auricles	O	O
19	conductive	BI	O
20	hearing	II	O
21	loss	II	O
22	ocular	BI	O
23	abnormalities	II	O
24	and	O	O
25	cleft	BU	O
26	lip	IU	O
27	and	IU	O
28	palate	IU	O
29	.	O	O

0	The	O	O
1	differential	O	O
2	diagnosis	O	O
3	of	O	O
4	cutis	O	O
5	laxa	O	O
6	in	O	O
7	association	O	O
8	with	O	O
9	postnatal	BI	O
10	growth	II	O
11	retardation	II	O
12	and	O	O
13	developmental	BI	O
14	delay	II	O
15	and	O	O
16	with	O	O
17	cardio-facio-cutaneous	O	O
18	and	O	O
19	Noonan	BU	O
20	syndromes	IU	O
21	is	O	O
22	discussed	O	O
23	.	O	O

0	Pendred	BU	O
1	syndrome	IU	O
2	caused	O	O
3	by	O	O
4	mutation	O	O
5	of	O	O
6	SLC26A4	O	O
7	is	O	O
8	one	O	O
9	of	O	O
10	the	O	O
11	common	O	O
12	causes	O	O
13	of	O	O
14	recessive	BI	O
15	syndromic	II	O
16	profound	II	O
17	HL	II	O
18	.	O	O

0	CHARGE	BU	O
1	association	IU	O
2	CA	O	O
3	consists	O	O
4	of	O	O
5	a	O	O
6	non-random	O	O
7	association	O	O
8	of	O	O
9	ocular	BU	O
10	coloboma	IU	O
11	C	O	O
12	heart	O	O
13	anomaly	O	O
14	H	O	O
15	atresia	O	O
16	of	O	O
17	choanae	O	O
18	A	O	O
19	retarded	BI	O
20	growth	II	O
21	and	II	O
22	or	II	O
23	development	II	O
24	R	O	O
25	genital	O	O
26	hypoplasia	O	O
27	G	O	O
28	and	O	O
29	ear	O	O
30	anomalies	O	O
31	and	O	O
32	or	O	O
33	hearing	BI	O
34	impairment	II	O
35	E	O	O
36	.	O	O

0	Cognitive	O	O
1	testing	O	O
2	revealed	O	O
3	that	O	O
4	184	O	O
5	patients	O	O
6	51.5%	O	O
7	had	O	O
8	ALS	BU	O
9	with	O	O
10	normal	O	O
11	cognition	O	O
12	51	O	O
13	14.3%	O	O
14	had	O	O
15	ALS	BU	O
16	with	O	O
17	FTD	BU	O
18	103	O	O
19	28.9%	O	O
20	had	O	O
21	ALS	BU	O
22	with	O	O
23	executive	O	O
24	or	O	O
25	nonexecutive	O	O
26	impairment	O	O
27	and	O	O
28	19	O	O
29	5.3%	O	O
30	had	O	O
31	ALS	BU	O
32	with	O	O
33	behavioral	BI	O
34	impairment	II	O
35	.	O	O

0	We	O	O
1	suggest	O	O
2	that	O	O
3	maternal	BU	O
4	PKU	IU	O
5	should	O	O
6	be	O	O
7	suspected	O	O
8	where	O	O
9	there	O	O
10	is	O	O
11	sibling	O	O
12	recurrence	O	O
13	of	O	O
14	cognitive	BI	O
15	impairment	II	O
16	particularly	O	O
17	where	O	O
18	the	O	O
19	mother	O	O
20	was	O	O
21	born	O	O
22	before	O	O
23	the	O	O
24	initiation	O	O
25	of	O	O
26	the	O	O
27	neonatal	O	O
28	screening	O	O
29	programme	O	O
30	for	O	O
31	PKU	O	O
32	.	O	O

0	In	O	O
1	this	O	O
2	article	O	O
3	we	O	O
4	report	O	O
5	a	O	O
6	new	O	O
7	patient	O	O
8	with	O	O
9	HHH	BU	O
10	syndrome	IU	O
11	a	O	O
12	52-year-old	O	O
13	woman	O	O
14	who	O	O
15	had	O	O
16	the	O	O
17	typical	O	O
18	clinical	O	O
19	features	O	O
20	except	O	O
21	for	O	O
22	an	O	O
23	absence	O	O
24	of	O	O
25	mental	BI	O
26	retardation	II	O
27	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	WHS	IU	O
3	encompasses	O	O
4	multiple	O	O
5	congenital	O	O
6	anomalies	O	O
7	and	O	O
8	mental	BI	O
9	retardation	II	O
10	and	O	O
11	is	O	O
12	caused	O	O
13	by	O	O
14	partial	O	O
15	deletions	O	O
16	in	O	O
17	the	O	O
18	short	O	O
19	arm	O	O
20	of	O	O
21	chromosome	O	O
22	4	O	O
23	.	O	O

0	This	O	O
1	combination	O	O
2	of	O	O
3	hereditary	BU	O
4	motor	IU	O
5	and	IU	O
6	sensory	IU	O
7	neuropathy	IU	O
8	with	O	O
9	spastic	BI	O
10	paraplegia	II	O
11	and	O	O
12	optic	BI	O
13	atrophy	II	O
14	shows	O	O
15	features	O	O
16	of	O	O
17	both	O	O
18	hereditary	O	O
19	motor	O	O
20	and	O	O
21	sensory	O	O
22	neuropathy	O	O
23	V	O	O
24	and	O	O
25	VI	O	O
26	according	O	O
27	to	O	O
28	the	O	O
29	classification	O	O
30	of	O	O
31	Dyck	O	O
32	indicating	O	O
33	that	O	O
34	these	O	O
35	subtypes	O	O
36	may	O	O
37	not	O	O
38	represent	O	O
39	distinct	O	O
40	entities	O	O
41	.	O	O

0	Inherited	BU	O
1	retinal	IU	O
2	dystrophies	IU	O
3	IRDs	IU	O
4	comprise	O	O
5	a	O	O
6	large	O	O
7	group	O	O
8	of	O	O
9	genetically	O	O
10	and	O	O
11	clinically	O	O
12	heterogeneous	O	O
13	diseases	O	O
14	that	O	O
15	lead	O	O
16	to	O	O
17	progressive	BI	O
18	vision	II	O
19	loss	II	O
20	for	O	O
21	which	O	O
22	a	O	O
23	paucity	O	O
24	of	O	O
25	disease-mimicking	O	O
26	animal	O	O
27	models	O	O
28	renders	O	O
29	preclinical	O	O
30	studies	O	O
31	difficult	O	O
32	.	O	O

0	Alport	BU	O
1	syndrome	IU	O
2	is	O	O
3	an	O	O
4	inherited	O	O
5	disease	O	O
6	characterized	O	O
7	by	O	O
8	hematuria	O	O
9	progressive	O	O
10	renal	O	O
11	failure	O	O
12	hearing	BI	O
13	loss	II	O
14	and	O	O
15	ocular	BI	O
16	abnormalities	II	O
17	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	children	O	O
4	with	O	O
5	CHARGE	BU	O
6	association	IU	O
7	have	O	O
8	a	O	O
9	propensity	O	O
10	for	O	O
11	airway	O	O
12	instability	O	O
13	and	O	O
14	that	O	O
15	cerebral	O	O
16	hypoxia	O	O
17	contributed	O	O
18	to	O	O
19	the	O	O
20	developmental	BI	O
21	delay	II	O
22	in	O	O
23	some	O	O
24	of	O	O
25	our	O	O
26	patients	O	O
27	.	O	O

0	Attention	BI	O
1	and	II	O
2	behavioral	II	O
3	issues	II	O
4	are	O	O
5	common	O	O
6	in	O	O
7	Sturge-Weber	BU	O
8	syndrome	IU	O
9	.	O	O

0	West	BU	O
1	syndrome	IU	O
2	WS	IU	O
3	an	O	O
4	age	O	O
5	dependent	O	O
6	epileptic	O	O
7	encephalopathy	O	O
8	is	O	O
9	identified	O	O
10	as	O	O
11	a	O	O
12	triad	O	O
13	of	O	O
14	infantile	BU	O
15	spasms	IU	O
16	IS	IU	O
17	psychomotor	BI	O
18	retardation	II	O
19	and	O	O
20	a	O	O
21	specific	O	O
22	EEG	O	O
23	pattern	O	O
24	known	O	O
25	as	O	O
26	hypsarrhythmia	O	O
27	.	O	O

0	Fraser	BU	O
1	syndrome	IU	O
2	FS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	inherited	O	O
9	disorder	O	O
10	characterized	O	O
11	by	O	O
12	cryptophthalmos	O	O
13	laryngeal	O	O
14	defects	O	O
15	and	O	O
16	oral	O	O
17	clefting	O	O
18	mental	BI	O
19	retardation	II	O
20	syndactyly	BU	O
21	and	O	O
22	urogenital	O	O
23	defects	O	O
24	.	O	O

0	Classically	O	O
1	patients	O	O
2	with	O	O
3	CJD	BU	O
4	present	O	O
5	with	O	O
6	rapidly	O	O
7	progressive	BI	O
8	cognitive	II	O
9	decline	II	O
10	ataxia	BI	O
11	and	O	O
12	myoclonus	O	O
13	.	O	O

0	Many	O	O
1	dermatologists	O	O
2	observe	O	O
3	in	O	O
4	patients	O	O
5	with	O	O
6	DD	BU	O
7	neuropsychiatric	O	O
8	disorders	O	O
9	psychosis	O	O
10	depression	O	O
11	and	O	O
12	rare	BI	O
13	mental	II	O
14	retardation	II	O
15	.	O	O

0	One	O	O
1	child	O	O
2	had	O	O
3	sensorineural	BI	O
4	hearing	II	O
5	loss	II	O
6	microcytic	O	O
7	anemia	O	O
8	and	O	O
9	a	O	O
10	tethered	O	O
11	spinal	O	O
12	cord	O	O
13	and	O	O
14	the	O	O
15	other	O	O
16	had	O	O
17	a	O	O
18	patent	BU	O
19	ductus	IU	O
20	arteriosus	IU	O
21	and	O	O
22	gonadal	O	O
23	dysgenesis	O	O
24	with	O	O
25	sex	O	O
26	reversal	O	O
27	karyotype	O	O
28	46	O	O
29	XY	O	O
30	female	O	O
31	.	O	O

0	It	O	O
1	is	O	O
2	well	O	O
3	known	O	O
4	that	O	O
5	HMSN	O	O
6	VI	O	O
7	is	O	O
8	an	O	O
9	axonal	O	O
10	CMT	BU	O
11	neuropathy	O	O
12	with	O	O
13	optic	BI	O
14	atrophy	II	O
15	.	O	O

0	The	O	O
1	lack	O	O
2	of	O	O
3	cardiovascular	O	O
4	disease	O	O
5	specific	BI	O
6	ocular	II	O
7	anomalies	II	O
8	and	O	O
9	mental	BI	O
10	retardation	II	O
11	are	O	O
12	presented	O	O
13	in	O	O
14	the	O	O
15	differential	O	O
16	diagnosis	O	O
17	of	O	O
18	the	O	O
19	C.C.A	BU	O
20	syndrome	IU	O
21	with	O	O
22	Marfans	BU	O
23	syndrome	IU	O
24	and	O	O
25	homocystinuria	O	O
26	.	O	O

0	L-2	BU	O
1	hydroxyglutaric	IU	O
2	aciduria	IU	O
3	is	O	O
4	a	O	O
5	neurodegenerative	O	O
6	disorder	O	O
7	with	O	O
8	insidious	O	O
9	onset	O	O
10	after	O	O
11	infancy	O	O
12	which	O	O
13	is	O	O
14	likely	O	O
15	inherited	O	O
16	in	O	O
17	an	O	O
18	autosomal	O	O
19	recessive	O	O
20	mode	O	O
21	characterized	O	O
22	by	O	O
23	mental	BI	O
24	retardation	II	O
25	progressive	BI	O
26	ataxia	II	O
27	epilepsy	O	O
28	macrocephaly	O	O
29	pyramidalism	O	O
30	and	O	O
31	extrapyramidal	O	O
32	symptoms	O	O
33	in	O	O
34	variable	O	O
35	combinations	O	O
36	with	O	O
37	subcortical	O	O
38	encephalopathy	O	O
39	and	O	O
40	cerebral	O	O
41	atrophy	O	O
42	in	O	O
43	neuroimaging	O	O
44	studies	O	O
45	.	O	O

0	BACKGROUND	O	O
1	Dilated	BU	O
2	cardiomyopathy	IU	O
3	DCM	IU	O
4	non-progressive	BI	O
5	cerebellar	II	O
6	ataxia	II	O
7	A	O	O
8	testicular	O	O
9	dysgenesis	O	O
10	growth	BI	O
11	failure	II	O
12	and	O	O
13	3-methylglutaconic	BU	O
14	aciduria	IU	O
15	are	O	O
16	the	O	O
17	hallmarks	O	O
18	of	O	O
19	DNAJC19	O	O
20	defect	O	O
21	or	O	O
22	DCMA	O	O
23	syndrome	O	O
24	due	O	O
25	to	O	O
26	biallelic	O	O
27	mutations	O	O
28	in	O	O
29	DNAJC19	O	O
30	.	O	O

0	DRS	BU	O
1	associated	O	O
2	with	O	O
3	intellectual	BI	O
4	disability	II	O
5	or	O	O
6	developmental	BI	O
7	delay	II	O
8	is	O	O
9	observed	O	O
10	in	O	O
11	several	O	O
12	genetic	O	O
13	diseases	O	O
14	syndromes	O	O
15	such	O	O
16	as	O	O
17	Goldenhar	O	O
18	or	O	O
19	Wildervanck	BU	O
20	syndrome	IU	O
21	and	O	O
22	chromosomal	O	O
23	anomalies	O	O
24	such	O	O
25	as	O	O
26	12q12	O	O
27	deletion	O	O
28	.	O	O

0	A	O	O
1	variety	O	O
2	of	O	O
3	clinical	O	O
4	complications	O	O
5	have	O	O
6	been	O	O
7	reported	O	O
8	including	O	O
9	seizures	O	O
10	hypotonia	O	O
11	heart	O	O
12	malformations	O	O
13	cardiomyopathy	BU	O
14	vision	BI	O
15	problems	II	O
16	and	O	O
17	hearing	BI	O
18	loss	II	O
19	.	O	O

0	BACKGROUND	O	O
1	The	O	O
2	spectrum	O	O
3	of	O	O
4	CHARGE	BU	O
5	association	IU	O
6	includes	O	O
7	coloboma	O	O
8	heart	O	O
9	disease	O	O
10	choanal	BU	O
11	atresia	IU	O
12	retarded	BI	O
13	growth	II	O
14	and	II	O
15	development	II	O
16	and	O	O
17	or	O	O
18	CNS	O	O
19	anomalies	O	O
20	genital	O	O
21	anomalies	O	O
22	and	O	O
23	or	O	O
24	hypogonadism	O	O
25	and	O	O
26	ear	O	O
27	anomalies	O	O
28	and	O	O
29	or	O	O
30	deafness	BI	O
31	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	female	O	O
5	patient	O	O
6	with	O	O
7	an	O	O
8	approximately	O	O
9	10	O	O
10	Mb	O	O
11	interstitial	O	O
12	deletion	O	O
13	with	O	O
14	many	O	O
15	of	O	O
16	the	O	O
17	features	O	O
18	of	O	O
19	Jacobsen	BU	O
20	syndrome	IU	O
21	A	O	O
22	congenital	O	O
23	heart	O	O
24	defect	O	O
25	dysmorphic	O	O
26	features	O	O
27	developmental	BI	O
28	delay	II	O
29	and	O	O
30	Paris-Trousseau	BU	O
31	syndrome	IU	O
32	.	O	O

0	MELAS	BU	O
1	syndrome	O	O
2	is	O	O
3	a	O	O
4	multi-organ	O	O
5	disease	O	O
6	with	O	O
7	broad	O	O
8	manifestations	O	O
9	including	O	O
10	stroke-like	O	O
11	episodes	O	O
12	dementia	BI	O
13	epilepsy	O	O
14	lactic	O	O
15	acidemia	O	O
16	myopathy	O	O
17	recurrent	O	O
18	headaches	O	O
19	hearing	BI	O
20	impairment	II	O
21	diabetes	O	O
22	and	O	O
23	short	O	O
24	stature	O	O
25	.	O	O

0	A	O	O
1	case	O	O
2	of	O	O
3	homocystinuria	O	O
4	with	O	O
5	lenticular	O	O
6	subluxation	O	O
7	was	O	O
8	misdiagnosed	O	O
9	as	O	O
10	Marfan	BU	O
11	syndrome	IU	O
12	since	O	O
13	the	O	O
14	patient	O	O
15	had	O	O
16	no	O	O
17	apparent	O	O
18	mental	BI	O
19	impairment	II	O
20	and	O	O
21	had	O	O
22	had	O	O
23	a	O	O
24	negative	O	O
25	neonatal	O	O
26	screen	O	O
27	for	O	O
28	homocystinuria	O	O
29	.	O	O

0	The	O	O
1	second	O	O
2	case	O	O
3	is	O	O
4	a	O	O
5	13-year-old	O	O
6	boy	O	O
7	with	O	O
8	a	O	O
9	ring	BU	O
10	chromosome	IU	O
11	15	IU	O
12	who	O	O
13	was	O	O
14	referred	O	O
15	to	O	O
16	the	O	O
17	Laboratory	O	O
18	of	O	O
19	Cytogenetic	O	O
20	and	O	O
21	Biology	O	O
22	of	O	O
23	Reproduction	O	O
24	in	O	O
25	Sousse	O	O
26	Tunisia	O	O
27	for	O	O
28	mental	BI	O
29	retardation	II	O
30	epilepsy	O	O
31	speech	BI	O
32	delay	II	O
33	hypotonia	O	O
34	and	O	O
35	other	O	O
36	mild	O	O
37	dysmorphic	O	O
38	features	O	O
39	.	O	O

0	Our	O	O
1	study	O	O
2	suggested	O	O
3	that	O	O
4	low	O	O
5	level	O	O
6	of	O	O
7	serum	O	O
8	uric	O	O
9	acid	O	O
10	was	O	O
11	associated	O	O
12	with	O	O
13	cognitive	BI	O
14	deficits	II	O
15	in	O	O
16	MSA	BU	O
17	.	O	O

0	However	O	O
1	emotional	BI	O
2	disturbances	II	O
3	in	O	O
4	CADASIL	BU	O
5	patients	O	O
6	are	O	O
7	incompletely	O	O
8	understood	O	O
9	.	O	O

0	Two	O	O
1	patients	O	O
2	were	O	O
3	diagnosed	O	O
4	as	O	O
5	having	O	O
6	secondary	O	O
7	distal	O	O
8	renal	O	O
9	acidosis	O	O
10	due	O	O
11	to	O	O
12	a	O	O
13	genetic	O	O
14	disorder	O	O
15	called	O	O
16	osteopetrosis	BU	O
17	they	O	O
18	are	O	O
19	brothers	O	O
20	and	O	O
21	their	O	O
22	audiograms	O	O
23	showed	O	O
24	a	O	O
25	mild	O	O
26	conductive	BI	O
27	hearing	II	O
28	loss	II	O
29	of	O	O
30	an	O	O
31	average	O	O
32	35	O	O
33	dB	O	O
34	bilaterally	O	O
35	.	O	O

0	The	O	O
1	CHARGE	BU	O
2	association	IU	O
3	was	O	O
4	described	O	O
5	as	O	O
6	a	O	O
7	cluster	O	O
8	of	O	O
9	multiple	BI	O
10	congenital	II	O
11	defects	II	O
12	by	O	O
13	Pagon	O	O
14	et	O	O
15	al	O	O
16	in	O	O
17	1981	O	O
18	.	O	O

0	Universal	O	O
1	screening	O	O
2	introduced	O	O
3	in	O	O
4	the	O	O
5	1960s	O	O
6	has	O	O
7	reduced	O	O
8	the	O	O
9	incidence	O	O
10	of	O	O
11	learning	BI	O
12	disability	II	O
13	resulting	O	O
14	from	O	O
15	phenylketonuria	BU	O
16	PKU	O	O
17	which	O	O
18	is	O	O
19	a	O	O
20	treatable	O	O
21	condition	O	O
22	.	O	O

0	A	O	O
1	follow-up	O	O
2	of	O	O
3	seven	O	O
4	patients	O	O
5	with	O	O
6	the	O	O
7	autosomal	O	O
8	recessive	O	O
9	inherited	O	O
10	syndrome	O	O
11	of	O	O
12	distal	BU	O
13	renal	IU	O
14	tubular	IU	O
15	acidosis	IU	O
16	RTA	O	O
17	and	O	O
18	sensorineural	BI	O
19	hearing	II	O
20	loss	II	O
21	is	O	O
22	described	O	O
23	.	O	O

0	Individuals	O	O
1	with	O	O
2	terminal	BU	O
3	and	IU	O
4	interstitial	IU	O
5	deletions	IU	O
6	of	IU	O
7	chromosome	IU	O
8	1p36	IU	O
9	have	O	O
10	a	O	O
11	spectrum	O	O
12	of	O	O
13	defects	O	O
14	that	O	O
15	includes	O	O
16	eye	O	O
17	anomalies	O	O
18	postnatal	BI	O
19	growth	II	O
20	deficiency	II	O
21	structural	O	O
22	brain	O	O
23	anomalies	O	O
24	seizures	O	O
25	cognitive	BI	O
26	impairment	II	O
27	delayed	BI	O
28	motor	II	O
29	development	II	O
30	behavior	BI	O
31	problems	II	O
32	hearing	BI	O
33	loss	II	O
34	cardiovascular	O	O
35	malformations	O	O
36	cardiomyopathy	BU	O
37	and	O	O
38	renal	O	O
39	anomalies	O	O
40	.	O	O

0	Duplication	O	O
1	of	O	O
2	17p11.2	O	O
3	also	O	O
4	known	O	O
5	as	O	O
6	Potocki-Lupski	BU	O
7	syndrome	IU	O
8	PTLS	O	O
9	is	O	O
10	a	O	O
11	well-described	O	O
12	microduplication	O	O
13	syndrome	O	O
14	featuring	O	O
15	cognitive	BI	O
16	and	II	O
17	language	II	O
18	deficits	II	O
19	developmental	BI	O
20	delay	II	O
21	autistic	BI	O
22	behavior	II	O
23	structural	O	O
24	cardiovascular	O	O
25	anomalies	O	O
26	hypotonia	O	O
27	failure	O	O
28	to	O	O
29	thrive	O	O
30	apnea	O	O
31	and	O	O
32	dysmorphism	O	O
33	.	O	O

0	Though	O	O
1	uncommon	O	O
2	Langerhans	BU	O
3	cell	IU	O
4	histiocytosis	IU	O
5	should	O	O
6	be	O	O
7	considered	O	O
8	among	O	O
9	the	O	O
10	differentials	O	O
11	of	O	O
12	persistent	O	O
13	otological	O	O
14	symptoms	O	O
15	as	O	O
16	its	O	O
17	progressive	O	O
18	nature	O	O
19	can	O	O
20	cause	O	O
21	bilateral	BI	O
22	irreversible	II	O
23	sensorineural	II	O
24	hearing	II	O
25	loss	II	O
26	.	O	O

0	CONCLUSIONS	O	O
1	Jervell	BU	O
2	and	IU	O
3	Lange-Nielsen	IU	O
4	syndrome	IU	O
5	is	O	O
6	a	O	O
7	very	O	O
8	rare	O	O
9	condition	O	O
10	even	O	O
11	in	O	O
12	a	O	O
13	population	O	O
14	with	O	O
15	hearing	BI	O
16	loss	II	O
17	.	O	O

0	Considering	O	O
1	that	O	O
2	CADASIL	BU	O
3	is	O	O
4	a	O	O
5	progressive	O	O
6	disease	O	O
7	with	O	O
8	deteriorating	O	O
9	patients	O	O
10	QOL	O	O
11	physicians	O	O
12	have	O	O
13	to	O	O
14	pay	O	O
15	more	O	O
16	attention	O	O
17	to	O	O
18	emotional	BI	O
19	problems	II	O
20	in	O	O
21	CADASIL	BU	O
22	patients	O	O
23	.	O	O

0	Speech	O	O
1	and	O	O
2	language	O	O
3	development	O	O
4	in	O	O
5	children	O	O
6	with	O	O
7	CCS	BU	O
8	is	O	O
9	notable	O	O
10	for	O	O
11	a	O	O
12	reduced	BI	O
13	receptive	II	O
14	vocabulary	II	O
15	and	O	O
16	a	O	O
17	profound	BI	O
18	deficit	II	O
19	in	II	O
20	expressive	II	O
21	language	II	O
22	.	O	O

0	1p36	BU	O
1	deletion	IU	O
2	monosomy	BU	O
3	1p36	IU	O
4	is	O	O
5	one	O	O
6	of	O	O
7	the	O	O
8	most	O	O
9	common	O	O
10	terminal	O	O
11	deletions	O	O
12	observed	O	O
13	in	O	O
14	humans	O	O
15	characterized	O	O
16	by	O	O
17	special	O	O
18	facial	O	O
19	features	O	O
20	mental	BI	O
21	retardation	II	O
22	heart	O	O
23	defects	O	O
24	development	BI	O
25	delay	II	O
26	and	O	O
27	epilepsy	O	O
28	.	O	O

0	Hearing	BI	O
1	impairment	II	O
2	has	O	O
3	long	O	O
4	been	O	O
5	associated	O	O
6	with	O	O
7	the	O	O
8	rarer	O	O
9	forms	O	O
10	of	O	O
11	severe	O	O
12	childhood	O	O
13	and	O	O
14	infantile	O	O
15	facioscapulohumeral	BU	O
16	muscular	IU	O
17	dystrophy	IU	O
18	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	sought	O	O
4	to	O	O
5	investigate	O	O
6	the	O	O
7	relationship	O	O
8	between	O	O
9	challenging	O	O
10	behavior	O	O
11	comorbid	O	O
12	psychopathology	O	O
13	and	O	O
14	Attention-Deficit	BI	O
15	Hyperactivity	BI	O
16	Disorder	II	O
17	AD	O	O
18	HD	O	O
19	in	O	O
20	Fragile	BU	O
21	X	IU	O
22	Syndrome	IU	O
23	FRAX	IU	O
24	.	O	O

0	A	O	O
1	56-year-old	O	O
2	man	O	O
3	with	O	O
4	the	O	O
5	prototypic	O	O
6	skeletal	O	O
7	defects	O	O
8	of	O	O
9	cleidocranial	BU	O
10	dysplasia	IU	O
11	and	O	O
12	a	O	O
13	RUNX2	O	O
14	deletion	O	O
15	presented	O	O
16	with	O	O
17	a	O	O
18	progressive	BI	O
19	cognitive	II	O
20	decline	II	O
21	after	O	O
22	the	O	O
23	age	O	O
24	of	O	O
25	40	O	O
26	years	O	O
27	.	O	O

0	Cockayne	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	autosomal	O	O
6	recessive	O	O
7	condition	O	O
8	characterized	O	O
9	by	O	O
10	growth	BI	O
11	failure	II	O
12	and	O	O
13	multisystem	O	O
14	progressive	O	O
15	degeneration	O	O
16	.	O	O

0	This	O	O
1	case	O	O
2	illustrates	O	O
3	the	O	O
4	importance	O	O
5	of	O	O
6	confirming	O	O
7	the	O	O
8	SMS	BU	O
9	diagnosis	O	O
10	which	O	O
11	is	O	O
12	associated	O	O
13	with	O	O
14	cognitive	BI	O
15	and	II	O
16	functional	II	O
17	impairment	II	O
18	as	O	O
19	well	O	O
20	as	O	O
21	significant	O	O
22	psychiatric	O	O
23	co-morbidities	O	O
24	and	O	O
25	behavioral	BI	O
26	problems	II	O
27	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	twentieth	O	O
4	patient	O	O
5	diagnosed	O	O
6	with	O	O
7	SHORT	BU	O
8	syndrome	IU	O
9	who	O	O
10	presented	O	O
11	with	O	O
12	growth	BI	O
13	retardation	II	O
14	sensorineural	BI	O
15	hearing	II	O
16	loss	II	O
17	and	O	O
18	minor	O	O
19	dysmorphic	O	O
20	features	O	O
21	consistent	O	O
22	with	O	O
23	the	O	O
24	phenotype	O	O
25	described	O	O
26	for	O	O
27	this	O	O
28	syndrome	O	O
29	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	Syndrome	IU	O
3	FXS	IU	O
4	is	O	O
5	a	O	O
6	leading	O	O
7	genetic	O	O
8	cause	O	O
9	of	O	O
10	intellectual	BI	O
11	disability	II	O
12	and	O	O
13	autism	BI	O
14	.	O	O

0	Ataxia	BU	O
1	telangiectasia	IU	O
2	is	O	O
3	an	O	O
4	autosomal	O	O
5	recessive	O	O
6	multisystem	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	progressive	BI	O
11	cerebellar	II	O
12	ataxia	II	O
13	with	O	O
14	onset	O	O
15	in	O	O
16	childhood	O	O
17	oculocutaneous	O	O
18	telangiectasia	O	O
19	increased	O	O
20	serum	O	O
21	alpha-fetoprotein	O	O
22	immunodeficiency	O	O
23	chromosomal	O	O
24	instability	O	O
25	and	O	O
26	radiation	O	O
27	hypersensitivity	O	O
28	.	O	O

0	The	O	O
1	most	O	O
2	consistently	O	O
3	present	O	O
4	components	O	O
5	include	O	O
6	facial	O	O
7	deformity	O	O
8	mental	BI	O
9	retardation	II	O
10	and	O	O
11	Hirschsprung	BU	O
12	disease	IU	O
13	.	O	O

0	Previous	O	O
1	research	O	O
2	has	O	O
3	suggested	O	O
4	that	O	O
5	the	O	O
6	pattern	O	O
7	and	O	O
8	severity	O	O
9	of	O	O
10	cognitive	BI	O
11	deficits	II	O
12	in	O	O
13	people	O	O
14	with	O	O
15	severe	O	O
16	chronic	O	O
17	schizophrenia	O	O
18	is	O	O
19	similar	O	O
20	to	O	O
21	that	O	O
22	observed	O	O
23	in	O	O
24	behavioural	BU	O
25	variant	IU	O
26	frontotemporal	IU	O
27	dementia	IU	O
28	bvFTD	IU	O
29	.	O	O

0	INTRODUCTION	O	O
1	Sjogren-Larsson	BU	O
2	syndrome	IU	O
3	SLS	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	the	O	O
8	triad	O	O
9	of	O	O
10	ichthyosis	BU	O
11	mental	BI	O
12	retardation	II	O
13	and	O	O
14	spastic	BI	O
15	diplegia	II	O
16	or	O	O
17	quadriplegia	BI	O
18	.	O	O

0	Providers	O	O
1	must	O	O
2	therefore	O	O
3	consider	O	O
4	del22q11	BU	O
5	as	O	O
6	a	O	O
7	potential	O	O
8	diagnosis	O	O
9	in	O	O
10	children	O	O
11	and	O	O
12	adults	O	O
13	with	O	O
14	behavioral	BI	O
15	and	II	O
16	psychiatric	II	O
17	problems	II	O
18	.	O	O

0	RESULTS	O	O
1	A	O	O
2	46-year-old	O	O
3	woman	O	O
4	presented	O	O
5	with	O	O
6	recently	O	O
7	reduced	BI	O
8	central	II	O
9	vision	II	O
10	and	O	O
11	clinical	O	O
12	findings	O	O
13	of	O	O
14	characteristic	O	O
15	yellow	O	O
16	flecks	O	O
17	consistent	O	O
18	with	O	O
19	Stargardt	BU	O
20	disease	IU	O
21	.	O	O

0	Hyperornithinemia	BU	O
1	hyperammonemia	IU	O
2	and	IU	O
3	homocitrullinuria	IU	O
4	HHH	IU	O
5	syndrome	IU	O
6	is	O	O
7	caused	O	O
8	by	O	O
9	mutations	O	O
10	in	O	O
11	the	O	O
12	SLC25A15	O	O
13	ORNT1	O	O
14	gene	O	O
15	encoding	O	O
16	the	O	O
17	mitochondrial	O	O
18	ornithine	O	O
19	transporter	O	O
20	but	O	O
21	the	O	O
22	mechanism	O	O
23	of	O	O
24	pathogenesis	O	O
25	of	O	O
26	the	O	O
27	encephalopathy	O	O
28	spastic	BI	O
29	paraparesis	II	O
30	and	O	O
31	hepatopathy	O	O
32	remains	O	O
33	undetermined	O	O
34	.	O	O

0	Clinical	O	O
1	features	O	O
2	were	O	O
3	characterized	O	O
4	by	O	O
5	neuroregression	O	O
6	retinitis	BU	O
7	pigmentosa	IU	O
8	hearing	BI	O
9	loss	II	O
10	peripheral	O	O
11	neuropathy	O	O
12	and	O	O
13	white	O	O
14	matter	O	O
15	signal	O	O
16	changes	O	O
17	on	O	O
18	magnetic	O	O
19	resonance	O	O
20	imaging	O	O
21	.	O	O

0	Clinical	O	O
1	and	O	O
2	electrophysiological	O	O
3	findings	O	O
4	are	O	O
5	described	O	O
6	in	O	O
7	three	O	O
8	patients	O	O
9	with	O	O
10	hereditary	BU	O
11	motor	IU	O
12	and	IU	O
13	sensory	IU	O
14	neuropathy	IU	O
15	in	O	O
16	association	O	O
17	with	O	O
18	optic	BI	O
19	atrophy	II	O
20	HMSN	O	O
21	VI	O	O
22	.	O	O

0	SUMMARY	O	O
1	OF	O	O
2	KEY	O	O
3	POINTS	O	O
4	Barth	O	O
5	Syndrome	O	O
6	is	O	O
7	an	O	O
8	unusual	O	O
9	pediatric	O	O
10	cardiovascular	O	O
11	and	O	O
12	neuromuscular	O	O
13	disorder	O	O
14	with	O	O
15	a	O	O
16	combination	O	O
17	of	O	O
18	features	O	O
19	including	O	O
20	dilated	BU	O
21	cardiomyopathy	IU	O
22	persistent	O	O
23	aciduria	O	O
24	skeletal	O	O
25	myopathy	O	O
26	severe	O	O
27	neutropenia	O	O
28	and	O	O
29	growth	BI	O
30	retardation	II	O
31	.	O	O

0	The	O	O
1	second	O	O
2	patient	O	O
3	was	O	O
4	a	O	O
5	14-year-old	O	O
6	girl	O	O
7	who	O	O
8	was	O	O
9	also	O	O
10	diagnosed	O	O
11	with	O	O
12	Treacher-Collins	BU	O
13	Syndrome	IU	O
14	with	O	O
15	bilateral	BI	O
16	moderate	II	O
17	conductive	II	O
18	hearing	II	O
19	loss	II	O
20	by	O	O
21	audiometry	O	O
22	.	O	O

0	Late-onset	BI	O
1	Friedreichs	II	O
2	ataxia	II	O
3	and	O	O
4	very-late-onset	BI	O
5	Friedreichs	II	O
6	ataxia	II	O
7	appear	O	O
8	to	O	O
9	belong	O	O
10	to	O	O
11	the	O	O
12	same	O	O
13	clinical	O	O
14	and	O	O
15	molecular	O	O
16	continuum	O	O
17	and	O	O
18	should	O	O
19	be	O	O
20	considered	O	O
21	together	O	O
22	as	O	O
23	"delayed-onset	BI	O
24	Friedreichs	II	O
25	ataxia."	II	O
26	As	O	O
27	the	O	O
28	most	O	O
29	frequently	O	O
30	inherited	BI	O
31	ataxia	II	O
32	Friedreichs	BI	O
33	ataxia	II	O
34	should	O	O
35	be	O	O
36	considered	O	O
37	facing	O	O
38	compatible	O	O
39	pictures	O	O
40	including	O	O
41	atypical	O	O
42	phenotypes	O	O
43	spastic	BU	O
44	ataxia	IU	O
45	retained	O	O
46	reflexes	O	O
47	lack	O	O
48	of	O	O
49	dysarthria	BI	O
50	and	O	O
51	lack	O	O
52	of	O	O
53	extraneurological	O	O
54	signs	O	O
55	delayed	O	O
56	disease	O	O
57	onset	O	O
58	even	O	O
59	after	O	O
60	60	O	O
61	years	O	O
62	of	O	O
63	age	O	O
64	and	O	O
65	or	O	O
66	slow	O	O
67	disease	O	O
68	progression	O	O
69	.	O	O

0	Much	O	O
1	progress	O	O
2	has	O	O
3	been	O	O
4	made	O	O
5	in	O	O
6	the	O	O
7	past	O	O
8	five	O	O
9	years	O	O
10	in	O	O
11	the	O	O
12	understanding	O	O
13	of	O	O
14	Leber	BU	O
15	congenital	IU	O
16	amaurosis	IU	O
17	LCA	IU	O
18	and	O	O
19	allied	O	O
20	early-onset	BI	O
21	retinal	II	O
22	dystrophies	II	O
23	various	O	O
24	forms	O	O
25	of	O	O
26	stationary	BI	O
27	sensory	II	O
28	retinal	II	O
29	blindness	II	O
30	and	O	O
31	genes	O	O
32	that	O	O
33	are	O	O
34	involved	O	O
35	in	O	O
36	the	O	O
37	development	O	O
38	of	O	O
39	the	O	O
40	retina	O	O
41	.	O	O

0	Missense	O	O
1	mutations	O	O
2	of	O	O
3	HSD10	O	O
4	may	O	O
5	cause	O	O
6	neurodegeneration	O	O
7	related	O	O
8	to	O	O
9	HSD10	BU	O
10	deficiency	IU	O
11	whereas	O	O
12	a	O	O
13	silent	O	O
14	mutation	O	O
15	of	O	O
16	HSD10	O	O
17	results	O	O
18	in	O	O
19	mental	BI	O
20	retardation	II	O
21	choreoathetosis	O	O
22	and	O	O
23	abnormal	BI	O
24	behavior	II	O
25	MRXS10	O	O
26	.	O	O

0	This	O	O
1	case	O	O
2	illustrates	O	O
3	that	O	O
4	frontotemporal	BU	O
5	dementia	IU	O
6	related	O	O
7	cognitive	BI	O
8	impairment	II	O
9	may	O	O
10	precede	O	O
11	behavioral	O	O
12	changes	O	O
13	in	O	O
14	VCP	O	O
15	disease	O	O
16	as	O	O
17	compared	O	O
18	with	O	O
19	predominance	O	O
20	of	O	O
21	behavioral	BI	O
22	impairment	II	O
23	reported	O	O
24	in	O	O
25	previous	O	O
26	studies	O	O
27	.	O	O

0	The	O	O
1	classic	O	O
2	phenotype	O	O
3	of	O	O
4	Friedreich	BU	O
5	ataxia	IU	O
6	is	O	O
7	characterized	O	O
8	by	O	O
9	dysarthria	BI	O
10	progressive	BI	O
11	limb	II	O
12	and	II	O
13	trunk	II	O
14	ataxia	II	O
15	loss	O	O
16	of	O	O
17	reflexes	O	O
18	and	O	O
19	gait	BI	O
20	disturbance	II	O
21	with	O	O
22	the	O	O
23	onset	O	O
24	of	O	O
25	disease	O	O
26	before	O	O
27	the	O	O
28	second	O	O
29	decade	O	O
30	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	a	O	O
4	case	O	O
5	of	O	O
6	Stargardt	BU	O
7	disease	IU	O
8	and	O	O
9	congenital	BI	O
10	stationary	II	O
11	night	II	O
12	blindness	II	O
13	CSNB	O	O
14	in	O	O
15	the	O	O
16	same	O	O
17	patient	O	O
18	and	O	O
19	the	O	O
20	identification	O	O
21	of	O	O
22	two	O	O
23	novel	O	O
24	in-frame	O	O
25	deletions	O	O
26	in	O	O
27	the	O	O
28	GRM6	O	O
29	gene	O	O
30	.	O	O

0	Mutations	O	O
1	in	O	O
2	carbonic	O	O
3	anhydrase	O	O
4	II	O	O
5	gene	O	O
6	lead	O	O
7	to	O	O
8	osteopetrosis	BU	O
9	RTA	O	O
10	pRTA	BU	O
11	distal	O	O
12	RTA	O	O
13	or	O	O
14	combined	O	O
15	proximal	O	O
16	and	O	O
17	distal	O	O
18	RTA	O	O
19	cerebral	O	O
20	calcification	O	O
21	and	O	O
22	mental	BI	O
23	retardation	II	O
24	.	O	O

0	Mowat-Wilson	BU	O
1	Syndrome	IU	O
2	is	O	O
3	a	O	O
4	recently	O	O
5	delineated	O	O
6	mental	BI	O
7	retardation	II	O
8	syndrome	O	O
9	usually	O	O
10	associated	O	O
11	with	O	O
12	multiple	O	O
13	malformations	O	O
14	and	O	O
15	a	O	O
16	recognizable	O	O
17	facial	O	O
18	phenotype	O	O
19	caused	O	O
20	by	O	O
21	defects	O	O
22	of	O	O
23	the	O	O
24	transcriptional	O	O
25	repressor	O	O
26	ZFHX1B	O	O
27	.	O	O

0	Students	O	O
1	at	O	O
2	two	O	O
3	schools	O	O
4	one	O	O
5	for	O	O
6	children	O	O
7	with	O	O
8	hearing	BI	O
9	impairment	II	O
10	were	O	O
11	screened	O	O
12	for	O	O
13	cataract	O	O
14	congenital	BU	O
15	glaucoma	IU	O
16	and	O	O
17	pigmentary	O	O
18	retinopathy	O	O
19	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	the	O	O
4	most	O	O
5	common	O	O
6	form	O	O
7	of	O	O
8	inherited	BI	O
9	intellectual	II	O
10	disability	II	O
11	is	O	O
12	caused	O	O
13	by	O	O
14	expansion	O	O
15	of	O	O
16	CGG	O	O
17	trinucleotide	O	O
18	repeat	O	O
19	at	O	O
20	the	O	O
21	5	O	O
22	untranslated	O	O
23	region	O	O
24	of	O	O
25	the	O	O
26	FMR1	O	O
27	gene	O	O
28	at	O	O
29	Xq27	O	O
30	.	O	O

0	Lennox-Gastaut	BU	O
1	syndrome	IU	O
2	is	O	O
3	an	O	O
4	epilepsy	O	O
5	syndrome	O	O
6	that	O	O
7	begins	O	O
8	in	O	O
9	childhood	O	O
10	between	O	O
11	1	O	O
12	and	O	O
13	8	O	O
14	years	O	O
15	of	O	O
16	age	O	O
17	worsens	O	O
18	during	O	O
19	latency	O	O
20	and	O	O
21	persists	O	O
22	frequently	O	O
23	into	O	O
24	adulthood	O	O
25	is	O	O
26	refractory	O	O
27	to	O	O
28	antiepileptic	O	O
29	medications	O	O
30	and	O	O
31	results	O	O
32	in	O	O
33	cognitive	BI	O
34	decline	II	O
35	and	O	O
36	behavioral	BI	O
37	problems	II	O
38	in	O	O
39	affected	O	O
40	individuals	O	O
41	.	O	O

0	Rett	BU	O
1	syndrome	IU	O
2	RS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	BI	O
6	dominant	II	O
7	neurodevelopmental	II	O
8	disorder	II	O
9	caused	O	O
10	by	O	O
11	mutations	O	O
12	in	O	O
13	MECP2	O	O
14	Xq28	O	O
15	and	O	O
16	characterized	O	O
17	by	O	O
18	normal	O	O
19	development	O	O
20	until	O	O
21	612	O	O
22	months	O	O
23	of	O	O
24	age	O	O
25	followed	O	O
26	by	O	O
27	regression	O	O
28	with	O	O
29	loss	O	O
30	of	O	O
31	acquired	O	O
32	skills	O	O
33	gradual	O	O
34	onset	O	O
35	of	O	O
36	microcephaly	O	O
37	stereotypic	O	O
38	hand	O	O
39	movements	O	O
40	and	O	O
41	psychomotor	BI	O
42	delay	II	O
43	.	O	O

0	Lambert-Eaton	BU	O
1	myasthenic	IU	O
2	syndrome	IU	O
3	LEMS	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	fluctuating	O	O
8	muscle	O	O
9	weakness	O	O
10	and	O	O
11	autonomic	BI	O
12	dysfunction	II	O
13	.	O	O

0	A	O	O
1	10-year-old	O	O
2	boy	O	O
3	presented	O	O
4	with	O	O
5	congenital	O	O
6	biliary	BU	O
7	atresia	IU	O
8	and	O	O
9	progressive	BI	O
10	gait	II	O
11	abnormality	II	O
12	.	O	O

0	Smith-Lemli-Opitz	BU	O
1	syndrome	IU	O
2	SLOS	IU	O
3	is	O	O
4	a	O	O
5	developmental	BI	O
6	disorder	II	O
7	resulting	O	O
8	from	O	O
9	mutations	O	O
10	to	O	O
11	the	O	O
12	Dhcr7	O	O
13	gene	O	O
14	which	O	O
15	is	O	O
16	required	O	O
17	for	O	O
18	cholesterol	O	O
19	synthesis	O	O
20	.	O	O

0	Additionally	O	O
1	this	O	O
2	article	O	O
3	gives	O	O
4	a	O	O
5	systematic	O	O
6	review	O	O
7	of	O	O
8	literature	O	O
9	regarding	O	O
10	psychiatric	BI	O
11	disorders	II	O
12	neurologic	O	O
13	symptoms	O	O
14	and	O	O
15	partly	O	O
16	corresponding	O	O
17	morphological	O	O
18	brain	O	O
19	abnormalities	O	O
20	in	O	O
21	22q11	BU	O
22	deletion	IU	O
23	syndromes	IU	O
24	.	O	O

0	Pendred	BU	O
1	syndrome	IU	O
2	the	O	O
3	most	O	O
4	frequent	O	O
5	syndromic	O	O
6	form	O	O
7	of	O	O
8	hereditary	BI	O
9	hearing	II	O
10	loss	II	O
11	is	O	O
12	associated	O	O
13	with	O	O
14	mutations	O	O
15	in	O	O
16	the	O	O
17	anion	O	O
18	exchanger	O	O
19	pendrin	O	O
20	.	O	O

0	In	O	O
1	conclusion	O	O
2	we	O	O
3	identified	O	O
4	expanded	O	O
5	CAG-repeats	O	O
6	in	O	O
7	the	O	O
8	SCA7	BU	O
9	gene	O	O
10	within	O	O
11	members	O	O
12	of	O	O
13	a	O	O
14	large	O	O
15	Chinese	O	O
16	family	O	O
17	with	O	O
18	spinocerebellar	BI	O
19	ataxia	II	O
20	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	BI	O
5	developmental	II	O
6	disorder	II	O
7	characterized	O	O
8	by	O	O
9	coarse	O	O
10	face	O	O
11	postnatal	BI	O
12	growth	II	O
13	retardation	II	O
14	skin	O	O
15	and	O	O
16	musculoskeletal	O	O
17	anomalies	O	O
18	cardiovascular	O	O
19	abnormalities	O	O
20	mental	BI	O
21	retardation	II	O
22	and	O	O
23	tumor	O	O
24	predisposition	O	O
25	.	O	O

0	One	O	O
1	aim	O	O
2	of	O	O
3	the	O	O
4	present	O	O
5	report	O	O
6	was	O	O
7	to	O	O
8	work	O	O
9	out	O	O
10	the	O	O
11	clinical	O	O
12	appearance	O	O
13	of	O	O
14	hearing	BI	O
15	loss	II	O
16	compared	O	O
17	to	O	O
18	hearing	BI	O
19	loss	II	O
20	in	O	O
21	Alports	BU	O
22	syndrome	IU	O
23	.	O	O

0	The	O	O
1	policy	O	O
2	of	O	O
3	limiting	O	O
4	medical	O	O
5	intervention	O	O
6	in	O	O
7	newborns	O	O
8	with	O	O
9	Edwards	BU	O
10	syndrome	IU	O
11	due	O	O
12	to	O	O
13	the	O	O
14	broad	O	O
15	spectrum	O	O
16	of	O	O
17	severe	O	O
18	congenital	O	O
19	malformations	O	O
20	severe	BI	O
21	mental	II	O
22	retard	II	O
23	and	O	O
24	reduced	O	O
25	life	O	O
26	expectancy	O	O
27	is	O	O
28	unanimously	O	O
29	accepted	O	O
30	but	O	O
31	yet	O	O
32	difficult	O	O
33	to	O	O
34	apply	O	O
35	from	O	O
36	an	O	O
37	ethical	O	O
38	point	O	O
39	of	O	O
40	view	O	O
41	.	O	O

0	Friedreich	BI	O
1	ataxia	II	O
2	is	O	O
3	an	O	O
4	autosomal	O	O
5	recessive	O	O
6	inherited	O	O
7	neuro-	O	O
8	and	O	O
9	cardio-degenerative	O	O
10	disorder	O	O
11	characterized	O	O
12	by	O	O
13	progressive	BI	O
14	ataxia	II	O
15	of	O	O
16	all	O	O
17	four	O	O
18	limbs	O	O
19	dysarthria	BI	O
20	areflexia	O	O
21	sensory	BI	O
22	loss	II	O
23	skeletal	O	O
24	deformities	O	O
25	and	O	O
26	hypertrophic	BU	O
27	cardiomyopathy	IU	O
28	.	O	O

0	Hearing	BI	O
1	impairment	II	O
2	was	O	O
3	detected	O	O
4	in	O	O
5	34	O	O
6	NS	BU	O
7	patients	O	O
8	.	O	O

0	Partial	O	O
1	trisomy	O	O
2	8q	O	O
3	is	O	O
4	rare	O	O
5	and	O	O
6	has	O	O
7	distinctive	O	O
8	clinical	O	O
9	features	O	O
10	including	O	O
11	severe	BI	O
12	mental	II	O
13	retardation	II	O
14	growth	BI	O
15	impairment	II	O
16	dysmorphic	O	O
17	facial	O	O
18	appearances	O	O
19	cleft	BU	O
20	palate	IU	O
21	congenital	O	O
22	heart	O	O
23	disease	O	O
24	and	O	O
25	urogenital	O	O
26	anomalies	O	O
27	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	3.5-year	O	O
7	old	O	O
8	47	O	O
9	XXY	O	O
10	male	O	O
11	with	O	O
12	the	O	O
13	classic	O	O
14	triad	O	O
15	of	O	O
16	Aicardi	BU	O
17	syndrome	IU	O
18	but	O	O
19	with	O	O
20	good	O	O
21	seizure	O	O
22	control	O	O
23	and	O	O
24	mild	BI	O
25	learning	II	O
26	disability	II	O
27	.	O	O

0	CONCLUSION	O	O
1	Mutations	O	O
2	in	O	O
3	tRNAIle	O	O
4	were	O	O
5	described	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	chronic	O	O
10	progressive	O	O
11	external	O	O
12	ophthalmoplegia	O	O
13	CPEO	O	O
14	prominent	BI	O
15	deafness	II	O
16	or	O	O
17	cardiomyopathy	BU	O
18	but	O	O
19	up	O	O
20	to	O	O
21	now	O	O
22	not	O	O
23	in	O	O
24	patients	O	O
25	with	O	O
26	myoclonic	O	O
27	epilepsy	O	O
28	.	O	O

0	NS	BU	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	dysmorphic	O	O
5	external	O	O
6	ear	O	O
7	anomalies	O	O
8	and	O	O
9	both	O	O
10	sensorineural	BI	O
11	and	II	O
12	conductive	II	O
13	hearing	II	O
14	impairment	II	O
15	.	O	O

0	Atypical	BU	O
1	nonketotic	IU	O
2	hyperglycinemia	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	heterogeneous	O	O
7	phenotypes	O	O
8	that	O	O
9	often	O	O
10	include	O	O
11	nonspecific	BI	O
12	behavioral	II	O
13	problems	II	O
14	cognitive	BI	O
15	deficits	II	O
16	and	O	O
17	developmental	BI	O
18	delays	II	O
19	.	O	O

0	Background	O	O
1	Congenital	BU	O
2	hypothyroidism	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	reason	O	O
8	of	O	O
9	mental	BI	O
10	retardation	II	O
11	and	O	O
12	normal	O	O
13	neurological	O	O
14	development	O	O
15	can	O	O
16	be	O	O
17	provided	O	O
18	by	O	O
19	early	O	O
20	and	O	O
21	effective	O	O
22	treatment	O	O
23	.	O	O

0	In	O	O
1	addition	O	O
2	Diamond-Blackfan	BU	O
3	anaemia	IU	O
4	patients	O	O
5	also	O	O
6	exhibit	O	O
7	a	O	O
8	number	O	O
9	of	O	O
10	behavioural	BI	O
11	abnormalities	II	O
12	.	O	O

0	We	O	O
1	conducted	O	O
2	a	O	O
3	prospective	O	O
4	placebo-controlled	O	O
5	study	O	O
6	to	O	O
7	determine	O	O
8	the	O	O
9	incidence	O	O
10	and	O	O
11	severity	O	O
12	of	O	O
13	inner	O	O
14	ear	O	O
15	involvement	O	O
16	and	O	O
17	hearing	BI	O
18	loss	II	O
19	in	O	O
20	patients	O	O
21	with	O	O
22	Behçet	BU	O
23	disease	IU	O
24	.	O	O

0	CASE	O	O
1	REPORT	O	O
2	A	O	O
3	21-year-old	O	O
4	woman	O	O
5	presented	O	O
6	with	O	O
7	seizures	O	O
8	mental	BI	O
9	retardation	II	O
10	spastic	BI	O
11	diplegia	II	O
12	and	O	O
13	ichthyosis	BU	O
14	since	O	O
15	birth	O	O
16	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	growth	BI	O
10	and	II	O
11	psychomotor	II	O
12	retardation	II	O
13	hypotonia	O	O
14	and	O	O
15	progressive	O	O
16	skeletal	O	O
17	changes	O	O
18	.	O	O

0	To	O	O
1	be	O	O
2	included	O	O
3	patients	O	O
4	had	O	O
5	to	O	O
6	present	O	O
7	with	O	O
8	the	O	O
9	following	O	O
10	triad	O	O
11	cleft	BU	O
12	palate	IU	O
13	facial	O	O
14	features	O	O
15	hypoplastic	O	O
16	midface	O	O
17	micrognathia	O	O
18	and	O	O
19	prominent	O	O
20	eyes	O	O
21	and	O	O
22	ocular	BI	O
23	anomalies	II	O
24	myopia	O	O
25	and	O	O
26	or	O	O
27	abnormalities	BI	O
28	of	II	O
29	the	II	O
30	retina	II	O
31	.	O	O

0	CONCLUSION	O	O
1	We	O	O
2	report	O	O
3	a	O	O
4	rare	O	O
5	case	O	O
6	of	O	O
7	psychomotor	BI	O
8	retardation	II	O
9	occurring	O	O
10	at	O	O
11	an	O	O
12	early	O	O
13	age	O	O
14	in	O	O
15	genetically	O	O
16	confirmed	O	O
17	GS	BU	O
18	.	O	O

0	The	O	O
1	differential	O	O
2	diagnosis	O	O
3	of	O	O
4	developmental	BI	O
5	delays	II	O
6	and	O	O
7	growth	BI	O
8	retardation	II	O
9	in	O	O
10	early	O	O
11	childhood	O	O
12	includes	O	O
13	the	O	O
14	allelic	O	O
15	lysosomal	O	O
16	sialic	O	O
17	acid	O	O
18	storage	O	O
19	disorders	O	O
20	Salla	BU	O
21	disease	IU	O
22	and	O	O
23	infantile	BU	O
24	free	IU	O
25	sialic	IU	O
26	acid	IU	O
27	storage	IU	O
28	disease	IU	O
29	ISSD	IU	O
30	.	O	O

0	Cohen	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	genetic	O	O
6	disorder	O	O
7	consisting	O	O
8	of	O	O
9	truncal	O	O
10	obesity	O	O
11	hypotonia	O	O
12	mental	BI	O
13	retardation	II	O
14	microcephalia	O	O
15	characteristic	O	O
16	facial	O	O
17	appearance	O	O
18	and	O	O
19	ocular	BI	O
20	anomalies	II	O
21	.	O	O

0	There	O	O
1	is	O	O
2	a	O	O
3	paucity	O	O
4	of	O	O
5	data	O	O
6	in	O	O
7	the	O	O
8	literature	O	O
9	regarding	O	O
10	epilepsy	O	O
11	in	O	O
12	Down	BU	O
13	syndrome	IU	O
14	and	O	O
15	its	O	O
16	relation	O	O
17	to	O	O
18	intellectual	BI	O
19	disability	II	O
20	.	O	O

0	We	O	O
1	aim	O	O
2	to	O	O
3	analyze	O	O
4	neurocognitive	O	O
5	functioning	O	O
6	of	O	O
7	school-aged	O	O
8	cystinosis	BU	O
9	patients	O	O
10	treated	O	O
11	with	O	O
12	cysteamine	O	O
13	in	O	O
14	order	O	O
15	to	O	O
16	identify	O	O
17	specific	O	O
18	deficits	O	O
19	that	O	O
20	can	O	O
21	lead	O	O
22	to	O	O
23	learning	BI	O
24	difficulties	II	O
25	.	O	O

0	OBJECTIVES	O	O
1	Kallmann	BU	O
2	syndrome	IU	O
3	KS	IU	O
4	usually	O	O
5	combines	O	O
6	an	O	O
7	anosmia	BI	O
8	and	O	O
9	a	O	O
10	hypogonadotrophic	O	O
11	hypogonadism	O	O
12	.	O	O

0	However	O	O
1	the	O	O
2	patient	O	O
3	still	O	O
4	suffered	O	O
5	many	O	O
6	complications	O	O
7	after	O	O
8	the	O	O
9	severe	O	O
10	metabolic	O	O
11	insult	O	O
12	with	O	O
13	hypoxic	O	O
14	ischemic	O	O
15	encephalopathy	O	O
16	cerebral	O	O
17	atrophy	O	O
18	global	BI	O
19	developmental	II	O
20	delay	II	O
21	and	O	O
22	cortical	BU	O
23	visual	IU	O
24	impairment	IU	O
25	.	O	O

0	Potocki-Lupski	BU	O
1	syndrome	IU	O
2	PTLS	IU	O
3	or	O	O
4	duplication	O	O
5	17p11.2	O	O
6	syndrome	O	O
7	is	O	O
8	a	O	O
9	newly	O	O
10	characterized	O	O
11	condition	O	O
12	causing	O	O
13	a	O	O
14	variety	O	O
15	of	O	O
16	health	O	O
17	problems	O	O
18	with	O	O
19	variable	O	O
20	severity	O	O
21	including	O	O
22	failure	O	O
23	to	O	O
24	thrive	O	O
25	in	O	O
26	infancy	O	O
27	and	O	O
28	childhood	O	O
29	hypotonia	O	O
30	structural	O	O
31	heart	O	O
32	anomalies	O	O
33	cognitive	BI	O
34	impairments	II	O
35	speech	BI	O
36	and	II	O
37	learning	II	O
38	difficulties	II	O
39	and	O	O
40	autism	BI	O
41	.	O	O

0	ALMS	O	O
1	an	O	O
2	autosomal	O	O
3	recessive	O	O
4	syndrome	O	O
5	causes	O	O
6	juvenile	BI	O
7	blindness	II	O
8	sensorineural	BI	O
9	hearing	II	O
10	loss	II	O
11	cardiomyopathy	BU	O
12	endocrinological	O	O
13	disorders	O	O
14	and	O	O
15	metabolic	O	O
16	dysfunction	O	O
17	.	O	O

0	Deletion	O	O
1	of	O	O
2	Lgr4	O	O
3	in	O	O
4	mouse	O	O
5	led	O	O
6	to	O	O
7	aniridia	BU	O
8	polycystic	O	O
9	kidney	O	O
10	disease	O	O
11	genitourinary	O	O
12	anomalies	O	O
13	and	O	O
14	mental	BI	O
15	retardation	II	O
16	similar	O	O
17	to	O	O
18	the	O	O
19	pathological	O	O
20	defects	O	O
21	of	O	O
22	AGR	O	O
23	syndrome	O	O
24	.	O	O

0	The	O	O
1	investigations	O	O
2	demonstrated	O	O
3	truncated	O	O
4	obesity	O	O
5	sensorineural	BI	O
6	deafness	II	O
7	and	O	O
8	impaired	O	O
9	glucose	O	O
10	tolerance	O	O
11	and	O	O
12	Alstrom-syndrome	BU	O
13	was	O	O
14	diagnosed	O	O
15	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	3year	O	O
4	old	O	O
5	child	O	O
6	with	O	O
7	BOR	BU	O
8	syndrome	IU	O
9	who	O	O
10	came	O	O
11	to	O	O
12	us	O	O
13	with	O	O
14	bilateral	O	O
15	low	O	O
16	set	O	O
17	malformed	O	O
18	ears	O	O
19	&	O	O
20	profound	BI	O
21	cochlear	II	O
22	hearing	II	O
23	loss	II	O
24	along	O	O
25	with	O	O
26	bilateral	O	O
27	branchial	O	O
28	fistulae	O	O
29	&	O	O
30	unilateral	O	O
31	renal	O	O
32	agenesis	O	O
33	.	O	O

0	18p	BU	O
1	deletion	IU	O
2	syndrome	IU	O
3	can	O	O
4	be	O	O
5	easily	O	O
6	missed	O	O
7	in	O	O
8	a	O	O
9	clinical	O	O
10	setting	O	O
11	as	O	O
12	the	O	O
13	facial	O	O
14	features	O	O
15	though	O	O
16	typical	O	O
17	can	O	O
18	be	O	O
19	overlooked	O	O
20	and	O	O
21	the	O	O
22	other	O	O
23	features	O	O
24	including	O	O
25	growth	BI	O
26	retardation	II	O
27	and	O	O
28	learning	BI	O
29	disability	II	O
30	are	O	O
31	nonspecific	O	O
32	.	O	O

0	METHODS	O	O
1	Fifty-six	O	O
2	patients	O	O
3	with	O	O
4	behavioural	BI	O
5	variant	II	O
6	frontotemporal	II	O
7	dementia	II	O
8	20	O	O
9	with	O	O
10	concomitant	BU	O
11	amyotrophic	IU	O
12	lateral	IU	O
13	sclerosis	IU	O
14	and	O	O
15	23	O	O
16	healthy	O	O
17	controls	O	O
18	underwent	O	O
19	neuropsychological	O	O
20	assessments	O	O
21	detailed	O	O
22	clinical	O	O
23	interview	O	O
24	for	O	O
25	assessment	O	O
26	of	O	O
27	psychosis	O	O
28	symptoms	O	O
29	brain	O	O
30	MRI	O	O
31	and	O	O
32	genetic	O	O
33	testing	O	O
34	.	O	O

0	Despite	O	O
1	a	O	O
2	reduction	O	O
3	in	O	O
4	disease	O	O
5	burden	O	O
6	of	O	O
7	several	O	O
8	vaccine-preventable	O	O
9	diseases	O	O
10	through	O	O
11	childhood	O	O
12	immunization	O	O
13	CRS	BU	O
14	continues	O	O
15	to	O	O
16	account	O	O
17	for	O	O
18	preventable	O	O
19	severe	O	O
20	morbidity	O	O
21	including	O	O
22	childhood	BI	O
23	blindness	II	O
24	deafness	BI	O
25	heart	O	O
26	disease	O	O
27	and	O	O
28	mental	BI	O
29	retardation	II	O
30	.	O	O

0	In	O	O
1	contrast	O	O
2	social	BI	O
3	and	II	O
4	emotional	II	O
5	disturbances	II	O
6	are	O	O
7	the	O	O
8	major	O	O
9	disabilities	O	O
10	and	O	O
11	targets	O	O
12	for	O	O
13	rehabilitation	O	O
14	in	O	O
15	behavioral	BU	O
16	variant	IU	O
17	frontotemporal	IU	O
18	dementia	IU	O
19	bvFTD	IU	O
20	an	O	O
21	incompletely	O	O
22	understood	O	O
23	non-Alzheimer	BI	O
24	dementia	II	O
25	.	O	O

0	Clinical	O	O
1	features	O	O
2	were	O	O
3	grouped	O	O
4	into	O	O
5	a	O	O
6	core	O	O
7	set	O	O
8	of	O	O
9	eight	O	O
10	features	O	O
11	cardiac	O	O
12	defects	O	O
13	non-visible	O	O
14	hypoplastic	O	O
15	thymus	O	O
16	or	O	O
17	infection	O	O
18	problems	O	O
19	hypocalcaemia	O	O
20	feeding	O	O
21	difficulties	O	O
22	cleft	BU	O
23	palate	IU	O
24	speech-language	BI	O
25	impairment	II	O
26	developmental	BI	O
27	delay	II	O
28	learning	BI	O
29	difficulties	II	O
30	characteristic	O	O
31	dysmorphic	O	O
32	features	O	O
33	and	O	O
34	other	O	O
35	malformations	O	O
36	and	O	O
37	deformities	O	O
38	.	O	O

0	Langer-Giedion	BU	O
1	Syndrome	IU	O
2	LGS	O	O
3	with	O	O
4	characteristic	O	O
5	phenotypic	O	O
6	features	O	O
7	including	O	O
8	craniofacial	O	O
9	dysmorphic	O	O
10	signs	O	O
11	postnatal	BI	O
12	growth	II	O
13	retardation	II	O
14	and	O	O
15	skeletal	O	O
16	abnormalities	O	O
17	mental	BI	O
18	impairment	II	O
19	urogenital	O	O
20	malformations	O	O
21	and	O	O
22	heart	O	O
23	defects	O	O
24	is	O	O
25	caused	O	O
26	by	O	O
27	partial	O	O
28	deletions	O	O
29	of	O	O
30	the	O	O
31	long	O	O
32	arm	O	O
33	of	O	O
34	chromosome	O	O
35	8	O	O
36	.	O	O

0	This	O	O
1	unique	O	O
2	combination	O	O
3	of	O	O
4	more	O	O
5	than	O	O
6	one	O	O
7	non-epileptic	BI	O
8	movement	II	O
9	disorder	II	O
10	and	O	O
11	epilepsy	O	O
12	deserves	O	O
13	further	O	O
14	semiological	O	O
15	and	O	O
16	genetic	O	O
17	study	O	O
18	both	O	O
19	for	O	O
20	the	O	O
21	patients	O	O
22	with	O	O
23	CLS	BU	O
24	and	O	O
25	for	O	O
26	the	O	O
27	wider	O	O
28	implications	O	O
29	.	O	O

0	Identified	O	O
1	risk	O	O
2	factors	O	O
3	for	O	O
4	infectious	O	O
5	complications	O	O
6	include	O	O
7	functional	BI	O
8	impairment	II	O
9	and	O	O
10	the	O	O
11	presence	O	O
12	of	O	O
13	dementia	BI	O
14	which	O	O
15	may	O	O
16	allow	O	O
17	for	O	O
18	better	O	O
19	risk	O	O
20	stratification	O	O
21	and	O	O
22	individualized	O	O
23	treatment	O	O
24	of	O	O
25	bullous	BU	O
26	pemphigoid	IU	O
27	.	O	O

0	A	O	O
1	comparison	O	O
2	group	O	O
3	of	O	O
4	visually	BI	O
5	impaired	II	O
6	subjects	O	O
7	with	O	O
8	isolated	BU	O
9	aniridia	IU	O
10	had	O	O
11	cognitive	O	O
12	functioning	O	O
13	comparable	O	O
14	to	O	O
15	that	O	O
16	of	O	O
17	healthy	O	O
18	controls	O	O
19	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	a	O	O
6	12-year-old	O	O
7	girl	O	O
8	with	O	O
9	Crouzon	BU	O
10	syndrome	IU	O
11	displaying	O	O
12	classic	O	O
13	facial	O	O
14	abnormalities	O	O
15	with	O	O
16	reduced	BI	O
17	vision	II	O
18	and	O	O
19	hearing	BI	O
20	loss	II	O
21	.	O	O

0	Although	O	O
1	the	O	O
2	literature	O	O
3	offers	O	O
4	conflicting	O	O
5	evidence	O	O
6	for	O	O
7	association	O	O
8	of	O	O
9	NF1	BU	O
10	and	O	O
11	autism	BI	O
12	there	O	O
13	has	O	O
14	been	O	O
15	no	O	O
16	systematic	O	O
17	evaluation	O	O
18	of	O	O
19	autism	BI	O
20	traits	II	O
21	in	O	O
22	the	O	O
23	RASopathies	O	O
24	as	O	O
25	a	O	O
26	class	O	O
27	to	O	O
28	support	O	O
29	a	O	O
30	role	O	O
31	for	O	O
32	germline	O	O
33	Ras	O	O
34	MAPK	O	O
35	activation	O	O
36	in	O	O
37	ASDs	O	O
38	.	O	O

0	In	O	O
1	clinical	O	O
2	and	O	O
3	radiologic	O	O
4	aspect	O	O
5	a	O	O
6	patient	O	O
7	with	O	O
8	multiple	O	O
9	exostoses	O	O
10	accompanying	O	O
11	with	O	O
12	syndromic	O	O
13	features	O	O
14	including	O	O
15	craniofacial	O	O
16	abnormalities	O	O
17	and	O	O
18	mental	BI	O
19	retardation	II	O
20	the	O	O
21	diagnosis	O	O
22	of	O	O
23	PSS	BU	O
24	should	O	O
25	be	O	O
26	considered	O	O
27	.	O	O

0	Cerebral	BU	O
1	autosomal	IU	O
2	dominant	IU	O
3	arteriopathy	IU	O
4	with	IU	O
5	subcortical	IU	O
6	infarcts	IU	O
7	and	IU	O
8	leukoencephalopathy	IU	O
9	CADASIL	IU	O
10	is	O	O
11	a	O	O
12	genetically	O	O
13	transmitted	O	O
14	small	O	O
15	vessel	O	O
16	disease	O	O
17	clinically	O	O
18	characterized	O	O
19	by	O	O
20	migraine	O	O
21	recurrent	O	O
22	subcortical	O	O
23	strokes	O	O
24	and	O	O
25	cognitive	BI	O
26	and	II	O
27	mood	II	O
28	disorders	II	O
29	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	HMSN	BU	O
4	and	O	O
5	optic	O	O
6	atrophy	O	O
7	a	O	O
8	20-year-old	O	O
9	man	O	O
10	suffered	O	O
11	from	O	O
12	sensorineural	BI	O
13	deafness	II	O
14	.	O	O

0	Leber	BU	O
1	congenital	IU	O
2	amaurosis	IU	O
3	LCA	IU	O
4	is	O	O
5	one	O	O
6	of	O	O
7	the	O	O
8	main	O	O
9	causes	O	O
10	of	O	O
11	childhood	BI	O
12	blindness	II	O
13	.	O	O

0	However	O	O
1	in	O	O
2	the	O	O
3	common	O	O
4	inherited	O	O
5	cancer	O	O
6	predisposition	O	O
7	syndrome	O	O
8	neurofibromatosis	BU	O
9	type	IU	O
10	1	IU	O
11	NF1	IU	O
12	the	O	O
13	prevalence	O	O
14	of	O	O
15	these	O	O
16	cognitive	BI	O
17	deficits	II	O
18	approaches	O	O
19	70%	O	O
20	.	O	O

0	HHH	BU	O
1	syndrome	IU	O
2	was	O	O
3	diagnosed	O	O
4	in	O	O
5	a	O	O
6	2-year-old	O	O
7	Palestinian	O	O
8	boy	O	O
9	with	O	O
10	developmental	BI	O
11	delay	II	O
12	and	O	O
13	seizures	O	O
14	and	O	O
15	subsequently	O	O
16	in	O	O
17	his	O	O
18	13-year-old	O	O
19	brother	O	O
20	with	O	O
21	developmental	BI	O
22	delay	II	O
23	.	O	O

0	Clinical	O	O
1	features	O	O
2	of	O	O
3	hereditary	BU	O
4	motor	IU	O
5	and	IU	O
6	sensory	IU	O
7	neuropathy	IU	O
8	type	IU	O
9	VI	IU	O
10	are	O	O
11	muscle	O	O
12	weakness	O	O
13	and	O	O
14	atrophy	O	O
15	in	O	O
16	leg	O	O
17	and	O	O
18	hand	O	O
19	muscles	O	O
20	leading	O	O
21	to	O	O
22	progressive	O	O
23	disability	O	O
24	and	O	O
25	loss	BI	O
26	of	II	O
27	vision	II	O
28	and	O	O
29	progressing	O	O
30	to	O	O
31	blindness	BI	O
32	due	O	O
33	to	O	O
34	optic	BI	O
35	atrophy	II	O
36	.	O	O

0	Both	O	O
1	affected	O	O
2	siblings	O	O
3	had	O	O
4	cone	BU	O
5	rod	IU	O
6	dystrophy	IU	O
7	with	O	O
8	impaired	BI	O
9	visual	II	O
10	acuity	II	O
11	sensorineural	BI	O
12	hearing	II	O
13	loss	II	O
14	and	O	O
15	truncal	O	O
16	obesity	O	O
17	.	O	O

0	CLINICAL	O	O
1	CHARACTERISTICS	O	O
2	Coffin-Siris	BU	O
3	syndrome	IU	O
4	CSS	IU	O
5	is	O	O
6	classically	O	O
7	characterized	O	O
8	by	O	O
9	aplasia	O	O
10	or	O	O
11	hypoplasia	O	O
12	of	O	O
13	the	O	O
14	distal	O	O
15	phalanx	O	O
16	or	O	O
17	nail	O	O
18	of	O	O
19	the	O	O
20	fifth	O	O
21	and	O	O
22	additional	O	O
23	digits	O	O
24	developmental	BI	O
25	or	II	O
26	cognitive	II	O
27	delay	II	O
28	of	O	O
29	varying	O	O
30	degree	O	O
31	distinctive	O	O
32	facial	O	O
33	features	O	O
34	hypotonia	O	O
35	hirutism	O	O
36	hypertrichosis	BU	O
37	and	O	O
38	sparse	O	O
39	scalp	O	O
40	hair	O	O
41	.	O	O

0	BFLS	BU	O
1	mental	BI	O
2	disability	II	O
3	is	O	O
4	evident	O	O
5	from	O	O
6	an	O	O
7	early	O	O
8	age	O	O
9	suggesting	O	O
10	a	O	O
11	developmental	BI	O
12	brain	II	O
13	defect	II	O
14	.	O	O

0	Screening	O	O
1	for	O	O
2	aspartylglucosaminuria	BU	O
3	should	O	O
4	be	O	O
5	done	O	O
6	in	O	O
7	all	O	O
8	patients	O	O
9	with	O	O
10	unexplained	BI	O
11	psychomotor	II	O
12	retardation	II	O
13	.	O	O

0	Three	O	O
1	children	O	O
2	with	O	O
3	CHARGE	BU	O
4	association	IU	O
5	coloboma	O	O
6	heart	O	O
7	defect	O	O
8	atresia	O	O
9	of	O	O
10	the	O	O
11	choanae	O	O
12	retarded	BI	O
13	growth	II	O
14	and	II	O
15	development	II	O
16	genital	O	O
17	hypoplasia	O	O
18	ear	O	O
19	anomalies	O	O
20	and	O	O
21	hearing	BI	O
22	defects	II	O
23	as	O	O
24	well	O	O
25	as	O	O
26	concomitant	BI	O
27	autistic	II	O
28	disorder	II	O
29	are	O	O
30	reported	O	O
31	.	O	O

0	Aicardi	BU	O
1	syndrome	IU	O
2	AS	IU	O
3	is	O	O
4	a	O	O
5	rare	BI	O
6	neurodevelopmental	II	O
7	disorder	II	O
8	characterized	O	O
9	by	O	O
10	the	O	O
11	triad	O	O
12	of	O	O
13	corpus	O	O
14	callosum	O	O
15	agenesis	O	O
16	chorioretinal	O	O
17	lacunae	O	O
18	and	O	O
19	infantile	BU	O
20	spasms	IU	O
21	.	O	O

0	Frontotemporal	BI	O
1	dementia	II	O
2	motor	O	O
3	neuron	O	O
4	disease	O	O
5	and	O	O
6	frontotemporal	BU	O
7	dementia-motor	IU	O
8	neuron	IU	O
9	disease	IU	O
10	are	O	O
11	characterised	O	O
12	by	O	O
13	overlapping	O	O
14	patterns	O	O
15	of	O	O
16	TAR	O	O
17	DNA	O	O
18	binding	O	O
19	protein	O	O
20	TDP-43	O	O
21	pathology	O	O
22	while	O	O
23	the	O	O
24	chromosome	O	O
25	9	O	O
26	open	O	O
27	reading	O	O
28	frame	O	O
29	72	O	O
30	C9orf72	O	O
31	repeat	O	O
32	expansion	O	O
33	is	O	O
34	common	O	O
35	across	O	O
36	the	O	O
37	disease	O	O
38	spectrum	O	O
39	.	O	O

0	In	O	O
1	addition	O	O
2	CMT	BU	O
3	patients	O	O
4	were	O	O
5	exposed	O	O
6	to	O	O
7	a	O	O
8	higher	O	O
9	risk	O	O
10	of	O	O
11	reduced	O	O
12	quality	O	O
13	of	O	O
14	life	O	O
15	and	O	O
16	significant	O	O
17	sleep	BI	O
18	impairment	II	O
19	.	O	O

0	Mucopolysaccharidosis	BU	O
1	type	IU	O
2	III	IU	O
3	MPS	IU	O
4	III	IU	O
5	is	O	O
6	characterized	O	O
7	by	O	O
8	progressive	O	O
9	neurological	O	O
10	deterioration	O	O
11	behavioral	BI	O
12	abnormalities	II	O
13	a	O	O
14	relatively	O	O
15	mild	O	O
16	somatic	O	O
17	phenotype	O	O
18	and	O	O
19	early	O	O
20	mortality	O	O
21	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	complex	BI	O
5	neurodevelopmental	II	O
6	disorder	II	O
7	that	O	O
8	includes	O	O
9	intellectual	BI	O
10	deficiency	II	O
11	speech	BI	O
12	delay	II	O
13	behavioral	BI	O
14	disturbance	II	O
15	and	O	O
16	typical	O	O
17	sleep	BI	O
18	disorders	II	O
19	.	O	O

0	PURPOSE	O	O
1	Survivors	O	O
2	of	O	O
3	childhood	O	O
4	acute	BU	O
5	lymphoblastic	IU	O
6	leukemia	IU	O
7	ALL	IU	O
8	treated	O	O
9	with	O	O
10	CNS-directed	O	O
11	chemotherapy	O	O
12	are	O	O
13	at	O	O
14	risk	O	O
15	for	O	O
16	neurocognitive	BI	O
17	deficits	II	O
18	.	O	O

0	In	O	O
1	addition	O	O
2	this	O	O
3	is	O	O
4	the	O	O
5	first	O	O
6	documented	O	O
7	case	O	O
8	in	O	O
9	a	O	O
10	girl	O	O
11	that	O	O
12	was	O	O
13	clearly	O	O
14	associated	O	O
15	with	O	O
16	intellectual	BI	O
17	disability	II	O
18	which	O	O
19	is	O	O
20	very	O	O
21	rare	O	O
22	in	O	O
23	females	O	O
24	with	O	O
25	Danon	BU	O
26	disease	IU	O
27	.	O	O

0	Choroideremia	BU	O
1	CHM	IU	O
2	an	O	O
3	X-linked	O	O
4	degeneration	O	O
5	of	O	O
6	the	O	O
7	retinal	O	O
8	pigmented	O	O
9	epithelium	O	O
10	RPE	O	O
11	photoreceptors	O	O
12	and	O	O
13	choroid	O	O
14	ultimately	O	O
15	leads	O	O
16	to	O	O
17	blindness	BI	O
18	.	O	O

0	Coarse	O	O
1	progeroid	O	O
2	facial	O	O
3	features	O	O
4	with	O	O
5	a	O	O
6	bulbous	O	O
7	nose	O	O
8	feeding	BI	O
9	difficulties	II	O
10	in	II	O
11	infancy	II	O
12	cardiac	O	O
13	involvement	O	O
14	with	O	O
15	cardiomyopathy	BU	O
16	or	O	O
17	conduction	O	O
18	defect	O	O
19	and	O	O
20	in	O	O
21	our	O	O
22	case	O	O
23	impaired	O	O
24	glucose	O	O
25	tolerance	O	O
26	also	O	O
27	presented	O	O
28	.	O	O

0	BACKGROUND	O	O
1	Pendred	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	condition	O	O
9	characterized	O	O
10	by	O	O
11	functional	BI	O
12	impairment	II	O
13	of	O	O
14	thyroid	O	O
15	gland	O	O
16	and	O	O
17	sensorineural	BI	O
18	hearing	II	O
19	loss	II	O
20	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	6-year-old	O	O
4	male	O	O
5	with	O	O
6	coarse	O	O
7	facial	O	O
8	features	O	O
9	developmental	BI	O
10	delay	II	O
11	refractory	O	O
12	seizures	O	O
13	hypertrophic	BU	O
14	cardiomyopathy	IU	O
15	who	O	O
16	was	O	O
17	later	O	O
18	found	O	O
19	to	O	O
20	have	O	O
21	Sandhoff	O	O
22	disease	O	O
23	.	O	O

0	The	O	O
1	major	O	O
2	manifestations	O	O
3	of	O	O
4	the	O	O
5	Wolf-Hirschhorn	BU	O
6	syndrome	IU	O
7	are	O	O
8	developmental	BI	O
9	delay	II	O
10	short	O	O
11	stature	O	O
12	mental	BI	O
13	impairment	II	O
14	and	O	O
15	epilepsy	O	O
16	.	O	O

0	Spinocerebellar	BU	O
1	ataxia	IU	O
2	type	IU	O
3	6	IU	O
4	SCA6	IU	O
5	is	O	O
6	caused	O	O
7	by	O	O
8	small	O	O
9	CAG	O	O
10	repeat	O	O
11	expansion	O	O
12	in	O	O
13	the	O	O
14	gene	O	O
15	encoding	O	O
16	the	O	O
17	1A-voltage-dependent-calcium	O	O
18	channel	O	O
19	subunit	O	O
20	CACNL1A4	O	O
21	on	O	O
22	chromosome	O	O
23	19p13	O	O
24	and	O	O
25	is	O	O
26	a	O	O
27	subgroup	O	O
28	of	O	O
29	the	O	O
30	late-onset	BI	O
31	pure	II	O
32	cerebellar	II	O
33	ataxia	II	O
34	ADCA	BU	O
35	III	IU	O
36	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	delineate	O	O
8	the	O	O
9	PIGV	O	O
10	mutation	O	O
11	spectrum	O	O
12	as	O	O
13	well	O	O
14	as	O	O
15	the	O	O
16	associated	O	O
17	phenotypic	O	O
18	spectrum	O	O
19	in	O	O
20	a	O	O
21	cohort	O	O
22	of	O	O
23	16	O	O
24	individuals	O	O
25	diagnosed	O	O
26	with	O	O
27	HPMRS	BU	O
28	on	O	O
29	the	O	O
30	basis	O	O
31	of	O	O
32	intellectual	BI	O
33	disability	II	O
34	and	O	O
35	elevated	O	O
36	serum	O	O
37	alkaline	O	O
38	phosphate	O	O
39	as	O	O
40	minimal	O	O
41	diagnostic	O	O
42	criteria	O	O
43	.	O	O

0	CONCLUSIONS	O	O
1	Darier	BU	O
2	disease	IU	O
3	is	O	O
4	associated	O	O
5	with	O	O
6	intellectual	BI	O
7	disability	II	O
8	and	O	O
9	subclinical	BI	O
10	impairments	II	O
11	in	II	O
12	cognitive	II	O
13	ability	II	O
14	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	type	O	O
8	of	O	O
9	inherited	BI	O
10	mental	II	O
11	retardation	II	O
12	caused	O	O
13	by	O	O
14	the	O	O
15	absence	O	O
16	of	O	O
17	FMRP	O	O
18	protein	O	O
19	a	O	O
20	RNA-binding	O	O
21	protein	O	O
22	implicated	O	O
23	in	O	O
24	the	O	O
25	regulation	O	O
26	of	O	O
27	mRNA	O	O
28	translation	O	O
29	and	O	O
30	transport	O	O
31	leading	O	O
32	to	O	O
33	protein	O	O
34	synthesis	O	O
35	.	O	O

0	Kearns-Sayre	BU	O
1	syndrome	IU	O
2	KSS	IU	O
3	is	O	O
4	a	O	O
5	mitochondrial	O	O
6	disorder	O	O
7	characterised	O	O
8	by	O	O
9	onset	O	O
10	before	O	O
11	the	O	O
12	age	O	O
13	of	O	O
14	20years	O	O
15	progressive	O	O
16	external	O	O
17	ophthalmoplegia	O	O
18	and	O	O
19	pigmentary	O	O
20	retinopathy	O	O
21	accompanied	O	O
22	by	O	O
23	either	O	O
24	cardiac	O	O
25	conduction	O	O
26	defects	O	O
27	elevated	O	O
28	cerebrospinal	O	O
29	fluid	O	O
30	protein	O	O
31	or	O	O
32	cerebellar	BI	O
33	ataxia	II	O
34	.	O	O

0	Autosomal	BU	O
1	dominant	IU	O
2	spinocerebellar	IU	O
3	ataxias	IU	O
4	SCAs	IU	O
5	are	O	O
6	a	O	O
7	group	O	O
8	of	O	O
9	rare	O	O
10	and	O	O
11	heterogeneous	O	O
12	neurodegenerative	O	O
13	diseases	O	O
14	characterized	O	O
15	by	O	O
16	the	O	O
17	presence	O	O
18	of	O	O
19	progressive	BI	O
20	cerebellar	II	O
21	ataxia	II	O
22	.	O	O

0	We	O	O
1	review	O	O
2	the	O	O
3	scanty	O	O
4	literature	O	O
5	data	O	O
6	on	O	O
7	the	O	O
8	association	O	O
9	of	O	O
10	Cowden	BU	O
11	syndrome	IU	O
12	and	O	O
13	autism	BI	O
14	and	O	O
15	emphasize	O	O
16	that	O	O
17	the	O	O
18	association	O	O
19	of	O	O
20	progressive	O	O
21	macrocephaly	O	O
22	and	O	O
23	pervasive	BI	O
24	developmental	II	O
25	disorder	II	O
26	seems	O	O
27	to	O	O
28	be	O	O
29	an	O	O
30	indication	O	O
31	for	O	O
32	screening	O	O
33	for	O	O
34	PTEN	O	O
35	mutations	O	O
36	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	semi-dominant	O	O
5	condition	O	O
6	characterized	O	O
7	by	O	O
8	severe	BI	O
9	psychomotor	II	O
10	retardation	II	O
11	with	O	O
12	facial	O	O
13	hand	O	O
14	and	O	O
15	skeletal	O	O
16	malformations	O	O
17	resulting	O	O
18	from	O	O
19	mutations	O	O
20	in	O	O
21	RSK2	O	O
22	gene	O	O
23	encoding	O	O
24	for	O	O
25	a	O	O
26	serine	O	O
27	threonine	O	O
28	kinase	O	O
29	.	O	O

0	The	O	O
1	patient	O	O
2	presented	O	O
3	psychomotor	BI	O
4	regression	II	O
5	late-onset	O	O
6	leukodystrophy	BU	O
7	peripheral	O	O
8	neuropathy	O	O
9	hearing	BI	O
10	impairment	II	O
11	a	O	O
12	renal	O	O
13	cyst	O	O
14	and	O	O
15	renal	O	O
16	hypertension	O	O
17	and	O	O
18	survived	O	O
19	until	O	O
20	the	O	O
21	age	O	O
22	of	O	O
23	36	O	O
24	.	O	O

0	OBJECTIVE	O	O
1	Muckle-Wells	BU	O
2	syndrome	IU	O
3	MWS	IU	O
4	is	O	O
5	an	O	O
6	inherited	O	O
7	autoinflammatory	O	O
8	disease	O	O
9	characterized	O	O
10	by	O	O
11	fevers	O	O
12	rashes	O	O
13	arthralgia	O	O
14	conjunctivitis	O	O
15	and	O	O
16	sensorineural	BI	O
17	hearing	II	O
18	loss	II	O
19	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	1	IU	O
3	WS1	IU	O
4	is	O	O
5	an	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	diabetes	O	O
12	insipidus	O	O
13	diabetes	O	O
14	mellitus	O	O
15	optic	BI	O
16	atrophy	II	O
17	and	O	O
18	deafness	BI	O
19	DIDMOAD	O	O
20	syndrome	O	O
21	.	O	O

0	Muckle-Wells	BU	O
1	syndrome	IU	O
2	is	O	O
3	characterized	O	O
4	by	O	O
5	recurrent	O	O
6	fever	O	O
7	and	O	O
8	urticarial	O	O
9	rash	O	O
10	progressive	BI	O
11	sensorineural	II	O
12	deafness	II	O
13	and	O	O
14	the	O	O
15	development	O	O
16	of	O	O
17	secondary	BU	O
18	amyloidosis	IU	O
19	but	O	O
20	it	O	O
21	is	O	O
22	not	O	O
23	considered	O	O
24	the	O	O
25	most	O	O
26	severe	O	O
27	disease	O	O
28	of	O	O
29	this	O	O
30	group	O	O
31	.	O	O

0	A	O	O
1	70-year-old	O	O
2	man	O	O
3	was	O	O
4	admitted	O	O
5	to	O	O
6	our	O	O
7	hospital	O	O
8	with	O	O
9	visual	BI	O
10	loss	II	O
11	dysesthesia	BU	O
12	gait	BI	O
13	disturbance	II	O
14	and	O	O
15	urinary	O	O
16	retention	O	O
17	.	O	O

0	Sjögren-Larsson	BU	O
1	syndrome	IU	O
2	is	O	O
3	an	O	O
4	autosomal-recessive	O	O
5	hereditary	O	O
6	disorder	O	O
7	involving	O	O
8	congenital	BU	O
9	ichthyosis	IU	O
10	mental	BI	O
11	retardation	II	O
12	and	O	O
13	spastic	BI	O
14	diplegia	II	O
15	or	O	O
16	tetraplegia	BI	O
17	.	O	O

0	Trisomy	BU	O
1	18	IU	O
2	or	O	O
3	Edwards	O	O
4	syndrome	O	O
5	is	O	O
6	a	O	O
7	rare	O	O
8	chromosomal	O	O
9	anomaly	O	O
10	associated	O	O
11	with	O	O
12	mild	BI	O
13	to	II	O
14	severe	II	O
15	intellectual	II	O
16	disabilities	II	O
17	and	O	O
18	multiple	O	O
19	congenital	O	O
20	anomalies	O	O
21	.	O	O

0	PATIENT	O	O
1	AND	O	O
2	METHODS	O	O
3	A	O	O
4	Turkish	O	O
5	boy	O	O
6	presented	O	O
7	at	O	O
8	age	O	O
9	2	O	O
10	months	O	O
11	with	O	O
12	dilated	BU	O
13	cardiomyopathy	IU	O
14	initially	O	O
15	worsening	O	O
16	then	O	O
17	stabilizing	O	O
18	in	O	O
19	the	O	O
20	second	O	O
21	year	O	O
22	of	O	O
23	life	O	O
24	growth	BI	O
25	failure	II	O
26	bilateral	O	O
27	cryptorchidism	O	O
28	and	O	O
29	facial	O	O
30	dysmorphism	O	O
31	.	O	O

0	The	O	O
1	second	O	O
2	case	O	O
3	was	O	O
4	a	O	O
5	6-year-old	O	O
6	boy	O	O
7	of	O	O
8	Asian	O	O
9	ancestry	O	O
10	who	O	O
11	presented	O	O
12	with	O	O
13	ataxia	O	O
14	exacerbated	O	O
15	by	O	O
16	intercurrent	O	O
17	illnesses	O	O
18	decreased	O	O
19	exercise	O	O
20	tolerance	O	O
21	gross	BI	O
22	motor	II	O
23	and	II	O
24	fine	II	O
25	motor	II	O
26	delays	II	O
27	anorexia	O	O
28	and	O	O
29	recurrent	O	O
30	episodes	O	O
31	of	O	O
32	vomiting	O	O
33	associated	O	O
34	with	O	O
35	dehydration	O	O
36	and	O	O
37	he	O	O
38	was	O	O
39	subsequently	O	O
40	diagnosed	O	O
41	with	O	O
42	KSS	BU	O
43	.	O	O

0	That	O	O
1	the	O	O
2	deletion	O	O
3	encompassed	O	O
4	FGD1	O	O
5	exons	O	O
6	2-8	O	O
7	explains	O	O
8	the	O	O
9	Aarskog	O	O
10	features	O	O
11	while	O	O
12	the	O	O
13	deletion	O	O
14	of	O	O
15	PHF8	O	O
16	most	O	O
17	likely	O	O
18	explains	O	O
19	the	O	O
20	cleft	BU	O
21	palate	IU	O
22	and	O	O
23	mild	BI	O
24	intellectual	II	O
25	disability	II	O
26	.	O	O

0	Currently	O	O
1	most	O	O
2	cases	O	O
3	of	O	O
4	trisomy	BU	O
5	18	IU	O
6	are	O	O
7	prenatally	O	O
8	diagnosed	O	O
9	based	O	O
10	on	O	O
11	screening	O	O
12	by	O	O
13	maternal	O	O
14	age	O	O
15	maternal	O	O
16	serum	O	O
17	marker	O	O
18	screening	O	O
19	or	O	O
20	detection	O	O
21	of	O	O
22	sonographic	O	O
23	abnormalities	O	O
24	e.g.	O	O
25	increased	O	O
26	nuchal	O	O
27	translucency	O	O
28	thickness	O	O
29	growth	BI	O
30	retardation	II	O
31	choroid	O	O
32	plexus	O	O
33	cyst	O	O
34	overlapping	O	O
35	of	O	O
36	fingers	O	O
37	and	O	O
38	congenital	O	O
39	heart	O	O
40	defects	O	O
41	.	O	O

0	WAGR	BU	O
1	Wilms	BU	O
2	tumour	IU	O
3	Aniridia	O	O
4	Genitourinary	O	O
5	anomalies	O	O
6	and	O	O
7	mental	BI	O
8	Retardation	II	O
9	syndrome	O	O
10	is	O	O
11	caused	O	O
12	by	O	O
13	11p13	O	O
14	deletions	O	O
15	of	O	O
16	variable	O	O
17	size	O	O
18	near	O	O
19	the	O	O
20	BDNF	O	O
21	locus	O	O
22	and	O	O
23	can	O	O
24	serve	O	O
25	as	O	O
26	a	O	O
27	model	O	O
28	for	O	O
29	studying	O	O
30	human	O	O
31	BDNF	O	O
32	haploinsufficiency	O	O
33	+	O	O
34	.	O	O

0	FTD	BU	O
1	is	O	O
2	heterogeneous	O	O
3	with	O	O
4	regard	O	O
5	to	O	O
6	clinical	O	O
7	manifestation	O	O
8	genetics	O	O
9	distribution	O	O
10	of	O	O
11	cortical	BI	O
12	atrophy	II	O
13	and	O	O
14	underlying	O	O
15	disease	O	O
16	.	O	O

0	Pelizaeus-Merzbacher	BU	O
1	disease	IU	O
2	PMD	O	O
3	MIM#312080	O	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	X-linked	O	O
8	leukodystrophy	O	O
9	presenting	O	O
10	with	O	O
11	motor	BI	O
12	developmental	II	O
13	delay	II	O
14	associated	O	O
15	with	O	O
16	spasticity	O	O
17	and	O	O
18	nystagmus	O	O
19	.	O	O

0	Each	O	O
1	patient	O	O
2	had	O	O
3	multiple	O	O
4	and	O	O
5	variable	O	O
6	anomalies	O	O
7	such	O	O
8	as	O	O
9	a	O	O
10	congenital	O	O
11	heart	O	O
12	defect	O	O
13	including	O	O
14	ventricular	BU	O
15	septal	IU	O
16	defect	IU	O
17	atrial	BU	O
18	septal	IU	O
19	defect	IU	O
20	and	O	O
21	patent	O	O
22	duct	O	O
23	arteriosus	O	O
24	ventriculomegaly	O	O
25	cryptorchism	O	O
26	or	O	O
27	hearing	BI	O
28	loss	II	O
29	.	O	O

0	The	O	O
1	index	O	O
2	patient	O	O
3	displayed	O	O
4	craniofacial	O	O
5	dysmorphisms	O	O
6	mild	BI	O
7	mental	II	O
8	retardation	II	O
9	and	O	O
10	postnatal	BI	O
11	growth	II	O
12	retardation	II	O
13	muscular	O	O
14	hypotonia	O	O
15	mild	O	O
16	periventricular	O	O
17	leukodystrophy	O	O
18	patent	BU	O
19	ductus	IU	O
20	arteriosus	IU	O
21	thrombocytopenia	O	O
22	recurrent	O	O
23	infections	O	O
24	inguinal	O	O
25	hernia	O	O
26	cryptorchidism	O	O
27	pes	O	O
28	equinovarus	O	O
29	and	O	O
30	hearing	BI	O
31	deficiencies	II	O
32	.	O	O

0	These	O	O
1	adults	O	O
2	have	O	O
3	moderate	BI	O
4	mental	II	O
5	retardation	II	O
6	ataxia	BI	O
7	retinitis	BU	O
8	pigmentosa	IU	O
9	peripheral	O	O
10	neuropathy	O	O
11	kyphoscoliosis	O	O
12	and	O	O
13	endocrinopathies	O	O
14	.	O	O

0	We	O	O
1	describe	O	O
2	a	O	O
3	girl	O	O
4	with	O	O
5	late-onset	O	O
6	nonketotic	BU	O
7	hyperglycinemia	IU	O
8	presenting	O	O
9	at	O	O
10	5	O	O
11	years	O	O
12	of	O	O
13	age	O	O
14	with	O	O
15	hypotonia	O	O
16	chorea	O	O
17	ataxia	BI	O
18	and	O	O
19	alterations	O	O
20	in	O	O
21	consciousness	O	O
22	in	O	O
23	the	O	O
24	setting	O	O
25	of	O	O
26	febrile	O	O
27	illness	O	O
28	.	O	O

0	GA	BU	O
1	1	IU	O
2	is	O	O
3	characterized	O	O
4	by	O	O
5	macrocephaly	O	O
6	subdural	O	O
7	hemorrhage	O	O
8	SDH	O	O
9	and	O	O
10	dystonic	BI	O
11	movement	II	O
12	disorder	II	O
13	after	O	O
14	acute	O	O
15	encephalopathic	O	O
16	crisis	O	O
17	.	O	O

0	Importantly	O	O
1	deregulation	O	O
2	of	O	O
3	PHF6	O	O
4	function	O	O
5	in	O	O
6	neuronal	O	O
7	migration	O	O
8	triggers	O	O
9	the	O	O
10	formation	O	O
11	of	O	O
12	white	O	O
13	matter	O	O
14	heterotopias	O	O
15	that	O	O
16	harbor	O	O
17	neuronal	O	O
18	hyperexcitability	O	O
19	which	O	O
20	may	O	O
21	be	O	O
22	relevant	O	O
23	to	O	O
24	the	O	O
25	pathogenesis	O	O
26	of	O	O
27	intellectual	BI	O
28	disability	II	O
29	and	O	O
30	seizures	O	O
31	in	O	O
32	BFLS	BU	O
33	.	O	O

0	The	O	O
1	major	O	O
2	clinical	O	O
3	features	O	O
4	presented	O	O
5	by	O	O
6	MSUD	BU	O
7	patients	O	O
8	include	O	O
9	ketoacidosis	O	O
10	failure	O	O
11	to	O	O
12	thrive	O	O
13	poor	O	O
14	feeding	O	O
15	apnea	O	O
16	ataxia	BI	O
17	seizures	O	O
18	coma	O	O
19	psychomotor	BI	O
20	delay	II	O
21	and	O	O
22	mental	BI	O
23	retardation	II	O
24	however	O	O
25	the	O	O
26	pathophysiology	O	O
27	of	O	O
28	this	O	O
29	disease	O	O
30	is	O	O
31	poorly	O	O
32	understood	O	O
33	.	O	O

0	Anecdotal	O	O
1	reports	O	O
2	suggest	O	O
3	a	O	O
4	relationship	O	O
5	between	O	O
6	Darier	BU	O
7	disease	IU	O
8	and	O	O
9	intellectual	BI	O
10	disabilities	II	O
11	but	O	O
12	these	O	O
13	reports	O	O
14	are	O	O
15	based	O	O
16	on	O	O
17	small	O	O
18	clinical	O	O
19	samples	O	O
20	and	O	O
21	limited	O	O
22	by	O	O
23	absence	O	O
24	of	O	O
25	control	O	O
26	populations	O	O
27	.	O	O

0	Alpers	BU	O
1	disease	IU	O
2	is	O	O
3	a	O	O
4	mitochondrial	O	O
5	depletion	O	O
6	syndrome	O	O
7	characterized	O	O
8	by	O	O
9	psychomotor	BI	O
10	retardation	II	O
11	intractable	O	O
12	epilepsy	O	O
13	and	O	O
14	liver	O	O
15	failure	O	O
16	.	O	O

0	A	O	O
1	9-year-old	O	O
2	boy	O	O
3	with	O	O
4	learning	BI	O
5	disability	II	O
6	and	O	O
7	intermittent	O	O
8	choreoathetosis	O	O
9	during	O	O
10	febrile	O	O
11	illnesses	O	O
12	had	O	O
13	elevated	O	O
14	plasma	O	O
15	glycine	O	O
16	level	O	O
17	and	O	O
18	CSF	O	O
19	plasma	O	O
20	glycine	O	O
21	ratio	O	O
22	0.044	O	O
23	and	O	O
24	a	O	O
25	novel	O	O
26	homozygous	O	O
27	missense	O	O
28	mutation	O	O
29	c.605C>T	O	O
30	p.Ala202Val	O	O
31	in	O	O
32	the	O	O
33	GLDC	O	O
34	gene	O	O
35	confirming	O	O
36	the	O	O
37	diagnosis	O	O
38	of	O	O
39	NKH	BU	O
40	.	O	O

0	MSUD	BU	O
1	is	O	O
2	a	O	O
3	complex	O	O
4	metabolic	O	O
5	disorder	O	O
6	that	O	O
7	has	O	O
8	been	O	O
9	associated	O	O
10	with	O	O
11	central	O	O
12	nervous	O	O
13	system	O	O
14	damage	O	O
15	developmental	BI	O
16	delays	II	O
17	and	O	O
18	neurocognitive	BI	O
19	deficits	II	O
20	.	O	O

0	Systematic	O	O
1	clinical	O	O
2	studies	O	O
3	revealed	O	O
4	features	O	O
5	consistent	O	O
6	with	O	O
7	SMS	BU	O
8	including	O	O
9	features	O	O
10	of	O	O
11	intellectual	BI	O
12	disability	II	O
13	speech	BI	O
14	and	II	O
15	gross	II	O
16	motor	II	O
17	delays	II	O
18	behavioral	BI	O
19	problems	II	O
20	and	O	O
21	ocular	BI	O
22	abnormalities	II	O
23	.	O	O

0	Individuals	O	O
1	with	O	O
2	NF1	BU	O
3	have	O	O
4	an	O	O
5	increased	O	O
6	incidence	O	O
7	of	O	O
8	learning	BI	O
9	disabilities	II	O
10	attention	BI	O
11	deficits	II	O
12	and	O	O
13	autism	BI	O
14	spectrum	II	O
15	disorders	II	O
16	.	O	O

0	The	O	O
1	most	O	O
2	severe	O	O
3	phenotypes	O	O
4	are	O	O
5	Walker-Warburg	BU	O
6	Syndrome	IU	O
7	WWS	IU	O
8	and	O	O
9	muscle-eye-brain	BU	O
10	disease	IU	O
11	MEB	O	O
12	presenting	O	O
13	with	O	O
14	lissencephaly	O	O
15	type	O	O
16	II	O	O
17	LIS	O	O
18	II	O	O
19	and	O	O
20	in	O	O
21	which	O	O
22	muscular	BU	O
23	dystrophy	IU	O
24	is	O	O
25	associated	O	O
26	with	O	O
27	mental	BI	O
28	retardation	II	O
29	and	O	O
30	eye	O	O
31	abnormalities	O	O
32	.	O	O

0	Further	O	O
1	we	O	O
2	describe	O	O
3	discoveries	O	O
4	from	O	O
5	these	O	O
6	models	O	O
7	that	O	O
8	have	O	O
9	uncovered	O	O
10	defects	O	O
11	in	O	O
12	the	O	O
13	regulation	O	O
14	of	O	O
15	Ras	O	O
16	activity	O	O
17	cAMP	O	O
18	generation	O	O
19	and	O	O
20	dopamine	O	O
21	homeostasis	O	O
22	as	O	O
23	key	O	O
24	mechanisms	O	O
25	important	O	O
26	for	O	O
27	cognitive	BI	O
28	dysfunction	II	O
29	in	O	O
30	children	O	O
31	with	O	O
32	NF1	BU	O
33	.	O	O

0	As	O	O
1	there	O	O
2	are	O	O
3	some	O	O
4	evidences	O	O
5	about	O	O
6	the	O	O
7	role	O	O
8	of	O	O
9	the	O	O
10	immune	O	O
11	system	O	O
12	defects	O	O
13	in	O	O
14	the	O	O
15	pathogenesis	O	O
16	of	O	O
17	autism	BI	O
18	specific	O	O
19	primary	BU	O
20	antibody	IU	O
21	deficiency	IU	O
22	diseases	O	O
23	such	O	O
24	as	O	O
25	CVID	O	O
26	might	O	O
27	predispose	O	O
28	some	O	O
29	affected	O	O
30	cases	O	O
31	to	O	O
32	such	O	O
33	neurodevelopmental	O	O
34	disorders	O	O
35	.	O	O

0	Main	O	O
1	features	O	O
2	are	O	O
3	immune	O	O
4	deficiency	O	O
5	manifested	O	O
6	by	O	O
7	recurrent	O	O
8	infections	O	O
9	especially	O	O
10	in	O	O
11	the	O	O
12	first	O	O
13	decade	O	O
14	of	O	O
15	life	O	O
16	skeletal	O	O
17	abnormalities	O	O
18	mild-to-moderate	O	O
19	dysostosis	BU	O
20	multiplex	O	O
21	scoliosis	O	O
22	and	O	O
23	deformation	O	O
24	of	O	O
25	the	O	O
26	sternum	O	O
27	hearing	BI	O
28	impairment	II	O
29	moderate-to-severe	BI	O
30	sensorineural	II	O
31	hearing	II	O
32	loss	II	O
33	gradual	BI	O
34	impairment	II	O
35	of	II	O
36	mental	II	O
37	functions	II	O
38	and	II	O
39	speech	II	O
40	and	O	O
41	often	O	O
42	periods	O	O
43	of	O	O
44	psychosis	O	O
45	.	O	O

0	Cornelia	BU	O
1	de	IU	O
2	Lange	IU	O
3	syndrome	IU	O
4	CdLS	IU	O
5	is	O	O
6	a	O	O
7	developmental	BI	O
8	disorder	II	O
9	characterized	O	O
10	by	O	O
11	limb	O	O
12	reduction	O	O
13	defects	O	O
14	characteristic	O	O
15	facial	O	O
16	features	O	O
17	and	O	O
18	impaired	BI	O
19	cognitive	II	O
20	development	II	O
21	.	O	O

0	CONCLUSION	O	O
1	CAPS	BU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	but	O	O
6	treatable	O	O
7	condition	O	O
8	that	O	O
9	may	O	O
10	be	O	O
11	encountered	O	O
12	by	O	O
13	neurologists	O	O
14	in	O	O
15	adult	O	O
16	clinical	O	O
17	practice	O	O
18	since	O	O
19	it	O	O
20	can	O	O
21	present	O	O
22	with	O	O
23	headache	O	O
24	myalgia	O	O
25	papilledema	O	O
26	sensorineural	BI	O
27	deafness	II	O
28	and	O	O
29	aseptic	O	O
30	meningitis	O	O
31	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	gene	O	O
4	encoding	O	O
5	neural	O	O
6	cell	O	O
7	adhesion	O	O
8	molecule	O	O
9	L1	O	O
10	L1CAM	O	O
11	are	O	O
12	involved	O	O
13	in	O	O
14	X-linked	O	O
15	hydrocephalus	O	O
16	HSAS	BU	O
17	hydrocephalus	O	O
18	due	O	O
19	to	O	O
20	stenosis	O	O
21	of	O	O
22	the	O	O
23	aqueduct	O	O
24	of	O	O
25	Sylvius	O	O
26	MASA	BU	O
27	syndrome	IU	O
28	mental	BI	O
29	retardation	II	O
30	aphasia	BI	O
31	shuffling	O	O
32	gait	O	O
33	and	O	O
34	adducted	O	O
35	thumbs	O	O
36	and	O	O
37	spastic	BI	O
38	paraplegia	II	O
39	type	II	O
40	1	II	O
41	.	O	O

0	Charcot-Marie-Tooth	BU	O
1	disease	IU	O
2	type	IU	O
3	4D	IU	O
4	CMT4D	IU	O
5	also	O	O
6	known	O	O
7	as	O	O
8	Hereditary	O	O
9	Motor	O	O
10	Sensory	O	O
11	Neuropathy	O	O
12	Lom	O	O
13	Type	O	O
14	HMSNL	O	O
15	is	O	O
16	an	O	O
17	autosomal	O	O
18	recessive	O	O
19	early-onset	O	O
20	severe	O	O
21	demyelinating	O	O
22	neuropathy	O	O
23	with	O	O
24	hearing	BI	O
25	loss	II	O
26	caused	O	O
27	by	O	O
28	NDRG1	O	O
29	mutations	O	O
30	.	O	O

0	The	O	O
1	aims	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	were	O	O
6	to	O	O
7	determine	O	O
8	the	O	O
9	otologic	O	O
10	characteristics	O	O
11	of	O	O
12	MWS	BU	O
13	define	O	O
14	trajectories	O	O
15	of	O	O
16	hearing	BI	O
17	loss	II	O
18	and	O	O
19	explore	O	O
20	the	O	O
21	association	O	O
22	with	O	O
23	distinct	O	O
24	NLRP3	O	O
25	genotypes	O	O
26	.	O	O

0	To	O	O
1	our	O	O
2	knowledge	O	O
3	sensorineural	BI	O
4	hearing	II	O
5	loss	II	O
6	is	O	O
7	described	O	O
8	in	O	O
9	the	O	O
10	literature	O	O
11	but	O	O
12	has	O	O
13	not	O	O
14	been	O	O
15	described	O	O
16	as	O	O
17	a	O	O
18	typical	O	O
19	phenotypic	O	O
20	symptom	O	O
21	of	O	O
22	tetrasomy	BU	O
23	18p	IU	O
24	.	O	O

0	Spinocerebellar	BU	O
1	ataxia	IU	O
2	type	IU	O
3	14	IU	O
4	SCA14	IU	O
5	is	O	O
6	an	O	O
7	autosomal	BI	O
8	dominant	II	O
9	hereditary	II	O
10	ataxia	II	O
11	characterized	O	O
12	by	O	O
13	a	O	O
14	relatively	O	O
15	pure	O	O
16	cerebellar	O	O
17	phenotype	O	O
18	.	O	O

0	RESULTS	O	O
1	Individuals	O	O
2	with	O	O
3	Darier	BU	O
4	disease	IU	O
5	had	O	O
6	a	O	O
7	sixfold	O	O
8	increased	O	O
9	risk	O	O
10	of	O	O
11	being	O	O
12	diagnosed	O	O
13	with	O	O
14	intellectual	BI	O
15	disability	II	O
16	risk	O	O
17	ratio	O	O
18	6.2	O	O
19	95%	O	O
20	confidence	O	O
21	interval	O	O
22	3.1-12.4	O	O
23	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	a	O	O
4	2-year-2-month	O	O
5	old	O	O
6	boy	O	O
7	with	O	O
8	Diamond-Blackfan	BU	O
9	anemia	IU	O
10	global	BI	O
11	developmental	II	O
12	delay	II	O
13	cognitive	BI	O
14	impairments	II	O
15	distinctive	O	O
16	facial	O	O
17	features	O	O
18	behavior	BI	O
19	problems	II	O
20	skeletal	O	O
21	and	O	O
22	genital	O	O
23	dysplasia	O	O
24	.	O	O

0	OBJECTIVE	O	O
1	Maternal	BU	O
2	phenylketonuria	IU	O
3	MPKU	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	intrauterine	O	O
8	growth	O	O
9	retardation	O	O
10	microcephaly	O	O
11	congenital	O	O
12	malformations	O	O
13	mainly	O	O
14	cardiac	O	O
15	defects	O	O
16	dysmorphic	O	O
17	facial	O	O
18	features	O	O
19	and	O	O
20	mental	BI	O
21	retardation	II	O
22	.	O	O

0	IMPORTANCE	O	O
1	Congenital	O	O
2	hypotrichosis	BU	O
3	with	IU	O
4	juvenile	IU	O
5	macular	IU	O
6	dystrophy	IU	O
7	HJMD	O	O
8	is	O	O
9	a	O	O
10	rare	O	O
11	disorder	O	O
12	presenting	O	O
13	in	O	O
14	childhood	O	O
15	and	O	O
16	adolescence	O	O
17	with	O	O
18	central	BI	O
19	visual	II	O
20	disturbance	II	O
21	and	O	O
22	sparse	O	O
23	scalp	O	O
24	hair	O	O
25	.	O	O

0	BACKGROUND	O	O
1	Pendred	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	common	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	O
9	causing	O	O
10	deafness	BI	O
11	.	O	O

0	A	O	O
1	48-year-old	O	O
2	man	O	O
3	presented	O	O
4	with	O	O
5	a	O	O
6	complex	O	O
7	phenotype	O	O
8	of	O	O
9	myoclonus	O	O
10	epilepsy	O	O
11	with	O	O
12	ragged-red	O	O
13	fibers	O	O
14	MERRF	O	O
15	syndrome	O	O
16	and	O	O
17	Kearns-Sayre	BU	O
18	syndrome	IU	O
19	KSS	IU	O
20	which	O	O
21	included	O	O
22	progressive	BU	O
23	myoclonus	IU	O
24	epilepsy	IU	O
25	cerebellar	BI	O
26	ataxia	II	O
27	hearing	BI	O
28	loss	II	O
29	myopathic	O	O
30	weakness	O	O
31	ophthalmoparesis	O	O
32	pigmentary	O	O
33	retinopathy	O	O
34	bifascicular	O	O
35	heart	O	O
36	block	O	O
37	and	O	O
38	ragged-red	O	O
39	fibers	O	O
40	.	O	O

0	Typically	O	O
1	the	O	O
2	deletions	O	O
3	span	O	O
4	<10	O	O
5	Mb	O	O
6	of	O	O
7	1pter-1p36.23	O	O
8	and	O	O
9	result	O	O
10	in	O	O
11	mental	BI	O
12	retardation	II	O
13	developmental	BI	O
14	delay	II	O
15	sensorineural	BI	O
16	hearing	II	O
17	loss	II	O
18	seizures	O	O
19	cardiomyopathy	BU	O
20	and	O	O
21	cardiovascular	O	O
22	malformations	O	O
23	and	O	O
24	distinct	O	O
25	facies	O	O
26	including	O	O
27	large	O	O
28	anterior	O	O
29	fontanel	O	O
30	deep-set	O	O
31	eyes	O	O
32	straight	O	O
33	eyebrows	O	O
34	flat	O	O
35	nasal	O	O
36	bridge	O	O
37	asymmetric	O	O
38	ears	O	O
39	and	O	O
40	pointed	O	O
41	chin	O	O
42	.	O	O

0	Hirschsprung	BU	O
1	disease	IU	O
2	malrotation	O	O
3	isochromia	O	O
4	a	O	O
5	profound	BI	O
6	sensorineural	II	O
7	hearing	II	O
8	loss	II	O
9	and	O	O
10	several	O	O
11	other	O	O
12	anomalies	O	O
13	were	O	O
14	found	O	O
15	in	O	O
16	an	O	O
17	infant	O	O
18	with	O	O
19	an	O	O
20	interstitial	O	O
21	deletion	O	O
22	of	O	O
23	13q	O	O
24	suggesting	O	O
25	the	O	O
26	existence	O	O
27	of	O	O
28	a	O	O
29	contiguous	O	O
30	gene	O	O
31	syndrome	O	O
32	involving	O	O
33	developmental	O	O
34	genes	O	O
35	necessary	O	O
36	for	O	O
37	the	O	O
38	normal	O	O
39	growth	O	O
40	of	O	O
41	the	O	O
42	neural	O	O
43	crest	O	O
44	derivatives	O	O
45	of	O	O
46	the	O	O
47	eye	O	O
48	inner	O	O
49	ear	O	O
50	and	O	O
51	colon	O	O
52	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	developmental	BI	O
5	disorder	II	O
6	associated	O	O
7	with	O	O
8	hemizygous	O	O
9	deletion	O	O
10	of	O	O
11	the	O	O
12	distal	O	O
13	short	O	O
14	arm	O	O
15	of	O	O
16	chromosome	O	O
17	4	O	O
18	.	O	O

0	OBJECTIVES	O	O
1	To	O	O
2	characterize	O	O
3	otologic	O	O
4	management	O	O
5	of	O	O
6	two	O	O
7	patient	O	O
8	groups	O	O
9	those	O	O
10	with	O	O
11	the	O	O
12	CHARGE	BU	O
13	association	IU	O
14	and	O	O
15	those	O	O
16	not	O	O
17	strictly	O	O
18	labeled	O	O
19	as	O	O
20	CHARGE	O	O
21	but	O	O
22	with	O	O
23	several	O	O
24	features	O	O
25	of	O	O
26	the	O	O
27	disorder	O	O
28	CHARGE-like	O	O
29	in	O	O
30	order	O	O
31	to	O	O
32	determine	O	O
33	1	O	O
34	the	O	O
35	clinical	O	O
36	validity	O	O
37	and	O	O
38	utility	O	O
39	of	O	O
40	managing	O	O
41	CHARGE-like	O	O
42	children	O	O
43	in	O	O
44	a	O	O
45	similar	O	O
46	manner	O	O
47	to	O	O
48	patients	O	O
49	with	O	O
50	the	O	O
51	strictly	O	O
52	defined	O	O
53	CHARGE	BU	O
54	association	IU	O
55	2	O	O
56	the	O	O
57	progression	O	O
58	and	O	O
59	prognosis	O	O
60	of	O	O
61	hearing	BI	O
62	loss	II	O
63	and	O	O
64	3	O	O
65	the	O	O
66	identification	O	O
67	of	O	O
68	factors	O	O
69	that	O	O
70	may	O	O
71	predict	O	O
72	the	O	O
73	degree	O	O
74	of	O	O
75	hearing	BI	O
76	loss	II	O
77	.	O	O

0	Monosomy	BU	O
1	1p36	IU	O
2	is	O	O
3	associated	O	O
4	with	O	O
5	mental	BI	O
6	retardation	II	O
7	developmental	BI	O
8	delay	II	O
9	hearing	BI	O
10	impairment	II	O
11	seizures	O	O
12	growth	BI	O
13	impairment	II	O
14	hypotonia	O	O
15	and	O	O
16	heart	O	O
17	defects	O	O
18	.	O	O

0	Spinocerebellar	BI	O
1	ataxia	II	O
2	type	II	O
3	7	II	O
4	SCA7	IU	O
5	in	O	O
6	which	O	O
7	the	O	O
8	degenerative	O	O
9	process	O	O
10	also	O	O
11	affect	O	O
12	the	O	O
13	retina	O	O
14	belongs	O	O
15	to	O	O
16	the	O	O
17	category	O	O
18	of	O	O
19	the	O	O
20	autosomal	BU	O
21	dominant	IU	O
22	cerebellar	IU	O
23	ataxia	IU	O
24	type	IU	O
25	II	IU	O
26	ADCA	IU	O
27	II	IU	O
28	.	O	O

0	Harlequin	BU	O
1	ichthyosis	IU	O
2	HI	IU	O
3	is	O	O
4	a	O	O
5	severe	BI	O
6	autosomal	II	O
7	recessive	II	O
8	developmental	II	O
9	disorder	II	O
10	of	O	O
11	the	O	O
12	skin	O	O
13	that	O	O
14	is	O	O
15	frequently	O	O
16	but	O	O
17	not	O	O
18	always	O	O
19	fatal	O	O
20	in	O	O
21	the	O	O
22	first	O	O
23	few	O	O
24	days	O	O
25	of	O	O
26	life	O	O
27	.	O	O

0	MAE	BU	O
1	prognosis	O	O
2	vary	O	O
3	from	O	O
4	spontaneous	O	O
5	remission	O	O
6	to	O	O
7	intractable	O	O
8	seizures	O	O
9	with	O	O
10	profound	BI	O
11	mental	II	O
12	retardation	II	O
13	.	O	O

0	Since	O	O
1	all	O	O
2	patients	O	O
3	with	O	O
4	BRESEK	O	O
5	BRESHECK	O	O
6	syndrome	O	O
7	are	O	O
8	male	O	O
9	and	O	O
10	X-linked	O	O
11	syndrome	O	O
12	of	O	O
13	ichthyosis	BU	O
14	follicularis	O	O
15	with	O	O
16	atrichia	O	O
17	and	O	O
18	photophobia	O	O
19	is	O	O
20	sometimes	O	O
21	associated	O	O
22	with	O	O
23	several	O	O
24	features	O	O
25	of	O	O
26	BRESEK	O	O
27	BRESHECK	BU	O
28	syndrome	IU	O
29	such	O	O
30	as	O	O
31	intellectual	BI	O
32	disability	II	O
33	vertebral	O	O
34	and	O	O
35	renal	O	O
36	anomalies	O	O
37	and	O	O
38	Hirschsprung	BU	O
39	disease	IU	O
40	we	O	O
41	analyzed	O	O
42	the	O	O
43	causal	O	O
44	gene	O	O
45	of	O	O
46	ichthyosis	BU	O
47	follicularis	O	O
48	with	O	O
49	atrichia	O	O
50	and	O	O
51	photophobia	O	O
52	syndrome	O	O
53	MBTPS2	O	O
54	in	O	O
55	the	O	O
56	present	O	O
57	patient	O	O
58	and	O	O
59	identified	O	O
60	an	O	O
61	p.Arg429His	O	O
62	mutation	O	O
63	.	O	O

0	Both	O	O
1	twins	O	O
2	displayed	O	O
3	disordered	BI	O
4	speech	II	O
5	development	II	O
6	impairments	BI	O
7	in	II	O
8	social	II	O
9	interaction	II	O
10	and	O	O
11	stereotyped	O	O
12	behaviors	O	O
13	consistent	O	O
14	with	O	O
15	autism	BI	O
16	spectrum	II	O
17	disorder	II	O
18	common	O	O
19	in	O	O
20	the	O	O
21	vast	O	O
22	majority	O	O
23	of	O	O
24	cases	O	O
25	of	O	O
26	SMS	BU	O
27	.	O	O

0	We	O	O
1	report	O	O
2	three	O	O
3	Tunisian	O	O
4	patients	O	O
5	affected	O	O
6	by	O	O
7	congenital	BU	O
8	muscular	IU	O
9	dystrophy	IU	O
10	with	O	O
11	mental	BI	O
12	retardation	II	O
13	and	O	O
14	cerebellar	O	O
15	cysts	O	O
16	on	O	O
17	cranial	O	O
18	magnetic	O	O
19	resonance	O	O
20	imaging	O	O
21	.	O	O

0	Maternal	BU	O
1	phenylketonuria	IU	O
2	MPKU	IU	O
3	is	O	O
4	a	O	O
5	syndrome	O	O
6	including	O	O
7	cardiovascular	O	O
8	malformations	O	O
9	CVMs	O	O
10	microcephaly	O	O
11	intellectual	BI	O
12	impairment	II	O
13	and	O	O
14	small	O	O
15	size	O	O
16	for	O	O
17	gestational	O	O
18	age	O	O
19	caused	O	O
20	by	O	O
21	in-utero	O	O
22	exposure	O	O
23	to	O	O
24	elevated	O	O
25	serum	O	O
26	phenylalanine	O	O
27	Phe	O	O
28	due	O	O
29	to	O	O
30	PKU	O	O
31	in	O	O
32	the	O	O
33	mother	O	O
34	.	O	O

0	Patients	O	O
1	with	O	O
2	PRS-I	BU	O
3	superactivity	IU	O
4	primarily	O	O
5	present	O	O
6	with	O	O
7	uric	O	O
8	acid	O	O
9	overproduction	O	O
10	mental	BI	O
11	retardation	II	O
12	ataxia	BI	O
13	hypotonia	O	O
14	and	O	O
15	hearing	BI	O
16	impairment	II	O
17	.	O	O

0	BACKGROUND	O	O
1	The	O	O
2	RSK2	O	O
3	gene	O	O
4	is	O	O
5	responsible	O	O
6	for	O	O
7	Coffin-Lowry	BU	O
8	syndrome	IU	O
9	an	O	O
10	X-linked	O	O
11	dominant	O	O
12	genetic	O	O
13	disorder	O	O
14	causing	O	O
15	mental	BI	O
16	retardation	II	O
17	skeletal	BI	O
18	growth	II	O
19	delays	II	O
20	with	O	O
21	craniofacial	O	O
22	and	O	O
23	digital	O	O
24	abnormalities	O	O
25	typically	O	O
26	associated	O	O
27	with	O	O
28	this	O	O
29	syndrome	O	O
30	.	O	O

0	Forty-four	O	O
1	NS	BU	O
2	patients	O	O
3	were	O	O
4	seen	O	O
5	by	O	O
6	an	O	O
7	otorhinolaryngologist	O	O
8	for	O	O
9	the	O	O
10	analysis	O	O
11	of	O	O
12	hearing	BI	O
13	impairment	II	O
14	.	O	O

0	Charcot-Marie-Tooth	BU	O
1	disease	IU	O
2	type	IU	O
3	4D	IU	O
4	CMT4D	IU	O
5	is	O	O
6	an	O	O
7	autosomal	O	O
8	recessive	O	O
9	demyelinating	O	O
10	polyneuropathy	O	O
11	associated	O	O
12	with	O	O
13	deafness	BI	O
14	exclusively	O	O
15	found	O	O
16	in	O	O
17	Gypsies	O	O
18	and	O	O
19	resulting	O	O
20	from	O	O
21	a	O	O
22	homozygous	O	O
23	R148X	O	O
24	mutation	O	O
25	in	O	O
26	the	O	O
27	N-myc	O	O
28	downstream-regulated	O	O
29	gene	O	O
30	1	O	O
31	NDRG1	O	O
32	.	O	O

0	Children	O	O
1	with	O	O
2	a	O	O
3	CHARGE	BU	O
4	association	IU	O
5	have	O	O
6	many	O	O
7	medical	O	O
8	problems	O	O
9	and	O	O
10	therefore	O	O
11	autistic	BI	O
12	behaviour	II	O
13	can	O	O
14	easily	O	O
15	be	O	O
16	overlooked	O	O
17	.	O	O

0	While	O	O
1	mouse	O	O
2	models	O	O
3	have	O	O
4	elucidated	O	O
5	molecular	O	O
6	and	O	O
7	cellular	O	O
8	mechanisms	O	O
9	underlying	O	O
10	learning	BI	O
11	deficits	II	O
12	associated	O	O
13	with	O	O
14	this	O	O
15	mutation	O	O
16	little	O	O
17	is	O	O
18	known	O	O
19	about	O	O
20	functional	O	O
21	brain	O	O
22	architecture	O	O
23	in	O	O
24	human	O	O
25	subjects	O	O
26	with	O	O
27	NF1	BU	O
28	.	O	O

0	Pitt-Hopkins	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	dysmorphic	BI	O
6	mental	II	O
7	retardation	II	O
8	syndrome	II	O
9	marked	O	O
10	by	O	O
11	daytime	O	O
12	spells	O	O
13	of	O	O
14	overbreathing	O	O
15	interrupted	O	O
16	by	O	O
17	apnoea	O	O
18	.	O	O

0	Periventricular	BU	O
1	nodular	IU	O
2	heterotopia	IU	O
3	PNH	IU	O
4	is	O	O
5	a	O	O
6	genetically	O	O
7	heterogeneous	O	O
8	neuronal	O	O
9	migration	O	O
10	disorder	O	O
11	characterized	O	O
12	by	O	O
13	subependymal	O	O
14	heterotopic	O	O
15	nodules	O	O
16	and	O	O
17	is	O	O
18	variably	O	O
19	associated	O	O
20	with	O	O
21	other	O	O
22	brain	O	O
23	malformations	O	O
24	epileptic	O	O
25	seizures	O	O
26	and	O	O
27	intellectual	BI	O
28	disability	II	O
29	.	O	O

0	Choroideremia	BU	O
1	CHM	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	X-linked	O	O
6	disease	O	O
7	leading	O	O
8	to	O	O
9	progressive	BI	O
10	retinal	II	O
11	degeneration	II	O
12	resulting	O	O
13	in	O	O
14	blindness	BI	O
15	.	O	O

0	These	O	O
1	results	O	O
2	reveal	O	O
3	that	O	O
4	face	BI	O
5	perception	II	O
6	and	II	O
7	face	II	O
8	memory	II	O
9	deficits	II	O
10	are	O	O
11	common	O	O
12	in	O	O
13	bvFTD	BU	O
14	and	O	O
15	SD	O	O
16	and	O	O
17	have	O	O
18	been	O	O
19	previously	O	O
20	underestimated	O	O
21	.	O	O

0	Here	O	O
1	we	O	O
2	report	O	O
3	on	O	O
4	a	O	O
5	15-year-old	O	O
6	boy	O	O
7	who	O	O
8	was	O	O
9	referred	O	O
10	for	O	O
11	MID1	O	O
12	mutation	O	O
13	analysis	O	O
14	with	O	O
15	findings	O	O
16	typical	O	O
17	of	O	O
18	OS	BU	O
19	including	O	O
20	apparent	O	O
21	hypertelorism	O	O
22	hypospadias	O	O
23	a	O	O
24	history	O	O
25	of	O	O
26	feeding	O	O
27	difficulties	O	O
28	dysphagia	O	O
29	secondary	O	O
30	to	O	O
31	esophageal	O	O
32	arteria	O	O
33	lusoria	O	O
34	growth	BI	O
35	retardation	II	O
36	and	O	O
37	developmental	O	O
38	delay	O	O
39	.	O	O

0	CONCLUSIONS	O	O
1	AND	O	O
2	RELEVANCE	O	O
3	C9ORF72	O	O
4	repeat	O	O
5	expansions	O	O
6	have	O	O
7	a	O	O
8	primary	O	O
9	role	O	O
10	in	O	O
11	increasing	O	O
12	the	O	O
13	risk	O	O
14	of	O	O
15	cognitive	BI	O
16	impairment	II	O
17	in	O	O
18	patients	O	O
19	with	O	O
20	ALS	BU	O
21	the	O	O
22	APOE	O	O
23	ε2	O	O
24	allele	O	O
25	to	O	O
26	a	O	O
27	lesser	O	O
28	extent	O	O
29	also	O	O
30	increases	O	O
31	the	O	O
32	risk	O	O
33	of	O	O
34	FTD	BU	O
35	.	O	O

0	PURPOSE	O	O
1	The	O	O
2	1p36	BU	O
3	deletion	IU	O
4	syndrome	IU	O
5	is	O	O
6	a	O	O
7	microdeletion	O	O
8	syndrome	O	O
9	characterized	O	O
10	by	O	O
11	developmental	BI	O
12	delays	II	O
13	intellectual	BI	O
14	disability	II	O
15	craniofacial	O	O
16	dysmorphism	O	O
17	and	O	O
18	other	O	O
19	congenital	O	O
20	anomalies	O	O
21	.	O	O

0	Using	O	O
1	diagnostic	O	O
2	measures	O	O
3	and	O	O
4	clinical	O	O
5	judgement	O	O
6	3	O	O
7	subjects	O	O
8	2	O	O
9	BDNF+	O	O
10	and	O	O
11	1	O	O
12	BDNF+	O	O
13	+	O	O
14	in	O	O
15	the	O	O
16	WAGR	BU	O
17	group	IU	O
18	10.7%	O	O
19	were	O	O
20	classified	O	O
21	with	O	O
22	autism	BI	O
23	spectrum	II	O
24	disorder	II	O
25	.	II	O

0	In	O	O
1	the	O	O
2	context	O	O
3	of	O	O
4	the	O	O
5	analyses	O	O
6	of	O	O
7	this	O	O
8	patient	O	O
9	and	O	O
10	other	O	O
11	cases	O	O
12	of	O	O
13	PTLS	BU	O
14	we	O	O
15	argue	O	O
16	that	O	O
17	the	O	O
18	central	O	O
19	feature	O	O
20	of	O	O
21	the	O	O
22	syndrome	O	O
23	appears	O	O
24	to	O	O
25	be	O	O
26	related	O	O
27	to	O	O
28	diminished	BI	O
29	speech	II	O
30	and	II	O
31	language	II	O
32	capacity	II	O
33	rather	O	O
34	than	O	O
35	the	O	O
36	specific	BI	O
37	social	II	O
38	deficits	II	O
39	central	O	O
40	to	O	O
41	autism	BI	O
42	.	O	O

0	2	O	O
1	Only	O	O
2	one	O	O
3	third	O	O
4	of	O	O
5	patients	O	O
6	with	O	O
7	Norrie	BU	O
8	disease	IU	O
9	have	O	O
10	sensorineural	BI	O
11	deafness	II	O
12	and	O	O
13	approximately	O	O
14	one	O	O
15	half	O	O
16	of	O	O
17	the	O	O
18	affected	O	O
19	individuals	O	O
20	exhibit	O	O
21	mental	BI	O
22	retardation	II	O
23	often	O	O
24	with	O	O
25	psychotic	O	O
26	features	O	O
27	.	O	O

0	His	O	O
1	mother	O	O
2	had	O	O
3	a	O	O
4	short	O	O
5	stature	O	O
6	mental	BI	O
7	retardation	II	O
8	and	O	O
9	similar	O	O
10	although	O	O
11	minor	O	O
12	manifestations	O	O
13	of	O	O
14	the	O	O
15	Coffin-Lowry	BU	O
16	syndrome	IU	O
17	in	O	O
18	her	O	O
19	face	O	O
20	hands	O	O
21	and	O	O
22	fingers	O	O
23	.	O	O

0	Hypomyelination	O	O
1	is	O	O
2	a	O	O
3	key	O	O
4	symptom	O	O
5	of	O	O
6	Allan-Herndon-Dudley	BU	O
7	syndrome	IU	O
8	AHDS	IU	O
9	a	O	O
10	psychomotor	BI	O
11	retardation	II	O
12	associated	O	O
13	with	O	O
14	mutations	O	O
15	in	O	O
16	the	O	O
17	thyroid-hormone	O	O
18	TH	O	O
19	transporter	O	O
20	MCT8	O	O
21	monocarboxylate	O	O
22	transporter	O	O
23	8	O	O
24	.	O	O

0	In	O	O
1	this	O	O
2	article	O	O
3	we	O	O
4	report	O	O
5	on	O	O
6	a	O	O
7	family	O	O
8	in	O	O
9	which	O	O
10	five	O	O
11	examined	O	O
12	members	O	O
13	showed	O	O
14	clinical	O	O
15	signs	O	O
16	of	O	O
17	Fechtner	BU	O
18	syndrome	IU	O
19	a	O	O
20	condition	O	O
21	which	O	O
22	consists	O	O
23	of	O	O
24	hearing	BI	O
25	loss	II	O
26	49%	O	O
27	macro-thrombocytopenia	O	O
28	100%	O	O
29	leukocyte	O	O
30	inclusion	O	O
31	bodies	O	O
32	100%	O	O
33	eye	O	O
34	anomalies	O	O
35	54.3%	O	O
36	and	O	O
37	nephritis	O	O
38	38.7%	O	O
39	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	distinctive	O	O
7	facial	O	O
8	features	O	O
9	that	O	O
10	progress	O	O
11	with	O	O
12	age	O	O
13	developmental	BI	O
14	delay	II	O
15	cognitive	BI	O
16	impairment	II	O
17	and	O	O
18	behavioral	BI	O
19	abnormalities	II	O
20	associated	O	O
21	with	O	O
22	molecular	O	O
23	anomaly	O	O
24	in	O	O
25	17p11.2	O	O
26	.	O	O

0	Childhood	O	O
1	narcolepsy	BU	O
2	with	IU	O
3	cataplexy	IU	O
4	represents	O	O
5	a	O	O
6	risk	O	O
7	factor	O	O
8	for	O	O
9	subtle	O	O
10	and	O	O
11	heterogeneous	O	O
12	cognitive	BI	O
13	impairments	II	O
14	potentially	O	O
15	resulting	O	O
16	in	O	O
17	academic	BI	O
18	failure	II	O
19	despite	O	O
20	the	O	O
21	normal	O	O
22	IQ	O	O
23	.	O	O

0	Children	O	O
1	with	O	O
2	CHARGE	BU	O
3	have	O	O
4	different	O	O
5	combinations	O	O
6	of	O	O
7	disabilities	O	O
8	of	O	O
9	which	O	O
10	impairments	BI	O
11	of	II	O
12	vision	II	O
13	and	II	O
14	hearing	II	O
15	as	O	O
16	well	O	O
17	as	O	O
18	balance	O	O
19	problems	O	O
20	and	O	O
21	facial	O	O
22	palsy	O	O
23	can	O	O
24	lead	O	O
25	to	O	O
26	developmental	BI	O
27	delay	II	O
28	.	O	O

0	Considering	O	O
1	all	O	O
2	of	O	O
3	the	O	O
4	321	O	O
5	patients	O	O
6	so	O	O
7	far	O	O
8	available	O	O
9	including	O	O
10	our	O	O
11	dataset	O	O
12	and	O	O
13	previously	O	O
14	published	O	O
15	cases	O	O
16	at	O	O
17	the	O	O
18	mean	O	O
19	age	O	O
20	of	O	O
21	approximately	O	O
22	35	O	O
23	years	O	O
24	the	O	O
25	clinical	O	O
26	picture	O	O
27	was	O	O
28	characterized	O	O
29	by	O	O
30	the	O	O
31	following	O	O
32	signs	O	O
33	symptoms	O	O
34	in	O	O
35	descending	O	O
36	order	O	O
37	myoclonus	O	O
38	muscle	O	O
39	weakness	O	O
40	ataxia	BI	O
41	35%-45%	O	O
42	of	O	O
43	patients	O	O
44	generalized	O	O
45	seizures	O	O
46	hearing	BI	O
47	loss	II	O
48	25%-34.9%	O	O
49	cognitive	BI	O
50	impairment	II	O
51	multiple	O	O
52	lipomatosis	O	O
53	neuropathy	O	O
54	exercise	O	O
55	intolerance	O	O
56	15%-24.9%	O	O
57	and	O	O
58	increased	O	O
59	creatine	O	O
60	kinase	O	O
61	levels	O	O
62	ptosis	BU	O
63	ophthalmoparesis	O	O
64	optic	BI	O
65	atrophy	II	O
66	cardiomyopathy	BU	O
67	muscle	O	O
68	wasting	O	O
69	respiratory	O	O
70	impairment	O	O
71	diabetes	O	O
72	muscle	O	O
73	pain	O	O
74	tremor	O	O
75	migraine	O	O
76	5%-14.9%	O	O
77	.	O	O

0	Huntington	BU	O
1	disease	IU	O
2	HD	IU	O
3	is	O	O
4	caused	O	O
5	by	O	O
6	an	O	O
7	expanded	O	O
8	HTT	O	O
9	CAG	O	O
10	repeat	O	O
11	that	O	O
12	leads	O	O
13	in	O	O
14	a	O	O
15	length-dependent	O	O
16	completely	O	O
17	dominant	O	O
18	manner	O	O
19	to	O	O
20	onset	O	O
21	of	O	O
22	a	O	O
23	characteristic	O	O
24	movement	BI	O
25	disorder	II	O
26	.	O	O

0	Human	O	O
1	genetic	O	O
2	defects	O	O
3	resulting	O	O
4	in	O	O
5	the	O	O
6	loss	O	O
7	one	O	O
8	of	O	O
9	two	O	O
10	REP	O	O
11	isoforms	O	O
12	REP-1	O	O
13	lead	O	O
14	to	O	O
15	underprenylation	O	O
16	of	O	O
17	RabGTPases	O	O
18	that	O	O
19	manifests	O	O
20	in	O	O
21	retinal	BI	O
22	degradation	II	O
23	and	O	O
24	blindness	BI	O
25	known	O	O
26	as	O	O
27	choroideremia	BU	O
28	.	O	O

0	METHODS	O	O
1	Publications	O	O
2	reporting	O	O
3	CRS	BU	O
4	prevalence	O	O
5	in	O	O
6	general	O	O
7	population	O	O
8	as	O	O
9	well	O	O
10	as	O	O
11	selected	O	O
12	subgroups	O	O
13	i.e.	O	O
14	suspected	O	O
15	intra-uterine	O	O
16	infection	O	O
17	congenital	BI	O
18	ocular	II	O
19	abnormalities	II	O
20	deafness	BI	O
21	congenital	O	O
22	heart	O	O
23	disease	O	O
24	mental	BI	O
25	retardation	II	O
26	and	O	O
27	congenital	O	O
28	malformations	O	O
29	seroprevalence	O	O
30	to	O	O
31	rubella	O	O
32	IgG	O	O
33	amongst	O	O
34	women	O	O
35	and	O	O
36	adolescents	O	O
37	and	O	O
38	immunogenicity	O	O
39	and	O	O
40	coverage	O	O
41	of	O	O
42	RCVs	O	O
43	in	O	O
44	Indian	O	O
45	population	O	O
46	were	O	O
47	retrieved	O	O
48	through	O	O
49	a	O	O
50	systematic	O	O
51	search	O	O
52	.	O	O

0	In	O	O
1	spite	O	O
2	of	O	O
3	being	O	O
4	a	O	O
5	rare	O	O
6	disorder	O	O
7	GS	BU	O
8	has	O	O
9	to	O	O
10	be	O	O
11	considered	O	O
12	in	O	O
13	children	O	O
14	with	O	O
15	developmental	BI	O
16	delay	II	O
17	and	O	O
18	muscle	O	O
19	weakness	O	O
20	.	O	O

0	BACKGROUND	O	O
1	Microscopically	O	O
2	chromosome	O	O
3	rearrangements	O	O
4	of	O	O
5	the	O	O
6	short	O	O
7	arm	O	O
8	of	O	O
9	chromosome	O	O
10	4	O	O
11	include	O	O
12	the	O	O
13	two	O	O
14	known	O	O
15	clinical	O	O
16	entities	O	O
17	partial	O	O
18	trisomy	BU	O
19	4p	IU	O
20	and	O	O
21	deletions	O	O
22	of	O	O
23	the	O	O
24	Wolf-Hirschhorn	O	O
25	critical	O	O
26	regions	O	O
27	1	O	O
28	and	O	O
29	2	O	O
30	WHSCR-1	O	O
31	and	O	O
32	WHSCR-2	O	O
33	respectively	O	O
34	which	O	O
35	cause	O	O
36	cranio-facial	O	O
37	anomalies	O	O
38	congenital	O	O
39	malformations	O	O
40	and	O	O
41	developmental	BI	O
42	delay	II	O
43	intellectual	BI	O
44	disability	II	O
45	.	O	O

0	The	O	O
1	first	O	O
2	point	O	O
3	mutation	O	O
4	of	O	O
5	mitochondrial	O	O
6	DNA	O	O
7	mtDNA	O	O
8	associated	O	O
9	with	O	O
10	the	O	O
11	maternally	BI	O
12	inherited	II	O
13	blinding	II	O
14	disorder	II	O
15	Lebers	BU	O
16	hereditary	IU	O
17	optic	IU	O
18	neuropathy	IU	O
19	LHON	IU	O
20	was	O	O
21	recognized	O	O
22	in	O	O
23	1988	O	O
24	.	O	O

0	Multiple	BI	O
1	congenital	II	O
2	anomalies	II	O
3	and	O	O
4	craniofacial	O	O
5	dysmorphism	O	O
6	are	O	O
7	characterizing	O	O
8	the	O	O
9	so-called	O	O
10	Emanuel	O	O
11	or	O	O
12	supernumerary	O	O
13	der22t1122	BU	O
14	syndrome	IU	O
15	OMIM609029	O	O
16	.	O	O

0	Partial	O	O
1	or	O	O
2	complete	O	O
3	trisomy	BU	O
4	5p	IU	O
5	has	O	O
6	been	O	O
7	associated	O	O
8	with	O	O
9	characteristic	O	O
10	facial	O	O
11	features	O	O
12	developmental	BI	O
13	delay	II	O
14	seizures	O	O
15	congenital	O	O
16	heart	O	O
17	defects	O	O
18	and	O	O
19	respiratory	O	O
20	compromise	O	O
21	.	O	O

0	In	O	O
1	this	O	O
2	report	O	O
3	we	O	O
4	present	O	O
5	the	O	O
6	case	O	O
7	of	O	O
8	a	O	O
9	7-year-old	O	O
10	boy	O	O
11	who	O	O
12	presented	O	O
13	with	O	O
14	mental	BI	O
15	retardation	II	O
16	atypical	BU	O
17	autism	IU	O
18	and	O	O
19	attention	BI	O
20	deficit	II	O
21	hyperactivity	II	O
22	disorder	II	O
23	.	O	O

0	Psychomotor	BI	O
1	retardation	II	O
2	is	O	O
3	not	O	O
4	uncommon	O	O
5	in	O	O
6	LEOPARD	BU	O
7	syndrome	IU	O
8	.	O	O

0	Cowchock	BU	O
1	syndrome	IU	O
2	CMTX4	IU	O
3	is	O	O
4	a	O	O
5	slowly	O	O
6	progressive	O	O
7	X-linked	O	O
8	recessive	O	O
9	disorder	O	O
10	with	O	O
11	axonal	O	O
12	neuropathy	O	O
13	deafness	BI	O
14	and	O	O
15	cognitive	BI	O
16	impairment	II	O
17	.	O	O

0	Patients	O	O
1	with	O	O
2	PRS-I	BU	O
3	superactivity	IU	O
4	demonstrate	O	O
5	uric	O	O
6	acid	O	O
7	overproduction	O	O
8	hypotonia	O	O
9	ataxia	BI	O
10	neurodevelopment	O	O
11	abnormalities	O	O
12	and	O	O
13	postlingual	BI	O
14	hearing	II	O
15	impairment	II	O
16	.	O	O

0	Type	BU	O
1	I	IU	O
2	autosomal	IU	O
3	dominant	IU	O
4	cerebellar	IU	O
5	ataxia	IU	O
6	ADCA	IU	O
7	is	O	O
8	a	O	O
9	type	O	O
10	of	O	O
11	spinocerebellar	BI	O
12	ataxia	II	O
13	SCA	O	O
14	characterized	O	O
15	by	O	O
16	ataxia	BI	O
17	with	O	O
18	other	O	O
19	neurological	O	O
20	signs	O	O
21	including	O	O
22	oculomotor	BI	O
23	disturbances	II	O
24	cognitive	BI	O
25	deficits	II	O
26	pyramidal	O	O
27	and	O	O
28	extrapyramidal	O	O
29	dysfunction	O	O
30	bulbar	O	O
31	spinal	O	O
32	and	O	O
33	peripheral	O	O
34	nervous	O	O
35	system	O	O
36	involvement	O	O
37	.	O	O

0	CONCLUSIONS	O	O
1	These	O	O
2	findings	O	O
3	demonstrate	O	O
4	that	O	O
5	DLG4	O	O
6	gene	O	O
7	disruption	O	O
8	in	O	O
9	mice	O	O
10	produces	O	O
11	a	O	O
12	complex	O	O
13	range	O	O
14	of	O	O
15	behavioral	O	O
16	and	O	O
17	molecular	O	O
18	abnormalities	O	O
19	relevant	O	O
20	to	O	O
21	autism	BI	O
22	spectrum	II	O
23	disorders	II	O
24	and	O	O
25	Williams	BU	O
26	syndrome	IU	O
27	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	O	O
6	semi-dominant	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	diverse	O	O
11	phenotypes	O	O
12	including	O	O
13	intellectual	BI	O
14	disability	II	O
15	facial	O	O
16	and	O	O
17	digital	O	O
18	anomalies	O	O
19	.	O	O

0	Episodic	BU	O
1	ataxia	IU	O
2	EA	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	paroxysmal	O	O
7	attacks	O	O
8	of	O	O
9	ataxia	BI	O
10	interspersed	O	O
11	by	O	O
12	asymptomatic	O	O
13	periods	O	O
14	.	O	O

0	We	O	O
1	describe	O	O
2	an	O	O
3	18-year-old	O	O
4	male	O	O
5	patient	O	O
6	with	O	O
7	myoclonic	BU	O
8	astatic	IU	O
9	epilepsy	IU	O
10	MAE	IU	O
11	moderate	BI	O
12	to	II	O
13	severe	II	O
14	intellectual	II	O
15	disability	II	O
16	behavioural	BI	O
17	problems	II	O
18	several	O	O
19	dysmorphisms	O	O
20	and	O	O
21	a	O	O
22	1.2-Mb	O	O
23	de	O	O
24	novo	O	O
25	deletion	O	O
26	on	O	O
27	chromosome	O	O
28	16p11.2	O	O
29	.	O	O

0	Recently	O	O
1	mutations	O	O
2	in	O	O
3	SOX10	O	O
4	a	O	O
5	well-known	O	O
6	causative	O	O
7	gene	O	O
8	of	O	O
9	Waardenburg	BU	O
10	syndrome	IU	O
11	WS	O	O
12	characterized	O	O
13	by	O	O
14	deafness	BI	O
15	skin	O	O
16	hair	O	O
17	iris	O	O
18	hypopigmentation	O	O
19	Hirschsprung	BU	O
20	disease	IU	O
21	and	O	O
22	neurological	O	O
23	defects	O	O
24	have	O	O
25	been	O	O
26	identified	O	O
27	in	O	O
28	a	O	O
29	few	O	O
30	patients	O	O
31	with	O	O
32	KS	BU	O
33	and	O	O
34	deafness	BI	O
35	.	O	O

0	METHODS	O	O
1	We	O	O
2	examined	O	O
3	the	O	O
4	association	O	O
5	of	O	O
6	autism	BI	O
7	traits	II	O
8	with	O	O
9	NF1	BU	O
10	NS	BU	O
11	CS	O	O
12	and	O	O
13	CFC	O	O
14	comparing	O	O
15	affected	O	O
16	probands	O	O
17	with	O	O
18	unaffected	O	O
19	sibling	O	O
20	controls	O	O
21	and	O	O
22	subjects	O	O
23	with	O	O
24	idiopathic	O	O
25	ASDs	O	O
26	using	O	O
27	the	O	O
28	qualitative	O	O
29	Social	O	O
30	Communication	O	O
31	Questionnaire	O	O
32	SCQ	O	O
33	and	O	O
34	the	O	O
35	quantitative	O	O
36	Social	O	O
37	Responsiveness	O	O
38	Scale	O	O
39	SRS	O	O
40	.	O	O

0	Danon	BU	O
1	disease	IU	O
2	primary	O	O
3	lysosome-associated	O	O
4	membrane	O	O
5	protein-2	O	O
6	LAMP-2	O	O
7	deficiency	O	O
8	is	O	O
9	characterized	O	O
10	clinically	O	O
11	by	O	O
12	cardiomyopathy	BU	O
13	myopathy	O	O
14	and	O	O
15	intellectual	BI	O
16	disability	II	O
17	in	O	O
18	boys	O	O
19	.	O	O

0	Rsk2	O	O
1	knockout	O	O
2	mice	O	O
3	a	O	O
4	murine	O	O
5	model	O	O
6	of	O	O
7	CLS	BU	O
8	exhibit	O	O
9	spatial	BI	O
10	learning	II	O
11	and	II	O
12	memory	II	O
13	impairments	II	O
14	yet	O	O
15	the	O	O
16	underlying	O	O
17	neural	O	O
18	mechanisms	O	O
19	are	O	O
20	unknown	O	O
21	.	O	O

0	Treacher	BU	O
1	Collins	IU	O
2	syndrome	IU	O
3	TCS	IU	O
4	OMIM	IU	O
5	154500	IU	O
6	is	O	O
7	a	O	O
8	well-defined	O	O
9	mandibulofacial	BU	O
10	dysostosis	IU	O
11	characterized	O	O
12	by	O	O
13	symmetric	O	O
14	facial	O	O
15	anomalies	O	O
16	consisting	O	O
17	of	O	O
18	malar	O	O
19	hypoplasia	O	O
20	coloboma	O	O
21	of	O	O
22	the	O	O
23	lower	O	O
24	eyelid	O	O
25	dysplastic	O	O
26	ears	O	O
27	micrognathia	O	O
28	cleft	BU	O
29	palate	IU	O
30	and	O	O
31	deafness	BI	O
32	.	O	O

0	BACKGROUND	O	O
1	Histopathological	O	O
2	examinations	O	O
3	and	O	O
4	computed	O	O
5	tomographic	O	O
6	scans	O	O
7	of	O	O
8	the	O	O
9	temporal	O	O
10	bone	O	O
11	in	O	O
12	patients	O	O
13	with	O	O
14	the	O	O
15	CHARGE	BU	O
16	association	IU	O
17	a	O	O
18	malformative	O	O
19	syndrome	O	O
20	that	O	O
21	includes	O	O
22	coloboma	O	O
23	heart	O	O
24	disease	O	O
25	choanal	BU	O
26	atresia	IU	O
27	retarded	BI	O
28	development	II	O
29	genital	O	O
30	hypoplasia	O	O
31	and	O	O
32	ear	O	O
33	anomalies	O	O
34	including	O	O
35	hypoplasia	O	O
36	of	O	O
37	the	O	O
38	external	O	O
39	ear	O	O
40	and	O	O
41	hearing	BI	O
42	loss	II	O
43	have	O	O
44	shown	O	O
45	an	O	O
46	absence	O	O
47	of	O	O
48	semicircular	O	O
49	canals	O	O
50	and	O	O
51	a	O	O
52	Mondini	O	O
53	form	O	O
54	of	O	O
55	cochlear	O	O
56	dysplasia	O	O
57	.	O	O

0	Four	O	O
1	NS	BU	O
2	patients	O	O
3	received	O	O
4	cochlear	O	O
5	implants	O	O
6	for	O	O
7	their	O	O
8	severe	BI	O
9	sensorineural	II	O
10	hearing	II	O
11	impairment	II	O
12	.	O	O

0	From	O	O
1	a	O	O
2	clinical	O	O
3	perspective	O	O
4	impaired	BI	O
5	ability	II	O
6	to	II	O
7	recognise	II	O
8	faces	II	O
9	is	O	O
10	common	O	O
11	in	O	O
12	bvFTD	BU	O
13	and	O	O
14	SD	O	O
15	and	O	O
16	therefore	O	O
17	strategies	O	O
18	to	O	O
19	improve	O	O
20	face	O	O
21	perception	O	O
22	and	O	O
23	memory	O	O
24	may	O	O
25	be	O	O
26	beneficial	O	O
27	for	O	O
28	these	O	O
29	patients	O	O
30	.	O	O

0	Our	O	O
1	results	O	O
2	argue	O	O
3	for	O	O
4	shared	O	O
5	neural	O	O
6	correlates	O	O
7	of	O	O
8	limb	BI	O
9	apraxia	II	O
10	in	O	O
11	AD	O	O
12	and	O	O
13	bvFTD	BU	O
14	and	O	O
15	validate	O	O
16	the	O	O
17	syndrome	O	O
18	as	O	O
19	an	O	O
20	important	O	O
21	neuropsychological	O	O
22	feature	O	O
23	across	O	O
24	different	O	O
25	etiologies	O	O
26	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	is	O	O
4	the	O	O
5	leading	O	O
6	single	O	O
7	gene	O	O
8	cause	O	O
9	of	O	O
10	intellectual	BI	O
11	disabilities	II	O
12	.	O	O

0	In	O	O
1	the	O	O
2	third	O	O
3	family	O	O
4	although	O	O
5	CLS	BU	O
6	had	O	O
7	been	O	O
8	suspected	O	O
9	the	O	O
10	clinical	O	O
11	features	O	O
12	were	O	O
13	atypical	O	O
14	and	O	O
15	the	O	O
16	degree	O	O
17	of	O	O
18	intellectual	BI	O
19	disability	II	O
20	much	O	O
21	less	O	O
22	than	O	O
23	expected	O	O
24	.	O	O

0	Hearing	BI	O
1	loss	II	O
2	occurs	O	O
3	in	O	O
4	variable	O	O
5	percentage	O	O
6	as	O	O
7	a	O	O
8	component	O	O
9	part	O	O
10	of	O	O
11	all	O	O
12	FGFR	O	O
13	related	O	O
14	craniosynostosis	BU	O
15	syndromes	O	O
16	.	O	O

0	Lowe	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	X-linked	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	bilateral	O	O
10	congenital	O	O
11	cataracts	O	O
12	renal	O	O
13	Fanconi	O	O
14	syndrome	O	O
15	and	O	O
16	mental	BI	O
17	retardation	II	O
18	.	O	O

0	l-2-Hydroxyglutaric	BU	O
1	aciduria	IU	O
2	l-2-HGA	IU	O
3	is	O	O
4	an	O	O
5	autosomal	O	O
6	recessive	O	O
7	neurometabolic	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	psychomotor	BI	O
12	delay	II	O
13	ataxia	BI	O
14	macrocephaly	O	O
15	and	O	O
16	typical	O	O
17	neuroradiological	O	O
18	findings	O	O
19	of	O	O
20	subcortical	O	O
21	leucoencephalopathy	O	O
22	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	severe	BI	O
4	developmental	II	O
5	retardation	II	O
6	hypotonia	O	O
7	postnatal	BI	O
8	growth	II	O
9	retardation	II	O
10	microcephaly	O	O
11	abnormal	O	O
12	breathing	O	O
13	and	O	O
14	characteristic	O	O
15	dysmorphic	O	O
16	features	O	O
17	both	O	O
18	had	O	O
19	epilepsy	O	O
20	and	O	O
21	intestinal	O	O
22	problems	O	O
23	with	O	O
24	severe	O	O
25	constipation	O	O
26	in	O	O
27	one	O	O
28	and	O	O
29	Hirschsprung	BU	O
30	disease	IU	O
31	in	O	O
32	the	O	O
33	other	O	O
34	.	O	O

0	The	O	O
1	current	O	O
2	results	O	O
3	provide	O	O
4	preliminary	O	O
5	evidence	O	O
6	for	O	O
7	a	O	O
8	distinct	O	O
9	schizophrenia	O	O
10	subgroup	O	O
11	distinguishable	O	O
12	from	O	O
13	other	O	O
14	chronic	O	O
15	schizophrenia	O	O
16	patients	O	O
17	by	O	O
18	poorer	O	O
19	clinical	O	O
20	and	O	O
21	functional	O	O
22	status	O	O
23	who	O	O
24	have	O	O
25	levels	O	O
26	of	O	O
27	cognitive	BI	O
28	impairment	II	O
29	comparable	O	O
30	to	O	O
31	those	O	O
32	seen	O	O
33	in	O	O
34	bvFTD	BU	O
35	patients	O	O
36	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	gene	O	O
4	coding	O	O
5	for	O	O
6	membrane-bound	O	O
7	fatty	O	O
8	aldehyde	O	O
9	dehydrogenase	O	O
10	FALDH	O	O
11	lead	O	O
12	to	O	O
13	toxic	O	O
14	accumulation	O	O
15	of	O	O
16	lipid	O	O
17	species	O	O
18	and	O	O
19	development	O	O
20	of	O	O
21	the	O	O
22	Sjögren-Larsson	BU	O
23	Syndrome	IU	O
24	SLS	IU	O
25	a	O	O
26	rare	O	O
27	disorder	O	O
28	characterized	O	O
29	by	O	O
30	skin	O	O
31	defects	O	O
32	and	O	O
33	mental	BI	O
34	retardation	II	O
35	.	O	O

0	Partial	O	O
1	deletion	O	O
2	of	O	O
3	the	O	O
4	long	O	O
5	arm	O	O
6	of	O	O
7	the	O	O
8	chromosome	O	O
9	13	O	O
10	13q	O	O
11	deletion	O	O
12	syndrome	O	O
13	is	O	O
14	a	O	O
15	rare	O	O
16	chromosomal	O	O
17	disorder	O	O
18	characterized	O	O
19	by	O	O
20	severe	BI	O
21	growth	II	O
22	and	II	O
23	mental	II	O
24	retardation	II	O
25	microcephaly	O	O
26	facial	O	O
27	dysmorphism	O	O
28	brain	BU	O
29	malformations	IU	O
30	holoprosencephaly	BU	O
31	Dandy-Walker	O	O
32	malformation	O	O
33	distal	O	O
34	limb	O	O
35	defects	O	O
36	eye	O	O
37	anomalies	O	O
38	genitourinary	O	O
39	and	O	O
40	gastrointestinal	O	O
41	tract	O	O
42	malformations	O	O
43	Hirschsprungs	O	O
44	disease	O	O
45	.	O	O

0	INTRODUCTION	O	O
1	Joubert	O	O
2	syndrome	O	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	O
9	whose	O	O
10	main	O	O
11	clinical	O	O
12	signs	O	O
13	are	O	O
14	hypotonia	O	O
15	ataxia	BI	O
16	mental	BI	O
17	retardation	II	O
18	abnormal	BU	O
19	eye	IU	O
20	movements	IU	O
21	and	O	O
22	a	O	O
23	respiratory	O	O
24	pattern	O	O
25	of	O	O
26	alternating	O	O
27	tachypnea-apnea	O	O
28	during	O	O
29	first	O	O
30	months	O	O
31	of	O	O
32	life	O	O
33	.	O	O

0	Mutations	O	O
1	in	O	O
2	human	O	O
3	RAB3GAP1	O	O
4	cause	O	O
5	Warburg	BU	O
6	micro	IU	O
7	syndrome	IU	O
8	WARBM	IU	O
9	a	O	O
10	severe	BI	O
11	developmental	II	O
12	disorder	II	O
13	characterized	O	O
14	by	O	O
15	abnormalities	O	O
16	of	O	O
17	the	O	O
18	eye	O	O
19	genitals	O	O
20	and	O	O
21	nervous	O	O
22	system	O	O
23	including	O	O
24	a	O	O
25	predominantly	O	O
26	axonal	O	O
27	peripheral	O	O
28	neuropathy	O	O
29	.	O	O

0	Infantile	O	O
1	vitamin	O	O
2	B12	O	O
3	deficiency	O	O
4	has	O	O
5	to	O	O
6	be	O	O
7	considered	O	O
8	in	O	O
9	the	O	O
10	differential	O	O
11	diagnosis	O	O
12	of	O	O
13	mental	BI	O
14	retardation	II	O
15	and	O	O
16	infantile	BU	O
17	spasms	IU	O
18	especially	O	O
19	if	O	O
20	maternal	O	O
21	nutritional	O	O
22	deficiency	O	O
23	might	O	O
24	be	O	O
25	suspected	O	O
26	.	O	O

0	Patients	O	O
1	with	O	O
2	CMTX5	BU	O
3	and	O	O
4	Arts	BU	O
5	syndrome	IU	O
6	have	O	O
7	peripheral	O	O
8	neuropathy	O	O
9	including	O	O
10	hearing	BI	O
11	impairment	II	O
12	and	O	O
13	optic	BI	O
14	atrophy	II	O
15	.	O	O

0	Thus	O	O
1	the	O	O
2	diagnosis	O	O
3	of	O	O
4	SMS	BU	O
5	can	O	O
6	be	O	O
7	made	O	O
8	from	O	O
9	a	O	O
10	simple	O	O
11	blood	O	O
12	sample	O	O
13	and	O	O
14	should	O	O
15	be	O	O
16	questioned	O	O
17	in	O	O
18	subjects	O	O
19	of	O	O
20	any	O	O
21	age	O	O
22	presenting	O	O
23	with	O	O
24	an	O	O
25	association	O	O
26	of	O	O
27	facial	O	O
28	dysmorphism	O	O
29	speech	BI	O
30	delay	II	O
31	with	O	O
32	behavioral	BI	O
33	and	II	O
34	sleep	II	O
35	wake	II	O
36	circadian	II	O
37	rhythm	II	O
38	disorders	II	O
39	and	O	O
40	other	O	O
41	anomalies	O	O
42	including	O	O
43	short	O	O
44	stature	O	O
45	and	O	O
46	mild	O	O
47	dysmorphic	O	O
48	features	O	O
49	.	O	O

0	Individuals	O	O
1	with	O	O
2	Mowat-Wilson	BU	O
3	syndrome	IU	O
4	MWS	O	O
5	OMIM#235730	O	O
6	have	O	O
7	characteristic	O	O
8	facial	O	O
9	features	O	O
10	a	O	O
11	variety	O	O
12	of	O	O
13	congenital	O	O
14	anomalies	O	O
15	such	O	O
16	as	O	O
17	Hirschsprung	BU	O
18	disease	IU	O
19	and	O	O
20	intellectual	BI	O
21	disabilities	II	O
22	caused	O	O
23	by	O	O
24	mutation	O	O
25	or	O	O
26	deletion	O	O
27	of	O	O
28	ZEB2	O	O
29	gene	O	O
30	.	O	O

0	About	O	O
1	10%	O	O
2	of	O	O
3	patients	O	O
4	with	O	O
5	SPS	BU	O
6	may	O	O
7	develop	O	O
8	ataxia	BI	O
9	.	O	O

0	The	O	O
1	aim	O	O
2	of	O	O
3	this	O	O
4	study	O	O
5	was	O	O
6	to	O	O
7	identify	O	O
8	the	O	O
9	causative	O	O
10	gene	O	O
11	in	O	O
12	a	O	O
13	family	O	O
14	with	O	O
15	CMTX	BU	O
16	with	O	O
17	peripheral	O	O
18	neuropathy	O	O
19	and	O	O
20	deafness	BI	O
21	.	O	O

0	Progressive	BI	O
1	sensorineural	II	O
2	hearing	II	O
3	loss	II	O
4	and	O	O
5	amyloidosis	BU	O
6	are	O	O
7	two	O	O
8	late	O	O
9	complications	O	O
10	.	O	O

0	Pelizaeus-Merzbacher	BU	O
1	disease	IU	O
2	PMD	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	X-linked	O	O
7	recessive	O	O
8	hypomyelination	O	O
9	disorder	O	O
10	characterized	O	O
11	by	O	O
12	nystagmus	O	O
13	ataxia	BI	O
14	impaired	BI	O
15	motor	II	O
16	development	II	O
17	and	O	O
18	progressive	O	O
19	spasticity	O	O
20	.	O	O

0	Möbius	BU	O
1	syndrome	IU	O
2	is	O	O
3	also	O	O
4	phenotypically	O	O
5	heterogeneous	O	O
6	with	O	O
7	minimal	O	O
8	diagnostic	O	O
9	criteria	O	O
10	of	O	O
11	nonprogressive	O	O
12	facial	O	O
13	weakness	O	O
14	and	O	O
15	impaired	O	O
16	ocular	O	O
17	abduction	O	O
18	mental	BI	O
19	retardation	II	O
20	autism	BI	O
21	motor	BI	O
22	disabilities	II	O
23	additional	O	O
24	eye	O	O
25	movements	O	O
26	restrictions	O	O
27	hearing	BI	O
28	loss	II	O
29	hypoventilation	O	O
30	and	O	O
31	craniofacial	O	O
32	lingual	O	O
33	and	O	O
34	limb	O	O
35	abnormalities	O	O
36	also	O	O
37	occur	O	O
38	.	O	O

0	SIGNIFICANCE	O	O
1	Fragile	BU	O
2	X	IU	O
3	Syndrome	IU	O
4	FXS	IU	O
5	is	O	O
6	the	O	O
7	leading	O	O
8	known	O	O
9	genetic	O	O
10	cause	O	O
11	of	O	O
12	autism	BI	O
13	spectrum	II	O
14	disorders	II	O
15	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	patient	O	O
5	carrying	O	O
6	an	O	O
7	isolated	O	O
8	complete	O	O
9	trisomy	BU	O
10	18p	IU	O
11	translocated	O	O
12	to	O	O
13	the	O	O
14	short	O	O
15	arm	O	O
16	of	O	O
17	chromosome	O	O
18	14	O	O
19	and	O	O
20	presenting	O	O
21	with	O	O
22	facial	O	O
23	dysmorphism	O	O
24	mild	BI	O
25	intellectual	II	O
26	disability	II	O
27	and	O	O
28	non-obstructive	O	O
29	azoospermia	O	O
30	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	4-1	O	O
5	2	O	O
6	year	O	O
7	old	O	O
8	girl	O	O
9	with	O	O
10	apparent	O	O
11	CHARGE	BU	O
12	association	IU	O
13	who	O	O
14	had	O	O
15	a	O	O
16	de	O	O
17	novo	O	O
18	inverted	O	O
19	duplication	O	O
20	14q22-->24.3	O	O
21	iris	O	O
22	colobomas	O	O
23	ventricular	BU	O
24	septal	IU	O
25	defect	IU	O
26	soft	O	O
27	tissue	O	O
28	choanal	BU	O
29	atresia	IU	O
30	intellectual	BI	O
31	impairment	II	O
32	growth	BI	O
33	retardation	II	O
34	sensorineural	BI	O
35	deafness	II	O
36	apparently	O	O
37	low	O	O
38	set	O	O
39	ears	O	O
40	and	O	O
41	upslanting	O	O
42	palpebral	O	O
43	fissures	O	O
44	.	O	O

0	Fragile-X	BU	O
1	syndrome	IU	O
2	FXS	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	form	O	O
8	of	O	O
9	inherited	BI	O
10	intellectual	II	O
11	disability	II	O
12	ID	O	O
13	and	O	O
14	affects	O	O
15	0.7-3.0%	O	O
16	of	O	O
17	intellectually	O	O
18	compromised	O	O
19	population	O	O
20	of	O	O
21	unknown	O	O
22	etiology	O	O
23	worldwide	O	O
24	.	O	O

0	We	O	O
1	reported	O	O
2	two	O	O
3	Chinese	O	O
4	families	O	O
5	with	O	O
6	partial	O	O
7	trisomy	BU	O
8	9p	IU	O
9	and	O	O
10	other	O	O
11	chromosome	O	O
12	partial	O	O
13	monosomy	O	O
14	clinical	O	O
15	features	O	O
16	of	O	O
17	mental	BI	O
18	retardation	II	O
19	and	O	O
20	mild	O	O
21	facial	O	O
22	and	O	O
23	pinkie	O	O
24	anomalies	O	O
25	.	O	O

0	CCS	BU	O
1	is	O	O
2	a	O	O
3	genetic	O	O
4	disorder	O	O
5	that	O	O
6	universally	O	O
7	results	O	O
8	in	O	O
9	profound	BI	O
10	deficits	II	O
11	in	II	O
12	expressive	II	O
13	speech	II	O
14	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	monogenetic	O	O
8	form	O	O
9	of	O	O
10	intellectual	BI	O
11	disability	II	O
12	and	O	O
13	is	O	O
14	a	O	O
15	leading	O	O
16	cause	O	O
17	of	O	O
18	autism	BI	O
19	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	distinctive	O	O
5	multiple	O	O
6	congenital	O	O
7	anomaly	O	O
8	syndrome	O	O
9	characterized	O	O
10	by	O	O
11	loose	O	O
12	soft	O	O
13	skin	O	O
14	with	O	O
15	deep	O	O
16	palmar	O	O
17	and	O	O
18	plantar	O	O
19	creases	O	O
20	loose	O	O
21	joints	O	O
22	distinctive	O	O
23	coarse	O	O
24	facial	O	O
25	features	O	O
26	skeletal	O	O
27	abnormalities	O	O
28	cardiac	O	O
29	abnormalities	O	O
30	cardiovascular	O	O
31	malformation	O	O
32	CVM	O	O
33	hypertrophic	BU	O
34	cardiomyopathy	IU	O
35	tachycardia	O	O
36	predisposition	O	O
37	to	O	O
38	malignancy	O	O
39	developmental	BI	O
40	delays	II	O
41	and	O	O
42	mental	BI	O
43	retardation	II	O
44	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	the	O	O
5	patients	O	O
6	clinical	O	O
7	manifestations	O	O
8	also	O	O
9	including	O	O
10	visual	BI	O
11	problems	II	O
12	and	O	O
13	moderate	BI	O
14	mental	II	O
15	retardation	II	O
16	are	O	O
17	those	O	O
18	typically	O	O
19	observed	O	O
20	in	O	O
21	the	O	O
22	1p36	BU	O
23	deletion	IU	O
24	syndrome	IU	O
25	.	O	O

0	The	O	O
1	occurrence	O	O
2	of	O	O
3	a	O	O
4	tumor	O	O
5	in	O	O
6	a	O	O
7	child	O	O
8	with	O	O
9	growth	BI	O
10	retardation	II	O
11	and	O	O
12	cutis	O	O
13	laxa	O	O
14	must	O	O
15	be	O	O
16	reminiscent	O	O
17	of	O	O
18	Costello	BU	O
19	syndrome	IU	O
20	.	O	O

0	Moreover	O	O
1	clinical	O	O
2	FTD	BU	O
3	manifestations	O	O
4	may	O	O
5	be	O	O
6	associated	O	O
7	with	O	O
8	TDP-43	O	O
9	proteolysis	O	O
10	since	O	O
11	impaired	BI	O
12	behaviors	II	O
13	in	O	O
14	TBI	O	O
15	rats	O	O
16	were	O	O
17	reminiscent	O	O
18	of	O	O
19	those	O	O
20	in	O	O
21	humans	O	O
22	with	O	O
23	FTD	BU	O
24	.	O	O

0	CONCLUSION	O	O
1	These	O	O
2	three	O	O
3	cases	O	O
4	confirm	O	O
5	the	O	O
6	association	O	O
7	of	O	O
8	optic	BI	O
9	atrophy	II	O
10	with	O	O
11	cblC	BU	O
12	disease	IU	O
13	.	O	O

0	Branchio-oculo-facial	BU	O
1	syndrome	IU	O
2	BOFS	O	O
3	OMIM#	O	O
4	113620	O	O
5	is	O	O
6	a	O	O
7	rare	O	O
8	autosomal	O	O
9	dominant	O	O
10	disorder	O	O
11	characterised	O	O
12	by	O	O
13	branchial	O	O
14	cleft	O	O
15	sinus	O	O
16	defects	O	O
17	ocular	BI	O
18	anomalies	II	O
19	and	O	O
20	facial	O	O
21	dysmorphisms	O	O
22	including	O	O
23	lip	O	O
24	or	O	O
25	palate	O	O
26	cleft	O	O
27	or	O	O
28	pseudocleft	O	O
29	and	O	O
30	is	O	O
31	associated	O	O
32	with	O	O
33	mutations	O	O
34	in	O	O
35	the	O	O
36	TFAP2A	O	O
37	gene	O	O
38	.	O	O

0	The	O	O
1	typical	O	O
2	cri	BU	O
3	du	IU	O
4	chat	IU	O
5	syndrome	IU	O
6	due	O	O
7	to	O	O
8	5p15.2	O	O
9	deletion	O	O
10	includes	O	O
11	severe	BI	O
12	intellectual	II	O
13	disability	II	O
14	facial	O	O
15	dysmorphisms	O	O
16	neonatal	O	O
17	hypotonia	O	O
18	and	O	O
19	pre-	BI	O
20	and	II	O
21	post-natal	II	O
22	growth	II	O
23	retardation	II	O
24	whereas	O	O
25	more	O	O
26	distal	O	O
27	deletions	O	O
28	in	O	O
29	5p15.3	O	O
30	lead	O	O
31	to	O	O
32	cat-like	O	O
33	cry	O	O
34	and	O	O
35	speech	BI	O
36	delay	II	O
37	and	O	O
38	produce	O	O
39	the	O	O
40	clinical	O	O
41	picture	O	O
42	of	O	O
43	the	O	O
44	atypical	O	O
45	cri	BU	O
46	du	IU	O
47	chat	IU	O
48	syndrome	IU	O
49	with	O	O
50	minimal	O	O
51	or	O	O
52	absent	O	O
53	intellectual	BI	O
54	impairment	II	O
55	.	O	O

0	These	O	O
1	findings	O	O
2	show	O	O
3	that	O	O
4	RSK2	O	O
5	loss-of-function	O	O
6	is	O	O
7	associated	O	O
8	in	O	O
9	the	O	O
10	dentate	O	O
11	gyrus	O	O
12	with	O	O
13	multi-level	O	O
14	alterations	O	O
15	that	O	O
16	encompass	O	O
17	modifications	O	O
18	of	O	O
19	glutamate	O	O
20	receptor	O	O
21	channel	O	O
22	properties	O	O
23	synaptic	O	O
24	transmission	O	O
25	plasticity-associated	O	O
26	gene	O	O
27	expression	O	O
28	and	O	O
29	spine	O	O
30	morphology	O	O
31	providing	O	O
32	novel	O	O
33	insights	O	O
34	into	O	O
35	the	O	O
36	mechanisms	O	O
37	contributing	O	O
38	to	O	O
39	cognitive	BI	O
40	impairments	II	O
41	in	O	O
42	CLS	BU	O
43	.	O	O

0	In	O	O
1	this	O	O
2	reported	O	O
3	case	O	O
4	of	O	O
5	Refsums	BU	O
6	disease	IU	O
7	despite	O	O
8	hearing	BI	O
9	loss	II	O
10	and	O	O
11	absence	O	O
12	of	O	O
13	response	O	O
14	in	O	O
15	ABR	O	O
16	robust	O	O
17	otoacoustic	O	O
18	emissions	O	O
19	were	O	O
20	measured	O	O
21	.	O	O

0	Subjects	O	O
1	included	O	O
2	muscular	BU	O
3	dystrophy	IU	O
4	MD	O	O
5	spinal	O	O
6	muscular	O	O
7	atrophy	O	O
8	Issacs	O	O
9	syndrome	O	O
10	idiopathic	O	O
11	muscle	O	O
12	spasms	O	O
13	psychiatric	O	O
14	disorders	O	O
15	such	O	O
16	as	O	O
17	autism	BI	O
18	anschizophrenia	O	O
19	and	O	O
20	normal	O	O
21	controls	O	O
22	.	O	O

0	CONCLUSIONS	O	O
1	Hearing	BI	O
2	loss	II	O
3	represents	O	O
4	a	O	O
5	characteristic	O	O
6	feature	O	O
7	of	O	O
8	FSHD	BU	O
9	patients	O	O
10	with	O	O
11	a	O	O
12	large	O	O
13	4q35	O	O
14	deletion	O	O
15	.	O	O

0	The	O	O
1	patient	O	O
2	had	O	O
3	hyperCKemia	O	O
4	hypertrophic	BU	O
5	cardiomyopathy	IU	O
6	no	O	O
7	muscle	O	O
8	weakness	O	O
9	and	O	O
10	slight	BI	O
11	mental	II	O
12	impairment	II	O
13	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	male	O	O
4	patient	O	O
5	with	O	O
6	sporadic	O	O
7	Aarskog	BU	O
8	syndrome	IU	O
9	cleft	BU	O
10	palate	IU	O
11	mild	BI	O
12	intellectual	II	O
13	disability	II	O
14	and	O	O
15	autism	BI	O
16	spectrum	II	O
17	disorder	II	O
18	ASD	O	O
19	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	O	O
6	disorder	O	O
7	associated	O	O
8	with	O	O
9	mental	BI	O
10	retardation	II	O
11	distinctive	O	O
12	facies	O	O
13	and	O	O
14	hands	O	O
15	hypotonia	O	O
16	and	O	O
17	skeletal	O	O
18	abnormalities	O	O
19	.	O	O

0	BACKGROUND	O	O
1	Costello	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	syndrome	O	O
7	of	O	O
8	multiple	BI	O
9	congenital	II	O
10	anomalies	II	O
11	.	O	O

0	Huntingtons	BU	O
1	disease	IU	O
2	HD	IU	O
3	is	O	O
4	an	O	O
5	inherited	O	O
6	neurodegenerative	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	dyskinesia	BI	O
11	cognitive	BI	O
12	impairment	II	O
13	and	O	O
14	emotional	BI	O
15	disturbances	II	O
16	presenting	O	O
17	progressive	O	O
18	neurodegeneration	O	O
19	in	O	O
20	the	O	O
21	striatum	O	O
22	and	O	O
23	intracellular	O	O
24	mutant	O	O
25	Huntingtin	O	O
26	mHTT	O	O
27	aggregates	O	O
28	in	O	O
29	various	O	O
30	areas	O	O
31	of	O	O
32	the	O	O
33	brain	O	O
34	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	but	O	O
7	well-documented	O	O
8	X-linked	O	O
9	disorder	O	O
10	characterized	O	O
11	by	O	O
12	small	O	O
13	size	O	O
14	developmental	BI	O
15	delay	II	O
16	mental	BI	O
17	retardation	II	O
18	and	O	O
19	characteristic	O	O
20	facial	O	O
21	and	O	O
22	skeletal	O	O
23	findings	O	O
24	in	O	O
25	affected	O	O
26	males	O	O
27	.	O	O

0	Danon	BU	O
1	disease	IU	O
2	an	O	O
3	X-linked	O	O
4	dominant	O	O
5	disorder	O	O
6	results	O	O
7	from	O	O
8	mutations	O	O
9	in	O	O
10	the	O	O
11	lysosome-associated	O	O
12	membrane	O	O
13	protein-2	O	O
14	LAMP2	O	O
15	gene	O	O
16	and	O	O
17	presents	O	O
18	with	O	O
19	hypertrophic	BU	O
20	cardiomyopathy	IU	O
21	skeletal	O	O
22	myopathy	O	O
23	and	O	O
24	mental	BI	O
25	retardation	II	O
26	.	O	O

0	Children	O	O
1	with	O	O
2	mucopolysaccharidosis	BU	O
3	I	IU	O
4	MPS	IU	O
5	I	IU	O
6	develop	O	O
7	hyperintense	O	O
8	white	O	O
9	matter	O	O
10	foci	O	O
11	on	O	O
12	T2-weighted	O	O
13	brain	O	O
14	magnetic	O	O
15	resonance	O	O
16	MR	O	O
17	imaging	O	O
18	that	O	O
19	are	O	O
20	associated	O	O
21	clinically	O	O
22	with	O	O
23	cognitive	BI	O
24	impairment	II	O
25	.	O	O

0	Rett	BU	O
1	syndrome	IU	O
2	RTT	IU	O
3	is	O	O
4	a	O	O
5	pervasive	BI	O
6	neurodevelopmental	II	O
7	disorder	II	O
8	mainly	O	O
9	caused	O	O
10	by	O	O
11	mutations	O	O
12	in	O	O
13	the	O	O
14	X-linked	O	O
15	MECP2	O	O
16	gene	O	O
17	associated	O	O
18	with	O	O
19	severe	BI	O
20	intellectual	II	O
21	disability	II	O
22	movement	BI	O
23	disorders	II	O
24	and	O	O
25	autistic-like	BI	O
26	behaviors	II	O
27	.	O	O

0	Friedreich	BI	O
1	ataxia	II	O
2	is	O	O
3	an	O	O
4	autosomal	O	O
5	recessive	O	O
6	neurodegenerative	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	ataxia	BI	O
11	of	O	O
12	all	O	O
13	four	O	O
14	limbs	O	O
15	dysarthria	BI	O
16	areflexia	O	O
17	and	O	O
18	cardiomyopathy	BU	O
19	.	O	O

0	Three	O	O
1	8q12	BU	O
2	duplications	IU	O
3	have	O	O
4	been	O	O
5	reported	O	O
6	with	O	O
7	shared	O	O
8	recognizable	O	O
9	phenotype	O	O
10	Duane	O	O
11	anomaly	O	O
12	developmental	BI	O
13	delay	II	O
14	and	O	O
15	dysmorphic	O	O
16	facial	O	O
17	features	O	O
18	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	WS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	autosomal	O	O
7	recessive	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	diabetes	O	O
12	insipidus	O	O
13	DI	O	O
14	insulin-dependent	O	O
15	diabetes	O	O
16	mellitus	O	O
17	DM	O	O
18	optic	BI	O
19	atrophy	II	O
20	OA	O	O
21	and	O	O
22	deafness	BI	O
23	caused	O	O
24	by	O	O
25	mutations	O	O
26	in	O	O
27	WFS1	O	O
28	gene	O	O
29	4p16.1	O	O
30	which	O	O
31	encodes	O	O
32	an	O	O
33	endoplasmic	O	O
34	reticulum	O	O
35	protein	O	O
36	called	O	O
37	Wolframin	O	O
38	.	O	O

0	Five	O	O
1	other	O	O
2	patients	O	O
3	with	O	O
4	Wolf-Hirschhorn	BU	O
5	syndrome	IU	O
6	and	O	O
7	early	O	O
8	onset	O	O
9	glaucoma	O	O
10	or	O	O
11	ocular	BI	O
12	anomalies	II	O
13	associated	O	O
14	with	O	O
15	early	O	O
16	onset	O	O
17	glaucoma	O	O
18	have	O	O
19	been	O	O
20	previously	O	O
21	described	O	O
22	suggesting	O	O
23	that	O	O
24	the	O	O
25	association	O	O
26	with	O	O
27	Wolf-Hirschhorn	BU	O
28	syndrome	IU	O
29	is	O	O
30	not	O	O
31	coincidental	O	O
32	.	O	O

0	Alport	BU	O
1	syndrome	IU	O
2	is	O	O
3	an	O	O
4	inherited	O	O
5	disorder	O	O
6	of	O	O
7	type	O	O
8	IV	O	O
9	collagen	O	O
10	with	O	O
11	progressive	O	O
12	nephropathy	O	O
13	ocular	BI	O
14	abnormalities	II	O
15	and	O	O
16	high-tone	BI	O
17	sensorineural	II	O
18	deafness	II	O
19	.	O	O

0	Since	O	O
1	cerebellar	O	O
2	ataxia	O	O
3	is	O	O
4	a	O	O
5	relatively	O	O
6	common	O	O
7	but	O	O
8	unspecific	O	O
9	neurological	O	O
10	symptom	O	O
11	in	O	O
12	toddlers	O	O
13	it	O	O
14	is	O	O
15	recommended	O	O
16	that	O	O
17	MLD	BU	O
18	be	O	O
19	considered	O	O
20	as	O	O
21	part	O	O
22	of	O	O
23	the	O	O
24	differential	O	O
25	diagnosis	O	O
26	even	O	O
27	if	O	O
28	the	O	O
29	initial	O	O
30	neuroimaging	O	O
31	studies	O	O
32	are	O	O
33	normal	O	O
34	and	O	O
35	ataxia	BI	O
36	is	O	O
37	the	O	O
38	only	O	O
39	clinical	O	O
40	symptom	O	O
41	of	O	O
42	the	O	O
43	disease	O	O
44	.	O	O

0	Lowe	BU	O
1	syndrome	IU	O
2	a	O	O
3	multisystem	O	O
4	disease	O	O
5	characterized	O	O
6	by	O	O
7	renal	O	O
8	tubulopathy	O	O
9	congenital	O	O
10	cataracts	O	O
11	and	O	O
12	mental	BI	O
13	retardation	II	O
14	is	O	O
15	associated	O	O
16	with	O	O
17	mutations	O	O
18	in	O	O
19	the	O	O
20	gene	O	O
21	OCRL1	O	O
22	which	O	O
23	encodes	O	O
24	a	O	O
25	phosphatidylinositol	O	O
26	45-bisphosphate	O	O
27	PIP2	O	O
28	5-phosphatase	O	O
29	.	O	O

0	Alström	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	autosomal	O	O
6	recessive	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	retinal	BI	O
11	degeneration	II	O
12	sensorineural	BI	O
13	hearing	II	O
14	loss	II	O
15	early-onset	O	O
16	obesity	O	O
17	and	O	O
18	non-insulin-dependent	O	O
19	diabetes	O	O
20	mellitus	O	O
21	.	O	O

0	Mucopolysaccharidosis	BU	O
1	type	IU	O
2	I	IU	O
3	MPS	IU	O
4	I	IU	O
5	is	O	O
6	an	O	O
7	autosomal	O	O
8	recessive	O	O
9	disease	O	O
10	that	O	O
11	is	O	O
12	systemic	O	O
13	including	O	O
14	progressive	O	O
15	neurodegeneration	O	O
16	mental	BI	O
17	retardation	II	O
18	and	O	O
19	death	O	O
20	before	O	O
21	the	O	O
22	age	O	O
23	of	O	O
24	10years	O	O
25	.	O	O

0	On	O	O
1	the	O	O
2	other	O	O
3	hand	O	O
4	decreased	O	O
5	activity	O	O
6	leads	O	O
7	to	O	O
8	X-linked	BI	O
9	nonsyndromic	II	O
10	sensorineural	II	O
11	deafness	II	O
12	DFNX-2	O	O
13	Charcot-Marie-Tooth	O	O
14	disease-5	O	O
15	CMTX5	O	O
16	and	O	O
17	Arts	BU	O
18	syndrome	IU	O
19	depending	O	O
20	on	O	O
21	the	O	O
22	residual	O	O
23	activity	O	O
24	of	O	O
25	PRS-I	O	O
26	.	O	O

0	PURPOSE	O	O
1	To	O	O
2	report	O	O
3	a	O	O
4	late-onset	O	O
5	cone-rod	O	O
6	dystrophy	O	O
7	that	O	O
8	revealed	O	O
9	a	O	O
10	familial	O	O
11	neurogenic	O	O
12	muscle	O	O
13	weakness	O	O
14	ataxia	BI	O
15	and	O	O
16	retinitis	BU	O
17	pigmentosa	IU	O
18	syndrome	O	O
19	as	O	O
20	a	O	O
21	consequence	O	O
22	of	O	O
23	the	O	O
24	T8993G	O	O
25	mitochondrial	O	O
26	mutation	O	O
27	.	O	O

0	Swallowing	BI	O
1	dysfunction	II	O
2	was	O	O
3	found	O	O
4	in	O	O
5	80%	O	O
6	of	O	O
7	patients	O	O
8	with	O	O
9	Kennedy	BU	O
10	disease	IU	O
11	.	O	O

0	Here	O	O
1	we	O	O
2	examined	O	O
3	basic	O	O
4	face	O	O
5	perception	O	O
6	Identity-Matching	O	O
7	face	O	O
8	recognition	O	O
9	Cambridge	O	O
10	Face	O	O
11	Memory	O	O
12	Task	O	O
13	and	O	O
14	object	O	O
15	recognition	O	O
16	Cambridge	O	O
17	Car	O	O
18	Memory	O	O
19	Task	O	O
20	in	O	O
21	11	O	O
22	semantic	BU	O
23	dementia	IU	O
24	SD	IU	O
25	patients	O	O
26	8	O	O
27	left-lateralised	O	O
28	3	O	O
29	right-lateralised	O	O
30	and	O	O
31	13	O	O
32	behavioural-variant	BI	O
33	frontotemporal	II	O
34	dementia	II	O
35	bvFTD	IU	O
36	patients	O	O
37	compared	O	O
38	with	O	O
39	11	O	O
40	controls	O	O
41	.	O	O

0	We	O	O
1	will	O	O
2	consider	O	O
3	mtDNA	O	O
4	based	O	O
5	syndromes	O	O
6	such	O	O
7	as	O	O
8	LHON	BU	O
9	dystonia	O	O
10	Mitochondrial	O	O
11	Encephalomyopahty	O	O
12	Lactic	O	O
13	Acidosis	O	O
14	Stroke-like	O	O
15	MELAS	BU	O
16	Leigh	O	O
17	overlapping	O	O
18	syndrome	O	O
19	or	O	O
20	nuclear	O	O
21	based	O	O
22	diseases	O	O
23	such	O	O
24	as	O	O
25	Friedreich	BU	O
26	ataxia	IU	O
27	mutations	O	O
28	in	O	O
29	FXN	O	O
30	gene	O	O
31	deafness	BI	O
32	dystonia	II	O
33	optic	BI	O
34	atrophy	II	O
35	MohrTranebjerg	O	O
36	syndrome	O	O
37	mutations	O	O
38	in	O	O
39	TIMM8A	O	O
40	complicated	BI	O
41	hereditary	II	O
42	spastic	II	O
43	paraplegia	II	O
44	mutations	O	O
45	in	O	O
46	SPG7	BU	O
47	DOA	O	O
48	plus	O	O
49	syndromes	O	O
50	mutations	O	O
51	in	O	O
52	OPA1	O	O
53	CharcotMarieTooth	BU	O
54	type	IU	O
55	2A	IU	O
56	CMT2A	IU	O
57	with	O	O
58	optic	BI	O
59	atrophy	II	O
60	or	O	O
61	hereditary	BU	O
62	motor	IU	O
63	and	IU	O
64	sensory	IU	O
65	neuropathy	IU	O
66	type	IU	O
67	VI	IU	O
68	HMSN	IU	O
69	VI	IU	O
70	mutations	O	O
71	in	O	O
72	MFN2	O	O
73	and	O	O
74	Costeff	O	O
75	syndrome	O	O
76	and	O	O
77	DOA	O	O
78	with	O	O
79	cataract	O	O
80	mutations	O	O
81	in	O	O
82	OPA3	O	O
83	.	O	O

0	Clinicians	O	O
1	should	O	O
2	be	O	O
3	cognizant	O	O
4	of	O	O
5	Stickler	BU	O
6	syndrome	IU	O
7	so	O	O
8	that	O	O
9	they	O	O
10	can	O	O
11	detect	O	O
12	the	O	O
13	disease	O	O
14	in	O	O
15	patients	O	O
16	and	O	O
17	their	O	O
18	family	O	O
19	members	O	O
20	prevent	O	O
21	functional	BI	O
22	impairments	II	O
23	organize	O	O
24	a	O	O
25	multidisciplinary	O	O
26	management	O	O
27	strategy	O	O
28	and	O	O
29	arrange	O	O
30	for	O	O
31	genetic	O	O
32	counseling	O	O
33	.	O	O

0	Pendred	BU	O
1	syndrome	IU	O
2	is	O	O
3	the	O	O
4	most	O	O
5	frequent	O	O
6	congenital	BI	O
7	deafness	II	O
8	syndrome	II	O
9	.	O	O

0	Leigh	BU	O
1	syndrome	IU	O
2	LS	IU	O
3	is	O	O
4	a	O	O
5	progressive	O	O
6	mitochondrial	O	O
7	neurodegenerative	O	O
8	disorder	O	O
9	whose	O	O
10	symptoms	O	O
11	most	O	O
12	commonly	O	O
13	include	O	O
14	psychomotor	BI	O
15	delay	II	O
16	with	O	O
17	regression	O	O
18	lactic	O	O
19	acidosis	O	O
20	and	O	O
21	a	O	O
22	failure	O	O
23	to	O	O
24	thrive	O	O
25	.	O	O

0	BACKGROUND	O	O
1	Huntingtons	BU	O
2	disease	IU	O
3	is	O	O
4	a	O	O
5	progressive	O	O
6	neurodegenerative	O	O
7	disease	O	O
8	with	O	O
9	autosomal	O	O
10	dominant	O	O
11	inheritance	O	O
12	characterized	O	O
13	by	O	O
14	motor	BI	O
15	disturbances	II	O
16	cognitive	BI	O
17	decline	II	O
18	and	O	O
19	behavioral	O	O
20	and	O	O
21	psychological	O	O
22	symptoms	O	O
23	.	O	O

0	Traumatic	BU	O
1	brain	IU	O
2	injury	IU	O
3	TBI	IU	O
4	is	O	O
5	a	O	O
6	major	O	O
7	risk	O	O
8	factor	O	O
9	for	O	O
10	dementia	BI	O
11	.	O	O

0	Importantly	O	O
1	both	O	O
2	bvFTD	BU	O
3	and	O	O
4	SD	O	O
5	also	O	O
6	demonstrated	O	O
7	impaired	BI	O
8	face	II	O
9	recognition	II	O
10	.	O	O

0	From	O	O
1	our	O	O
2	series	O	O
3	of	O	O
4	patients	O	O
5	one	O	O
6	patient	O	O
7	with	O	O
8	PKAN	O	O
9	and	O	O
10	a	O	O
11	progressive	O	O
12	severe	O	O
13	dystonic	O	O
14	syndrome	O	O
15	cerebellar	BI	O
16	ataxia	II	O
17	retinitis	BU	O
18	pigmentosa	IU	O
19	and	O	O
20	eventual	O	O
21	anarthria	O	O
22	had	O	O
23	a	O	O
24	novel	O	O
25	combination	O	O
26	of	O	O
27	two	O	O
28	compound	O	O
29	heterozygote	O	O
30	mutations	O	O
31	identified	O	O
32	in	O	O
33	the	O	O
34	PANK2	O	O
35	gene	O	O
36	G-->A	O	O
37	transition	O	O
38	at	O	O
39	base	O	O
40	1238	O	O
41	G411R	O	O
42	and	O	O
43	a	O	O
44	C-->A	O	O
45	transition	O	O
46	at	O	O
47	base	O	O
48	1184	O	O
49	A395E	O	O
50	.	O	O

0	CASES	O	O
1	REPORTS	O	O
2	 The	O	O
3	first	O	O
4	patient	O	O
5	was	O	O
6	a	O	O
7	52-year-old	O	O
8	woman	O	O
9	diagnosed	O	O
10	with	O	O
11	Treacher-Collins	BU	O
12	syndrome	IU	O
13	who	O	O
14	presented	O	O
15	with	O	O
16	severe	BI	O
17	bilateral	II	O
18	mixed	II	O
19	hearing	II	O
20	loss	II	O
21	and	O	O
22	a	O	O
23	history	O	O
24	of	O	O
25	unsuccessful	O	O
26	previous	O	O
27	use	O	O
28	of	O	O
29	a	O	O
30	bone	O	O
31	contact	O	O
32	conduction	O	O
33	device	O	O
34	.	O	O

0	Cockayne	BU	O
1	syndrome	IU	O
2	CS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	genetic	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	a	O	O
11	variety	O	O
12	of	O	O
13	growth	BI	O
14	and	II	O
15	developmental	II	O
16	defects	II	O
17	photosensitivity	O	O
18	cachectic	O	O
19	dwarfism	O	O
20	hearing	BI	O
21	loss	II	O
22	skeletal	O	O
23	abnormalities	O	O
24	progressive	O	O
25	neurological	O	O
26	degeneration	O	O
27	and	O	O
28	premature	O	O
29	aging	O	O
30	.	O	O

0	Fukuyama	BU	O
1	congenital	IU	O
2	muscular	IU	O
3	dystrophy	IU	O
4	FCMD	IU	O
5	characterized	O	O
6	by	O	O
7	intellectual	BI	O
8	impairment	II	O
9	associated	O	O
10	with	O	O
11	cortical	O	O
12	migration	O	O
13	defects	O	O
14	is	O	O
15	an	O	O
16	autosomal	O	O
17	recessive	O	O
18	disorder	O	O
19	caused	O	O
20	by	O	O
21	mutation	O	O
22	in	O	O
23	the	O	O
24	fukutin	O	O
25	gene	O	O
26	.	O	O

0	Individuals	O	O
1	with	O	O
2	propionic	BU	O
3	acidemia	IU	O
4	often	O	O
5	have	O	O
6	life-threatening	O	O
7	episodes	O	O
8	of	O	O
9	hyperammonemia	O	O
10	and	O	O
11	metabolic	O	O
12	acidosis	O	O
13	as	O	O
14	well	O	O
15	as	O	O
16	intellectual	BI	O
17	disability	II	O
18	.	O	O

0	These	O	O
1	findings	O	O
2	suggest	O	O
3	the	O	O
4	necessity	O	O
5	of	O	O
6	an	O	O
7	adequate	O	O
8	support	O	O
9	for	O	O
10	developmental	BI	O
11	delay	II	O
12	and	O	O
13	periodical	O	O
14	screening	O	O
15	for	O	O
16	hepatoblastoma	BU	O
17	in	O	O
18	the	O	O
19	affected	O	O
20	patients	O	O
21	and	O	O
22	some	O	O
23	phenotypic	O	O
24	overlap	O	O
25	between	O	O
26	UPD14pat	O	O
27	and	O	O
28	related	O	O
29	conditions	O	O
30	and	O	O
31	Beckwith-Wiedemann	BU	O
32	syndrome	IU	O
33	.	O	O

0	Leber	BU	O
1	hereditary	IU	O
2	optic	IU	O
3	neuropathy	IU	O
4	LHON	IU	O
5	acute	BI	O
6	or	II	O
7	subacute	II	O
8	vision	II	O
9	loss	II	O
10	due	O	O
11	to	O	O
12	retinal	O	O
13	ganglion	O	O
14	cell	O	O
15	death	O	O
16	which	O	O
17	in	O	O
18	the	O	O
19	long	O	O
20	run	O	O
21	leads	O	O
22	to	O	O
23	optic	O	O
24	nerve	O	O
25	atrophy	O	O
26	is	O	O
27	one	O	O
28	of	O	O
29	the	O	O
30	most	O	O
31	widely	O	O
32	studied	O	O
33	maternally	O	O
34	inherited	O	O
35	diseases	O	O
36	caused	O	O
37	by	O	O
38	mutations	O	O
39	in	O	O
40	mitochondrial	O	O
41	DNA	O	O
42	.	O	O

0	DESIGN	O	O
1	The	O	O
2	frequency	O	O
3	severity	O	O
4	and	O	O
5	type	O	O
6	of	O	O
7	hearing	BI	O
8	impairment	II	O
9	was	O	O
10	characterized	O	O
11	prospectively	O	O
12	using	O	O
13	pure-tone	O	O
14	audiometry	O	O
15	tympanometry	O	O
16	stapedial	O	O
17	reflexes	O	O
18	otoacoustic	O	O
19	emissions	O	O
20	and	O	O
21	brainstem-evoked	O	O
22	response	O	O
23	audiometry	O	O
24	in	O	O
25	adult	O	O
26	patients	O	O
27	on	O	O
28	enzyme	O	O
29	replacement	O	O
30	therapy	O	O
31	for	O	O
32	genetically	O	O
33	confirmed	O	O
34	Pompe	BU	O
35	disease	IU	O
36	.	O	O

0	Besides	O	O
1	tapetoretinal	BI	O
2	degeneration	II	O
3	additional	O	O
4	symptoms	O	O
5	are	O	O
6	anosmia	O	O
7	skeletal	O	O
8	malformations	O	O
9	chronic	O	O
10	polyneuropathy	O	O
11	cerebellar	BI	O
12	ataxia	II	O
13	sensorineural	BI	O
14	hearing	II	O
15	loss	II	O
16	ichthyosis	BU	O
17	and	O	O
18	cardiac	O	O
19	abnormalities	O	O
20	.	O	O

0	RESULTS	O	O
1	All	O	O
2	patients	O	O
3	exhibited	O	O
4	the	O	O
5	core	O	O
6	clinical	O	O
7	symptoms	O	O
8	of	O	O
9	WHS	BU	O
10	including	O	O
11	severe	BI	O
12	growth	II	O
13	delay	II	O
14	a	O	O
15	Greek	O	O
16	warrior	O	O
17	helmet	O	O
18	facial	O	O
19	appearance	O	O
20	differing	O	O
21	degrees	O	O
22	of	O	O
23	intellectual	BI	O
24	disability	II	O
25	and	O	O
26	epilepsy	O	O
27	or	O	O
28	electroencephalogram	O	O
29	anomalies	O	O
30	.	O	O

0	Findings	O	O
1	from	O	O
2	studies	O	O
3	of	O	O
4	other	O	O
5	genetic	BU	O
6	dementias	IU	O
7	have	O	O
8	shown	O	O
9	neuroimaging	O	O
10	and	O	O
11	cognitive	O	O
12	changes	O	O
13	before	O	O
14	symptoms	O	O
15	onset	O	O
16	and	O	O
17	we	O	O
18	aimed	O	O
19	to	O	O
20	identify	O	O
21	whether	O	O
22	such	O	O
23	changes	O	O
24	could	O	O
25	be	O	O
26	shown	O	O
27	in	O	O
28	frontotemporal	BI	O
29	dementia	II	O
30	.	O	O

0	SCA1	BU	O
1	may	O	O
2	rarely	O	O
3	present	O	O
4	with	O	O
5	pure	BI	O
6	spastic	II	O
7	paraplegia	II	O
8	resembling	O	O
9	hereditary	BU	O
10	spastic	IU	O
11	paraplegia	IU	O
12	before	O	O
13	the	O	O
14	appearance	O	O
15	of	O	O
16	cerebellar	O	O
17	signs	O	O
18	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	well-defined	O	O
5	clinical	O	O
6	entity	O	O
7	classically	O	O
8	associated	O	O
9	with	O	O
10	moderate	O	O
11	to	O	O
12	severe	BI	O
13	mental	II	O
14	retardation	II	O
15	characteristic	O	O
16	facial	O	O
17	features	O	O
18	skeletal	O	O
19	deformities	O	O
20	and	O	O
21	tapering	O	O
22	fingers	O	O
23	.	O	O

0	Features	O	O
1	such	O	O
2	as	O	O
3	bodyweight	O	O
4	and	O	O
5	height	O	O
6	stagnation	O	O
7	language	BI	O
8	delay	II	O
9	abnormal	O	O
10	nutritional	O	O
11	pathways	O	O
12	tube	O	O
13	feeding	O	O
14	and	O	O
15	renal	O	O
16	failure	O	O
17	were	O	O
18	more	O	O
19	prominent	O	O
20	in	O	O
21	the	O	O
22	20	O	O
23	deceased	O	O
24	CS	BU	O
25	type	IU	O
26	1	IU	O
27	patients	O	O
28	than	O	O
29	in	O	O
30	the	O	O
31	21	O	O
32	surviving	O	O
33	CS	O	O
34	type	O	O
35	1	O	O
36	patients	O	O
37	.	O	O

0	This	O	O
1	report	O	O
2	presents	O	O
3	a	O	O
4	sporadic	O	O
5	case	O	O
6	of	O	O
7	the	O	O
8	Rieger	BU	O
9	syndrome	IU	O
10	the	O	O
11	findings	O	O
12	in	O	O
13	which	O	O
14	include	O	O
15	the	O	O
16	characteristic	O	O
17	ocular	BI	O
18	anomalies	II	O
19	shortness	O	O
20	of	O	O
21	stature	O	O
22	mental	BI	O
23	retardation	II	O
24	absent	O	O
25	dental	O	O
26	defects	O	O
27	and	O	O
28	a	O	O
29	peculiar	O	O
30	heretofore	O	O
31	unobserved	O	O
32	myopathy	O	O
33	.	O	O

0	This	O	O
1	mutation	O	O
2	has	O	O
3	been	O	O
4	reported	O	O
5	with	O	O
6	MELAS	BU	O
7	myopathy	O	O
8	and	O	O
9	deafness	BI	O
10	with	O	O
11	cognitive	BI	O
12	impairment	II	O
13	.	O	O

0	Mowat-Wilson	BU	O
1	syndrome	IU	O
2	MWS	IU	O
3	is	O	O
4	a	O	O
5	developmental	BI	O
6	disorder	II	O
7	presenting	O	O
8	with	O	O
9	mental	BI	O
10	retardation	II	O
11	delayed	BI	O
12	motor	II	O
13	development	II	O
14	and	O	O
15	a	O	O
16	wide	O	O
17	spectrum	O	O
18	of	O	O
19	clinical	O	O
20	features	O	O
21	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	de	O	O
4	novo	O	O
5	heterozygous	O	O
6	5013940	O	O
7	bp	O	O
8	terminal	BU	O
9	deletion	IU	O
10	of	IU	O
11	chromosome	IU	O
12	15q26	IU	O
13	in	O	O
14	a	O	O
15	13	O	O
16	9	O	O
17	12	O	O
18	-year-old	O	O
19	Japanese	O	O
20	girl	O	O
21	with	O	O
22	short	O	O
23	stature	O	O
24	-3.9	O	O
25	SD	O	O
26	mild	BI	O
27	mental	II	O
28	retardation	II	O
29	and	O	O
30	ventricular	BU	O
31	septal	IU	O
32	defect	IU	O
33	VSD	IU	O
34	.	O	O

0	The	O	O
1	first	O	O
2	reported	O	O
3	patient	O	O
4	had	O	O
5	been	O	O
6	diagnosed	O	O
7	as	O	O
8	having	O	O
9	Ramsay	BU	O
10	Hunt	IU	O
11	syndrome	IU	O
12	associated	O	O
13	with	O	O
14	Friedreichs	BI	O
15	ataxia	II	O
16	.	O	O

0	WWS	BU	O
1	presents	O	O
2	at	O	O
3	birth	O	O
4	with	O	O
5	generalized	O	O
6	hypotonia	O	O
7	muscle	O	O
8	weakness	O	O
9	developmental	BI	O
10	delay	II	O
11	with	O	O
12	mental	BI	O
13	retardation	II	O
14	and	O	O
15	occasional	O	O
16	seizures	O	O
17	.	O	O

0	The	O	O
1	maternal	BU	O
2	PKU	IU	O
3	MPKU	O	O
4	syndrome	O	O
5	is	O	O
6	caused	O	O
7	by	O	O
8	high	O	O
9	blood	O	O
10	Phe	O	O
11	concentrations	O	O
12	during	O	O
13	pregnancy	O	O
14	and	O	O
15	presents	O	O
16	with	O	O
17	serious	O	O
18	foetal	O	O
19	anomalies	O	O
20	especially	O	O
21	microcephaly	O	O
22	congenital	O	O
23	heart	O	O
24	disease	O	O
25	and	O	O
26	mental	BI	O
27	retardation	II	O
28	.	O	O

0	The	O	O
1	model	O	O
2	is	O	O
3	consistent	O	O
4	with	O	O
5	reductions	O	O
6	in	O	O
7	CRS	BU	O
8	based	O	O
9	on	O	O
10	surveillance	O	O
11	of	O	O
12	congenital	BI	O
13	hearing	II	O
14	impairment	II	O
15	.	O	O

0	The	O	O
1	main	O	O
2	clinical	O	O
3	features	O	O
4	are	O	O
5	retinitis	BU	O
6	pigmentosa	IU	O
7	cerebellar	BI	O
8	ataxia	II	O
9	and	O	O
10	chronic	O	O
11	polyneuropathy	O	O
12	.	O	O

0	Hunter	BU	O
1	syndrome	IU	O
2	is	O	O
3	generally	O	O
4	considered	O	O
5	to	O	O
6	have	O	O
7	two	O	O
8	manifestations	O	O
9	an	O	O
10	attenuated	O	O
11	form	O	O
12	and	O	O
13	a	O	O
14	severe	O	O
15	form	O	O
16	in	O	O
17	the	O	O
18	latter	O	O
19	the	O	O
20	person	O	O
21	has	O	O
22	pronounced	O	O
23	cognitive	BI	O
24	decline	II	O
25	.	O	O

0	Rats	O	O
1	developed	O	O
2	behavioral	BI	O
3	impairments	II	O
4	similar	O	O
5	to	O	O
6	those	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	FTD	BU	O
11	after	O	O
12	TBI	O	O
13	.	O	O

0	Diamond-Blackfan	BU	O
1	anaemia	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	disease	O	O
6	caused	O	O
7	by	O	O
8	insufficient	O	O
9	expression	O	O
10	of	O	O
11	ribosomal	O	O
12	proteins	O	O
13	and	O	O
14	is	O	O
15	characterized	O	O
16	by	O	O
17	erythroid	O	O
18	hypoplasia	O	O
19	often	O	O
20	accompanied	O	O
21	by	O	O
22	growth	BI	O
23	retardation	II	O
24	congenital	O	O
25	craniofacial	O	O
26	and	O	O
27	limb	O	O
28	abnormalities	O	O
29	.	O	O

0	Untreated	O	O
1	PKU	BU	O
2	is	O	O
3	associated	O	O
4	with	O	O
5	an	O	O
6	abnormal	O	O
7	phenotype	O	O
8	which	O	O
9	includes	O	O
10	growth	BI	O
11	failure	II	O
12	seizures	O	O
13	global	BI	O
14	developmental	II	O
15	delay	II	O
16	and	O	O
17	severe	BI	O
18	intellectual	II	O
19	impairment	II	O
20	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	type	O	O
5	of	O	O
6	RASopathy	O	O
7	mapped	O	O
8	to	O	O
9	HRAS	O	O
10	gene	O	O
11	in	O	O
12	chromosome	O	O
13	11	O	O
14	characterized	O	O
15	by	O	O
16	prenatal	O	O
17	overgrowth	O	O
18	postnatal	O	O
19	failure	O	O
20	to	O	O
21	thrive	O	O
22	classic	O	O
23	facial	O	O
24	gestalt	O	O
25	and	O	O
26	multisystem	O	O
27	involvement	O	O
28	including	O	O
29	cardiomyopathy	BU	O
30	and	O	O
31	intellectual	BI	O
32	disability	II	O
33	.	O	O

0	The	O	O
1	Mohr-Tranebjaerg	BU	O
2	syndrome	IU	O
3	MIM	IU	O
4	304700	IU	O
5	and	O	O
6	the	O	O
7	Jensen	BU	O
8	syndrome	IU	O
9	MIM	O	O
10	311150	O	O
11	were	O	O
12	previously	O	O
13	reported	O	O
14	as	O	O
15	separate	O	O
16	X-linked	O	O
17	recessive	O	O
18	deafness	O	O
19	syndromes	O	O
20	associated	O	O
21	with	O	O
22	progressive	BI	O
23	visual	II	O
24	deterioration	II	O
25	dystonia	O	O
26	dementia	BI	O
27	and	O	O
28	psychiatric	BI	O
29	abnormalities	II	O
30	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	centrosomal-ciliary	O	O
4	gene	O	O
5	CEP290	O	O
6	NPHP6	O	O
7	are	O	O
8	associated	O	O
9	with	O	O
10	Joubert	O	O
11	syndrome	O	O
12	and	O	O
13	are	O	O
14	the	O	O
15	most	O	O
16	common	O	O
17	cause	O	O
18	of	O	O
19	the	O	O
20	childhood	BI	O
21	recessive	II	O
22	blindness	II	O
23	known	O	O
24	as	O	O
25	Leber	BU	O
26	congenital	IU	O
27	amaurosis	IU	O
28	LCA	IU	O
29	.	O	O

0	Patients	O	O
1	with	O	O
2	mitochondrial	O	O
3	ornithine	O	O
4	transporter	O	O
5	deficiency	O	O
6	or	O	O
7	HHH	BU	O
8	syndrome	IU	O
9	present	O	O
10	with	O	O
11	various	O	O
12	neurological	O	O
13	symptoms	O	O
14	including	O	O
15	mental	BI	O
16	retardation	II	O
17	spastic	BI	O
18	paraparesis	II	O
19	with	II	O
20	pyramidal	II	O
21	signs	II	O
22	cerebellar	BI	O
23	ataxia	II	O
24	and	O	O
25	episodic	O	O
26	disturbance	O	O
27	of	O	O
28	consciousness	O	O
29	or	O	O
30	coma	O	O
31	due	O	O
32	to	O	O
33	hyperammonemia	O	O
34	.	O	O

0	This	O	O
1	could	O	O
2	be	O	O
3	helpful	O	O
4	in	O	O
5	elucidating	O	O
6	the	O	O
7	pathogenesis	O	O
8	of	O	O
9	hearing	BI	O
10	impairment	II	O
11	in	O	O
12	MWS	BU	O
13	.	O	O

0	In	O	O
1	contrast	O	O
2	only	O	O
3	bvFTD	BU	O
4	showed	O	O
5	impaired	BI	O
6	object	II	O
7	recognition	II	O
8	with	O	O
9	SD	O	O
10	performing	O	O
11	within	O	O
12	normal	O	O
13	limits	O	O
14	on	O	O
15	this	O	O
16	task	O	O
17	.	O	O

0	Most	O	O
1	patients	O	O
2	with	O	O
3	Townes-Brocks	BU	O
4	syndrome	IU	O
5	have	O	O
6	normal	O	O
7	intelligence	O	O
8	although	O	O
9	mental	BI	O
10	retardation	II	O
11	has	O	O
12	been	O	O
13	noted	O	O
14	in	O	O
15	a	O	O
16	few	O	O
17	.	O	O

0	Neuro-Behçet	BU	O
1	disease	IU	O
2	NBD	IU	O
3	can	O	O
4	be	O	O
5	categorized	O	O
6	clinically	O	O
7	as	O	O
8	the	O	O
9	acute	O	O
10	type--characterized	O	O
11	by	O	O
12	meningoencephalitis--and	O	O
13	the	O	O
14	chronic	O	O
15	progressive	O	O
16	type-	O	O
17	characterized	O	O
18	by	O	O
19	slowly	BI	O
20	progressive	II	O
21	dementia	II	O
22	ataxia	BI	O
23	and	O	O
24	dysarthria	BI	O
25	.	O	O

0	He	O	O
1	presents	O	O
2	mental	BI	O
3	retardation	II	O
4	axial	O	O
5	hypotonia	O	O
6	hypertonia	O	O
7	of	O	O
8	arms	O	O
9	and	O	O
10	legs	O	O
11	paroxysmal	BU	O
12	dyskinesias	IU	O
13	seizures	O	O
14	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	RSK2	O	O
4	gene	O	O
5	RPS6KA3	O	O
6	on	O	O
7	chromosome	O	O
8	Xp22.2	O	O
9	have	O	O
10	been	O	O
11	found	O	O
12	to	O	O
13	cause	O	O
14	Coffin-Lowry	BU	O
15	syndrome	IU	O
16	CLS	IU	O
17	an	O	O
18	X-linked	O	O
19	disorder	O	O
20	characterized	O	O
21	by	O	O
22	psychomotor	BI	O
23	retardation	II	O
24	characteristic	O	O
25	facial	O	O
26	and	O	O
27	digital	O	O
28	abnormalities	O	O
29	and	O	O
30	progressive	O	O
31	skeletal	O	O
32	deformations	O	O
33	.	O	O

0	One	O	O
1	hundred	O	O
2	and	O	O
3	fifty	O	O
4	years	O	O
5	since	O	O
6	Nikolaus	O	O
7	Friedreichs	O	O
8	first	O	O
9	description	O	O
10	of	O	O
11	the	O	O
12	degenerative	O	O
13	ataxic	O	O
14	syndrome	O	O
15	which	O	O
16	bears	O	O
17	his	O	O
18	name	O	O
19	his	O	O
20	description	O	O
21	remains	O	O
22	at	O	O
23	the	O	O
24	core	O	O
25	of	O	O
26	the	O	O
27	classical	O	O
28	clinical	O	O
29	phenotype	O	O
30	of	O	O
31	gait	BI	O
32	and	II	O
33	limb	II	O
34	ataxia	II	O
35	poor	O	O
36	balance	O	O
37	and	O	O
38	coordination	O	O
39	leg	O	O
40	weakness	O	O
41	sensory	BI	O
42	loss	II	O
43	areflexia	O	O
44	impaired	BI	O
45	walking	II	O
46	dysarthria	BI	O
47	dysphagia	O	O
48	eye	O	O
49	movement	O	O
50	abnormalities	O	O
51	scoliosis	O	O
52	foot	O	O
53	deformities	O	O
54	cardiomyopathy	BU	O
55	and	O	O
56	diabetes	O	O
57	.	O	O

0	This	O	O
1	confirmed	O	O
2	the	O	O
3	expanding	O	O
4	phenotypic	O	O
5	spectrum	O	O
6	of	O	O
7	MEB	BU	O
8	disease	IU	O
9	with	O	O
10	varying	O	O
11	degrees	O	O
12	of	O	O
13	hypotonia	O	O
14	myopia	O	O
15	and	O	O
16	cognitive	BI	O
17	impairment	II	O
18	.	O	O

0	The	O	O
1	grandson	O	O
2	the	O	O
3	proband	O	O
4	presented	O	O
5	as	O	O
6	a	O	O
7	teenager	O	O
8	with	O	O
9	progressive	BU	O
10	myoclonic	IU	O
11	epilepsy	IU	O
12	dysarthria	BI	O
13	ataxia	BI	O
14	and	O	O
15	cognitive	BI	O
16	decline	II	O
17	having	O	O
18	manifesting	O	O
19	learning	BI	O
20	difficulties	II	O
21	from	O	O
22	the	O	O
23	age	O	O
24	5	O	O
25	years	O	O
26	.	O	O

0	The	O	O
1	Stickler	BU	O
2	syndrome	IU	O
3	is	O	O
4	an	O	O
5	autosomal	O	O
6	dominant	O	O
7	genetic	O	O
8	disorder	O	O
9	characterised	O	O
10	by	O	O
11	ocular	BI	O
12	orofacial	II	O
13	and	II	O
14	skeletal	II	O
15	anomalies	II	O
16	and	O	O
17	or	O	O
18	auditory	BI	O
19	loss	II	O
20	.	O	O

0	INTRODUCTION	O	O
1	Costello	BU	O
2	syndrome	IU	O
3	CS	IU	O
4	is	O	O
5	a	O	O
6	multisystemic	O	O
7	disorder	O	O
8	characterized	O	O
9	by	O	O
10	postnatal	BI	O
11	reduced	II	O
12	growth	II	O
13	facial	O	O
14	dysmorphism	O	O
15	cardiac	O	O
16	defects	O	O
17	cognitive	BI	O
18	impairment	II	O
19	skin	O	O
20	and	O	O
21	musculo-skeletal	O	O
22	anomalies	O	O
23	and	O	O
24	predisposition	O	O
25	to	O	O
26	certain	O	O
27	cancers	O	O
28	.	O	O

0	Alport	BU	O
1	syndrome	IU	O
2	AS	IU	O
3	is	O	O
4	caused	O	O
5	by	O	O
6	pathogenic	O	O
7	mutations	O	O
8	in	O	O
9	the	O	O
10	genes	O	O
11	encoding	O	O
12	α3	O	O
13	α4	O	O
14	or	O	O
15	α5	O	O
16	chains	O	O
17	of	O	O
18	collagen	O	O
19	IV	O	O
20	COL4A3	O	O
21	COL4A4	O	O
22	COL4A5	O	O
23	resulting	O	O
24	in	O	O
25	hematuria	O	O
26	chronic	O	O
27	renal	O	O
28	failure	O	O
29	CRF	O	O
30	sensorineural	BI	O
31	hearing	II	O
32	loss	II	O
33	SNHL	O	O
34	and	O	O
35	ocular	BI	O
36	abnormalities	II	O
37	.	O	O

0	The	O	O
1	Usher	BU	O
2	syndrome	IU	O
3	USH	IU	O
4	is	O	O
5	the	O	O
6	most	O	O
7	prevalent	O	O
8	cause	O	O
9	of	O	O
10	inherited	BI	O
11	deaf-blindness	II	O
12	.	O	O

0	Among	O	O
1	known	O	O
2	etiologic	O	O
3	causes	O	O
4	congenital	BU	O
5	rubella	IU	O
6	syndrome	IU	O
7	CRS	IU	O
8	is	O	O
9	reported	O	O
10	to	O	O
11	be	O	O
12	one	O	O
13	of	O	O
14	the	O	O
15	infections	O	O
16	associated	O	O
17	with	O	O
18	neurodevelopmental	BI	O
19	disorders	II	O
20	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	female	O	O
4	child	O	O
5	with	O	O
6	tetrasomy	BU	O
7	of	IU	O
8	the	IU	O
9	15q11-q13	IU	O
10	chromosomal	O	O
11	region	O	O
12	and	O	O
13	autistic	BI	O
14	disorder	II	O
15	associated	O	O
16	with	O	O
17	mental	BI	O
18	retardation	II	O
19	developmental	O	O
20	problems	O	O
21	and	O	O
22	behavioral	BI	O
23	disorders	II	O
24	.	O	O

0	Four	O	O
1	children	O	O
2	showed	O	O
3	symptoms	O	O
4	characteristic	O	O
5	of	O	O
6	Stickler	BU	O
7	syndrome	IU	O
8	including	O	O
9	moderate-to-severe	BI	O
10	sensorineural	II	O
11	hearing	II	O
12	loss	II	O
13	moderate-to-high	O	O
14	myopia	O	O
15	with	O	O
16	vitreoretinopathy	BU	O
17	and	O	O
18	epiphyseal	O	O
19	dysplasia	O	O
20	.	O	O

0	If	O	O
1	a	O	O
2	child	O	O
3	has	O	O
4	progressive	BI	O
5	sensorineural	II	O
6	deafness	II	O
7	and	O	O
8	a	O	O
9	widened	O	O
10	vestibular	O	O
11	aqueduct	O	O
12	it	O	O
13	is	O	O
14	important	O	O
15	to	O	O
16	consider	O	O
17	a	O	O
18	diagnosis	O	O
19	of	O	O
20	Pendred	BU	O
21	syndrome	IU	O
22	.	O	O

0	We	O	O
1	identified	O	O
2	2	O	O
3	AHDS	BU	O
4	patients	O	O
5	with	O	O
6	developmental	BI	O
7	delays	II	O
8	truncal	O	O
9	hypotonia	O	O
10	and	O	O
11	spastic	BI	O
12	paraplegia	II	O
13	.	O	O

0	Genetic	O	O
1	analysis	O	O
2	of	O	O
3	the	O	O
4	GFAP	O	O
5	gene	O	O
6	is	O	O
7	recommended	O	O
8	for	O	O
9	all	O	O
10	patients	O	O
11	with	O	O
12	late-onset	BI	O
13	progressive	II	O
14	ataxia	II	O
15	and	O	O
16	suspected	O	O
17	of	O	O
18	having	O	O
19	adult-onset	O	O
20	Alexander	BU	O
21	disease	IU	O
22	on	O	O
23	the	O	O
24	basis	O	O
25	of	O	O
26	MRI	O	O
27	findings	O	O
28	.	O	O

0	Untreated	O	O
1	profound	O	O
2	biotinidase	BU	O
3	deficiency	IU	O
4	results	O	O
5	in	O	O
6	a	O	O
7	wide	O	O
8	range	O	O
9	of	O	O
10	clinical	O	O
11	features	O	O
12	including	O	O
13	optic	BI	O
14	atrophy	II	O
15	cutaneous	O	O
16	abnormalities	O	O
17	hearing	BI	O
18	loss	II	O
19	and	O	O
20	developmental	BI	O
21	delay	II	O
22	.	O	O

0	CASE	O	O
1	REPORT	O	O
2	A	O	O
3	Japanese	O	O
4	male	O	O
5	patient	O	O
6	presented	O	O
7	with	O	O
8	sensory	BI	O
9	deafness	II	O
10	blue	O	O
11	irises	O	O
12	and	O	O
13	anosmia	O	O
14	but	O	O
15	no	O	O
16	hair	O	O
17	skin	O	O
18	hypopigmentation	O	O
19	Hirschsprung	BU	O
20	disease	IU	O
21	or	O	O
22	neurological	O	O
23	abnormalities	O	O
24	.	O	O

0	BACKGROUND	O	O
1	Pendred-syndrome	BU	O
2	is	O	O
3	an	O	O
4	autosomal	O	O
5	recessive	O	O
6	disease	O	O
7	that	O	O
8	is	O	O
9	classically	O	O
10	characterised	O	O
11	by	O	O
12	sensorineural	BI	O
13	hearing	II	O
14	loss	II	O
15	and	O	O
16	enlargement	O	O
17	of	O	O
18	the	O	O
19	thyroid	O	O
20	gland	O	O
21	.	O	O

0	The	O	O
1	Wolf-Hirschhorn	BU	O
2	syndrome	IU	O
3	WHS	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	severe	BI	O
8	pre-	II	O
9	and	II	O
10	postnatal	II	O
11	growth	II	O
12	retardation	II	O
13	specific	O	O
14	pattern	O	O
15	of	O	O
16	dysmorphisms	O	O
17	and	O	O
18	severe	BI	O
19	developmental	II	O
20	delay	II	O
21	.	O	O

0	Allan-Herndon-Dudley	BU	O
1	syndrome	IU	O
2	AHDS	IU	O
3	an	O	O
4	X	O	O
5	linked	O	O
6	condition	O	O
7	is	O	O
8	characterized	O	O
9	by	O	O
10	severe	BI	O
11	intellectual	II	O
12	disability	II	O
13	dysarthria	BI	O
14	athetoid	BI	O
15	movements	II	O
16	muscle	O	O
17	hypoplasia	O	O
18	and	O	O
19	spastic	BI	O
20	paraplegia	II	O
21	in	O	O
22	combination	O	O
23	with	O	O
24	altered	O	O
25	TH	O	O
26	levels	O	O
27	in	O	O
28	particular	O	O
29	high	O	O
30	serum	O	O
31	T3	O	O
32	levels	O	O
33	.	O	O

0	One	O	O
1	of	O	O
2	our	O	O
3	adult	O	O
4	patients	O	O
5	had	O	O
6	several	O	O
7	types	O	O
8	of	O	O
9	movement	BI	O
10	disorder	II	O
11	and	O	O
12	epilepsy	O	O
13	that	O	O
14	merged	O	O
15	seamlessly	O	O
16	there	O	O
17	was	O	O
18	true	O	O
19	cataplexy	O	O
20	triggered	O	O
21	by	O	O
22	telling	O	O
23	a	O	O
24	joke	O	O
25	something	O	O
26	close	O	O
27	to	O	O
28	cataplexy	O	O
29	cataplexy	O	O
30	triggered	O	O
31	by	O	O
32	sound-startle	O	O
33	a	O	O
34	predominantly	O	O
35	hypertonic	O	O
36	reaction	O	O
37	varying	O	O
38	from	O	O
39	hyperekplexia	BU	O
40	to	O	O
41	a	O	O
42	more	O	O
43	prolonged	O	O
44	tonic	O	O
45	reaction	O	O
46	resembling	O	O
47	startle	BU	O
48	epilepsy	IU	O
49	and	O	O
50	true	O	O
51	unprovoked	O	O
52	epileptic	O	O
53	seizures	O	O
54	.	O	O

0	If	O	O
1	hypogonadism	O	O
2	ataxia	BI	O
3	retinitis	O	O
4	cardiomyopathy	BU	O
5	or	O	O
6	dwarfism	O	O
7	is	O	O
8	present	O	O
9	other	O	O
10	diagnosis	O	O
11	rather	O	O
12	than	O	O
13	SLS	O	O
14	should	O	O
15	be	O	O
16	investigated	O	O
17	.	O	O

0	INTRODUCTION	O	O
1	Mowat-Wilson	BU	O
2	syndrome	IU	O
3	MWS	IU	O
4	is	O	O
5	characterised	O	O
6	by	O	O
7	severe	BI	O
8	mental	II	O
9	retardation	II	O
10	and	O	O
11	multiple	O	O
12	congenital	O	O
13	anomalies	O	O
14	.	O	O

0	Other	O	O
1	clinical	O	O
2	findings	O	O
3	are	O	O
4	respiratory	O	O
5	rhythm	O	O
6	abnormalities	O	O
7	abnormal	O	O
8	retinal	O	O
9	pigmentation	O	O
10	mouth-tongye-facial	BI	O
11	dyskinesias	II	O
12	ptosis	BU	O
13	polydactyly	O	O
14	scoliosis	O	O
15	congenital	O	O
16	heart	O	O
17	defects	O	O
18	polycystic	O	O
19	kidneys	O	O
20	and	O	O
21	seizures	O	O
22	.	O	O

0	Pelizaeus-Merzbacher-like	BU	O
1	disease	IU	O
2	PMLD	IU	O
3	is	O	O
4	an	O	O
5	autosomal	O	O
6	recessive	O	O
7	hypomyelinating	O	O
8	disorder	O	O
9	of	O	O
10	the	O	O
11	central	O	O
12	nervous	O	O
13	system	O	O
14	characterized	O	O
15	by	O	O
16	nystagmus	O	O
17	motor	BI	O
18	developmental	II	O
19	delay	II	O
20	ataxia	BI	O
21	and	O	O
22	progressive	O	O
23	spasticity	O	O
24	.	O	O

0	We	O	O
1	report	O	O
2	two	O	O
3	family	O	O
4	cases	O	O
5	of	O	O
6	two	O	O
7	sisters	O	O
8	and	O	O
9	two	O	O
10	brothers	O	O
11	with	O	O
12	homocystinuria	O	O
13	revealed	O	O
14	by	O	O
15	lenticular	O	O
16	dislocation	O	O
17	into	O	O
18	the	O	O
19	anterior	O	O
20	chamber	O	O
21	associated	O	O
22	with	O	O
23	mental	BI	O
24	and	II	O
25	growth	II	O
26	retardation	II	O
27	and	O	O
28	an	O	O
29	isolated	O	O
30	case	O	O
31	of	O	O
32	homocystinuria	O	O
33	revealed	O	O
34	by	O	O
35	poor	O	O
36	vision	O	O
37	with	O	O
38	Marfan	BU	O
39	syndrome	IU	O
40	and	O	O
41	mental	BI	O
42	retardation	II	O
43	.	O	O

0	Many	O	O
1	neurodevelopmental	BI	O
2	disorders	II	O
3	exhibit	O	O
4	syndromic	BU	O
5	obesity	IU	O
6	including	O	O
7	SMS	BU	O
8	.	O	O

0	Diagnosis	O	O
1	was	O	O
2	infantile	BU	O
3	malignant	IU	O
4	osteopetrosis	BU	O
5	but	O	O
6	the	O	O
7	patient	O	O
8	can	O	O
9	not	O	O
10	be	O	O
11	referred	O	O
12	to	O	O
13	bone	O	O
14	marrow	O	O
15	transplantation	O	O
16	due	O	O
17	to	O	O
18	delay	O	O
19	in	O	O
20	diagnosis	O	O
21	and	O	O
22	irreversible	BI	O
23	visual	II	O
24	and	II	O
25	hearing	II	O
26	loss	II	O
27	and	O	O
28	lack	O	O
29	of	O	O
30	medullary	O	O
31	space	O	O
32	for	O	O
33	marrow	O	O
34	engraftment	O	O
35	.	O	O

0	Oxidative	O	O
1	stress	O	O
2	is	O	O
3	involved	O	O
4	in	O	O
5	the	O	O
6	pathogenesis	O	O
7	of	O	O
8	multiple	BU	O
9	system	IU	O
10	atrophy	IU	O
11	MSA	O	O
12	and	O	O
13	cognitive	BI	O
14	impairment	II	O
15	.	O	O

0	The	O	O
1	spinocerebellar	BU	O
2	ataxia	IU	O
3	type	IU	O
4	7	IU	O
5	SCA7	IU	O
6	is	O	O
7	associated	O	O
8	with	O	O
9	pigmentary	O	O
10	macular	O	O
11	dystrophy	O	O
12	and	O	O
13	retinal	O	O
14	degeneration	O	O
15	leading	O	O
16	to	O	O
17	blindness	BI	O
18	caused	O	O
19	by	O	O
20	a	O	O
21	CAG	O	O
22	polyglutamine	O	O
23	polyGln	O	O
24	expansion	O	O
25	in	O	O
26	the	O	O
27	coding	O	O
28	region	O	O
29	of	O	O
30	the	O	O
31	SCA7	O	O
32	gene	O	O
33	protein	O	O
34	.	O	O

0	Aspartylglucosaminuria	BU	O
1	is	O	O
2	a	O	O
3	rare	O	O
4	autosomal	O	O
5	recessive	O	O
6	lysosomal	O	O
7	storage	O	O
8	disorder	O	O
9	leading	O	O
10	early	BI	O
11	to	II	O
12	a	II	O
13	progressive	II	O
14	intellectual	II	O
15	disability	II	O
16	.	O	O

0	We	O	O
1	used	O	O
2	the	O	O
3	Behavior	O	O
4	Problems	O	O
5	Inventory-01	O	O
6	to	O	O
7	categorize	O	O
8	the	O	O
9	frequency	O	O
10	and	O	O
11	severity	O	O
12	of	O	O
13	behavioral	BI	O
14	abnormalities	II	O
15	in	O	O
16	a	O	O
17	SMS	BU	O
18	cohort	O	O
19	relative	O	O
20	to	O	O
21	individuals	O	O
22	with	O	O
23	intellectual	BI	O
24	disability	II	O
25	of	O	O
26	heterogeneous	O	O
27	etiology	O	O
28	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	the	O	O
4	result	O	O
5	of	O	O
6	an	O	O
7	interstitial	O	O
8	deletion	O	O
9	within	O	O
10	chromosome	O	O
11	17p11.2	O	O
12	is	O	O
13	a	O	O
14	disorder	O	O
15	that	O	O
16	may	O	O
17	include	O	O
18	minor	O	O
19	dysmorphic	O	O
20	features	O	O
21	brachydactyly	BU	O
22	short	O	O
23	stature	O	O
24	hypotonia	O	O
25	speech	BI	O
26	delays	II	O
27	cognitive	BI	O
28	deficits	II	O
29	signs	O	O
30	of	O	O
31	peripheral	O	O
32	neuropathy	O	O
33	scoliosis	O	O
34	and	O	O
35	neurobehavioral	O	O
36	problems	O	O
37	including	O	O
38	sleep	BI	O
39	disturbances	II	O
40	and	O	O
41	maladaptive	BI	O
42	repetitive	II	O
43	and	II	O
44	self-injurious	II	O
45	behaviors	II	O
46	.	O	O

0	Despite	O	O
1	its	O	O
2	frequent	O	O
3	occurrence	O	O
4	as	O	O
5	an	O	O
6	early	O	O
7	symptom	O	O
8	in	O	O
9	both	O	O
10	Alzheimers	BI	O
11	dementia	II	O
12	AD	O	O
13	and	O	O
14	behavioural	BU	O
15	variant	IU	O
16	frontotemporal	IU	O
17	dementia	IU	O
18	bvFTD	IU	O
19	neural	O	O
20	correlates	O	O
21	of	O	O
22	limb	BI	O
23	apraxia	II	O
24	within	O	O
25	these	O	O
26	patient	O	O
27	groups	O	O
28	remain	O	O
29	unexplored	O	O
30	.	O	O

0	The	O	O
1	typical	O	O
2	clinical	O	O
3	features	O	O
4	in	O	O
5	JBS	O	O
6	include	O	O
7	intellectual	BI	O
8	disability	II	O
9	growth	BI	O
10	retardation	II	O
11	craniofacial	O	O
12	dysmorphism	O	O
13	as	O	O
14	well	O	O
15	as	O	O
16	craniosynostosis	BU	O
17	congenital	O	O
18	heart	O	O
19	disease	O	O
20	and	O	O
21	platelet	O	O
22	abnormalities	O	O
23	.	O	O

0	Of	O	O
1	the	O	O
2	three	O	O
3	cases	O	O
4	of	O	O
5	CRS	BU	O
6	that	O	O
7	occurred	O	O
8	in	O	O
9	2012	O	O
10	conditions	O	O
11	included	O	O
12	cardiac	O	O
13	defects	O	O
14	cataracts	O	O
15	hearing	BI	O
16	impairment	II	O
17	and	O	O
18	pericardial	O	O
19	effusion	O	O
20	in	O	O
21	one	O	O
22	infant	O	O
23	patent	BU	O
24	ductus	IU	O
25	arteriosus	IU	O
26	cardiomegaly	O	O
27	thrombocytopenia	O	O
28	and	O	O
29	pneumonitis	O	O
30	in	O	O
31	a	O	O
32	second	O	O
33	infant	O	O
34	and	O	O
35	cataracts	O	O
36	thrombocytopenia	O	O
37	and	O	O
38	cardiac	O	O
39	defects	O	O
40	in	O	O
41	a	O	O
42	third	O	O
43	infant	O	O
44	.	O	O

0	RESULTS	O	O
1	Delayed-onset	BI	O
2	Friedreichs	II	O
3	ataxia	II	O
4	late-onset	BI	O
5	Friedreichs	II	O
6	ataxia	II	O
7	and	O	O
8	very-late-onset	BI	O
9	Friedreichs	II	O
10	ataxia	II	O
11	had	O	O
12	less	O	O
13	frequently	O	O
14	dysarthria	BI	O
15	abolished	O	O
16	tendon	O	O
17	reflexes	O	O
18	extensor	O	O
19	plantar	O	O
20	reflexes	O	O
21	weakness	O	O
22	amyotrophy	O	O
23	ganglionopathy	O	O
24	cerebellar	O	O
25	atrophy	O	O
26	scoliosis	O	O
27	and	O	O
28	cardiomyopathy	BU	O
29	than	O	O
30	typical-onset	BI	O
31	Friedreichs	II	O
32	ataxia	II	O
33	along	O	O
34	with	O	O
35	less	O	O
36	severe	BI	O
37	functional	II	O
38	disability	II	O
39	and	O	O
40	shorter	O	O
41	GAA	O	O
42	expansion	O	O
43	on	O	O
44	the	O	O
45	smaller	O	O
46	allele	O	O
47	P < 0.001	O	O
48	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	FXS	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	immature	O	O
8	dendritic	O	O
9	spine	O	O
10	architectures	O	O
11	and	O	O
12	cognitive	BI	O
13	impairment	II	O
14	.	O	O

0	The	O	O
1	hearing	BI	O
2	impairment	II	O
3	due	O	O
4	to	O	O
5	USH	BU	O
6	gene	O	O
7	defects	O	O
8	has	O	O
9	been	O	O
10	shown	O	O
11	to	O	O
12	result	O	O
13	from	O	O
14	improper	O	O
15	organisation	O	O
16	of	O	O
17	the	O	O
18	hair	O	O
19	bundle	O	O
20	the	O	O
21	sound	O	O
22	receptive	O	O
23	structure	O	O
24	of	O	O
25	sensory	O	O
26	hair	O	O
27	cells	O	O
28	.	O	O

0	This	O	O
1	report	O	O
2	provides	O	O
3	evidence	O	O
4	for	O	O
5	intrafamilial	O	O
6	phenotypic	O	O
7	variability	O	O
8	of	O	O
9	paternal	O	O
10	dup	BU	O
11	15q11-q13	IU	O
12	ranging	O	O
13	from	O	O
14	normal	O	O
15	to	O	O
16	intellectual	BI	O
17	disability	II	O
18	and	O	O
19	seizures	O	O
20	and	O	O
21	potentially	O	O
22	expanding	O	O
23	the	O	O
24	phenotype	O	O
25	of	O	O
26	paternal	O	O
27	15q11-q13	O	O
28	interstitial	O	O
29	duplications	O	O
30	.	O	O

0	The	O	O
1	neuropsychological	O	O
2	pattern	O	O
3	in	O	O
4	possible	O	O
5	bvFTD	BU	O
6	and	O	O
7	pre-bvFTD	O	O
8	was	O	O
9	similar	O	O
10	although	O	O
11	possible	O	O
12	bvFTD	BU	O
13	showed	O	O
14	more	O	O
15	behavioral	BI	O
16	abnormalities	II	O
17	.	O	O

0	The	O	O
1	main	O	O
2	features	O	O
3	of	O	O
4	FCMD	BU	O
5	are	O	O
6	a	O	O
7	combination	O	O
8	of	O	O
9	infantile-onset	O	O
10	hypotonia	O	O
11	generalized	O	O
12	muscle	O	O
13	weakness	O	O
14	eye	O	O
15	abnormalities	O	O
16	and	O	O
17	mental	BI	O
18	retardation	II	O
19	associated	O	O
20	with	O	O
21	cortical	O	O
22	migration	O	O
23	defects	O	O
24	and	O	O
25	most	O	O
26	patients	O	O
27	are	O	O
28	never	O	O
29	able	O	O
30	to	O	O
31	walk	O	O
32	.	O	O

0	The	O	O
1	present	O	O
2	case	O	O
3	is	O	O
4	that	O	O
5	of	O	O
6	an	O	O
7	infant	O	O
8	with	O	O
9	acquired	O	O
10	hydrocephalus	O	O
11	psychomotor	BI	O
12	retardation	II	O
13	and	O	O
14	myoclonic	O	O
15	seizures	O	O
16	in	O	O
17	whom	O	O
18	the	O	O
19	final	O	O
20	diagnosis	O	O
21	was	O	O
22	nonketotic	BU	O
23	hyperglycinemia	IU	O
24	.	O	O

0	Typically	O	O
1	NARP	O	O
2	syndrome	O	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	developmental	BI	O
7	delay	II	O
8	seizures	O	O
9	dementia	BI	O
10	retinitis	BU	O
11	pigmentosa	IU	O
12	ataxia	BI	O
13	sensory	O	O
14	neuropathy	O	O
15	and	O	O
16	proximal	O	O
17	weakness	O	O
18	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	central	O	O
4	nervous	O	O
5	system	O	O
6	manifestations	O	O
7	were	O	O
8	transient	O	O
9	and	O	O
10	included	O	O
11	dysarthria	BI	O
12	ataxia	BI	O
13	hemiparesis	BI	O
14	and	O	O
15	tetraparesis	BI	O
16	resembling	O	O
17	periodic	BU	O
18	paralysis	IU	O
19	.	O	O

0	Serious	O	O
1	manifestations	O	O
2	of	O	O
3	CRS	BU	O
4	include	O	O
5	deafness	BI	O
6	cataracts	O	O
7	cardiac	O	O
8	defects	O	O
9	mental	BI	O
10	retardation	II	O
11	and	O	O
12	death	O	O
13	.	O	O

0	Furthermore	O	O
1	behavioral	BI	O
2	and	II	O
3	psychiatric	II	O
4	problems	II	O
5	need	O	O
6	to	O	O
7	be	O	O
8	looked	O	O
9	for	O	O
10	when	O	O
11	caring	O	O
12	for	O	O
13	children	O	O
14	and	O	O
15	adolescents	O	O
16	with	O	O
17	a	O	O
18	known	O	O
19	diagnosis	O	O
20	of	O	O
21	del22q11	BU	O
22	.	O	O

0	Both	O	O
1	the	O	O
2	patients	O	O
3	had	O	O
4	generalized	O	O
5	ichthyosis	BU	O
6	and	O	O
7	the	O	O
8	older	O	O
9	one	O	O
10	had	O	O
11	spastic	BI	O
12	paraplegia	II	O
13	and	O	O
14	mental	BI	O
15	retardation	II	O
16	and	O	O
17	the	O	O
18	fundus	O	O
19	examination	O	O
20	revealed	O	O
21	foveal	O	O
22	and	O	O
23	parafoveal	O	O
24	glistening	O	O
25	dots	O	O
26	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	family	O	O
4	that	O	O
5	suffers	O	O
6	an	O	O
7	autosomal	O	O
8	dominant	O	O
9	Alport	BU	O
10	syndrome	IU	O
11	caused	O	O
12	by	O	O
13	a	O	O
14	previously	O	O
15	undescribed	O	O
16	mutation	O	O
17	in	O	O
18	the	O	O
19	COL4A3	O	O
20	gene	O	O
21	in	O	O
22	which	O	O
23	several	O	O
24	members	O	O
25	have	O	O
26	hearing	BI	O
27	impairment	II	O
28	as	O	O
29	the	O	O
30	only	O	O
31	clinical	O	O
32	manifestation	O	O
33	suggesting	O	O
34	that	O	O
35	in	O	O
36	this	O	O
37	family	O	O
38	deafness	O	O
39	can	O	O
40	occur	O	O
41	independent	O	O
42	of	O	O
43	renal	O	O
44	disease	O	O
45	.	O	O

0	Low	O	O
1	uric	O	O
2	acid	O	O
3	level	O	O
4	predicting	O	O
5	cognitive	BI	O
6	decline	II	O
7	in	O	O
8	MSA	BU	O
9	needs	O	O
10	more	O	O
11	studies	O	O
12	.	O	O

0	BACKGROUND	O	O
1	The	O	O
2	main	O	O
3	features	O	O
4	of	O	O
5	the	O	O
6	Coffin-Lowry	BU	O
7	syndrome	IU	O
8	are	O	O
9	mental	BI	O
10	retardation	II	O
11	and	O	O
12	features	O	O
13	of	O	O
14	a	O	O
15	peculiar	O	O
16	pugilistic	O	O
17	nose	O	O
18	large	O	O
19	ears	O	O
20	tapered	O	O
21	fingers	O	O
22	drumstick	O	O
23	terminal	O	O
24	phalanges	O	O
25	by	O	O
26	X-rays	O	O
27	and	O	O
28	kyphoscoliosis	O	O
29	.	O	O

0	Considering	O	O
1	the	O	O
2	comorbidity	O	O
3	of	O	O
4	CMT	BU	O
5	with	O	O
6	other	O	O
7	psychiatric	BI	O
8	disorders	II	O
9	the	O	O
10	heterogeneity	O	O
11	of	O	O
12	the	O	O
13	instruments	O	O
14	used	O	O
15	to	O	O
16	evaluate	O	O
17	the	O	O
18	psychiatric	O	O
19	symptoms	O	O
20	compromised	O	O
21	the	O	O
22	ability	O	O
23	to	O	O
24	compare	O	O
25	the	O	O
26	studies	O	O
27	examined	O	O
28	.	O	O

0	PURPOSE	O	O
1	To	O	O
2	report	O	O
3	the	O	O
4	association	O	O
5	of	O	O
6	optic	BI	O
7	atrophy	II	O
8	with	O	O
9	cobalamin	BU	O
10	C	IU	O
11	cblC	IU	O
12	disease	IU	O
13	.	O	O

0	The	O	O
1	oculoauriculovertebral	BU	O
2	dysplasia	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	congenital	O	O
7	malformation	O	O
8	that	O	O
9	is	O	O
10	characterized	O	O
11	by	O	O
12	a	O	O
13	hemifacial	BU	O
14	microsomia	IU	O
15	with	O	O
16	ocular	BI	O
17	abnormalities	II	O
18	and	O	O
19	coexisting	O	O
20	disorders	O	O
21	in	O	O
22	the	O	O
23	spinal	O	O
24	column	O	O
25	and	O	O
26	other	O	O
27	organs	O	O
28	.	O	O

0	The	O	O
1	Smith-Magenis	BU	O
2	syndrome	IU	O
3	SMS	IU	O
4	is	O	O
5	a	O	O
6	complex	O	O
7	and	O	O
8	rare	O	O
9	congenital	O	O
10	condition	O	O
11	that	O	O
12	is	O	O
13	characterized	O	O
14	by	O	O
15	minor	O	O
16	craniofacial	O	O
17	anomalies	O	O
18	short	O	O
19	stature	O	O
20	sleep	BI	O
21	disturbances	II	O
22	behavioral	BI	O
23	and	II	O
24	neurocognitive	II	O
25	abnormalities	II	O
26	as	O	O
27	well	O	O
28	as	O	O
29	variable	O	O
30	multisystemic	O	O
31	manifestations	O	O
32	.	O	O

0	Detection	O	O
1	by	O	O
2	newborn	O	O
3	screening	O	O
4	NBS	O	O
5	and	O	O
6	treatment	O	O
7	of	O	O
8	babies	O	O
9	with	O	O
10	congenital	BU	O
11	hypothyroidism	IU	O
12	CH	IU	O
13	has	O	O
14	largely	O	O
15	eliminated	O	O
16	the	O	O
17	intellectual	BI	O
18	disability	II	O
19	caused	O	O
20	by	O	O
21	this	O	O
22	disorder	O	O
23	.	O	O

0	Alport	BU	O
1	syndrome	IU	O
2	is	O	O
3	often	O	O
4	associated	O	O
5	with	O	O
6	sensorineural	BI	O
7	hearing	II	O
8	loss	II	O
9	and	O	O
10	ocular	BI	O
11	abnormalities	II	O
12	and	O	O
13	patients	O	O
14	suffering	O	O
15	from	O	O
16	typical	O	O
17	Alport	BU	O
18	syndrome	IU	O
19	usually	O	O
20	develop	O	O
21	end	O	O
22	stage	O	O
23	renal	O	O
24	disease	O	O
25	during	O	O
26	adolescence	O	O
27	or	O	O
28	young	O	O
29	adulthood	O	O
30	.	O	O

0	Johanson	BU	O
1	Blizzard	IU	O
2	syndrome	IU	O
3	JBS	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	multi-system	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	congenital	O	O
12	aplasia	O	O
13	or	O	O
14	hypoplasia	O	O
15	of	O	O
16	alae	O	O
17	nasi	O	O
18	exocrine	O	O
19	pancreatic	O	O
20	insufficiency	O	O
21	hypothyroidism	O	O
22	deafness	O	O
23	growth	O	O
24	retardation	O	O
25	varying	O	O
26	degree	O	O
27	of	O	O
28	mental	BI	O
29	retardation	II	O
30	alopecia	O	O
31	wide	O	O
32	open	O	O
33	fontanels	O	O
34	anti-mongoloid	O	O
35	slant	O	O
36	café-au-lait	O	O
37	spots	O	O
38	and	O	O
39	absent	O	O
40	of	O	O
41	permanent	O	O
42	teeth	O	O
43	.	O	O

0	Rubinstein-Taybi	BU	O
1	syndrome	IU	O
2	RSTS	IU	O
3	is	O	O
4	one	O	O
5	of	O	O
6	the	O	O
7	neurodevelopmental	BI	O
8	disorders	II	O
9	caused	O	O
10	by	O	O
11	mutations	O	O
12	of	O	O
13	epigenetic	O	O
14	genes	O	O
15	.	O	O

0	CONCLUSION	O	O
1	When	O	O
2	ichthyosis	BU	O
3	is	O	O
4	associated	O	O
5	with	O	O
6	spasticity	O	O
7	and	O	O
8	mental	BI	O
9	retardation	II	O
10	one	O	O
11	should	O	O
12	consider	O	O
13	SLS	O	O
14	.	O	O

0	Sjögren-Larsson	BU	O
1	syndrome	IU	O
2	SLS	IU	O
3	is	O	O
4	an	O	O
5	autosomal	O	O
6	recessive	O	O
7	neurocutaneous	O	O
8	disorder	O	O
9	most	O	O
10	commonly	O	O
11	seen	O	O
12	in	O	O
13	the	O	O
14	Scandinavian	O	O
15	population	O	O
16	and	O	O
17	characterized	O	O
18	by	O	O
19	congenital	BU	O
20	ichthyosis	IU	O
21	mental	BI	O
22	retardation	II	O
23	and	O	O
24	spastic	BI	O
25	diplegia	II	O
26	or	O	O
27	quadriplegia	BI	O
28	.	O	O

0	We	O	O
1	describe	O	O
2	three	O	O
3	siblings	O	O
4	of	O	O
5	a	O	O
6	consanguineous	O	O
7	family	O	O
8	manifesting	O	O
9	the	O	O
10	typical	O	O
11	infantile-onset	O	O
12	Pelizaeus-Merzbacher	BU	O
13	disease-like	IU	O
14	phenotype	O	O
15	slowly	O	O
16	evolving	O	O
17	into	O	O
18	a	O	O
19	form	O	O
20	of	O	O
21	complicated	BU	O
22	hereditary	IU	O
23	spastic	IU	O
24	paraplegia	IU	O
25	with	O	O
26	mental	BI	O
27	retardation	II	O
28	dysarthria	BI	O
29	optic	BI	O
30	atrophy	II	O
31	and	O	O
32	peripheral	O	O
33	neuropathy	O	O
34	in	O	O
35	adulthood	O	O
36	.	O	O

0	CONCLUSIONS	O	O
1	This	O	O
2	report	O	O
3	expands	O	O
4	the	O	O
5	ophthalmological	O	O
6	phenotype	O	O
7	of	O	O
8	the	O	O
9	late-onset	O	O
10	neurodegenerative	O	O
11	form	O	O
12	of	O	O
13	CHS	BU	O
14	to	O	O
15	include	O	O
16	optic	O	O
17	neuropathy	O	O
18	with	O	O
19	progressive	BI	O
20	vision	II	O
21	loss	II	O
22	even	O	O
23	in	O	O
24	the	O	O
25	absence	O	O
26	of	O	O
27	ocular	BU	O
28	albinism	IU	O
29	and	O	O
30	abnormal	O	O
31	prominence	O	O
32	of	O	O
33	the	O	O
34	interdigitation	O	O
35	zone	O	O
36	between	O	O
37	cone	O	O
38	outer	O	O
39	segment	O	O
40	tips	O	O
41	and	O	O
42	apical	O	O
43	processes	O	O
44	of	O	O
45	retinal	O	O
46	pigment	O	O
47	epithelium	O	O
48	cells	O	O
49	on	O	O
50	macular	O	O
51	OCT	O	O
52	.	O	O

0	The	O	O
1	differential	O	O
2	diagnosis	O	O
3	of	O	O
4	postnatal	BI	O
5	developmental	II	O
6	delay	II	O
7	should	O	O
8	include	O	O
9	free	O	O
10	sialic	O	O
11	acid	O	O
12	storage	O	O
13	disorders	O	O
14	such	O	O
15	as	O	O
16	ISSD	BU	O
17	and	O	O
18	Salla	BU	O
19	disease	IU	O
20	.	O	O

0	Waardenburg-Shah	BU	O
1	syndrome	IU	O
2	Waardenburg	O	O
3	syndrome	O	O
4	type	O	O
5	IV-WS4	O	O
6	is	O	O
7	an	O	O
8	auditory-pigmentary	O	O
9	disorder	O	O
10	that	O	O
11	combines	O	O
12	clinical	O	O
13	features	O	O
14	of	O	O
15	pigmentary	O	O
16	abnormalities	O	O
17	of	O	O
18	the	O	O
19	skin	O	O
20	hair	O	O
21	and	O	O
22	irides	O	O
23	sensorineural	BI	O
24	hearing	II	O
25	loss	II	O
26	and	O	O
27	Hirschsprung	BU	O
28	disease	IU	O
29	HSCR	O	O
30	.	O	O

0	The	O	O
1	previously	O	O
2	described	O	O
3	critical	O	O
4	region	O	O
5	for	O	O
6	the	O	O
7	speech	BI	O
8	delay	II	O
9	may	O	O
10	be	O	O
11	narrowed	O	O
12	down	O	O
13	and	O	O
14	microcephaly	O	O
15	growth	BI	O
16	retardation	II	O
17	and	O	O
18	dysmorphic	O	O
19	facial	O	O
20	features	O	O
21	can	O	O
22	be	O	O
23	included	O	O
24	in	O	O
25	the	O	O
26	phenotypic	O	O
27	expression	O	O
28	of	O	O
29	the	O	O
30	atypical	O	O
31	cri	BU	O
32	du	IU	O
33	chat	IU	O
34	syndrome	IU	O
35	due	O	O
36	to	O	O
37	5p15.3	O	O
38	deletions	O	O
39	.	O	O

0	The	O	O
1	term	O	O
2	pre-bvFTD	O	O
3	was	O	O
4	adopted	O	O
5	for	O	O
6	patients	O	O
7	with	O	O
8	cognitive	BI	O
9	and	II	O
10	or	II	O
11	behavioral	II	O
12	impairment	II	O
13	not	O	O
14	fulfilling	O	O
15	bvFTD	BU	O
16	criteria	O	O
17	and	O	O
18	no	O	O
19	deficits	BI	O
20	in	II	O
21	activities	II	O
22	of	II	O
23	daily	II	O
24	living	II	O
25	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	WFS	IU	O
3	a	O	O
4	rare	O	O
5	neurodegenerative	O	O
6	disorder	O	O
7	is	O	O
8	characterized	O	O
9	by	O	O
10	early	O	O
11	onset	O	O
12	insulin-dependent	O	O
13	diabetes	O	O
14	mellitus	O	O
15	optic	BI	O
16	atrophy	II	O
17	deafness	BI	O
18	diabetes	O	O
19	insipidus	O	O
20	and	O	O
21	neurological	O	O
22	abnormalities	O	O
23	.	O	O

0	BACKGROUND	O	O
1	Autosomal	BU	O
2	recessive	IU	O
3	hereditary	IU	O
4	spastic	IU	O
5	paraplegia	IU	O
6	with	O	O
7	thin	O	O
8	corpus	O	O
9	callosum	O	O
10	is	O	O
11	a	O	O
12	neurodegenerative	O	O
13	disorder	O	O
14	characterized	O	O
15	by	O	O
16	spastic	BI	O
17	paraparesis	II	O
18	cognitive	BI	O
19	impairment	II	O
20	and	O	O
21	peripheral	O	O
22	neuropathy	O	O
23	.	O	O

0	In	O	O
1	light	O	O
2	of	O	O
3	these	O	O
4	findings	O	O
5	we	O	O
6	concluded	O	O
7	that	O	O
8	a	O	O
9	25%	O	O
10	of	O	O
11	CH	O	O
12	patients	O	O
13	detected	O	O
14	by	O	O
15	CH	O	O
16	screening	O	O
17	may	O	O
18	show	O	O
19	at	O	O
20	a	O	O
21	median	O	O
22	age	O	O
23	of	O	O
24	15.4	O	O
25	years	O	O
26	a	O	O
27	mild	O	O
28	and	O	O
29	subclinical	O	O
30	hearing	O	O
31	impairment	O	O
32	despite	O	O
33	early	O	O
34	and	O	O
35	adequate	O	O
36	replacement	O	O
37	treatment	O	O
38	b	O	O
39	the	O	O
40	risk	O	O
41	of	O	O
42	hearing	O	O
43	loss	O	O
44	is	O	O
45	higher	O	O
46	in	O	O
47	CH	O	O
48	young	O	O
49	patients	O	O
50	than	O	O
51	in	O	O
52	age-matched	O	O
53	control	O	O
54	subjects	O	O
55	without	O	O
56	CH	O	O
57	c	O	O
58	the	O	O
59	risk	O	O
60	of	O	O
61	hearing	BI	O
62	loss	II	O
63	is	O	O
64	closely	O	O
65	associated	O	O
66	with	O	O
67	the	O	O
68	severity	O	O
69	of	O	O
70	CH	BU	O
71	d	O	O
72	this	O	O
73	risk	O	O
74	is	O	O
75	particularly	O	O
76	relevant	O	O
77	in	O	O
78	the	O	O
79	children	O	O
80	with	O	O
81	pre-natal	O	O
82	onset	O	O
83	of	O	O
84	hypothyroidism	O	O
85	.	O	O

0	In	O	O
1	gastrocnemius	O	O
2	muscles	O	O
3	MAPs	O	O
4	increased	O	O
5	in	O	O
6	disorders	O	O
7	such	O	O
8	as	O	O
9	Duchenne	O	O
10	MD	O	O
11	Fukuyama	O	O
12	type	O	O
13	congenital	O	O
14	MD	O	O
15	facioscapulohumeral	O	O
16	MD	O	O
17	myotonic	O	O
18	dystrophy	O	O
19	dermatomyositis	BU	O
20	Kugelberg-Welander	O	O
21	syndrome	O	O
22	viral	O	O
23	myelitis	O	O
24	malignant	O	O
25	hyperpyrexia	O	O
26	autism	BI	O
27	and	O	O
28	schizophrenia	O	O
29	.	O	O

0	Crouzon	BU	O
1	syndrome	IU	O
2	should	O	O
3	be	O	O
4	managed	O	O
5	as	O	O
6	early	O	O
7	as	O	O
8	possible	O	O
9	as	O	O
10	it	O	O
11	results	O	O
12	in	O	O
13	airway	O	O
14	obstruction	O	O
15	decreased	BI	O
16	vision	II	O
17	mental	BI	O
18	retardation	II	O
19	and	O	O
20	poor	O	O
21	cosmetic	O	O
22	appearance	O	O
23	.	O	O

0	They	O	O
1	revealed	O	O
2	the	O	O
3	presence	O	O
4	of	O	O
5	aniridia	BU	O
6	bilateral	O	O
7	cataract	O	O
8	and	O	O
9	cryptorchidism	O	O
10	in	O	O
11	1	O	O
12	24	O	O
13	children	O	O
14	mental	BI	O
15	retardation	II	O
16	small	O	O
17	stigated	O	O
18	congenital	O	O
19	major	O	O
20	and	O	O
21	minor	O	O
22	anomalies	O	O
23	in	O	O
24	40	O	O
25	chidism	O	O
26	in	O	O
27	1	O	O
28	40	O	O
29	children	O	O
30	mental	BI	O
31	retardation	II	O
32	small	O	O
33	stature	O	O
34	and	O	O
35	a	O	O
36	cystic	O	O
37	kidney	O	O
38	in	O	O
39	1	O	O
40	40	O	O
41	mental	BI	O
42	retardation	II	O
43	in	O	O
44	3	O	O
45	40	O	O
46	.	O	O

0	Frontotemporal	BU	O
1	dementia	IU	O
2	FTD	IU	O
3	is	O	O
4	a	O	O
5	not-uncommon	O	O
6	explanation	O	O
7	for	O	O
8	progressive	BI	O
9	cognitive	II	O
10	deficit	II	O
11	in	O	O
12	patients	O	O
13	who	O	O
14	often	O	O
15	have	O	O
16	a	O	O
17	genetic	O	O
18	susceptibility	O	O
19	for	O	O
20	such	O	O
21	a	O	O
22	neurodegenerative	O	O
23	process	O	O
24	.	O	O

0	In	O	O
1	order	O	O
2	to	O	O
3	identify	O	O
4	novel	O	O
5	genes	O	O
6	involved	O	O
7	in	O	O
8	mental	BI	O
9	retardation	II	O
10	intellectual	BI	O
11	disability	II	O
12	we	O	O
13	focused	O	O
14	on	O	O
15	a	O	O
16	microdeletion	O	O
17	reported	O	O
18	in	O	O
19	a	O	O
20	patient	O	O
21	with	O	O
22	a	O	O
23	mild	O	O
24	form	O	O
25	of	O	O
26	Wolf-Hirschhorn	BU	O
27	syndrome	IU	O
28	.	O	O

0	CLINICAL	O	O
1	CHARACTERISTICS	O	O
2	Russell-Silver	BU	O
3	syndrome	IU	O
4	RSS	IU	O
5	is	O	O
6	characterized	O	O
7	by	O	O
8	intrauterine	O	O
9	growth	O	O
10	retardation	O	O
11	accompanied	O	O
12	by	O	O
13	postnatal	BI	O
14	growth	II	O
15	deficiency	II	O
16	.	O	O

0	Analyses	O	O
1	of	O	O
2	these	O	O
3	mice	O	O
4	revealed	O	O
5	microphthalmia	O	O
6	postnatal	BI	O
7	growth	II	O
8	deficiency	II	O
9	brain	O	O
10	hypoplasia	O	O
11	decreased	O	O
12	numbers	O	O
13	of	O	O
14	neuronal	O	O
15	nuclear	O	O
16	antigen	O	O
17	NeuN-positive	O	O
18	hippocampal	O	O
19	neurons	O	O
20	hearing	BI	O
21	loss	II	O
22	cardiovascular	O	O
23	malformations-aortic	O	O
24	arch	O	O
25	anomalies	O	O
26	double	BU	O
27	outlet	IU	O
28	right	IU	O
29	ventricle	IU	O
30	and	O	O
31	transposition	BU	O
32	of	IU	O
33	the	IU	O
34	great	IU	O
35	arteries	IU	O
36	and	O	O
37	perimembranous	O	O
38	ventricular	O	O
39	septal	O	O
40	defects-spontaneous	O	O
41	development	O	O
42	of	O	O
43	cardiac	O	O
44	fibrosis	O	O
45	and	O	O
46	renal	O	O
47	agenesis	O	O
48	.	O	O

0	CASE	O	O
1	REPORTS	O	O
2	A	O	O
3	44-Year-old	O	O
4	man	O	O
5	who	O	O
6	complained	O	O
7	of	O	O
8	visual	BI	O
9	loss	II	O
10	presented	O	O
11	bilateral	O	O
12	congenital	BU	O
13	aniridia	IU	O
14	with	O	O
15	corneal	BU	O
16	dystrophy	IU	O
17	and	O	O
18	dense	O	O
19	cataract	O	O
20	.	O	O

0	BACKGROUND	O	O
1	Cornelia	BU	O
2	de	IU	O
3	Lange	IU	O
4	syndrome	IU	O
5	CdLS	IU	O
6	is	O	O
7	a	O	O
8	dominantly	O	O
9	inherited	O	O
10	disorder	O	O
11	characterized	O	O
12	by	O	O
13	facial	O	O
14	dysmorphism	O	O
15	growth	BI	O
16	and	II	O
17	cognitive	II	O
18	impairment	II	O
19	limb	O	O
20	malformations	O	O
21	and	O	O
22	multiple	O	O
23	organ	O	O
24	involvement	O	O
25	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	14-year-old	O	O
4	girl	O	O
5	with	O	O
6	mental	BI	O
7	retardation	II	O
8	behavioral	BI	O
9	abnormalities	II	O
10	and	O	O
11	facial	O	O
12	dysmorphism	O	O
13	with	O	O
14	SMS	BU	O
15	diagnosis	O	O
16	confirmed	O	O
17	by	O	O
18	cytogenetic	O	O
19	analysis	O	O
20	and	O	O
21	in	O	O
22	situ	O	O
23	hydridization	O	O
24	FISH	O	O
25	.	O	O

0	Recent	O	O
1	studies	O	O
2	have	O	O
3	uncovered	O	O
4	mechanisms	O	O
5	by	O	O
6	which	O	O
7	mutations	O	O
8	of	O	O
9	the	O	O
10	gene	O	O
11	encoding	O	O
12	plant	O	O
13	homeodomain	O	O
14	PHD-like	O	O
15	finger	O	O
16	protein	O	O
17	6	O	O
18	PHF6	O	O
19	contribute	O	O
20	to	O	O
21	the	O	O
22	pathogenesis	O	O
23	of	O	O
24	the	O	O
25	X-linked	BI	O
26	intellectual	II	O
27	disability	II	O
28	disorder	II	O
29	Borjeson-Forssman-Lehmann	BU	O
30	syndrome	IU	O
31	BFLS	IU	O
32	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	a	O	O
5	mental	BI	O
6	retardation	II	O
7	syndrome	O	O
8	with	O	O
9	distinctive	O	O
10	behavioral	O	O
11	characteristics	O	O
12	dysmorphic	O	O
13	features	O	O
14	and	O	O
15	congenital	O	O
16	anomalies	O	O
17	ascribed	O	O
18	to	O	O
19	an	O	O
20	interstitial	O	O
21	deletion	O	O
22	of	O	O
23	chromosome	O	O
24	17p11.2	O	O
25	.	O	O

0	To	O	O
1	date	O	O
2	the	O	O
3	development	O	O
4	of	O	O
5	a	O	O
6	quantitative	O	O
7	motor	O	O
8	scale	O	O
9	for	O	O
10	FMCD	O	O
11	has	O	O
12	been	O	O
13	difficult	O	O
14	due	O	O
15	to	O	O
16	the	O	O
17	moderate-to-severe	BI	O
18	intellectual	II	O
19	impairment	II	O
20	that	O	O
21	accompanies	O	O
22	FCMD	BU	O
23	.	O	O

0	We	O	O
1	report	O	O
2	the	O	O
3	case	O	O
4	of	O	O
5	two	O	O
6	Egyptian	O	O
7	sibling	O	O
8	patients	O	O
9	suspected	O	O
10	of	O	O
11	Canavan	BU	O
12	disease	IU	O
13	CD	IU	O
14	showing	O	O
15	clinical	O	O
16	deterioration	O	O
17	white	O	O
18	matter	O	O
19	degeneration	O	O
20	megalencephaly	BU	O
21	and	O	O
22	severe	BI	O
23	intellectual	II	O
24	impairment	II	O
25	.	O	O

0	INTRODUCTION	O	O
1	Choroideremia	BU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	X-linked	O	O
6	disorder	O	O
7	recognized	O	O
8	by	O	O
9	its	O	O
10	specific	O	O
11	ocular	O	O
12	phenotype	O	O
13	as	O	O
14	a	O	O
15	progressive	O	O
16	degenerative	O	O
17	retinopathy	O	O
18	resulting	O	O
19	in	O	O
20	blindness	BI	O
21	.	O	O

0	The	O	O
1	second	O	O
2	case	O	O
3	was	O	O
4	a	O	O
5	6-year-old	O	O
6	boy	O	O
7	of	O	O
8	Asian	O	O
9	ancestry	O	O
10	who	O	O
11	presented	O	O
12	with	O	O
13	ataxia	BI	O
14	exacerbated	O	O
15	by	O	O
16	intercurrent	O	O
17	illnesses	O	O
18	decreased	O	O
19	exercise	O	O
20	tolerance	O	O
21	gross	O	O
22	motor	O	O
23	and	O	O
24	fine	O	O
25	motor	O	O
26	delays	O	O
27	anorexia	O	O
28	and	O	O
29	recurrent	O	O
30	episodes	O	O
31	of	O	O
32	vomiting	O	O
33	associated	O	O
34	with	O	O
35	dehydration	O	O
36	and	O	O
37	he	O	O
38	was	O	O
39	subsequently	O	O
40	diagnosed	O	O
41	with	O	O
42	KSS	BU	O
43	.	O	O

0	WDR45	O	O
1	is	O	O
2	an	O	O
3	X-linked	O	O
4	gene	O	O
5	associated	O	O
6	with	O	O
7	a	O	O
8	dominant	O	O
9	form	O	O
10	of	O	O
11	Neurodegeneration	BU	O
12	with	IU	O
13	Brain	IU	O
14	Iron	IU	O
15	Accumulation	IU	O
16	NBIA	IU	O
17	manifested	O	O
18	by	O	O
19	progressive	O	O
20	disabilities	O	O
21	dystonia	O	O
22	cognitive	BI	O
23	decline	II	O
24	spastic	BI	O
25	paraplegia	II	O
26	neuropsychiatric	O	O
27	abnormalities	O	O
28	and	O	O
29	iron	O	O
30	deposition	O	O
31	in	O	O
32	the	O	O
33	basal	O	O
34	ganglia	O	O
35	on	O	O
36	brain	O	O
37	imaging	O	O
38	.	O	O

0	However	O	O
1	current	O	O
2	evidence	O	O
3	suggests	O	O
4	that	O	O
5	anakinra	O	O
6	has	O	O
7	limited	O	O
8	effectiveness	O	O
9	in	O	O
10	reversing	O	O
11	the	O	O
12	sensorineural	BI	O
13	hearing	II	O
14	loss	II	O
15	seen	II	O
16	in	O	O
17	CINCA	BU	O
18	syndrome	IU	O
19	.	IU	O

0	Individuals	O	O
1	with	O	O
2	Costello	BU	O
3	syndrome	IU	O
4	usually	O	O
5	present	O	O
6	with	O	O
7	severe	O	O
8	feeding	O	O
9	difficulties	O	O
10	in	O	O
11	infancy	O	O
12	short	O	O
13	stature	O	O
14	coarse	O	O
15	facial	O	O
16	features	O	O
17	increased	O	O
18	tumor	O	O
19	risks	O	O
20	cardiac	O	O
21	and	O	O
22	neurological	O	O
23	complications	O	O
24	intellectual	BI	O
25	disability	II	O
26	and	O	O
27	orthopedic	O	O
28	complications	O	O
29	.	O	O

0	BACKGROUND	O	O
1	Frontotemporal	BU	O
2	dementia	IU	O
3	is	O	O
4	thought	O	O
5	to	O	O
6	be	O	O
7	the	O	O
8	second	O	O
9	most	O	O
10	common	O	O
11	form	O	O
12	of	O	O
13	dementia	BI	O
14	after	O	O
15	Alzheimers	O	O
16	disease	O	O
17	.	O	O

0	MCT8	O	O
1	mutations	O	O
2	cause	O	O
3	an	O	O
4	X-linked	O	O
5	syndromic	O	O
6	disorder	O	O
7	known	O	O
8	as	O	O
9	Allan-Herndon-Dudley	BU	O
10	syndrome	IU	O
11	AHDS	BU	O
12	that	O	O
13	is	O	O
14	characterized	O	O
15	by	O	O
16	severe	BI	O
17	psychomotor	II	O
18	delays	II	O
19	abnormal	O	O
20	thyroid	O	O
21	function	O	O
22	and	O	O
23	hypomyelinated	O	O
24	leukodystrophies	O	O
25	.	O	O

0	Hereditary	BU	O
1	motor	IU	O
2	and	IU	O
3	sensory	IU	O
4	neuropathy	IU	O
5	type	IU	O
6	VI	IU	O
7	was	O	O
8	first	O	O
9	reported	O	O
10	in	O	O
11	1879	O	O
12	by	O	O
13	Vizioli	O	O
14	who	O	O
15	described	O	O
16	a	O	O
17	kinship	O	O
18	in	O	O
19	which	O	O
20	a	O	O
21	father	O	O
22	and	O	O
23	two	O	O
24	sons	O	O
25	presented	O	O
26	with	O	O
27	peroneal	O	O
28	muscular	O	O
29	atrophy	O	O
30	in	O	O
31	association	O	O
32	with	O	O
33	optic	BI	O
34	atrophy	II	O
35	.	O	O

0	Mosaic	O	O
1	inactivation	O	O
2	of	O	O
3	the	O	O
4	normal	O	O
5	gene	O	O
6	may	O	O
7	cause	O	O
8	expression	O	O
9	of	O	O
10	the	O	O
11	mutation	O	O
12	with	O	O
13	severe	BI	O
14	vision	II	O
15	loss	II	O
16	in	O	O
17	choroideremia	BU	O
18	carriers	O	O
19	.	O	O

0	The	O	O
1	Rieger	BU	O
2	syndrome	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	mesoectodermal	O	O
7	dysplasia	O	O
8	of	O	O
9	the	O	O
10	iris	O	O
11	and	O	O
12	cornea	O	O
13	dental	O	O
14	defects	O	O
15	in	O	O
16	some	O	O
17	cases	O	O
18	short	O	O
19	stature	O	O
20	abnormal	O	O
21	external	O	O
22	ears	O	O
23	hypertelorism	O	O
24	arachnodactyly	O	O
25	polydactyly	O	O
26	scoliosis	O	O
27	kyphosis	O	O
28	imperforate	O	O
29	anus	O	O
30	umbilical	O	O
31	hernia	O	O
32	myopathy	O	O
33	and	O	O
34	in	O	O
35	a	O	O
36	few	O	O
37	cases	O	O
38	mental	BI	O
39	retardation	II	O
40	.	O	O

0	In	O	O
1	general	O	O
2	the	O	O
3	cognitive	O	O
4	profile	O	O
5	in	O	O
6	CS	BU	O
7	is	O	O
8	characterized	O	O
9	by	O	O
10	intellectual	BI	O
11	disability	II	O
12	ranging	O	O
13	from	O	O
14	mild	O	O
15	to	O	O
16	severe	O	O
17	impairment	O	O
18	.	O	O

0	In	O	O
1	children	O	O
2	with	O	O
3	severe	BU	O
4	generalized	IU	O
5	recessive	IU	O
6	dystrophic	IU	O
7	epidermolysis	IU	O
8	bullosa	IU	O
9	RDEB	IU	O
10	esophageal	O	O
11	scarring	O	O
12	leads	O	O
13	to	O	O
14	esophageal	O	O
15	strictures	O	O
16	with	O	O
17	dysphagia	O	O
18	followed	O	O
19	by	O	O
20	malnutrition	O	O
21	and	O	O
22	delayed	BI	O
23	development	II	O
24	.	O	O

0	Cerebellar	BI	O
1	and	II	O
2	retinal	II	O
3	degeneration	II	O
4	and	O	O
5	possible	O	O
6	stunted	O	O
7	dendritogenesis	O	O
8	may	O	O
9	be	O	O
10	due	O	O
11	to	O	O
12	plasmalogen	O	O
13	deficiency	O	O
14	which	O	O
15	is	O	O
16	the	O	O
17	most	O	O
18	severe	O	O
19	biochemical	O	O
20	abnormality	O	O
21	in	O	O
22	RCDP	BU	O
23	.	O	O

0	This	O	O
1	study	O	O
2	is	O	O
3	aimed	O	O
4	to	O	O
5	conduct	O	O
6	a	O	O
7	systematic	O	O
8	literature	O	O
9	review	O	O
10	regarding	O	O
11	the	O	O
12	associations	O	O
13	between	O	O
14	psychiatric	O	O
15	symptoms	O	O
16	functional	BI	O
17	impairments	II	O
18	and	O	O
19	quality	O	O
20	of	O	O
21	life	O	O
22	in	O	O
23	patients	O	O
24	with	O	O
25	CMT	BU	O
26	Charcot-Marie-Tooth	O	O
27	.	O	O

0	A	O	O
1	6-year-old	O	O
2	boy	O	O
3	with	O	O
4	formerly	O	O
5	diagnosed	O	O
6	Klippel-Feil	BU	O
7	syndrome	IU	O
8	KFS	IU	O
9	presented	O	O
10	with	O	O
11	complaints	O	O
12	of	O	O
13	hearing	BI	O
14	loss	II	O
15	speech	BI	O
16	disorder	II	O
17	and	O	O
18	problems	O	O
19	related	O	O
20	to	O	O
21	his	O	O
22	hearing	O	O
23	aid	O	O
24	.	O	O

0	Langerhans	BU	O
1	cell	IU	O
2	histiocytosis	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	disorder	O	O
7	with	O	O
8	resultant	O	O
9	bilateral	BI	O
10	sensorineural	II	O
11	hearing	II	O
12	loss	II	O
13	unreported	O	O
14	in	O	O
15	adults	O	O
16	.	O	O

0	Recessive	O	O
1	mutations	O	O
2	of	O	O
3	the	O	O
4	SLC26A4	O	O
5	PDS	O	O
6	gene	O	O
7	on	O	O
8	chromosome	O	O
9	7q31	O	O
10	can	O	O
11	cause	O	O
12	sensorineural	BI	O
13	hearing	II	O
14	loss	II	O
15	with	O	O
16	goiter	O	O
17	Pendred	BU	O
18	syndrome	IU	O
19	or	O	O
20	non-syndromic	BI	O
21	autosomal	II	O
22	recessive	II	O
23	hearing	II	O
24	loss	II	O
25	DFNB4	O	O
26	.	O	O

0	Although	O	O
1	recent	O	O
2	studies	O	O
3	support	O	O
4	the	O	O
5	potential	O	O
6	therapeutic	O	O
7	benefits	O	O
8	of	O	O
9	targeting	O	O
10	the	O	O
11	skeletal	O	O
12	muscle	O	O
13	in	O	O
14	ALS	BU	O
15	relatively	O	O
16	little	O	O
17	is	O	O
18	known	O	O
19	about	O	O
20	inflammation	O	O
21	and	O	O
22	glial	O	O
23	responses	O	O
24	in	O	O
25	skeletal	O	O
26	muscle	O	O
27	and	O	O
28	near	O	O
29	NMJs	O	O
30	or	O	O
31	how	O	O
32	these	O	O
33	responses	O	O
34	contribute	O	O
35	to	O	O
36	motor	O	O
37	neuron	O	O
38	survival	O	O
39	neuromuscular	O	O
40	innervation	O	O
41	or	O	O
42	motor	BI	O
43	dysfunction	II	O
44	in	O	O
45	ALS	BU	O
46	.	O	O

0	Lysosome-associated	O	O
1	membrane	O	O
2	protein-2	O	O
3	LAMP-2	O	O
4	is	O	O
5	the	O	O
6	gene	O	O
7	responsible	O	O
8	for	O	O
9	Danon	BU	O
10	disease	IU	O
11	which	O	O
12	is	O	O
13	characterized	O	O
14	by	O	O
15	cardiomyopathy	BU	O
16	autophagic	O	O
17	vacuolar	BU	O
18	myopathy	IU	O
19	and	O	O
20	variable	BI	O
21	mental	II	O
22	retardation	II	O
23	.	O	O

0	Despite	O	O
1	epidemiologic	O	O
2	data	O	O
3	showing	O	O
4	that	O	O
5	patients	O	O
6	with	O	O
7	FTD	BU	O
8	may	O	O
9	have	O	O
10	experienced	O	O
11	previous	O	O
12	psychiatric	BI	O
13	disorders	II	O
14	and	O	O
15	that	O	O
16	patients	O	O
17	with	O	O
18	psychotic	O	O
19	disorders	O	O
20	may	O	O
21	develop	O	O
22	dementia	BI	O
23	more	O	O
24	often	O	O
25	than	O	O
26	expected	O	O
27	in	O	O
28	the	O	O
29	nonaffected	O	O
30	population	O	O
31	the	O	O
32	overlap	O	O
33	between	O	O
34	these	O	O
35	two	O	O
36	conditions	O	O
37	has	O	O
38	been	O	O
39	underestimated	O	O
40	.	O	O

0	KS	BU	O
1	is	O	O
2	occasionally	O	O
3	associated	O	O
4	with	O	O
5	deafness	BI	O
6	.	O	O

0	Among	O	O
1	the	O	O
2	"unusual"	O	O
3	patients	O	O
4	two	O	O
5	patients	O	O
6	had	O	O
7	clinical	O	O
8	features	O	O
9	of	O	O
10	charge	BU	O
11	syndrome	IU	O
12	including	O	O
13	choanal	BU	O
14	atresia	IU	O
15	coloboma	O	O
16	cardiac	O	O
17	defects	O	O
18	genitourinary	O	O
19	anomaly	O	O
20	1	O	O
21	2	O	O
22	and	O	O
23	severe	BI	O
24	intellectual	II	O
25	disability	II	O
26	two	O	O
27	patients	O	O
28	had	O	O
29	craniosynostosis	BU	O
30	and	O	O
31	three	O	O
32	patients	O	O
33	had	O	O
34	mild	BI	O
35	intellectual	II	O
36	disability	II	O
37	.	O	O

0	Hearing	BI	O
1	loss	II	O
2	in	O	O
3	Fechtner	BU	O
4	syndrome	IU	O
5	develops	O	O
6	from	O	O
7	the	O	O
8	second	O	O
9	decade	O	O
10	of	O	O
11	life	O	O
12	and	O	O
13	progresses	O	O
14	slowly	O	O
15	with	O	O
16	several	O	O
17	episodes	O	O
18	of	O	O
19	sudden	BI	O
20	deafness	II	O
21	.	O	O

0	When	O	O
1	severe	O	O
2	congenital	BU	O
3	contractural	IU	O
4	arachnodactyly	IU	O
5	is	O	O
6	diagnosed	O	O
7	in	O	O
8	the	O	O
9	newborn	O	O
10	period	O	O
11	parents	O	O
12	need	O	O
13	to	O	O
14	be	O	O
15	aware	O	O
16	that	O	O
17	long-term	O	O
18	survival	O	O
19	is	O	O
20	possible	O	O
21	particularly	O	O
22	if	O	O
23	no	O	O
24	significant	O	O
25	extraskeletal	O	O
26	complications	O	O
27	are	O	O
28	present	O	O
29	and	O	O
30	that	O	O
31	significant	O	O
32	neurodevelopmental	BI	O
33	delay	II	O
34	may	O	O
35	occur	O	O
36	.	O	O

0	To	O	O
1	assess	O	O
2	the	O	O
3	role	O	O
4	of	O	O
5	oxidative	O	O
6	stress	O	O
7	in	O	O
8	lipid	O	O
9	peroxidation	O	O
10	in	O	O
11	Friedreich	BI	O
12	ataxia	II	O
13	we	O	O
14	used	O	O
15	the	O	O
16	novel	O	O
17	approach	O	O
18	of	O	O
19	treating	O	O
20	Friedreich	BU	O
21	ataxia	IU	O
22	cell	O	O
23	models	O	O
24	with	O	O
25	polyunsaturated	O	O
26	fatty	O	O
27	acids	O	O
28	PUFAs	O	O
29	deuterated	O	O
30	at	O	O
31	bis-allylic	O	O
32	sites	O	O
33	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	boy	O	O
4	with	O	O
5	developmental	BI	O
6	delay	II	O
7	and	O	O
8	multiple	O	O
9	anomalies	O	O
10	consistent	O	O
11	with	O	O
12	the	O	O
13	supernumerary	BU	O
14	der22	IU	O
15	syndrome	IU	O
16	.	O	O

0	In	O	O
1	the	O	O
2	41	O	O
3	CS	BU	O
4	type	IU	O
5	1	IU	O
6	patients	O	O
7	seven	O	O
8	findings	O	O
9	i.e.	O	O
10	failure	O	O
11	to	O	O
12	thrive	O	O
13	photosensitivity	O	O
14	deafness	BI	O
15	characteristic	O	O
16	facial	O	O
17	appearance	O	O
18	of	O	O
19	CS	O	O
20	[sunken	O	O
21	eyes]	O	O
22	foot	O	O
23	joint	O	O
24	contracture	O	O
25	intellectual	BI	O
26	disability	II	O
27	and	O	O
28	basal	O	O
29	ganglia	O	O
30	calcification	O	O
31	on	O	O
32	computed	O	O
33	tomography	O	O
34	[CT]	O	O
35	were	O	O
36	observed	O	O
37	in	O	O
38	>90%	O	O
39	of	O	O
40	patients	O	O
41	.	O	O

0	All	O	O
1	three	O	O
2	children	O	O
3	were	O	O
4	adversely	O	O
5	affected	O	O
6	by	O	O
7	the	O	O
8	fetopathy	O	O
9	of	O	O
10	the	O	O
11	maternal	BU	O
12	phenylketonuria	IU	O
13	syndrome	IU	O
14	each	O	O
15	with	O	O
16	evidence	O	O
17	of	O	O
18	growth	BI	O
19	failure	II	O
20	and	O	O
21	impaired	O	O
22	neurodevelopment	O	O
23	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	multiple	O	O
6	congenital	O	O
7	anomaly	O	O
8	syndrome	O	O
9	caused	O	O
10	by	O	O
11	heterozygous	O	O
12	germline	O	O
13	HRAS	O	O
14	mutations	O	O
15	which	O	O
16	is	O	O
17	characterized	O	O
18	by	O	O
19	intellectual	BI	O
20	disability	II	O
21	growth	BI	O
22	retardation	II	O
23	distinctive	O	O
24	facies	O	O
25	loose	O	O
26	skin	O	O
27	cardiomyopathy	BU	O
28	and	O	O
29	a	O	O
30	preposition	O	O
31	to	O	O
32	malignancies	O	O
33	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	SLC26A4	O	O
4	gene	O	O
5	cause	O	O
6	both	O	O
7	Pendred	BU	O
8	syndrome	IU	O
9	and	O	O
10	autosomal	BI	O
11	recessive	II	O
12	nonsyndromic	II	O
13	hearing	II	O
14	loss	II	O
15	ARNSHL	O	O
16	at	O	O
17	the	O	O
18	DFNB4	O	O
19	locus	O	O
20	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	syndromic	O	O
5	form	O	O
6	of	O	O
7	mental	BI	O
8	retardation	II	O
9	caused	O	O
10	by	O	O
11	mutations	O	O
12	of	O	O
13	the	O	O
14	Rps6ka3	O	O
15	gene	O	O
16	encoding	O	O
17	ribosomal	O	O
18	s6	O	O
19	kinase	O	O
20	RSK2	O	O
21	.	O	O

0	Fragile	BU	O
1	X	IU	O
2	syndrome	IU	O
3	FXS	IU	O
4	is	O	O
5	the	O	O
6	most	O	O
7	frequent	O	O
8	inherited	O	O
9	form	O	O
10	of	O	O
11	human	O	O
12	mental	BI	O
13	retardation	II	O
14	.	O	O

0	We	O	O
1	advocate	O	O
2	brain-imaging	O	O
3	studies	O	O
4	of	O	O
5	patients	O	O
6	with	O	O
7	LEOPARD	BU	O
8	syndrome	IU	O
9	and	O	O
10	neurologic	O	O
11	abnormalities	O	O
12	such	O	O
13	as	O	O
14	developmental	BI	O
15	delay	II	O
16	or	O	O
17	epilepsy	O	O
18	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	new	O	O
4	visual	BI	O
5	problem	II	O
6	associated	O	O
7	with	O	O
8	DRPLA	BU	O
9	optic	BI	O
10	atrophy	II	O
11	.	O	O

0	To	O	O
1	review	O	O
2	what	O	O
3	progress	O	O
4	has	O	O
5	been	O	O
6	made	O	O
7	towards	O	O
8	the	O	O
9	application	O	O
10	of	O	O
11	ocular	O	O
12	gene	O	O
13	therapy	O	O
14	to	O	O
15	prevent	O	O
16	progressive	BI	O
17	vision	II	O
18	loss	II	O
19	in	O	O
20	patients	O	O
21	affected	O	O
22	by	O	O
23	choroideremia	BU	O
24	.	O	O

0	CONCLUSION	O	O
1	Stapedial	O	O
2	fixation	O	O
3	can	O	O
4	be	O	O
5	the	O	O
6	cause	O	O
7	of	O	O
8	hearing	BI	O
9	impairment	II	O
10	in	O	O
11	Stickler	BU	O
12	syndrome	IU	O
13	type	IU	O
14	I	IU	O
15	COL2A1	O	O
16	.	O	O

0	Our	O	O
1	findings	O	O
2	suggest	O	O
3	that	O	O
4	the	O	O
5	MDS	O	O
6	PDD	O	O
7	short	O	O
8	screening	O	O
9	test	O	O
10	may	O	O
11	be	O	O
12	useful	O	O
13	for	O	O
14	the	O	O
15	diagnosis	O	O
16	of	O	O
17	MSA	BU	O
18	dementia	BI	O
19	.	O	O

0	The	O	O
1	patients	O	O
2	had	O	O
3	typical	O	O
4	cerebellar	BI	O
5	ataxia	II	O
6	achromatopsia	BU	O
7	and	O	O
8	macular	O	O
9	degeneration	O	O
10	and	O	O
11	displayed	O	O
12	a	O	O
13	rare	O	O
14	phenotype	O	O
15	manifesting	O	O
16	as	O	O
17	a	O	O
18	combination	O	O
19	of	O	O
20	cerebellar	BI	O
21	ataxia	II	O
22	and	O	O
23	craniocervical	O	O
24	dystonia	O	O
25	.	O	O

0	Derivative	BU	O
1	22	IU	O
2	[der22]	IU	O
3	syndrome	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	disorder	O	O
8	associated	O	O
9	with	O	O
10	multiple	O	O
11	congenital	O	O
12	anomalies	O	O
13	including	O	O
14	pre-auricular	O	O
15	skin	O	O
16	tags	O	O
17	or	O	O
18	pits	O	O
19	conotruncal	O	O
20	heart	O	O
21	defects	O	O
22	and	O	O
23	profound	BI	O
24	mental	II	O
25	retardation	II	O
26	.	O	O

0	Pendred	BU	O
1	syndrome	IU	O
2	is	O	O
3	one	O	O
4	of	O	O
5	the	O	O
6	most	O	O
7	common	O	O
8	hereditary	O	O
9	determined	O	O
10	diseases	O	O
11	in	O	O
12	patients	O	O
13	with	O	O
14	syndromic	BI	O
15	sensorineural	II	O
16	hearing	II	O
17	impairment	II	O
18	.	O	O

0	However	O	O
1	nowadays	O	O
2	the	O	O
3	previously	O	O
4	reported	O	O
5	cases	O	O
6	as	O	O
7	having	O	O
8	Ramsay	BU	O
9	Hunt	IU	O
10	syndrome	IU	O
11	associated	O	O
12	with	O	O
13	Friedreichs	BI	O
14	ataxia	II	O
15	are	O	O
16	regarded	O	O
17	as	O	O
18	having	O	O
19	been	O	O
20	suffered	O	O
21	from	O	O
22	MERRF	O	O
23	.	O	O

0	Other	O	O
1	features	O	O
2	characteristic	O	O
3	of	O	O
4	the	O	O
5	syndrome	O	O
6	included	O	O
7	intrauterine	O	O
8	growth	BI	O
9	retardation	II	O
10	IUGR	O	O
11	slow	O	O
12	weight	O	O
13	gain	O	O
14	frequent	O	O
15	illness	O	O
16	triangular	O	O
17	face	O	O
18	anteverted	O	O
19	ears	O	O
20	telecanthus	BU	O
21	deeply	O	O
22	set	O	O
23	eyes	O	O
24	wide	O	O
25	nasal	O	O
26	bridge	O	O
27	hypoplastic	O	O
28	alae	O	O
29	nasi	O	O
30	chin	O	O
31	dimple	O	O
32	micrognathia	O	O
33	clinodactyly	O	O
34	partial	O	O
35	lipodystrophy	O	O
36	hearing	BI	O
37	loss	II	O
38	functional	O	O
39	heart	O	O
40	murmur	O	O
41	delayed	O	O
42	bone	O	O
43	age	O	O
44	delayed	BI	O
45	speech	II	O
46	normal	O	O
47	intellect	O	O
48	glucose	O	O
49	intolerance	O	O
50	and	O	O
51	insulinopenic	O	O
52	diabetes	O	O
53	.	O	O

0	Heterozygous	O	O
1	germline	O	O
2	mutations	O	O
3	in	O	O
4	the	O	O
5	proto-oncogene	O	O
6	HRAS	O	O
7	cause	O	O
8	Costello	BU	O
9	syndrome	IU	O
10	CS	IU	O
11	an	O	O
12	intellectual	BI	O
13	disability	II	O
14	condition	O	O
15	with	O	O
16	severe	O	O
17	failure	O	O
18	to	O	O
19	thrive	O	O
20	cardiac	O	O
21	abnormalities	O	O
22	predisposition	O	O
23	to	O	O
24	tumors	O	O
25	and	O	O
26	neurologic	O	O
27	abnormalities	O	O
28	.	O	O

0	This	O	O
1	suggests	O	O
2	that	O	O
3	while	O	O
4	SCA17	BU	O
5	typically	O	O
6	slowly	O	O
7	progresses	O	O
8	over	O	O
9	years	O	O
10	its	O	O
11	repertoire	O	O
12	of	O	O
13	presentations	O	O
14	should	O	O
15	be	O	O
16	expanded	O	O
17	to	O	O
18	include	O	O
19	rapidly	O	O
20	progressive	O	O
21	isolated	O	O
22	ataxia	BI	O
23	resembling	O	O
24	paraneoplastic	O	O
25	disorders	O	O
26	or	O	O
27	prion	O	O
28	disease	O	O
29	.	O	O

0	In	O	O
1	rare	O	O
2	recessively	O	O
3	inherited	O	O
4	CARASIL	BU	O
5	the	O	O
6	clinical	O	O
7	picture	O	O
8	and	O	O
9	white	O	O
10	matter	O	O
11	changes	O	O
12	are	O	O
13	similar	O	O
14	as	O	O
15	in	O	O
16	CADASIL	BU	O
17	but	O	O
18	cognitive	BI	O
19	decline	II	O
20	begins	O	O
21	earlier	O	O
22	.	O	O

0	In	O	O
1	TRPS	BU	O
2	II	IU	O
3	intellectual	BI	O
4	disability	II	O
5	is	O	O
6	present	O	O
7	in	O	O
8	most	O	O
9	but	O	O
10	not	O	O
11	all	O	O
12	and	O	O
13	again	O	O
14	typically	O	O
15	mild	O	O
16	to	O	O
17	moderate	O	O
18	in	O	O
19	severity	O	O
20	.	O	O

0	The	O	O
1	moderate	O	O
2	phenotypic	O	O
3	expression	O	O
4	of	O	O
5	this	O	O
6	mutation	O	O
7	extends	O	O
8	the	O	O
9	CLS	BU	O
10	phenotype	O	O
11	to	O	O
12	include	O	O
13	less	BI	O
14	severe	II	O
15	mental	II	O
16	retardation	II	O
17	and	O	O
18	minor	O	O
19	hitherto	O	O
20	unreported	O	O
21	signs	O	O
22	.	O	O

0	Choroideremia	BU	O
1	is	O	O
2	an	O	O
3	X-linked	O	O
4	recessive	O	O
5	disease	O	O
6	that	O	O
7	leads	O	O
8	to	O	O
9	blindness	BI	O
10	due	O	O
11	to	O	O
12	mutations	O	O
13	in	O	O
14	the	O	O
15	CHM	O	O
16	gene	O	O
17	which	O	O
18	encodes	O	O
19	the	O	O
20	Rab	O	O
21	escort	O	O
22	protein	O	O
23	1	O	O
24	REP1	O	O
25	.	O	O

0	Conclusively	O	O
1	most	O	O
2	bvFTD	BU	O
3	patients	O	O
4	fulfill	O	O
5	current	O	O
6	diagnostic	O	O
7	criteria	O	O
8	at	O	O
9	first	O	O
10	admission	O	O
11	whereas	O	O
12	a	O	O
13	relatively	O	O
14	small	O	O
15	group	O	O
16	is	O	O
17	characterized	O	O
18	by	O	O
19	mild	BI	O
20	behavioral	II	O
21	and	II	O
22	or	II	O
23	cognitive	II	O
24	abnormalities	II	O
25	in	O	O
26	spite	O	O
27	of	O	O
28	frontotemporal	O	O
29	gray	O	O
30	matter	O	O
31	atrophy	O	O
32	.	O	O

0	Frontotemporal	BU	O
1	dementia	IU	O
2	FTD	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	frequently	O	O
7	occurring	O	O
8	dementia	BI	O
9	in	O	O
10	the	O	O
11	presenile	O	O
12	population	O	O
13	.	O	O

0	Our	O	O
1	findings	O	O
2	may	O	O
3	help	O	O
4	to	O	O
5	explain	O	O
6	locomotor	BI	O
7	and	II	O
8	cognitive	II	O
9	deficits	II	O
10	seen	O	O
11	in	O	O
12	mice	O	O
13	with	O	O
14	MPS	BU	O
15	I	IU	O
16	.	O	O

0	Deficiency	BU	O
1	of	IU	O
2	liver	IU	O
3	arginase	IU	O
4	AI	IU	O
5	causes	IU	O
6	hyperargininemia	BU	O
7	OMIM	IU	O
8	207800	O	O
9	a	O	O
10	disorder	O	O
11	characterized	O	O
12	by	O	O
13	progressive	BI	O
14	mental	II	O
15	impairment	II	O
16	growth	BI	O
17	retardation	II	O
18	and	O	O
19	spasticity	O	O
20	and	O	O
21	punctuated	O	O
22	by	O	O
23	sometimes	O	O
24	fatal	O	O
25	episodes	O	O
26	of	O	O
27	hyperammonemia	O	O
28	.	O	O

0	Three	O	O
1	children	O	O
2	were	O	O
3	diagnosed	O	O
4	with	O	O
5	the	O	O
6	intermediate	O	O
7	form	O	O
8	of	O	O
9	maple	BU	O
10	syrup	IU	O
11	urine	IU	O
12	disease	IU	O
13	during	O	O
14	routine	O	O
15	evaluation	O	O
16	of	O	O
17	mental	BI	O
18	retardation	II	O
19	.	O	O

0	It	O	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	a	O	O
5	distinctive	O	O
6	facial	O	O
7	appearance	O	O
8	in	O	O
9	association	O	O
10	with	O	O
11	intellectual	BI	O
12	disability	II	O
13	ID	O	O
14	and	O	O
15	variable	O	O
16	other	O	O
17	features	O	O
18	including	O	O
19	agenesis	O	O
20	of	O	O
21	the	O	O
22	corpus	O	O
23	callosum	O	O
24	seizures	O	O
25	congenital	O	O
26	heart	O	O
27	defects	O	O
28	microcephaly	O	O
29	short	O	O
30	stature	O	O
31	hypotonia	O	O
32	and	O	O
33	Hirschsprung	BU	O
34	disease	IU	O
35	.	O	O

0	Huntingtons	BU	O
1	disease	IU	O
2	HD	O	O
3	is	O	O
4	a	O	O
5	neurodegenerative	O	O
6	disorder	O	O
7	of	O	O
8	the	O	O
9	central	O	O
10	nervous	O	O
11	system	O	O
12	characterised	O	O
13	by	O	O
14	the	O	O
15	presence	O	O
16	of	O	O
17	choreic	BI	O
18	abnormal	II	O
19	movements	II	O
20	behavioural	BI	O
21	or	II	O
22	psychiatric	II	O
23	disturbances	II	O
24	and	O	O
25	dementia	BI	O
26	.	O	O

0	Cri-du-chat	BU	O
1	is	O	O
2	a	O	O
3	rare	O	O
4	congenital	O	O
5	syndrome	O	O
6	characterized	O	O
7	by	O	O
8	intellectual	BI	O
9	disability	II	O
10	severe	BI	O
11	speech	II	O
12	developmental	II	O
13	delay	II	O
14	dysmorphic	O	O
15	features	O	O
16	and	O	O
17	additional	O	O
18	syndromic	O	O
19	findings	O	O
20	.	O	O

0	The	O	O
1	prevalence	O	O
2	of	O	O
3	hearing	BI	O
4	impairment	II	O
5	was	O	O
6	significantly	O	O
7	higher	O	O
8	in	O	O
9	CH	BU	O
10	patients	O	O
11	than	O	O
12	in	O	O
13	32	O	O
14	age-matched	O	O
15	control	O	O
16	subjects	O	O
17	with	O	O
18	no	O	O
19	CH	O	O
20	2=6.3	O	O
21	p<0.025	O	O
22	.	O	O

0	Severe	BU	O
1	achondroplasia	IU	O
2	with	IU	O
3	developmental	IU	O
4	delay	IU	O
5	and	IU	O
6	acanthosis	IU	O
7	nigricans	IU	O
8	SADDAN	IU	O
9	is	O	O
10	an	O	O
11	extremely	O	O
12	rare	O	O
13	severe	O	O
14	skeletal	O	O
15	dysplasia	O	O
16	characterized	O	O
17	by	O	O
18	significant	O	O
19	developmental	BI	O
20	delay	II	O
21	brain	O	O
22	structural	O	O
23	abnormalities	O	O
24	hearing	BI	O
25	loss	II	O
26	and	O	O
27	acanthosis	O	O
28	nigricans	O	O
29	.	O	O

0	Neuralgic	BU	O
1	amyotrophy--also	IU	O
2	known	O	O
3	as	O	O
4	Parsonage-Turner	O	O
5	syndrome	O	O
6	or	O	O
7	brachial	BU	O
8	plexus	IU	O
9	neuritis--is	IU	O
10	a	O	O
11	distinct	O	O
12	and	O	O
13	painful	O	O
14	peripheral	O	O
15	neuropathy	O	O
16	that	O	O
17	causes	O	O
18	episodes	O	O
19	of	O	O
20	multifocal	BI	O
21	paresis	II	O
22	and	O	O
23	sensory	BI	O
24	loss	II	O
25	in	O	O
26	a	O	O
27	brachial	O	O
28	plexus	O	O
29	distribution	O	O
30	with	O	O
31	concomitant	O	O
32	involvement	O	O
33	of	O	O
34	other	O	O
35	PNS	O	O
36	structures	O	O
37	such	O	O
38	as	O	O
39	the	O	O
40	lumbosacral	O	O
41	plexus	O	O
42	or	O	O
43	phrenic	O	O
44	nerve	O	O
45	in	O	O
46	a	O	O
47	large	O	O
48	number	O	O
49	of	O	O
50	patients	O	O
51	.	O	O

0	Clinical	O	O
1	manifestations	O	O
2	of	O	O
3	PMD	BU	O
4	are	O	O
5	variable	O	O
6	and	O	O
7	major	O	O
8	features	O	O
9	include	O	O
10	progressive	O	O
11	nystagmus	O	O
12	spasticity	O	O
13	tremor	O	O
14	ataxia	BI	O
15	and	O	O
16	psychomotor	BI	O
17	delay	II	O
18	.	O	O

0	In	O	O
1	contrast	O	O
2	the	O	O
3	cellular	O	O
4	basis	O	O
5	of	O	O
6	the	O	O
7	visual	BI	O
8	defect	II	O
9	is	O	O
10	less	O	O
11	well	O	O
12	understood	O	O
13	as	O	O
14	this	O	O
15	phenotype	O	O
16	is	O	O
17	absent	O	O
18	in	O	O
19	almost	O	O
20	all	O	O
21	the	O	O
22	USH	BU	O
23	mouse	O	O
24	models	O	O
25	that	O	O
26	faithfully	O	O
27	mimic	O	O
28	the	O	O
29	human	O	O
30	hearing	BI	O
31	impairment	II	O
32	.	O	O

0	In	O	O
1	contrast	O	O
2	to	O	O
3	this	O	O
4	picture	O	O
5	the	O	O
6	present	O	O
7	case	O	O
8	report	O	O
9	describes	O	O
10	the	O	O
11	cognitive	O	O
12	and	O	O
13	behavioural	O	O
14	profile	O	O
15	of	O	O
16	a	O	O
17	young	O	O
18	female	O	O
19	with	O	O
20	cri	BU	O
21	du	IU	O
22	chat	IU	O
23	syndrome	IU	O
24	who	O	O
25	displays	O	O
26	no	O	O
27	evidence	O	O
28	of	O	O
29	severe	BI	O
30	learning	II	O
31	disability	II	O
32	.	O	O

0	CONCLUSIONS	O	O
1	These	O	O
2	results	O	O
3	highlight	O	O
4	the	O	O
5	significance	O	O
6	of	O	O
7	SOX10	O	O
8	haploinsufficiency	O	O
9	as	O	O
10	a	O	O
11	genetic	O	O
12	cause	O	O
13	of	O	O
14	KS	BU	O
15	with	O	O
16	deafness	BI	O
17	.	O	O

0	We	O	O
1	report	O	O
2	a	O	O
3	ten-month	O	O
4	old	O	O
5	boy	O	O
6	with	O	O
7	Canavan	BU	O
8	disease	IU	O
9	who	O	O
10	presented	O	O
11	with	O	O
12	global	BI	O
13	developmental	II	O
14	delay	II	O
15	seizures	O	O
16	abnormal	BU	O
17	eye	IU	O
18	movements	IU	O
19	and	O	O
20	microcephaly	O	O
21	.	O	O

0	Loss-of	O	O
1	function	O	O
2	mutations	O	O
3	in	O	O
4	the	O	O
5	RPS6KA3	O	O
6	gene	O	O
7	which	O	O
8	encodes	O	O
9	the	O	O
10	RSK2	O	O
11	protein	O	O
12	have	O	O
13	been	O	O
14	implicated	O	O
15	in	O	O
16	Coffin-Lowry	BU	O
17	Syndrome	IU	O
18	CLS	IU	O
19	an	O	O
20	X-linked	BI	O
21	mental	II	O
22	retardation	II	O
23	disorder	II	O
24	associated	O	O
25	with	O	O
26	cognitive	BI	O
27	deficits	II	O
28	and	O	O
29	behavioral	BI	O
30	impairments	II	O
31	.	O	O

0	Despite	O	O
1	a	O	O
2	general	O	O
3	favorable	O	O
4	outcome	O	O
5	more	O	O
6	severe	O	O
7	epilepsy	O	O
8	syndromes	O	O
9	may	O	O
10	develop	O	O
11	after	O	O
12	MEI	BU	O
13	and	O	O
14	mental	BI	O
15	retardation	II	O
16	is	O	O
17	sometimes	O	O
18	observed	O	O
19	.	O	O

0	These	O	O
1	cases	O	O
2	suggest	O	O
3	that	O	O
4	there	O	O
5	may	O	O
6	be	O	O
7	an	O	O
8	increased	O	O
9	incidence	O	O
10	of	O	O
11	mental	BI	O
12	retardation	II	O
13	in	O	O
14	individuals	O	O
15	with	O	O
16	TBS	BU	O
17	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	21-year	O	O
5	old	O	O
6	woman	O	O
7	with	O	O
8	intellectual	BI	O
9	disability	II	O
10	autistic	BI	O
11	features	II	O
12	severe	O	O
13	obesity	O	O
14	and	O	O
15	facial	O	O
16	dysmorphisms	O	O
17	suggestive	O	O
18	of	O	O
19	Wolf-Hirschhorn	BU	O
20	syndrome	IU	O
21	WHS	IU	O
22	.	O	O

0	Particularly	O	O
1	schizophrenic	O	O
2	psychosis	O	O
3	attention-deficit	BI	O
4	hyperactivity	BI	O
5	disorder	II	O
6	ADHD	O	O
7	intellectual	BI	O
8	impairment	II	O
9	and	O	O
10	learning	BI	O
11	disabilities	II	O
12	seizures	O	O
13	and	O	O
14	motoric	BI	O
15	abnormalities	II	O
16	have	O	O
17	been	O	O
18	identified	O	O
19	in	O	O
20	patients	O	O
21	with	O	O
22	22q11DS	BU	O
23	.	O	O

0	CADASIL	O	O
1	and	O	O
2	CARASIL	BU	O
3	are	O	O
4	hereditary	O	O
5	small	O	O
6	vessel	O	O
7	diseases	O	O
8	leading	O	O
9	to	O	O
10	vascular	BI	O
11	dementia	II	O
12	.	O	O

0	We	O	O
1	present	O	O
2	an	O	O
3	8-year-old	O	O
4	girl	O	O
5	with	O	O
6	cleidocranial	BU	O
7	dysplasia	IU	O
8	psychomotor	BI	O
9	developmental	II	O
10	delay	II	O
11	poor	O	O
12	wound	O	O
13	healing	O	O
14	and	O	O
15	a	O	O
16	6p21.2p12.3	O	O
17	deletion	O	O
18	detected	O	O
19	by	O	O
20	aCGH	O	O
21	.	O	O

0	CONCLUSION	O	O
1	Patients	O	O
2	with	O	O
3	MWS	BU	O
4	are	O	O
5	at	O	O
6	risk	O	O
7	of	O	O
8	developing	O	O
9	progressive	BI	O
10	sensorineural	II	O
11	hearing	II	O
12	loss	II	O
13	without	II	O
14	vestibular	II	O
15	involvement	II	O
16	.	O	O

0	AHDS	BU	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	severe	BI	O
5	intellectual	II	O
6	deficiency	II	O
7	neuromuscular	O	O
8	impairment	O	O
9	and	O	O
10	brain	O	O
11	hypothyroidism	O	O
12	.	O	O

0	These	O	O
1	patients	O	O
2	constituted	O	O
3	a	O	O
4	particular	O	O
5	form	O	O
6	of	O	O
7	congenital	BU	O
8	muscular	IU	O
9	dystrophy	IU	O
10	with	O	O
11	a	O	O
12	combination	O	O
13	of	O	O
14	severe	BI	O
15	motor	II	O
16	delay	II	O
17	mental	BI	O
18	retardation	II	O
19	partial	O	O
20	merosin	O	O
21	deficiency	O	O
22	and	O	O
23	cerebellar	O	O
24	cysts	O	O
25	.	O	O

0	Williams	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	BI	O
5	congenital	II	O
6	developmental	II	O
7	disorder	II	O
8	characterized	O	O
9	by	O	O
10	a	O	O
11	constellation	O	O
12	of	O	O
13	distinctive	O	O
14	facial	O	O
15	dysmorphisms	O	O
16	mental	BI	O
17	retardation	II	O
18	cardiovascular	O	O
19	anomalies	O	O
20	infantile	O	O
21	hypercalcemia	O	O
22	delayed	O	O
23	developmental	O	O
24	milestones	O	O
25	dental	O	O
26	and	O	O
27	musculoskeletal	O	O
28	anomalies	O	O
29	and	O	O
30	distinctive	O	O
31	personality	O	O
32	traits	O	O
33	.	O	O

0	Usually	O	O
1	late-onset	O	O
2	NKH	BU	O
3	only	O	O
4	manifests	O	O
5	mild	BI	O
6	mental	II	O
7	deterioration	II	O
8	character	O	O
9	change	O	O
10	seizure	O	O
11	ataxia	BI	O
12	or	O	O
13	spastic	BI	O
14	paraparesis	II	O
15	which	O	O
16	sometimes	O	O
17	makes	O	O
18	difficulty	O	O
19	in	O	O
20	differentiating	O	O
21	this	O	O
22	disease	O	O
23	from	O	O
24	other	O	O
25	hereditary	BI	O
26	cerebellar	II	O
27	ataxia	II	O
28	or	O	O
29	spastic	BI	O
30	paraparesis	II	O
31	.	O	O

0	We	O	O
1	retrospectively	O	O
2	reviewed	O	O
3	80	O	O
4	patients	O	O
5	with	O	O
6	nonsyndromic	O	O
7	mitochondrial	O	O
8	cytopathies	O	O
9	ie	O	O
10	not	O	O
11	Kearns-Sayre	BU	O
12	syndrome	IU	O
13	myoclonus	O	O
14	epilepsy	O	O
15	associated	O	O
16	with	O	O
17	ragged	O	O
18	red	O	O
19	fibers	O	O
20	[MERRF]	O	O
21	mitochondrial	O	O
22	encephalomyopathy	O	O
23	lactic	O	O
24	acidosis	O	O
25	and	O	O
26	strokelike	O	O
27	episodes	O	O
28	[MELAS]	BU	O
29	neuropathy	BI	O
30	ataxia	II	O
31	and	O	O
32	retinitis	BU	O
33	pigmentosa	IU	O
34	Leigh	O	O
35	disease	O	O
36	maternally	O	O
37	inherited	O	O
38	diabetes	O	O
39	and	O	O
40	deafness	BI	O
41	and	O	O
42	myoneurogastrointestinal	O	O
43	disorder	O	O
44	and	O	O
45	encephalopathy	O	O
46	and	O	O
47	found	O	O
48	10	O	O
49	cases	O	O
50	of	O	O
51	optic	O	O
52	nerve	O	O
53	hypoplasia	O	O
54	.	O	O

0	Mitochondrial	O	O
1	ornithine	O	O
2	transporter	O	O
3	deficiency	O	O
4	or	O	O
5	HHH	BU	O
6	syndrome	IU	O
7	is	O	O
8	a	O	O
9	metabolic	O	O
10	disorder	O	O
11	resulting	O	O
12	in	O	O
13	various	O	O
14	neurologic	O	O
15	symptoms	O	O
16	including	O	O
17	mental	BI	O
18	retardation	II	O
19	spastic	BI	O
20	paraparesis	II	O
21	with	II	O
22	pyramidal	II	O
23	signs	II	O
24	cerebellar	BI	O
25	ataxia	II	O
26	and	O	O
27	episodic	O	O
28	disturbance	O	O
29	of	O	O
30	consciousness	O	O
31	or	O	O
32	coma	O	O
33	caused	O	O
34	by	O	O
35	hyperammonemia	O	O
36	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	the	O	O
4	case	O	O
5	of	O	O
6	a	O	O
7	17-year-old	O	O
8	boy	O	O
9	with	O	O
10	clinical	O	O
11	features	O	O
12	compatible	O	O
13	with	O	O
14	Lowry-Wood	BU	O
15	syndrome	IU	O
16	microcephaly	O	O
17	short	O	O
18	stature	O	O
19	multiple	BU	O
20	epiphyseal	IU	O
21	dysplasia	IU	O
22	tapetoretinal	BI	O
23	degeneration	II	O
24	and	O	O
25	mental	BI	O
26	retardation	II	O
27	.	O	O

0	The	O	O
1	Wolf-Hirschhorn	BU	O
2	syndrome	IU	O
3	WHS	IU	O
4	is	O	O
5	a	O	O
6	rare	O	O
7	genetic	O	O
8	condition	O	O
9	presenting	O	O
10	with	O	O
11	severe	BI	O
12	mental	II	O
13	disability	II	O
14	growth	BI	O
15	retardation	II	O
16	muscular	O	O
17	hypotonia	O	O
18	seizures	O	O
19	craniofacial	O	O
20	abnormalities	O	O
21	and	O	O
22	defects	O	O
23	in	O	O
24	the	O	O
25	cardiovascular	O	O
26	genitourinary	O	O
27	and	O	O
28	digestive	O	O
29	apparata	O	O
30	.	O	O

0	Cognitive	BI	O
1	impairments	II	O
2	in	O	O
3	ataxia-telangiectasia	BU	O
4	present	O	O
5	early	O	O
6	coinciding	O	O
7	with	O	O
8	cerebellar	O	O
9	pathology	O	O
10	and	O	O
11	are	O	O
12	characteristic	O	O
13	of	O	O
14	the	O	O
15	cerebellar	O	O
16	cognitive	O	O
17	affective	O	O
18	syndrome	O	O
19	.	O	O

0	Joubert	BU	O
1	syndrome	IU	O
2	JS	IU	O
3	is	O	O
4	a	O	O
5	clinically	O	O
6	and	O	O
7	genetically	O	O
8	heterogeneous	O	O
9	ciliopathy	BU	O
10	characterized	O	O
11	by	O	O
12	episodic	O	O
13	hyperpnea	O	O
14	and	O	O
15	apnea	O	O
16	hypotonia	O	O
17	ataxia	BI	O
18	cognitive	BI	O
19	impairment	II	O
20	and	O	O
21	ocular	BI	O
22	motor	II	O
23	apraxia	II	O
24	.	O	O

0	In	O	O
1	the	O	O
2	group	O	O
3	of	O	O
4	congenital	O	O
5	myopathic	O	O
6	dystrophies	O	O
7	associated	O	O
8	with	O	O
9	mental	BI	O
10	retardation	II	O
11	and	O	O
12	structural	O	O
13	brain	O	O
14	abnormalities	O	O
15	two	O	O
16	main	O	O
17	entities	O	O
18	are	O	O
19	genetically	O	O
20	characterized	O	O
21	1	O	O
22	Fukuyama	BU	O
23	congenital	IU	O
24	myopathic	IU	O
25	dystrophy	IU	O
26	affecting	O	O
27	the	O	O
28	Japanese	O	O
29	population	O	O
30	is	O	O
31	due	O	O
32	to	O	O
33	fukutin	O	O
34	gene	O	O
35	mutations	O	O
36	and	O	O
37	2	O	O
38	the	O	O
39	muscle	BU	O
40	eye	IU	O
41	brain	IU	O
42	syndrome	IU	O
43	assigned	O	O
44	to	O	O
45	chromosome	O	O
46	1p32-34	O	O
47	.	O	O

0	Kabuki	BU	O
1	Niikawa-Kuroki	IU	O
2	syndrome	IU	O
3	is	O	O
4	associated	O	O
5	with	O	O
6	growth	BI	O
7	retardation	II	O
8	developmental	BI	O
9	delay	II	O
10	congenital	O	O
11	heart	O	O
12	disease	O	O
13	cleft	BU	O
14	palate	IU	O
15	and	O	O
16	characteristic	O	O
17	facial	O	O
18	features	O	O
19	.	O	O

0	Hereditary	BU	O
1	motor	IU	O
2	and	IU	O
3	sensory	IU	O
4	neuropathy	IU	O
5	associated	O	O
6	with	O	O
7	agenesis	O	O
8	of	O	O
9	the	O	O
10	corpus	O	O
11	callosum	O	O
12	OMIM	O	O
13	218000	O	O
14	is	O	O
15	an	O	O
16	autosomal	O	O
17	recessive	O	O
18	disease	O	O
19	of	O	O
20	early	O	O
21	onset	O	O
22	characterized	O	O
23	by	O	O
24	a	O	O
25	delay	O	O
26	in	O	O
27	developmental	O	O
28	milestones	O	O
29	a	O	O
30	severe	O	O
31	sensory-motor	O	O
32	polyneuropathy	O	O
33	with	O	O
34	areflexia	O	O
35	a	O	O
36	variable	O	O
37	degree	O	O
38	of	O	O
39	agenesis	O	O
40	of	O	O
41	the	O	O
42	corpus	O	O
43	callosum	O	O
44	amyotrophy	O	O
45	hypotonia	O	O
46	and	O	O
47	cognitive	BI	O
48	impairment	II	O
49	.	O	O

0	The	O	O
1	patient	O	O
2	was	O	O
3	diagnosed	O	O
4	with	O	O
5	Cockayne	BU	O
6	syndrome	IU	O
7	in	O	O
8	the	O	O
9	pediatrics	O	O
10	clinic	O	O
11	for	O	O
12	growth	BI	O
13	failure	II	O
14	and	O	O
15	developmental	BI	O
16	delay	II	O
17	.	O	O

0	Three	O	O
1	patients	O	O
2	with	O	O
3	Dent-2	BU	O
4	disease	IU	O
5	had	O	O
6	mild	O	O
7	peripheral	O	O
8	cataract	O	O
9	and	O	O
10	9	O	O
11	patients	O	O
12	were	O	O
13	noted	O	O
14	to	O	O
15	have	O	O
16	some	O	O
17	degree	O	O
18	of	O	O
19	mental	BI	O
20	retardation	II	O
21	.	O	O

0	In	O	O
1	areas	O	O
2	without	O	O
3	expanded	O	O
4	newborn	O	O
5	screening	O	O
6	instead	O	O
7	of	O	O
8	presenting	O	O
9	neonatally	O	O
10	patients	O	O
11	with	O	O
12	arginase	BU	O
13	deficiency	IU	O
14	typically	O	O
15	present	O	O
16	with	O	O
17	spastic	BI	O
18	paraplegia	II	O
19	in	O	O
20	early	O	O
21	childhood	O	O
22	.	O	O

0	Monosomy	BU	O
1	1p36	IU	O
2	is	O	O
3	a	O	O
4	common	O	O
5	subtelomeric	O	O
6	microdeletion	O	O
7	syndrome	O	O
8	characterized	O	O
9	by	O	O
10	craniofacial	O	O
11	dysmorphisms	O	O
12	developmental	BI	O
13	delay	II	O
14	mental	BI	O
15	retardation	II	O
16	hypotonia	O	O
17	epilepsy	O	O
18	cardiovascular	O	O
19	complications	O	O
20	and	O	O
21	hearing	BI	O
22	impairment	II	O
23	deleted	O	O
24	regions	O	O
25	have	O	O
26	been	O	O
27	mapped	O	O
28	within	O	O
29	10.0	O	O
30	Mb	O	O
31	from	O	O
32	the	O	O
33	telomere	O	O
34	in	O	O
35	most	O	O
36	documented	O	O
37	cases	O	O
38	.	O	O

0	Our	O	O
1	results	O	O
2	show	O	O
3	the	O	O
4	difficulty	O	O
5	of	O	O
6	distinguishing	O	O
7	AHDS	BU	O
8	from	O	O
9	patients	O	O
10	with	O	O
11	X-linked	BI	O
12	intellectual	II	O
13	disability	II	O
14	solely	O	O
15	on	O	O
16	the	O	O
17	basis	O	O
18	of	O	O
19	clinical	O	O
20	features	O	O
21	and	O	O
22	biochemical	O	O
23	tests	O	O
24	and	O	O
25	we	O	O
26	advise	O	O
27	screening	O	O
28	for	O	O
29	MCT8	O	O
30	mutations	O	O
31	in	O	O
32	either	O	O
33	young	O	O
34	or	O	O
35	older	O	O
36	patients	O	O
37	with	O	O
38	severe	BI	O
39	intellectual	II	O
40	disability	II	O
41	axial	O	O
42	hypotonia	O	O
43	dystonia	O	O
44	poor	O	O
45	head	O	O
46	control	O	O
47	spastic	BI	O
48	paraplegia	II	O
49	and	O	O
50	athetoid	BI	O
51	movements	II	O
52	even	O	O
53	when	O	O
54	they	O	O
55	have	O	O
56	normal	O	O
57	thyroid	O	O
58	hormone	O	O
59	profiles	O	O
60	.	O	O

0	MPS	BU	O
1	IIIA	IU	O
2	is	O	O
3	an	O	O
4	inherited	O	O
5	neurodegenerative	O	O
6	lysosomal	O	O
7	storage	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	cognitive	BI	O
12	impairment	II	O
13	sleepwake	O	O
14	cycle	O	O
15	disturbance	O	O
16	speech	BI	O
17	difficulties	II	O
18	eventual	BI	O
19	mental	II	O
20	regression	II	O
21	and	O	O
22	early	O	O
23	death	O	O
24	.	O	O

0	Frontotemporal	BU	O
1	dementia	IU	O
2	is	O	O
3	a	O	O
4	common	O	O
5	type	O	O
6	of	O	O
7	dementia	BI	O
8	particularly	O	O
9	in	O	O
10	patients	O	O
11	younger	O	O
12	than	O	O
13	65	O	O
14	years	O	O
15	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	human	O	O
4	mitochondrial	O	O
5	ATP6	O	O
6	gene	O	O
7	encoding	O	O
8	ATP	O	O
9	synthase	O	O
10	subunit	O	O
11	a	O	O
12	6	O	O
13	referred	O	O
14	to	O	O
15	as	O	O
16	Atp6p	O	O
17	in	O	O
18	yeast	O	O
19	are	O	O
20	at	O	O
21	the	O	O
22	base	O	O
23	of	O	O
24	neurodegenerative	O	O
25	disorders	O	O
26	like	O	O
27	Neurogenic	BI	O
28	Ataxia	II	O
29	and	O	O
30	Retinitis	O	O
31	Pigmentosa	O	O
32	NARP	O	O
33	Leigh	BU	O
34	syndrome	IU	O
35	LS	IU	O
36	Charcot-Marie-Tooth	BU	O
37	CMT	IU	O
38	and	O	O
39	ataxia	BI	O
40	telangiectasia	II	O
41	.	O	O

0	Subsequent	O	O
1	cytogenetic	O	O
2	analysis	O	O
3	in	O	O
4	her	O	O
5	elder	O	O
6	brother	O	O
7	who	O	O
8	presented	O	O
9	with	O	O
10	learning	BI	O
11	difficulties	II	O
12	showed	O	O
13	partial	O	O
14	trisomy	BU	O
15	18p	IU	O
16	and	O	O
17	the	O	O
18	maternal	O	O
19	karyotype	O	O
20	is	O	O
21	46	O	O
22	XX1518p11.2p11.2	O	O
23	.	O	O

0	Medical	O	O
1	problems	O	O
2	commonly	O	O
3	caused	O	O
4	by	O	O
5	terminal	O	O
6	deletions	BU	O
7	of	IU	O
8	1p36	IU	O
9	include	O	O
10	developmental	BI	O
11	delay	II	O
12	intellectual	BI	O
13	disability	II	O
14	seizures	O	O
15	vision	BI	O
16	problems	II	O
17	hearing	BI	O
18	loss	II	O
19	short	O	O
20	stature	O	O
21	distinctive	O	O
22	facial	O	O
23	features	O	O
24	brain	O	O
25	anomalies	O	O
26	orofacial	O	O
27	clefting	O	O
28	congenital	O	O
29	heart	O	O
30	defects	O	O
31	cardiomyopathy	BU	O
32	and	O	O
33	renal	O	O
34	anomalies	O	O
35	.	O	O

0	Treatment	O	O
1	of	O	O
2	a	O	O
3	Drosophila	O	O
4	model	O	O
5	of	O	O
6	Fragile	BU	O
7	X	IU	O
8	syndrome	IU	O
9	with	O	O
10	metabotropic	O	O
11	glutamate	O	O
12	receptor	O	O
13	mGluR	O	O
14	antagonists	O	O
15	or	O	O
16	lithium	O	O
17	rescues	O	O
18	social	BI	O
19	and	II	O
20	cognitive	II	O
21	impairments	II	O
22	.	O	O

0	Alpers	BU	O
1	disease	IU	O
2	a	O	O
3	neurodegenerative	O	O
4	disease	O	O
5	usually	O	O
6	presents	O	O
7	in	O	O
8	the	O	O
9	first	O	O
10	years	O	O
11	of	O	O
12	life	O	O
13	as	O	O
14	a	O	O
15	progressive	O	O
16	encephalopathy	O	O
17	with	O	O
18	multifocal	O	O
19	myoclonic	O	O
20	seizures	O	O
21	developmental	BI	O
22	regression	II	O
23	cortical	BI	O
24	blindness	II	O
25	and	O	O
26	early	O	O
27	death	O	O
28	.	O	O

0	The	O	O
1	adult	O	O
2	form	O	O
3	of	O	O
4	CHS	BU	O
5	has	O	O
6	a	O	O
7	milder	O	O
8	course	O	O
9	no	O	O
10	lymphohistiocytic	O	O
11	infiltration	O	O
12	and	O	O
13	is	O	O
14	characterized	O	O
15	by	O	O
16	neurological	O	O
17	manifestations	O	O
18	such	O	O
19	as	O	O
20	polyneuropathy	O	O
21	parkinsonism	O	O
22	dementia	BI	O
23	and	O	O
24	ataxia	BI	O
25	.	O	O

0	Dementia	BI	O
1	is	O	O
2	an	O	O
3	exclusion	O	O
4	criterion	O	O
5	in	O	O
6	current	O	O
7	consensus	O	O
8	diagnostic	O	O
9	criteria	O	O
10	while	O	O
11	growing	O	O
12	evidence	O	O
13	suggests	O	O
14	the	O	O
15	occurrence	O	O
16	of	O	O
17	cognitive	BI	O
18	dysfunction	II	O
19	and	O	O
20	even	O	O
21	dementia	BI	O
22	in	O	O
23	multiple	BU	O
24	system	IU	O
25	atrophy	IU	O
26	MSA	O	O
27	patients	O	O
28	.	O	O

0	The	O	O
1	classical	O	O
2	aspartylglucosaminuria	BU	O
3	phenotype	O	O
4	progressive	BI	O
5	speech	II	O
6	delay	II	O
7	psychomotor	BI	O
8	retardation	II	O
9	and	O	O
10	behavioral	BI	O
11	abnormalities	II	O
12	was	O	O
13	observed	O	O
14	in	O	O
15	3	O	O
16	Turkish	O	O
17	siblings	O	O
18	.	O	O

0	In	O	O
1	addition	O	O
2	to	O	O
3	severe	BI	O
4	growth	II	O
5	retardation	II	O
6	and	O	O
7	moderate	BI	O
8	psychomotor	II	O
9	delay	II	O
10	he	O	O
11	presented	O	O
12	a	O	O
13	dysmorphic	O	O
14	syndrome	O	O
15	compatible	O	O
16	with	O	O
17	the	O	O
18	clinical	O	O
19	diagnostic	O	O
20	of	O	O
21	Aarskog	BU	O
22	syndrome	IU	O
23	.	O	O

0	This	O	O
1	condition	O	O
2	termed	O	O
3	the	O	O
4	Allan-Herndon	BU	O
5	syndrome	IU	O
6	appears	O	O
7	distinct	O	O
8	from	O	O
9	other	O	O
10	X-linked	O	O
11	disorders	O	O
12	having	O	O
13	mental	BI	O
14	retardation	II	O
15	muscle	O	O
16	hypoplasia	O	O
17	and	O	O
18	spastic	BI	O
19	paraplegia	II	O
20	.	O	O

0	CHARGE	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	polymalformative	O	O
6	disease	O	O
7	representing	O	O
8	one	O	O
9	of	O	O
10	the	O	O
11	major	O	O
12	causes	O	O
13	of	O	O
14	associated	O	O
15	blindness	BI	O
16	and	O	O
17	deafness	BI	O
18	.	O	O

0	The	O	O
1	present	O	O
2	study	O	O
3	confirmed	O	O
4	mental	BI	O
5	disability	II	O
6	particularly	O	O
7	within	O	O
8	the	O	O
9	moderate	O	O
10	category	O	O
11	as	O	O
12	a	O	O
13	consistent	O	O
14	feature	O	O
15	of	O	O
16	children	O	O
17	and	O	O
18	adults	O	O
19	with	O	O
20	SMS	BU	O
21	.	O	O

0	The	O	O
1	Coffin-Lowry	BU	O
2	syndrome	IU	O
3	CLS	IU	O
4	is	O	O
5	a	O	O
6	syndromic	O	O
7	form	O	O
8	of	O	O
9	intellectual	BI	O
10	disability	II	O
11	caused	O	O
12	by	O	O
13	loss-of-function	O	O
14	of	O	O
15	the	O	O
16	RSK2	O	O
17	serine	O	O
18	threonine	O	O
19	kinase	O	O
20	encoded	O	O
21	by	O	O
22	the	O	O
23	rsk2	O	O
24	gene	O	O
25	.	O	O

0	However	O	O
1	findings	O	O
2	related	O	O
3	to	O	O
4	WS4	BU	O
5	were	O	O
6	variable	O	O
7	Patient	O	O
8	1	O	O
9	had	O	O
10	hypopigmentation	O	O
11	of	O	O
12	the	O	O
13	irides	O	O
14	and	O	O
15	HSCR	O	O
16	Patient	O	O
17	2	O	O
18	had	O	O
19	prominent	O	O
20	bicolored	O	O
21	irides	O	O
22	and	O	O
23	mild	BI	O
24	bilateral	II	O
25	hearing	II	O
26	loss	II	O
27	and	O	O
28	Patient	O	O
29	3	O	O
30	had	O	O
31	only	O	O
32	mild	BI	O
33	unilateral	II	O
34	hearing	II	O
35	loss	II	O
36	.	O	O

0	Herein	O	O
1	we	O	O
2	report	O	O
3	a	O	O
4	13-year-old	O	O
5	male	O	O
6	with	O	O
7	common	BU	O
8	variable	IU	O
9	immunodeficiency	IU	O
10	CVID	IU	O
11	who	O	O
12	was	O	O
13	diagnosed	O	O
14	with	O	O
15	autism	BI	O
16	at	O	O
17	the	O	O
18	age	O	O
19	of	O	O
20	3	O	O
21	years	O	O
22	old	O	O
23	.	O	O

0	Williams	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	neurodevelopmental	BI	O
5	disorder	II	O
6	associated	O	O
7	with	O	O
8	cardiovascular	O	O
9	problems	O	O
10	facial	O	O
11	abnormalities	O	O
12	and	O	O
13	several	BI	O
14	behavioural	II	O
15	and	II	O
16	neurological	II	O
17	disabilities	II	O
18	.	O	O

0	Affected	O	O
1	males	O	O
2	presented	O	O
3	with	O	O
4	mental	BI	O
5	retardation	II	O
6	accompanied	O	O
7	by	O	O
8	postaxial	O	O
9	polydactyly	O	O
10	and	O	O
11	retinitis	BU	O
12	pigmentosa	IU	O
13	.	O	O

0	Two	O	O
1	of	O	O
2	whom	O	O
3	became	O	O
4	symptomatic	O	O
5	with	O	O
6	abnormal	O	O
7	gait	O	O
8	alopecia	BU	O
9	skin	O	O
10	rashes	O	O
11	and	O	O
12	developmental	BI	O
13	delay	II	O
14	.	O	O

0	AIM	O	O
1	We	O	O
2	aimed	O	O
3	to	O	O
4	investigate	O	O
5	the	O	O
6	relationship	O	O
7	between	O	O
8	movement	BI	O
9	disorders	II	O
10	changes	O	O
11	on	O	O
12	brain	O	O
13	magnetic	O	O
14	resonance	O	O
15	imaging	O	O
16	MRI	O	O
17	and	O	O
18	vigabatrin	O	O
19	therapy	O	O
20	in	O	O
21	children	O	O
22	with	O	O
23	infantile	BU	O
24	spasms	IU	O
25	.	O	O

0	The	O	O
1	diagnosis	O	O
2	of	O	O
3	PMR	BU	O
4	is	O	O
5	based	O	O
6	on	O	O
7	clinical	O	O
8	features	O	O
9	such	O	O
10	as	O	O
11	new-onset	O	O
12	bilateral	O	O
13	shoulder	O	O
14	pain	O	O
15	including	O	O
16	subdeltoid	O	O
17	bursitis	O	O
18	muscle	O	O
19	or	O	O
20	joint	O	O
21	stiffness	O	O
22	and	O	O
23	functional	BI	O
24	impairment	II	O
25	.	O	O

0	We	O	O
1	now	O	O
2	confirm	O	O
3	by	O	O
4	electrophysiology	O	O
5	that	O	O
6	a	O	O
7	progressive	O	O
8	sensorimotor	O	O
9	polyneuropathy	O	O
10	does	O	O
11	indeed	O	O
12	segregate	O	O
13	with	O	O
14	the	O	O
15	mutation	O	O
16	and	O	O
17	expand	O	O
18	the	O	O
19	TUBB3	O	O
20	E410K	O	O
21	phenotype	O	O
22	to	O	O
23	include	O	O
24	Kallmann	BU	O
25	syndrome	IU	O
26	hypogonadotropic	O	O
27	hypogonadism	O	O
28	and	O	O
29	anosmia	BI	O
30	stereotyped	O	O
31	midface	O	O
32	hypoplasia	O	O
33	intellectual	BI	O
34	disabilities	II	O
35	and	O	O
36	in	O	O
37	some	O	O
38	cases	O	O
39	vocal	O	O
40	cord	O	O
41	paralysis	O	O
42	tracheomalacia	O	O
43	and	O	O
44	cyclic	O	O
45	vomiting	O	O
46	.	O	O

0	Our	O	O
1	results	O	O
2	are	O	O
3	consistent	O	O
4	with	O	O
5	a	O	O
6	role	O	O
7	for	O	O
8	lipid	O	O
9	peroxidation	O	O
10	in	O	O
11	Friedreich	BI	O
12	ataxia	II	O
13	pathology	O	O
14	and	O	O
15	suggest	O	O
16	that	O	O
17	the	O	O
18	novel	O	O
19	approach	O	O
20	of	O	O
21	oral	O	O
22	delivery	O	O
23	of	O	O
24	isotope-reinforced	O	O
25	PUFAs	O	O
26	may	O	O
27	have	O	O
28	therapeutic	O	O
29	potential	O	O
30	in	O	O
31	Friedreich	BU	O
32	ataxia	IU	O
33	and	O	O
34	other	O	O
35	disorders	O	O
36	involving	O	O
37	oxidative	O	O
38	stress	O	O
39	and	O	O
40	lipid	O	O
41	peroxidation	O	O
42	.	O	O

0	When	O	O
1	confronted	O	O
2	with	O	O
3	a	O	O
4	patient	O	O
5	with	O	O
6	an	O	O
7	isolated	BI	O
8	movement	II	O
9	disorder	II	O
10	that	O	O
11	is	O	O
12	without	O	O
13	ataxia	BI	O
14	there	O	O
15	is	O	O
16	currently	O	O
17	no	O	O
18	reason	O	O
19	to	O	O
20	routinely	O	O
21	screen	O	O
22	for	O	O
23	SCA	O	O
24	gene	O	O
25	mutations	O	O
26	the	O	O
27	only	O	O
28	exceptions	O	O
29	being	O	O
30	SCA2	BU	O
31	in	O	O
32	autosomal	O	O
33	dominant	O	O
34	parkinsonism	O	O
35	particularly	O	O
36	in	O	O
37	Asian	O	O
38	patients	O	O
39	and	O	O
40	SCA17	O	O
41	in	O	O
42	the	O	O
43	case	O	O
44	of	O	O
45	a	O	O
46	Huntingtons	O	O
47	disease-like	O	O
48	presentation	O	O
49	without	O	O
50	an	O	O
51	HTT	O	O
52	mutation	O	O
53	.	O	O

0	Down	BU	O
1	Syndrome	IU	O
2	DS	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	common	O	O
7	genetic	O	O
8	cause	O	O
9	of	O	O
10	mental	BI	O
11	retardation	II	O
12	with	O	O
13	a	O	O
14	reported	O	O
15	frequency	O	O
16	of	O	O
17	epilepsy	O	O
18	between	O	O
19	1.4-17%	O	O
20	1	O	O
21	.	O	O

0	Headache	O	O
1	and	O	O
2	visual	BI	O
3	disturbances	II	O
4	including	O	O
5	loss	BI	O
6	of	II	O
7	vision	II	O
8	are	O	O
9	characteristic	O	O
10	of	O	O
11	GCA	BU	O
12	.	O	O

0	Coffin-Lowry	BU	O
1	Syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	an	O	O
5	X-linked	O	O
6	genetic	O	O
7	disorder	O	O
8	associated	O	O
9	with	O	O
10	cognitive	BI	O
11	and	II	O
12	behavioural	II	O
13	impairments	II	O
14	.	O	O

0	Pelizaeus-Merzbacher	BU	O
1	disease	IU	O
2	PMD	IU	O
3	is	O	O
4	a	O	O
5	severe	O	O
6	hypomyelinating	O	O
7	disease	O	O
8	characterized	O	O
9	by	O	O
10	ataxia	BI	O
11	intellectual	BI	O
12	disability	II	O
13	epilepsy	O	O
14	and	O	O
15	premature	O	O
16	death	O	O
17	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	WHS	IU	O
3	represents	O	O
4	a	O	O
5	complex	BI	O
6	developmental	II	O
7	disorder	II	O
8	characterized	O	O
9	by	O	O
10	craniofacial	O	O
11	dysmorphism	O	O
12	short	O	O
13	stature	O	O
14	hypotonia	O	O
15	psychomotor	BI	O
16	retardation	II	O
17	and	O	O
18	seizures	O	O
19	caused	O	O
20	by	O	O
21	a	O	O
22	terminal	O	O
23	deletion	O	O
24	of	O	O
25	the	O	O
26	short	O	O
27	arm	O	O
28	of	O	O
29	chromosome	O	O
30	4	O	O
31	.	O	O

0	Hirschsprung	BU	O
1	disease	IU	O
2	is	O	O
3	a	O	O
4	developmental	BI	O
5	disorder	II	O
6	resulting	O	O
7	from	O	O
8	the	O	O
9	arrest	O	O
10	of	O	O
11	the	O	O
12	craniocaudal	O	O
13	migration	O	O
14	of	O	O
15	enteric	O	O
16	neurons	O	O
17	from	O	O
18	the	O	O
19	neural	O	O
20	crest	O	O
21	along	O	O
22	gastrointestinal	O	O
23	segments	O	O
24	of	O	O
25	variable	O	O
26	length	O	O
27	see	O	O
28	Behrman	O	O
29	[Nelson	O	O
30	textbook	O	O
31	of	O	O
32	pediatrics	O	O
33	1992954-956]	O	O
34	.	O	O

0	To	O	O
1	evaluate	O	O
2	hearing	BI	O
3	impairment	II	O
4	and	O	O
5	cochlear	O	O
6	function	O	O
7	in	O	O
8	non-ocular	BU	O
9	Stickler	IU	O
10	syndrome	IU	O
11	.	O	O

0	Infantile	BU	O
1	Refsum	IU	O
2	disease	IU	O
3	IRD	IU	O
4	appears	O	O
5	with	O	O
6	varying	O	O
7	degrees	O	O
8	of	O	O
9	impaired	BI	O
10	vision	II	O
11	hearing	BI	O
12	loss	II	O
13	developmental	BI	O
14	delays	II	O
15	and	O	O
16	neuromotor	O	O
17	deficiencies	O	O
18	.	O	O

0	The	O	O
1	majority	O	O
2	of	O	O
3	the	O	O
4	hearing	BI	O
5	loss	II	O
6	is	O	O
7	a	O	O
8	conductive	BI	O
9	hearing	II	O
10	loss	II	O
11	with	O	O
12	the	O	O
13	exception	O	O
14	of	O	O
15	Muenke	O	O
16	syndrome	O	O
17	where	O	O
18	the	O	O
19	majority	O	O
20	of	O	O
21	patients	O	O
22	have	O	O
23	a	O	O
24	sensorineural	BI	O
25	hearing	II	O
26	loss	II	O
27	and	O	O
28	Crouzon	BU	O
29	syndrome	IU	O
30	where	O	O
31	almost	O	O
32	half	O	O
33	of	O	O
34	patients	O	O
35	have	O	O
36	a	O	O
37	pure	O	O
38	or	O	O
39	component	O	O
40	of	O	O
41	sensorineural	BI	O
42	hearing	II	O
43	loss	II	O
44	.	O	O

0	BACKGROUND	O	O
1	Gillespie	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	variant	O	O
7	form	O	O
8	of	O	O
9	aniridia	BU	O
10	characterized	O	O
11	by	O	O
12	mental	BI	O
13	retardation	II	O
14	nonprogressive	BI	O
15	cerebellar	II	O
16	ataxia	II	O
17	and	O	O
18	iris	O	O
19	hypoplasia	O	O
20	.	O	O

0	Schinzel-Giedion	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	recognizable	O	O
6	malformation	O	O
7	syndrome	O	O
8	defined	O	O
9	by	O	O
10	characteristic	O	O
11	facial	O	O
12	features	O	O
13	profound	BI	O
14	developmental	II	O
15	delay	II	O
16	severe	BI	O
17	growth	II	O
18	failure	II	O
19	and	O	O
20	multiple	O	O
21	congenital	O	O
22	anomalies	O	O
23	.	O	O

0	The	O	O
1	results	O	O
2	of	O	O
3	our	O	O
4	survey	O	O
5	suggest	O	O
6	that	O	O
7	a	O	O
8	number	O	O
9	of	O	O
10	patients	O	O
11	with	O	O
12	SMA	BU	O
13	type	O	O
14	II	O	O
15	have	O	O
16	limited	BI	O
17	jaw	II	O
18	opening	II	O
19	and	O	O
20	chewing	BI	O
21	and	II	O
22	swallowing	II	O
23	difficulties	II	O
24	.	O	O

0	This	O	O
1	constellation	O	O
2	of	O	O
3	measurements	O	O
4	of	O	O
5	thyroid	O	O
6	function	O	O
7	enables	O	O
8	quick	O	O
9	screening	O	O
10	for	O	O
11	AHDS	BU	O
12	in	O	O
13	males	O	O
14	presenting	O	O
15	with	O	O
16	cognitive	BI	O
17	impairment	II	O
18	congenital	O	O
19	hypotonia	O	O
20	and	O	O
21	generalized	O	O
22	muscle	O	O
23	weakness	O	O
24	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	a	O	O
5	neurodevelopmental	BI	O
6	disorder	II	O
7	associated	O	O
8	with	O	O
9	intellectual	BI	O
10	disability	II	O
11	sleep	BI	O
12	disturbances	II	O
13	early	O	O
14	onset	O	O
15	obesity	O	O
16	and	O	O
17	vast	BI	O
18	behavioral	II	O
19	deficits	II	O
20	.	O	O

0	We	O	O
1	discuss	O	O
2	the	O	O
3	involvement	O	O
4	of	O	O
5	the	O	O
6	other	O	O
7	deleted	O	O
8	genes	O	O
9	such	O	O
10	as	O	O
11	CAMK2A	O	O
12	or	O	O
13	SLC6A7	O	O
14	in	O	O
15	the	O	O
16	cognitive	BI	O
17	development	II	O
18	delay	II	O
19	of	O	O
20	the	O	O
21	patients	O	O
22	reported	O	O
23	and	O	O
24	we	O	O
25	propose	O	O
26	the	O	O
27	systematic	O	O
28	investigation	O	O
29	for	O	O
30	5q32	O	O
31	deletion	O	O
32	when	O	O
33	intellectual	BI	O
34	disability	II	O
35	is	O	O
36	associated	O	O
37	with	O	O
38	Treacher	BU	O
39	Collins	IU	O
40	syndrome	IU	O
41	.	O	O

0	Children	O	O
1	with	O	O
2	nephropathic	BU	O
3	cystinosis	IU	O
4	NCTN	IU	O
5	have	O	O
6	evidence	O	O
7	of	O	O
8	defective	BI	O
9	intellectual	II	O
10	functions	II	O
11	and	O	O
12	behavioral	BI	O
13	disorders	II	O
14	.	O	O

0	Chromosome	O	O
1	testing	O	O
2	confirmed	O	O
3	for	O	O
4	both	O	O
5	a	O	O
6	17p11.2	O	O
7	interstitial	O	O
8	microdeletion	O	O
9	commonly	O	O
10	seen	O	O
11	in	O	O
12	Smith-Magenis	BU	O
13	syndrome	IU	O
14	SMS	IU	O
15	which	O	O
16	is	O	O
17	characterized	O	O
18	by	O	O
19	developmental	BI	O
20	delay	II	O
21	cognitive	BI	O
22	impairment	II	O
23	and	O	O
24	facial	O	O
25	and	O	O
26	behavioral	O	O
27	phenotype	O	O
28	.	O	O

0	The	O	O
1	hearing	BI	O
2	loss	II	O
3	in	O	O
4	Townes-Brocks	BU	O
5	syndrome	IU	O
6	is	O	O
7	predominantly	O	O
8	sensorineural	O	O
9	affects	O	O
10	high-frequency	O	O
11	thresholds	O	O
12	more	O	O
13	than	O	O
14	low-frequency	O	O
15	thresholds	O	O
16	and	O	O
17	has	O	O
18	a	O	O
19	variable	O	O
20	usually	O	O
21	small	O	O
22	conductive	O	O
23	component	O	O
24	.	O	O

0	Aicardi	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	congenital	BI	O
5	neurodevelopmental	II	O
6	disorder	II	O
7	associated	O	O
8	with	O	O
9	significant	O	O
10	cognitive	BI	O
11	and	II	O
12	motor	II	O
13	impairment	II	O
14	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	WS	IU	O
3	is	O	O
4	a	O	O
5	severe	O	O
6	autosomal	O	O
7	recessive	O	O
8	pleiotropic	O	O
9	disease	O	O
10	primarily	O	O
11	characterized	O	O
12	by	O	O
13	the	O	O
14	association	O	O
15	of	O	O
16	juvenile-onset	O	O
17	diabetes	O	O
18	mellitus	O	O
19	and	O	O
20	optic	BI	O
21	atrophy	II	O
22	.	O	O

0	Hearing	BI	O
1	impairment	II	O
2	in	O	O
3	non-ocular	BU	O
4	Stickler	IU	O
5	syndrome	IU	O
6	is	O	O
7	characterized	O	O
8	by	O	O
9	non-progressive	BI	O
10	hearing	II	O
11	loss	II	O
12	present	O	O
13	since	O	O
14	childhood	O	O
15	and	O	O
16	mostly	O	O
17	mild	O	O
18	to	O	O
19	moderate	O	O
20	in	O	O
21	severity	O	O
22	.	O	O

0	Whereas	O	O
1	the	O	O
2	time	O	O
3	frame	O	O
4	for	O	O
5	the	O	O
6	development	O	O
7	of	O	O
8	therapies	O	O
9	for	O	O
10	some	O	O
11	retinal	BI	O
12	dystrophies	II	O
13	may	O	O
14	be	O	O
15	in	O	O
16	the	O	O
17	years	O	O
18	hence	O	O
19	gene	O	O
20	therapy	O	O
21	trials	O	O
22	for	O	O
23	choroideremia	BU	O
24	have	O	O
25	started	O	O
26	in	O	O
27	the	O	O
28	United	O	O
29	Kingdom	O	O
30	and	O	O
31	results	O	O
32	are	O	O
33	pending	O	O
34	.	O	O

0	Choroideremia	BU	O
1	is	O	O
2	a	O	O
3	rare	O	O
4	hereditary	O	O
5	disease	O	O
6	with	O	O
7	characteristic	O	O
8	fundus	O	O
9	that	O	O
10	causes	O	O
11	night	BI	O
12	blindness	II	O
13	and	O	O
14	peripheral	BI	O
15	visual	II	O
16	field	II	O
17	loss	II	O
18	.	O	O

0	Dendrite	O	O
1	and	O	O
2	spine	O	O
3	abnormalities	O	O
4	have	O	O
5	been	O	O
6	implicated	O	O
7	in	O	O
8	several	BI	O
9	psychiatric	II	O
10	disorders	II	O
11	such	O	O
12	as	O	O
13	Fragile	BU	O
14	X	IU	O
15	syndrome	IU	O
16	where	O	O
17	neurons	O	O
18	show	O	O
19	a	O	O
20	high	O	O
21	density	O	O
22	of	O	O
23	long	O	O
24	thin	O	O
25	and	O	O
26	immature	O	O
27	dendritic	O	O
28	spines	O	O
29	.	O	O

0	Typical	O	O
1	JBS	BU	O
2	features	O	O
3	include	O	O
4	developmental	BI	O
5	delay	II	O
6	mental	BI	O
7	retardation	II	O
8	short	O	O
9	stature	O	O
10	congenital	O	O
11	heart	O	O
12	defects	O	O
13	thrombocytopenia	O	O
14	and	O	O
15	characteristic	O	O
16	dysmorphic	O	O
17	facial	O	O
18	features	O	O
19	.	O	O

0	The	O	O
1	first	O	O
2	case	O	O
3	is	O	O
4	an	O	O
5	8.5-year-old	O	O
6	girl	O	O
7	with	O	O
8	an	O	O
9	inv	BU	O
10	dup	IU	O
11	15	IU	O
12	syndrome	O	O
13	mental	BI	O
14	retardation	II	O
15	and	O	O
16	dysmorphic	O	O
17	features	O	O
18	.	O	O

0	Mutations	O	O
1	described	O	O
2	thus	O	O
3	far	O	O
4	in	O	O
5	PRPS1	O	O
6	are	O	O
7	all	O	O
8	missense	O	O
9	mutations	O	O
10	that	O	O
11	result	O	O
12	in	O	O
13	PRS-I	BU	O
14	superactivity	IU	O
15	or	O	O
16	in	O	O
17	variable	O	O
18	levels	O	O
19	of	O	O
20	decreased	O	O
21	activity	O	O
22	resulting	O	O
23	in	O	O
24	X-linked	BU	O
25	Charcot-Marie-Tooth	IU	O
26	disease-5	IU	O
27	CMTX5	IU	O
28	Arts	BU	O
29	syndrome	IU	O
30	and	O	O
31	X-linked	BI	O
32	nonsyndromic	II	O
33	sensorineural	II	O
34	deafness	II	O
35	DFN2	O	O
36	.	O	O

0	Other	O	O
1	mental	BI	O
2	retardation	II	O
3	disorders	II	O
4	are	O	O
5	also	O	O
6	linked	O	O
7	to	O	O
8	the	O	O
9	disruption	O	O
10	of	O	O
11	genes	O	O
12	involved	O	O
13	in	O	O
14	epigenetic	O	O
15	mechanisms	O	O
16	such	O	O
17	disorders	O	O
18	include	O	O
19	alpha	O	O
20	thalassaemia	O	O
21	mental	O	O
22	retardation	O	O
23	X-linked	O	O
24	syndrome	O	O
25	Rubinstein-Taybi	O	O
26	syndrome	O	O
27	and	O	O
28	Coffin-Lowry	BU	O
29	syndrome	IU	O
30	.	O	O

0	The	O	O
1	daughter	O	O
2	and	O	O
3	mother	O	O
4	with	O	O
5	infantile	BU	O
6	spasms	IU	O
7	and	O	O
8	the	O	O
9	autistic	BI	O
10	son	O	O
11	had	O	O
12	the	O	O
13	duplication	O	O
14	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	disorder	O	O
5	that	O	O
6	primarily	O	O
7	involves	O	O
8	ectodermal	O	O
9	tissues	O	O
10	and	O	O
11	is	O	O
12	characterized	O	O
13	by	O	O
14	mental	BI	O
15	and	II	O
16	growth	II	O
17	retardation	II	O
18	distinctive	O	O
19	coarse	O	O
20	facies	O	O
21	redundant	O	O
22	skin	O	O
23	neck	O	O
24	palms	O	O
25	and	O	O
26	soles	O	O
27	and	O	O
28	papillomata	O	O
29	perioral	O	O
30	nasal	O	O
31	and	O	O
32	anal	O	O
33	.	O	O

0	The	O	O
1	authors	O	O
2	emphasise	O	O
3	the	O	O
4	need	O	O
5	to	O	O
6	consider	O	O
7	monosomy	BU	O
8	1p36	IU	O
9	as	O	O
10	a	O	O
11	cause	O	O
12	of	O	O
13	severe	BI	O
14	psychomotor	II	O
15	delay	II	O
16	and	O	O
17	obesity	O	O
18	.	O	O

0	BRESEK	O	O
1	BRESHECK	BU	O
2	syndrome	IU	O
3	is	O	O
4	a	O	O
5	multiple	O	O
6	congenital	O	O
7	malformation	O	O
8	characterized	O	O
9	by	O	O
10	brain	O	O
11	anomalies	O	O
12	intellectual	BI	O
13	disability	II	O
14	ectodermal	BU	O
15	dysplasia	IU	O
16	skeletal	O	O
17	deformities	O	O
18	ear	O	O
19	or	O	O
20	eye	O	O
21	anomalies	O	O
22	and	O	O
23	renal	O	O
24	anomalies	O	O
25	or	O	O
26	small	O	O
27	kidneys	O	O
28	with	O	O
29	or	O	O
30	without	O	O
31	Hirschsprung	BU	O
32	disease	IU	O
33	and	O	O
34	cleft	BU	O
35	palate	IU	O
36	or	O	O
37	cryptorchidism	O	O
38	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	a	O	O
4	case	O	O
5	of	O	O
6	late	O	O
7	infantile	O	O
8	MLD	BU	O
9	presenting	O	O
10	with	O	O
11	cerebellar	O	O
12	ataxia	BI	O
13	as	O	O
14	the	O	O
15	only	O	O
16	first	O	O
17	clinical	O	O
18	sign	O	O
19	preceding	O	O
20	even	O	O
21	changes	O	O
22	in	O	O
23	white	O	O
24	matter	O	O
25	visible	O	O
26	in	O	O
27	MR	O	O
28	imaging	O	O
29	.	O	O

0	The	O	O
1	Pendred	BU	O
2	syndrome	IU	O
3	associated	O	O
4	with	O	O
5	the	O	O
6	hearing	BI	O
7	impairment	II	O
8	is	O	O
9	characterized	O	O
10	by	O	O
11	a	O	O
12	prelingual	O	O
13	bilateral	O	O
14	sever	O	O
15	to	O	O
16	profound	O	O
17	SNHL	O	O
18	goiter	O	O
19	and	O	O
20	iodine	O	O
21	organification	O	O
22	defect	O	O
23	.	O	O

0	Psychiatric	BI	O
1	disorders	II	O
2	and	O	O
3	psychosocial	BI	O
4	impairment	II	O
5	are	O	O
6	common	O	O
7	yet	O	O
8	poorly	O	O
9	characterized	O	O
10	findings	O	O
11	in	O	O
12	EDS	BU	O
13	patients	O	O
14	.	O	O

0	Salla	BU	O
1	disease	IU	O
2	must	O	O
3	be	O	O
4	suspected	O	O
5	in	O	O
6	patients	O	O
7	with	O	O
8	unexplained	BI	O
9	psychomotor	II	O
10	retardation	II	O
11	associated	O	O
12	with	O	O
13	ataxia	BI	O
14	and	O	O
15	or	O	O
16	pyramidal	O	O
17	symptoms	O	O
18	and	O	O
19	MRI	O	O
20	findings	O	O
21	consistent	O	O
22	with	O	O
23	cerebral	O	O
24	hypomyelination	O	O
25	irrespective	O	O
26	of	O	O
27	the	O	O
28	patients	O	O
29	ethnic	O	O
30	origin	O	O
31	.	O	O

0	The	O	O
1	first	O	O
2	case	O	O
3	was	O	O
4	a	O	O
5	boy	O	O
6	of	O	O
7	Blackfoot	O	O
8	Aboriginal	O	O
9	ancestry	O	O
10	who	O	O
11	presented	O	O
12	with	O	O
13	failure	O	O
14	to	O	O
15	thrive	O	O
16	developmental	BI	O
17	delay	II	O
18	and	O	O
19	Fanconi	O	O
20	syndrome	O	O
21	and	O	O
22	was	O	O
23	diagnosed	O	O
24	with	O	O
25	KSS	BU	O
26	at	O	O
27	3years	O	O
28	of	O	O
29	age	O	O
30	.	O	O

0	WHS	BU	O
1	is	O	O
2	characterized	O	O
3	by	O	O
4	typical	O	O
5	facial	O	O
6	appearance	O	O
7	"Greek	O	O
8	helmet	O	O
9	facies"	O	O
10	mental	BI	O
11	retardation	II	O
12	congenital	O	O
13	hypotonia	O	O
14	and	O	O
15	growth	BI	O
16	retardation	II	O
17	.	O	O

0	Kabuki	BU	O
1	syndrome	IU	O
2	KS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	genetic	O	O
7	condition	O	O
8	characterized	O	O
9	by	O	O
10	a	O	O
11	distinctive	O	O
12	facies	O	O
13	intellectual	BI	O
14	disability	II	O
15	growth	BI	O
16	delay	II	O
17	and	O	O
18	a	O	O
19	variety	O	O
20	of	O	O
21	skeletal	O	O
22	visceral	O	O
23	and	O	O
24	other	O	O
25	anomalies	O	O
26	including	O	O
27	anorectal	BU	O
28	malformations	IU	O
29	ARMs	O	O
30	.	O	O

0	Costello	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	congenital	O	O
5	disorder	O	O
6	comprising	O	O
7	a	O	O
8	characteristic	O	O
9	face	O	O
10	severe	O	O
11	feeding	O	O
12	difficulties	O	O
13	skeletal	O	O
14	cardiac	O	O
15	and	O	O
16	skin	O	O
17	abnormalities	O	O
18	intellectual	BI	O
19	disability	II	O
20	and	O	O
21	predisposition	O	O
22	to	O	O
23	malignancies	O	O
24	.	O	O

0	Mowat-Wilson	BU	O
1	syndrome	IU	O
2	MWS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	genetic	O	O
7	syndrome	O	O
8	characterized	O	O
9	by	O	O
10	a	O	O
11	specific	O	O
12	facial	O	O
13	gestalt	O	O
14	intellectual	BI	O
15	deficiency	II	O
16	Hirschsprung	BU	O
17	disease	IU	O
18	and	O	O
19	multiple	O	O
20	congenital	O	O
21	anomalies	O	O
22	.	O	O

0	We	O	O
1	present	O	O
2	a	O	O
3	case	O	O
4	of	O	O
5	steroid-dependent	O	O
6	auditory	O	O
7	neuropathy	O	O
8	associated	O	O
9	with	O	O
10	CMT	BU	O
11	in	O	O
12	which	O	O
13	the	O	O
14	patient	O	O
15	experienced	O	O
16	3	O	O
17	episodes	O	O
18	of	O	O
19	acute	O	O
20	exacerbation	O	O
21	of	O	O
22	hearing	BI	O
23	loss	II	O
24	and	O	O
25	successful	O	O
26	rescue	O	O
27	of	O	O
28	hearing	O	O
29	by	O	O
30	prednisolone	O	O
31	.	O	O

0	Interstitial	O	O
1	chromosome	O	O
2	15q11-q13	BU	O
3	duplications	IU	O
4	are	O	O
5	associated	O	O
6	with	O	O
7	developmental	BI	O
8	delay	II	O
9	behavioral	BI	O
10	problems	II	O
11	and	O	O
12	additional	O	O
13	manifestations	O	O
14	including	O	O
15	epilepsy	O	O
16	.	O	O

0	22q13	BU	O
1	deletion	IU	O
2	syndrome	IU	O
3	also	O	O
4	known	O	O
5	as	O	O
6	Phelan-McDermid	BU	O
7	syndrome	IU	O
8	is	O	O
9	a	O	O
10	neurodevelopmental	BI	O
11	disorder	II	O
12	characterized	O	O
13	by	O	O
14	intellectual	BI	O
15	disability	II	O
16	hypotonia	O	O
17	delayed	BI	O
18	or	II	O
19	absent	II	O
20	speech	II	O
21	and	O	O
22	autistic	BI	O
23	features	II	O
24	.	O	O

0	Patients	O	O
1	with	O	O
2	SLC26A4	O	O
3	mutations	O	O
4	have	O	O
5	variable	O	O
6	phenotypes	O	O
7	ranging	O	O
8	from	O	O
9	non-syndromic	BI	O
10	hearing	II	O
11	loss	II	O
12	to	O	O
13	Pendred	BU	O
14	syndrome	IU	O
15	.	O	O

0	Shprintzen-Goldberg	BU	O
1	syndrome	IU	O
2	SGS	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	severe	O	O
7	marfanoid	O	O
8	habitus	O	O
9	intellectual	BI	O
10	disability	II	O
11	camptodactyly	O	O
12	typical	O	O
13	facial	O	O
14	dysmorphism	O	O
15	and	O	O
16	craniosynostosis	BU	O
17	.	O	O

0	When	O	O
1	cardinal	O	O
2	features	O	O
3	are	O	O
4	lacking	O	O
5	the	O	O
6	diagnosis	O	O
7	of	O	O
8	Cockayne	BU	O
9	syndrome	IU	O
10	should	O	O
11	be	O	O
12	considered	O	O
13	when	O	O
14	presented	O	O
15	with	O	O
16	growth	BI	O
17	retardation	II	O
18	microcephaly	O	O
19	and	O	O
20	one	O	O
21	of	O	O
22	the	O	O
23	suggesting	O	O
24	features	O	O
25	such	O	O
26	as	O	O
27	enophthalmia	O	O
28	limb	BI	O
29	ataxia	II	O
30	abnormal	O	O
31	auditory	O	O
32	evoked	O	O
33	responses	O	O
34	or	O	O
35	increased	O	O
36	ventricular	O	O
37	size	O	O
38	on	O	O
39	cerebral	O	O
40	imaging	O	O
41	.	O	O

0	Danon	BU	O
1	disease	IU	O
2	is	O	O
3	an	O	O
4	extremely	O	O
5	rare	O	O
6	X-linked	O	O
7	dominant	O	O
8	disorder	O	O
9	characterized	O	O
10	by	O	O
11	progressive	O	O
12	cardiomyopathy	BU	O
13	muscle	O	O
14	weakness	O	O
15	and	O	O
16	mild	BI	O
17	mental	II	O
18	retardation	II	O
19	.	O	O

0	Mowat-Wilson	BU	O
1	syndrome	IU	O
2	MWS	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	moderate	BI	O
7	to	II	O
8	severe	II	O
9	intellectual	II	O
10	disability	II	O
11	and	O	O
12	distinctive	O	O
13	facial	O	O
14	features	O	O
15	in	O	O
16	association	O	O
17	with	O	O
18	variable	O	O
19	structural	O	O
20	congenital	O	O
21	anomalies	O	O
22	clinical	O	O
23	features	O	O
24	including	O	O
25	congenital	O	O
26	heart	O	O
27	disease	O	O
28	Hirschsprung	BU	O
29	disease	IU	O
30	hypospadias	O	O
31	agenesis	O	O
32	of	O	O
33	the	O	O
34	corpus	O	O
35	callosum	O	O
36	short	O	O
37	stature	O	O
38	epilepsy	O	O
39	and	O	O
40	microcephaly	O	O
41	.	O	O

0	Virtual	O	O
1	reality	O	O
2	is	O	O
3	a	O	O
4	technology	O	O
5	that	O	O
6	holds	O	O
7	great	O	O
8	promise	O	O
9	for	O	O
10	the	O	O
11	evaluation	O	O
12	and	O	O
13	rehabilitation	O	O
14	of	O	O
15	patients	O	O
16	with	O	O
17	bvFTD	BU	O
18	and	O	O
19	other	O	O
20	non-Alzheimer	BI	O
21	dementias	II	O
22	and	O	O
23	preliminary	O	O
24	evidence	O	O
25	suggests	O	O
26	that	O	O
27	this	O	O
28	technology	O	O
29	is	O	O
30	feasible	O	O
31	in	O	O
32	patients	O	O
33	with	O	O
34	bvFTD	BU	O
35	.	O	O

0	Cranial	O	O
1	nerve	O	O
2	involvement	O	O
3	responsible	O	O
4	for	O	O
5	hearing	BI	O
6	loss	II	O
7	bilateral	BI	O
8	optic	II	O
9	atrophy	II	O
10	and	O	O
11	or	O	O
12	facial	O	O
13	palsy	O	O
14	was	O	O
15	present	O	O
16	in	O	O
17	14	O	O
18	patients	O	O
19	but	O	O
20	was	O	O
21	clearly	O	O
22	attributable	O	O
23	to	O	O
24	ADO	BU	O
25	II	IU	O
26	in	O	O
27	only	O	O
28	6	O	O
29	cases	O	O
30	16%	O	O
31	.	O	O

0	CONCLUSION	O	O
1	The	O	O
2	description	O	O
3	of	O	O
4	a	O	O
5	hearing	BI	O
6	defect	II	O
7	in	O	O
8	2	O	O
9	brothers	O	O
10	with	O	O
11	Kallmann	BU	O
12	syndrome	IU	O
13	allows	O	O
14	asserting	O	O
15	that	O	O
16	deafness	BI	O
17	is	O	O
18	part	O	O
19	of	O	O
20	the	O	O
21	clinical	O	O
22	features	O	O
23	of	O	O
24	this	O	O
25	disease	O	O
26	and	O	O
27	must	O	O
28	lead	O	O
29	the	O	O
30	physician	O	O
31	to	O	O
32	monitor	O	O
33	the	O	O
34	hearing	O	O
35	function	O	O
36	of	O	O
37	Kallmann	O	O
38	patients	O	O
39	.	O	O

0	Research	O	O
1	on	O	O
2	triple	BU	O
3	X	IU	O
4	syndrome	IU	O
5	may	O	O
6	yield	O	O
7	more	O	O
8	insight	O	O
9	into	O	O
10	brain	O	O
11	and	O	O
12	behaviour	O	O
13	relations	O	O
14	developmental	O	O
15	psychopathology	O	O
16	auditory-processing	BI	O
17	disorders	II	O
18	EEG	O	O
19	disorders	O	O
20	personality	BI	O
21	and	II	O
22	psychotic	II	O
23	disorders	II	O
24	etc	O	O
25	.	O	O

0	We	O	O
1	have	O	O
2	observed	O	O
3	that	O	O
4	patients	O	O
5	with	O	O
6	8q12	BU	O
7	duplication	IU	O
8	share	O	O
9	a	O	O
10	common	O	O
11	recognizable	O	O
12	phenotype	O	O
13	characterized	O	O
14	by	O	O
15	DRS	O	O
16	developmental	BI	O
17	delay	II	O
18	and	O	O
19	facial	O	O
20	features	O	O
21	.	O	O

0	Taken	O	O
1	together	O	O
2	our	O	O
3	data	O	O
4	indicate	O	O
5	that	O	O
6	redox	O	O
7	homeostasis	O	O
8	is	O	O
9	disturbed	O	O
10	by	O	O
11	the	O	O
12	major	O	O
13	metabolites	O	O
14	accumulating	O	O
15	in	O	O
16	HHH	BU	O
17	syndrome	O	O
18	and	O	O
19	that	O	O
20	this	O	O
21	mechanism	O	O
22	may	O	O
23	be	O	O
24	implicated	O	O
25	in	O	O
26	the	O	O
27	ataxia	BI	O
28	and	O	O
29	cerebellar	O	O
30	abnormalities	O	O
31	observed	O	O
32	in	O	O
33	this	O	O
34	disorder	O	O
35	.	O	O

0	MAS	BU	O
1	can	O	O
2	involve	O	O
3	the	O	O
4	orbit	O	O
5	region	O	O
6	and	O	O
7	cause	O	O
8	stenosis	O	O
9	in	O	O
10	the	O	O
11	optic	O	O
12	canal	O	O
13	leading	O	O
14	the	O	O
15	patient	O	O
16	to	O	O
17	a	O	O
18	progressive	BI	O
19	visual	II	O
20	loss	II	O
21	.	O	O

0	We	O	O
1	conclude	O	O
2	that	O	O
3	all	O	O
4	patients	O	O
5	with	O	O
6	Behçet	BU	O
7	disease	IU	O
8	should	O	O
9	be	O	O
10	screened	O	O
11	for	O	O
12	hearing	BI	O
13	impairment	II	O
14	and	O	O
15	subsequently	O	O
16	treated	O	O
17	if	O	O
18	an	O	O
19	impairment	O	O
20	is	O	O
21	discovered	O	O
22	.	O	O

0	The	O	O
1	most	O	O
2	common	O	O
3	diagnoses	O	O
4	known	O	O
5	in	O	O
6	129	O	O
7	were	O	O
8	Angelman	BI	O
9	syndrome	II	O
10	n=16	O	O
11	ataxia	BI	O
12	telangiectasia	II	O
13	n=13	O	O
14	mitochondrial	BU	O
15	disease	IU	O
16	n=9	O	O
17	Friedreich	BI	O
18	ataxia	II	O
19	n=7	O	O
20	stroke	O	O
21	n=7	O	O
22	and	O	O
23	familial	BI	O
24	genetic	II	O
25	episodic	II	O
26	ataxia	II	O
27	n=7	O	O
28	.	O	O

0	Wolf-Hirschhorn	BU	O
1	syndrome	IU	O
2	WHS	IU	O
3	is	O	O
4	a	O	O
5	contiguous	O	O
6	gene	O	O
7	deletion	O	O
8	syndrome	O	O
9	associated	O	O
10	with	O	O
11	growth	BI	O
12	retardation	II	O
13	developmental	BI	O
14	disabilities	II	O
15	epileptic	O	O
16	seizures	O	O
17	and	O	O
18	distinct	O	O
19	facial	O	O
20	features	O	O
21	resulting	O	O
22	from	O	O
23	a	O	O
24	deletion	O	O
25	of	O	O
26	the	O	O
27	short	O	O
28	arm	O	O
29	of	O	O
30	chromosome	O	O
31	4	O	O
32	.	O	O

0	Charcot-Marie-Tooth	BU	O
1	CMT	IU	O
2	disease	IU	O
3	is	O	O
4	characterized	O	O
5	by	O	O
6	hereditary	O	O
7	sensorimotor	O	O
8	polyneuropathy	O	O
9	with	O	O
10	foot	O	O
11	deformity	O	O
12	sensorineural	BI	O
13	hearing	II	O
14	loss	II	O
15	moderate	BI	O
16	developmental	II	O
17	delay	II	O
18	and	O	O
19	gait	BI	O
20	disturbance	II	O
21	.	O	O

0	Neuropathy	O	O
1	ataxia	BI	O
2	and	O	O
3	retinitis	BU	O
4	pigmentosa	IU	O
5	NARP	O	O
6	syndrome	O	O
7	and	O	O
8	maternally	O	O
9	inherited	O	O
10	Leighs	O	O
11	syndrome	O	O
12	have	O	O
13	been	O	O
14	associated	O	O
15	with	O	O
16	T8993G	O	O
17	point	O	O
18	mutations	O	O
19	in	O	O
20	the	O	O
21	mitochondrial	O	O
22	adenosine	O	O
23	triphosphatase	O	O
24	6	O	O
25	gene	O	O
26	.	O	O

0	Protein-energy	O	O
1	malnutrition	O	O
2	PEM	O	O
3	is	O	O
4	poorly	O	O
5	reported	O	O
6	in	O	O
7	cri	BU	O
8	du	IU	O
9	chat	IU	O
10	syndrome	IU	O
11	CDCS	IU	O
12	OMIM	O	O
13	#123450	O	O
14	a	O	O
15	genetic	O	O
16	disease	O	O
17	that	O	O
18	causes	O	O
19	developmental	BI	O
20	delay	II	O
21	and	O	O
22	global	BI	O
23	growth	II	O
24	retardation	II	O
25	.	O	O

0	We	O	O
1	describe	O	O
2	the	O	O
3	clinical	O	O
4	course	O	O
5	as	O	O
6	well	O	O
7	as	O	O
8	cytogenetic	O	O
9	and	O	O
10	molecular	O	O
11	findings	O	O
12	of	O	O
13	a	O	O
14	3-year-old	O	O
15	obese	O	O
16	boy	O	O
17	with	O	O
18	psychomotor	BI	O
19	retardation	II	O
20	who	O	O
21	exhibited	O	O
22	two	O	O
23	rare	O	O
24	conditions	O	O
25	succinic	BU	O
26	semialdehyde	IU	O
27	dehydrogenase	IU	O
28	deficiency	IU	O
29	SSADH	IU	O
30	deficiency	IU	O
31	MIM	IU	O
32	271980	IU	O
33	a	O	O
34	disorder	O	O
35	of	O	O
36	-aminobutyric	O	O
37	acid	O	O
38	metabolism	O	O
39	with	O	O
40	a	O	O
41	heterogeneous	O	O
42	clinical	O	O
43	spectrum	O	O
44	and	O	O
45	partial	O	O
46	Wilms	O	O
47	tumor	O	O
48	aniridia	BU	O
49	genital	O	O
50	abnormalities	O	O
51	and	O	O
52	mental	BI	O
53	retardation	II	O
54	WAGR	BU	O
55	syndrome	O	O
56	an	O	O
57	association	O	O
58	between	O	O
59	Wilms	O	O
60	tumor	O	O
61	aniridia	BU	O
62	genitourinary	O	O
63	malformations	O	O
64	and	O	O
65	mental	BI	O
66	retardation	II	O
67	due	O	O
68	to	O	O
69	mutations	O	O
70	involving	O	O
71	the	O	O
72	short	O	O
73	arm	O	O
74	of	O	O
75	chromosome	O	O
76	11	O	O
77	particularly	O	O
78	deletions	O	O
79	at	O	O
80	the	O	O
81	chromosomal	O	O
82	region	O	O
83	11p13	O	O
84	MIM	O	O
85	194072	O	O
86	.	O	O

0	Nonketotic	BU	O
1	hyperglycinemia	IU	O
2	is	O	O
3	a	O	O
4	neurometabolic	O	O
5	disorder	O	O
6	characterized	O	O
7	by	O	O
8	intellectual	BI	O
9	disability	II	O
10	seizures	O	O
11	and	O	O
12	spasticity	O	O
13	.	O	O

0	She	O	O
1	developed	O	O
2	progressive	BI	O
3	sensorineural	II	O
4	hearing	II	O
5	loss	II	O
6	myopathy	O	O
7	ptosis	BU	O
8	short	O	O
9	stature	O	O
10	and	O	O
11	mild	BI	O
12	developmental	II	O
13	delays	II	O
14	after	O	O
15	normal	O	O
16	early	O	O
17	development	O	O
18	.	O	O

0	Clinical	O	O
1	manifestations	O	O
2	of	O	O
3	CRS	BU	O
4	included	O	O
5	low	O	O
6	birth	O	O
7	weight	O	O
8	<2500g	O	O
9	86.0%	O	O
10	congenital	O	O
11	heart	O	O
12	disease	O	O
13	63.7%	O	O
14	hearing	BI	O
15	impairment	II	O
16	63.7%	O	O
17	and	O	O
18	ophthalmological	BI	O
19	abnormalities	II	O
20	46.9%	O	O
21	.	O	O

0	We	O	O
1	report	O	O
2	herein	O	O
3	a	O	O
4	five-year-old	O	O
5	girl	O	O
6	with	O	O
7	severe	O	O
8	ophthalmological	O	O
9	findings	O	O
10	facial	O	O
11	dysmorphism	O	O
12	and	O	O
13	psychomotor	O	O
14	retardation	O	O
15	with	O	O
16	normal	O	O
17	platelet	O	O
18	function	O	O
19	in	O	O
20	whom	O	O
21	a	O	O
22	de	O	O
23	novo	O	O
24	11q23	O	O
25	deletion	O	O
26	was	O	O
27	detected	O	O
28	suggesting	O	O
29	that	O	O
30	distal	BU	O
31	11q	IU	O
32	monosomy	IU	O
33	should	O	O
34	be	O	O
35	kept	O	O
36	in	O	O
37	mind	O	O
38	in	O	O
39	patients	O	O
40	presenting	O	O
41	with	O	O
42	dysmorphic	O	O
43	facial	O	O
44	features	O	O
45	and	O	O
46	psychomotor	BI	O
47	retardation	II	O
48	even	O	O
49	in	O	O
50	the	O	O
51	absence	O	O
52	of	O	O
53	hematological	O	O
54	findings	O	O
55	.	O	O

0	Alström	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	clinically	O	O
5	complex	O	O
6	disorder	O	O
7	characterized	O	O
8	by	O	O
9	progressive	BI	O
10	degeneration	II	O
11	of	II	O
12	sensory	II	O
13	functions	II	O
14	resulting	O	O
15	in	O	O
16	visual	BI	O
17	and	II	O
18	audiological	II	O
19	impairment	II	O
20	as	O	O
21	well	O	O
22	as	O	O
23	metabolic	O	O
24	disturbances	O	O
25	.	O	O

0	Five	O	O
1	patients	O	O
2	were	O	O
3	diagnosed	O	O
4	as	O	O
5	having	O	O
6	primary	O	O
7	distal	BU	O
8	renal	IU	O
9	tubular	IU	O
10	acidosis	IU	O
11	and	O	O
12	rickets	O	O
13	four	O	O
14	were	O	O
15	found	O	O
16	to	O	O
17	have	O	O
18	severe	O	O
19	sensorineural	BI	O
20	hearing	II	O
21	loss	II	O
22	of	O	O
23	over	O	O
24	80	O	O
25	dB	O	O
26	two	O	O
27	of	O	O
28	which	O	O
29	are	O	O
30	brothers	O	O
31	.	O	O

0	We	O	O
1	report	O	O
2	on	O	O
3	two	O	O
4	patients	O	O
5	presenting	O	O
6	with	O	O
7	mandibulofacial	O	O
8	dysostosis	O	O
9	characteristic	O	O
10	of	O	O
11	Treacher	BU	O
12	Collins	IU	O
13	syndrome	IU	O
14	but	O	O
15	associated	O	O
16	with	O	O
17	unexpected	BI	O
18	intellectual	II	O
19	disability	II	O
20	due	O	O
21	to	O	O
22	a	O	O
23	large	O	O
24	deletion	O	O
25	encompassing	O	O
26	several	O	O
27	genes	O	O
28	including	O	O
29	the	O	O
30	TCOF1	O	O
31	gene	O	O
32	.	O	O

0	Importantly	O	O
1	our	O	O
2	data	O	O
3	imply	O	O
4	that	O	O
5	the	O	O
6	same	O	O
7	SOX10	O	O
8	mutations	O	O
9	can	O	O
10	underlie	O	O
11	both	O	O
12	typical	O	O
13	WS	O	O
14	and	O	O
15	KS	BU	O
16	with	O	O
17	deafness	BI	O
18	without	O	O
19	skin	O	O
20	hair	O	O
21	hypopigmentation	O	O
22	Hirschsprung	BU	O
23	disease	IU	O
24	or	O	O
25	neurological	O	O
26	defects	O	O
27	.	O	O

0	MPS	BU	O
1	VII	IU	O
2	is	O	O
3	associated	O	O
4	with	O	O
5	mixed	O	O
6	conductive	O	O
7	and	O	O
8	sensorineural	O	O
9	hearing	BI	O
10	loss	II	O
11	vision	BI	O
12	defects	II	O
13	shortened	O	O
14	stature	O	O
15	mental	BI	O
16	retardation	II	O
17	and	O	O
18	decreased	O	O
19	lifespan	O	O
20	.	O	O

0	There	O	O
1	is	O	O
2	no	O	O
3	consensus	O	O
4	about	O	O
5	its	O	O
6	name	O	O
7	despite	O	O
8	the	O	O
9	fact	O	O
10	that	O	O
11	its	O	O
12	clinical	O	O
13	and	O	O
14	radiological	O	O
15	features	O	O
16	are	O	O
17	well-defined	O	O
18	and	O	O
19	distinguish	O	O
20	it	O	O
21	from	O	O
22	other	O	O
23	types	O	O
24	of	O	O
25	FTD	BU	O
26	including	O	O
27	semantic	BI	O
28	dementia	II	O
29	.	O	O

0	Pallister-Killian	BU	O
1	syndrome	IU	O
2	PKS	IU	O
3	is	O	O
4	a	O	O
5	potentially	O	O
6	lethal	O	O
7	disorder	O	O
8	with	O	O
9	facial	O	O
10	dysmorphism	O	O
11	pigmentary	O	O
12	skin	O	O
13	anomalies	O	O
14	developmental	BI	O
15	delay	II	O
16	and	O	O
17	major	O	O
18	visceral	O	O
19	anomalies	O	O
20	such	O	O
21	as	O	O
22	diaphragmatic	O	O
23	hernia	O	O
24	anorectal	BU	O
25	malformation	IU	O
26	and	O	O
27	congenital	O	O
28	heart	O	O
29	disease	O	O
30	.	O	O

0	RESULTS	O	O
1	Twenty-six	O	O
2	participants	O	O
3	23%	O	O
4	of	O	O
5	total	O	O
6	sample	O	O
7	screened	O	O
8	positive	O	O
9	for	O	O
10	prior	O	O
11	DV	O	O
12	with	O	O
13	one	O	O
14	or	O	O
15	more	O	O
16	of	O	O
17	the	O	O
18	following	O	O
19	delayed	O	O
20	early	O	O
21	motor	O	O
22	and	O	O
23	or	O	O
24	language	O	O
25	milestones	O	O
26	that	O	O
27	required	O	O
28	intervention	O	O
29	n	O	O
30	=	O	O
31	17	O	O
32	prior	O	O
33	diagnosis	O	O
34	of	O	O
35	Down	BU	O
36	syndrome	IU	O
37	n	O	O
38	=	O	O
39	3	O	O
40	prior	O	O
41	diagnosis	O	O
42	of	O	O
43	autism	BI	O
44	spectrum	II	O
45	disorder	II	O
46	n	O	O
47	=	O	O
48	1	O	O
49	prior	O	O
50	diagnosis	O	O
51	of	O	O
52	attention-deficit	BI	O
53	hyperactivity	BI	O
54	disorder	II	O
55	and	O	O
56	or	O	O
57	learning	BI	O
58	disability	II	O
59	n	O	O
60	=	O	O
61	6	O	O
62	or	O	O
63	prior	O	O
64	neurological	O	O
65	conditions	O	O
66	n	O	O
67	=	O	O
68	5	O	O
69	.	O	O

0	Furthermore	O	O
1	1p36	BU	O
2	deletion	IU	O
3	syndrome	IU	O
4	should	O	O
5	be	O	O
6	considered	O	O
7	for	O	O
8	patients	O	O
9	presenting	O	O
10	seizure	O	O
11	and	O	O
12	moderate-to-severe	BI	O
13	developmental	II	O
14	delay	II	O
15	particularly	O	O
16	if	O	O
17	the	O	O
18	patient	O	O
19	exhibits	O	O
20	dysmorphic	O	O
21	features	O	O
22	short	O	O
23	stature	O	O
24	and	O	O
25	hypotonia	O	O
26	.	O	O

0	These	O	O
1	results	O	O
2	further	O	O
3	implicate	O	O
4	that	O	O
5	trisomy	BU	O
6	9p	IU	O
7	is	O	O
8	associated	O	O
9	with	O	O
10	mental	BI	O
11	retardation	II	O
12	and	O	O
13	that	O	O
14	there	O	O
15	may	O	O
16	be	O	O
17	key	O	O
18	gene	O	O
19	duplication	O	O
20	on	O	O
21	chromosome	O	O
22	9p21.3→9pter	O	O
23	responsible	O	O
24	for	O	O
25	mental	BI	O
26	retardation	II	O
27	and	O	O
28	mild	O	O
29	facial	O	O
30	anomaly	O	O
31	.	O	O

0	Mild	O	O
1	PRS-I	O	O
2	deficiency	O	O
3	DFNX-2	BU	O
4	results	O	O
5	in	O	O
6	non-syndromic	BI	O
7	progressive	II	O
8	hearing	II	O
9	loss	II	O
10	whereas	O	O
11	moderate	O	O
12	PRS-I	O	O
13	deficiency	O	O
14	CMTX5	O	O
15	and	O	O
16	severe	O	O
17	PRS-I	O	O
18	deficiency	O	O
19	Arts	O	O
20	syndrome	O	O
21	present	O	O
22	with	O	O
23	peripheral	O	O
24	or	O	O
25	optic	O	O
26	neuropathy	O	O
27	prelingual	O	O
28	progressive	O	O
29	sensorineural	O	O
30	hearing	O	O
31	loss	O	O
32	and	O	O
33	central	O	O
34	nervous	O	O
35	system	O	O
36	impairment	O	O
37	.	O	O

0	Early-onset	O	O
1	childhood	O	O
2	dentatorubral-pallidoluysian	BU	O
3	atrophy	IU	O
4	involved	O	O
5	mental	BI	O
6	retardation	II	O
7	whereas	O	O
8	myoclonic	O	O
9	epilepsy	O	O
10	was	O	O
11	the	O	O
12	predominant	O	O
13	complaint	O	O
14	in	O	O
15	later-onset	O	O
16	childhood	O	O
17	version	O	O
18	of	O	O
19	the	O	O
20	disease	O	O
21	.	O	O

0	PURPOSE	O	O
1	Wolfram	BU	O
2	syndrome	IU	O
3	WS	IU	O
4	or	O	O
5	diabetes	O	O
6	insipidus	O	O
7	diabetes	O	O
8	mellitus	O	O
9	optic	BI	O
10	atrophy	II	O
11	and	O	O
12	deafness	BI	O
13	DIDMOAD	O	O
14	OMIM	O	O
15	222300	O	O
16	is	O	O
17	an	O	O
18	inherited	O	O
19	neurodegenerative	O	O
20	disease	O	O
21	characterized	O	O
22	by	O	O
23	diabetes	O	O
24	mellitus	O	O
25	and	O	O
26	optic	BI	O
27	atrophy	II	O
28	as	O	O
29	the	O	O
30	2	O	O
31	major	O	O
32	criteria	O	O
33	followed	O	O
34	later	O	O
35	in	O	O
36	life	O	O
37	by	O	O
38	deafness	BI	O
39	diabetes	O	O
40	insipidus	O	O
41	and	O	O
42	various	O	O
43	signs	O	O
44	of	O	O
45	neurologic	O	O
46	impairment	O	O
47	.	O	O

0	Menkes	BU	O
1	disease	IU	O
2	presents	O	O
3	in	O	O
4	the	O	O
5	first	O	O
6	several	O	O
7	months	O	O
8	of	O	O
9	life	O	O
10	with	O	O
11	failure	O	O
12	to	O	O
13	thrive	O	O
14	developmental	BI	O
15	delay	II	O
16	and	O	O
17	seizures	O	O
18	.	O	O

0	Ellis-van	BU	O
1	Creveld	IU	O
2	syndrome	IU	O
3	EVC	O	O
4	is	O	O
5	a	O	O
6	chondral	O	O
7	and	O	O
8	ectodermal	BU	O
9	dysplasia	IU	O
10	characterized	O	O
11	by	O	O
12	short	O	O
13	ribs	O	O
14	polydactyly	O	O
15	growth	BI	O
16	retardation	II	O
17	and	O	O
18	ectodermal	O	O
19	and	O	O
20	heart	O	O
21	defects	O	O
22	.	O	O

0	Although	O	O
1	the	O	O
2	molecular	O	O
3	pathophysiology	O	O
4	underlying	O	O
5	behavioral	O	O
6	changes	O	O
7	in	O	O
8	SLOS	BU	O
9	and	O	O
10	autism	BI	O
11	spectrum	II	O
12	disorders	II	O
13	is	O	O
14	poorly	O	O
15	understood	O	O
16	there	O	O
17	is	O	O
18	evidence	O	O
19	for	O	O
20	the	O	O
21	involvement	O	O
22	of	O	O
23	the	O	O
24	serotonergic	O	O
25	system	O	O
26	in	O	O
27	SLOS	BU	O
28	and	O	O
29	autism	BI	O
30	in	O	O
31	general	O	O
32	.	O	O

0	Genotypephenotype	O	O
1	analysis	O	O
2	confirmed	O	O
3	that	O	O
4	ZFHX1B	O	O
5	deletions	O	O
6	and	O	O
7	stop	O	O
8	mutations	O	O
9	result	O	O
10	in	O	O
11	a	O	O
12	recognizable	O	O
13	facial	O	O
14	dysmorphism	O	O
15	with	O	O
16	associated	O	O
17	severe	BI	O
18	mental	II	O
19	retardation	II	O
20	and	O	O
21	variable	O	O
22	malformations	O	O
23	such	O	O
24	as	O	O
25	Hirschsprung	BU	O
26	disease	IU	O
27	and	O	O
28	congenital	O	O
29	heart	O	O
30	defects	O	O
31	.	O	O

0	CHARGE	BU	O
1	association	IU	O
2	is	O	O
3	the	O	O
4	sporadic	O	O
5	non-random	O	O
6	concurrence	O	O
7	of	O	O
8	Coloboma	O	O
9	of	O	O
10	the	O	O
11	eye	O	O
12	Heart	O	O
13	anomalies	O	O
14	choanal	O	O
15	Atresia	O	O
16	Retardation	BI	O
17	of	II	O
18	growth	II	O
19	and	II	O
20	development	II	O
21	Genitourinary	O	O
22	anomalies	O	O
23	Ear	O	O
24	anomalies	O	O
25	and	O	O
26	deafness	BI	O
27	CHARGE	BU	O
28	association	IU	O
29	.	O	O

0	Cri	BU	O
1	du	IU	O
2	chat	IU	O
3	syndrome	IU	O
4	is	O	O
5	characterized	O	O
6	by	O	O
7	cat-like	O	O
8	cry	O	O
9	facial	O	O
10	dysmorphisms	O	O
11	microcephaly	O	O
12	speech	BI	O
13	delay	II	O
14	intellectual	BI	O
15	disability	II	O
16	and	O	O
17	slow	O	O
18	growth	O	O
19	rate	O	O
20	which	O	O
21	are	O	O
22	present	O	O
23	with	O	O
24	variable	O	O
25	frequency	O	O
26	.	O	O

0	Familial	BU	O
1	Danish	IU	O
2	Dementia	IU	O
3	FDD	IU	O
4	is	O	O
5	an	O	O
6	autosomal	O	O
7	disease	O	O
8	which	O	O
9	is	O	O
10	distinguished	O	O
11	by	O	O
12	gradual	BI	O
13	loss	II	O
14	of	II	O
15	vision	II	O
16	deafness	BI	O
17	progressive	BI	O
18	ataxia	II	O
19	and	O	O
20	dementia	BI	O
21	.	O	O

0	Type	BU	O
1	III	IU	O
2	3-methylglutaconic	IU	O
3	aciduria	IU	O
4	MGA	IU	O
5	MIM	O	O
6	258501	O	O
7	consists	O	O
8	of	O	O
9	early	BI	O
10	bilateral	II	O
11	optic	II	O
12	atrophy	II	O
13	later	O	O
14	development	O	O
15	of	O	O
16	spasticity	O	O
17	extrapyramidal	O	O
18	dysfunction	O	O
19	and	O	O
20	occasionally	O	O
21	cognitive	BI	O
22	deficits	II	O
23	and	O	O
24	urinary	O	O
25	excretion	O	O
26	of	O	O
27	3-methylglutaconic	O	O
28	acid	O	O
29	and	O	O
30	3-methylglutaric	O	O
31	acid	O	O
32	.	O	O

0	Opitz	BU	O
1	G	IU	O
2	BBB	IU	O
3	syndrome	IU	O
4	OS	IU	O
5	is	O	O
6	a	O	O
7	congenital	O	O
8	midline	O	O
9	malformation	O	O
10	syndrome	O	O
11	characterized	O	O
12	by	O	O
13	hypertelorism	O	O
14	hypospadias	O	O
15	cleft	O	O
16	lip	O	O
17	palate	O	O
18	laryngotracheoesophageal	O	O
19	abnormalities	O	O
20	imperforate	O	O
21	anus	O	O
22	developmental	BI	O
23	delay	II	O
24	and	O	O
25	cardiac	O	O
26	defects	O	O
27	.	O	O

0	Huntingtons	BU	O
1	disease	IU	O
2	HD	IU	O
3	is	O	O
4	caused	O	O
5	by	O	O
6	an	O	O
7	expansion	O	O
8	of	O	O
9	the	O	O
10	trinucleotide	O	O
11	poly	O	O
12	CAG	O	O
13	tract	O	O
14	located	O	O
15	in	O	O
16	exon	O	O
17	1	O	O
18	of	O	O
19	the	O	O
20	huntingtin	O	O
21	Htt	O	O
22	gene	O	O
23	leading	O	O
24	to	O	O
25	progressive	O	O
26	neurodegeneration	O	O
27	in	O	O
28	selected	O	O
29	brain	O	O
30	regions	O	O
31	and	O	O
32	associated	O	O
33	functional	BI	O
34	impairments	II	O
35	in	II	O
36	motor	II	O
37	cognitive	II	O
38	and	II	O
39	psychiatric	II	O
40	domains	II	O
41	.	O	O

0	Widespread	BI	O
1	and	II	O
2	deeper	II	O
3	cognitive	II	O
4	deficits	II	O
5	manifest	O	O
6	in	O	O
7	later	O	O
8	stages	O	O
9	of	O	O
10	ataxia-telangiectasia	BU	O
11	when	O	O
12	additional	O	O
13	noncerebellar	O	O
14	pathology	O	O
15	develops	O	O
16	.	O	O

0	Angelman	BU	O
1	Syndrome	IU	O
2	AS	IU	O
3	is	O	O
4	a	O	O
5	devastating	O	O
6	neurodevelopmental	BI	O
7	disorder	II	O
8	characterized	O	O
9	by	O	O
10	developmental	BI	O
11	delay	II	O
12	speech	BI	O
13	impairment	II	O
14	movement	BI	O
15	disorder	II	O
16	sleep	BI	O
17	disorders	II	O
18	and	O	O
19	refractory	O	O
20	epilepsy	O	O
21	.	O	O

0	Mutations	O	O
1	in	O	O
2	the	O	O
3	thyroid	O	O
4	hormone	O	O
5	TH	O	O
6	transporter	O	O
7	MCT8	O	O
8	have	O	O
9	been	O	O
10	identified	O	O
11	as	O	O
12	the	O	O
13	cause	O	O
14	for	O	O
15	Allan-Herndon-Dudley	BU	O
16	Syndrome	IU	O
17	AHDS	IU	O
18	characterized	O	O
19	by	O	O
20	severe	BI	O
21	psychomotor	II	O
22	retardation	II	O
23	and	O	O
24	altered	O	O
25	TH	O	O
26	serum	O	O
27	levels	O	O
28	.	O	O

0	The	O	O
1	risk	O	O
2	of	O	O
3	being	O	O
4	diagnosed	O	O
5	with	O	O
6	intellectual	BI	O
7	disability	II	O
8	was	O	O
9	estimated	O	O
10	in	O	O
11	770	O	O
12	individuals	O	O
13	with	O	O
14	Darier	BU	O
15	disease	IU	O
16	compared	O	O
17	with	O	O
18	matched	O	O
19	comparison	O	O
20	individuals	O	O
21	without	O	O
22	Darier	BU	O
23	disease	IU	O
24	.	O	O

0	BACKGROUND	O	O
1	The	O	O
2	aim	O	O
3	of	O	O
4	the	O	O
5	study	O	O
6	was	O	O
7	to	O	O
8	determine	O	O
9	whether	O	O
10	electrocardiogram	O	O
11	ECG	O	O
12	screening	O	O
13	could	O	O
14	reduce	O	O
15	the	O	O
16	risk	O	O
17	of	O	O
18	sudden	O	O
19	cardiac	O	O
20	death	O	O
21	in	O	O
22	patients	O	O
23	with	O	O
24	hearing	BI	O
25	loss	II	O
26	through	O	O
27	the	O	O
28	early	O	O
29	diagnosis	O	O
30	of	O	O
31	Jervell	BU	O
32	and	IU	O
33	Lange-Nielsen	IU	O
34	syndrome	IU	O
35	and	O	O
36	the	O	O
37	introduction	O	O
38	of	O	O
39	the	O	O
40	therapy	O	O
41	.	O	O

0	Patients	O	O
1	with	O	O
2	SLOS	BU	O
3	typically	O	O
4	exhibit	O	O
5	a	O	O
6	number	O	O
7	of	O	O
8	severe	BI	O
9	behavioral	II	O
10	deficits	II	O
11	and	O	O
12	many	O	O
13	are	O	O
14	diagnosed	O	O
15	with	O	O
16	autistic	BI	O
17	spectrum	II	O
18	disorder	II	O
19	.	O	O

0	The	O	O
1	term	O	O
2	West	BU	O
3	syndrome	IU	O
4	WS	IU	O
5	refers	O	O
6	to	O	O
7	a	O	O
8	form	O	O
9	a	O	O
10	subset	O	O
11	of	O	O
12	ISs	O	O
13	characterised	O	O
14	by	O	O
15	the	O	O
16	combination	O	O
17	of	O	O
18	clustered	O	O
19	spasms	O	O
20	and	O	O
21	hypsarrhythmia	O	O
22	on	O	O
23	an	O	O
24	EEG	O	O
25	and	O	O
26	delayed	BI	O
27	brain	II	O
28	development	II	O
29	or	II	O
30	regression	II	O
31	[currently	O	O
32	it	O	O
33	is	O	O
34	no	O	O
35	longer	O	O
36	required	O	O
37	that	O	O
38	delayed	BI	O
39	development	II	O
40	occur	O	O
41	before	O	O
42	the	O	O
43	onset	O	O
44	of	O	O
45	spasms]	O	O
46	.	O	O

0	OBJECTIVES	O	O
1	To	O	O
2	better	O	O
3	establish	O	O
4	the	O	O
5	incidence	O	O
6	and	O	O
7	types	O	O
8	of	O	O
9	otologic	O	O
10	and	O	O
11	auditory	BI	O
12	abnormalities	II	O
13	in	O	O
14	patients	O	O
15	with	O	O
16	Crouzon	BU	O
17	syndrome	IU	O
18	.	O	O

0	We	O	O
1	report	O	O
2	two	O	O
3	male	O	O
4	siblings	O	O
5	ages	O	O
6	19	O	O
7	and	O	O
8	14	O	O
9	and	O	O
10	an	O	O
11	unrelated	O	O
12	6-year	O	O
13	old	O	O
14	female	O	O
15	with	O	O
16	early	O	O
17	onset	O	O
18	muscular	BU	O
19	dystrophy	IU	O
20	and	O	O
21	intellectual	BI	O
22	disability	II	O
23	with	O	O
24	minimal	O	O
25	structural	O	O
26	brain	O	O
27	anomalies	O	O
28	and	O	O
29	no	O	O
30	ocular	BI	O
31	abnormalities	II	O
32	.	O	O

0	In	O	O
1	one	O	O
2	patient	O	O
3	earlier	O	O
4	onset	O	O
5	before	O	O
6	the	O	O
7	age	O	O
8	of	O	O
9	2 years	O	O
10	was	O	O
11	associated	O	O
12	with	O	O
13	a	O	O
14	more	O	O
15	complex	O	O
16	clinical	O	O
17	picture	O	O
18	with	O	O
19	abnormal	BU	O
20	eye	IU	O
21	movements	IU	O
22	progressive	BI	O
23	cognitive	II	O
24	impairment	II	O
25	and	O	O
26	a	O	O
27	more	O	O
28	rapid	O	O
29	and	O	O
30	severe	O	O
31	course	O	O
32	.	O	O

0	Various	O	O
1	congenital	O	O
2	malformations	O	O
3	mental	BI	O
4	retardation	II	O
5	and	O	O
6	high	O	O
7	rate	O	O
8	of	O	O
9	infant	O	O
10	mortality	O	O
11	in	O	O
12	the	O	O
13	first	O	O
14	year	O	O
15	of	O	O
16	life	O	O
17	are	O	O
18	characteristic	O	O
19	features	O	O
20	of	O	O
21	trisomy	BU	O
22	18	IU	O
23	.	O	O

0	Argininosuccinate	BU	O
1	lyase	IU	O
2	deficiency	IU	O
3	is	O	O
4	a	O	O
5	urea	O	O
6	cycle	O	O
7	disorder	O	O
8	which	O	O
9	can	O	O
10	present	O	O
11	in	O	O
12	the	O	O
13	neonatal	O	O
14	period	O	O
15	with	O	O
16	hyperammonemic	O	O
17	encephalopathy	O	O
18	or	O	O
19	later	O	O
20	in	O	O
21	childhood	O	O
22	with	O	O
23	episodic	O	O
24	vomiting	O	O
25	growth	BI	O
26	and	II	O
27	developmental	II	O
28	delay	II	O
29	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	a	O	O
5	syndromic	O	O
6	form	O	O
7	of	O	O
8	X-linked	O	O
9	mental	BI	O
10	retardation	II	O
11	characterized	O	O
12	in	O	O
13	male	O	O
14	patients	O	O
15	by	O	O
16	psychomotor	BI	O
17	and	II	O
18	growth	II	O
19	retardation	II	O
20	and	O	O
21	various	O	O
22	skeletal	O	O
23	anomalies	O	O
24	.	O	O

0	Deficiency	O	O
1	of	O	O
2	CAII	O	O
3	gives	O	O
4	rise	O	O
5	to	O	O
6	a	O	O
7	syndrome	O	O
8	of	O	O
9	osteopetrosis	BU	O
10	renal	O	O
11	tubular	O	O
12	acidosis	O	O
13	RTA	O	O
14	and	O	O
15	cerebral	O	O
16	calcification	O	O
17	with	O	O
18	associated	O	O
19	developmental	BI	O
20	delay	II	O
21	.	O	O

0	Steroid-responsive	O	O
1	cases	O	O
2	of	O	O
3	CMT	BU	O
4	have	O	O
5	been	O	O
6	reported	O	O
7	but	O	O
8	this	O	O
9	is	O	O
10	the	O	O
11	first	O	O
12	case	O	O
13	report	O	O
14	of	O	O
15	steroid-responsive	BI	O
16	sensorineural	II	O
17	hearing	II	O
18	loss	II	O
19	in	O	O
20	CMT	BU	O
21	.	O	O

0	Allan-Herndon-Dudley	BU	O
1	syndrome	IU	O
2	an	O	O
3	X-linked	O	O
4	condition	O	O
5	characterized	O	O
6	by	O	O
7	severe	BI	O
8	intellectual	II	O
9	disability	II	O
10	dysarthria	BI	O
11	athetoid	BI	O
12	movements	II	O
13	muscle	O	O
14	hypoplasia	O	O
15	and	O	O
16	spastic	BI	O
17	paraplegia	II	O
18	is	O	O
19	associated	O	O
20	with	O	O
21	defects	O	O
22	in	O	O
23	the	O	O
24	monocarboxylate	O	O
25	transporter	O	O
26	8	O	O
27	gene	O	O
28	MCT8	O	O
29	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	is	O	O
3	characterized	O	O
4	by	O	O
5	multiple	O	O
6	congenital	O	O
7	anomalies	O	O
8	and	O	O
9	mental	BI	O
10	retardation	II	O
11	caused	O	O
12	by	O	O
13	the	O	O
14	heterozygous	O	O
15	deletion	O	O
16	of	O	O
17	chromosomal	O	O
18	region	O	O
19	17p11.2	O	O
20	.	O	O

0	We	O	O
1	describe	O	O
2	arginase	O	O
3	deficiency	O	O
4	in	O	O
5	a	O	O
6	20-year-old	O	O
7	woman	O	O
8	with	O	O
9	spastic	BI	O
10	paraplegia	II	O
11	progressive	O	O
12	dystonia	O	O
13	dementia	BI	O
14	peripheral	O	O
15	neuropathy	O	O
16	epilepsy	O	O
17	liver	O	O
18	cirrhosis	O	O
19	and	O	O
20	non-B	O	O
21	non-C	O	O
22	hepatocellular	BU	O
23	carcinoma	IU	O
24	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	WS	IU	O
3	also	O	O
4	known	O	O
5	as	O	O
6	DIDMOAD	O	O
7	Diabetes	O	O
8	Insipidus	O	O
9	Diabetes	O	O
10	Mellitus	O	O
11	Optic	BI	O
12	Atrophy	II	O
13	and	O	O
14	Deafness	BI	O
15	is	O	O
16	a	O	O
17	rare	O	O
18	autosomal	O	O
19	recessive	O	O
20	syndrome	O	O
21	1	O	O
22	770000	O	O
23	in	O	O
24	the	O	O
25	United	O	O
26	Kingdom	O	O
27	characterised	O	O
28	by	O	O
29	juvenile	O	O
30	onset	O	O
31	of	O	O
32	diabetes	O	O
33	mellitus	O	O
34	optic	BI	O
35	nerve	II	O
36	atrophy	II	O
37	diabetes	O	O
38	insipidus	O	O
39	sensorineural	BI	O
40	deafness	II	O
41	renal	O	O
42	tract	O	O
43	and	O	O
44	neurological	O	O
45	abnormalities	O	O
46	and	O	O
47	primary	O	O
48	gonadal	O	O
49	atrophy	O	O
50	.	O	O

0	Children	O	O
1	with	O	O
2	cystinosis	BU	O
3	seem	O	O
4	to	O	O
5	have	O	O
6	a	O	O
7	normal	O	O
8	intelligence	O	O
9	but	O	O
10	frequently	O	O
11	show	O	O
12	learning	BI	O
13	difficulties	II	O
14	.	O	O

0	We	O	O
1	identified	O	O
2	several	O	O
3	rarely	O	O
4	reported	O	O
5	phenotypes	O	O
6	in	O	O
7	infantile	O	O
8	FSHD	BU	O
9	including	O	O
10	cardiac	O	O
11	arrhythmia	O	O
12	respiratory	O	O
13	insufficiency	O	O
14	and	O	O
15	swallowing	BI	O
16	difficulties	II	O
17	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	also	O	O
3	named	O	O
4	DIDMOAD	O	O
5	diabetes	O	O
6	insipidus	O	O
7	diabetes	O	O
8	mellitus	O	O
9	optic	BI	O
10	atrophy	II	O
11	and	O	O
12	deafness	BI	O
13	is	O	O
14	an	O	O
15	inherited	O	O
16	association	O	O
17	of	O	O
18	juvenile-onset	O	O
19	diabetes	O	O
20	mellitus	O	O
21	and	O	O
22	optic	BI	O
23	atrophy	II	O
24	as	O	O
25	key	O	O
26	diagnostic	O	O
27	criteria	O	O
28	.	O	O

0	Within	O	O
1	the	O	O
2	WAGR	BU	O
3	group	O	O
4	BDNF+	O	O
5	subjects	O	O
6	n=15	O	O
7	compared	O	O
8	with	O	O
9	BDNF	O	O
10	intact	O	O
11	+	O	O
12	+	O	O
13	subjects	O	O
14	n=13	O	O
15	had	O	O
16	lower	BI	O
17	adaptive	II	O
18	behaviour	II	O
19	p=.02	II	O
20	reduced	BI	O
21	cognitive	II	O
22	functioning	II	O
23	p=.04	II	O
24	higher	O	O
25	levels	O	O
26	of	O	O
27	reported	O	O
28	historical	O	O
29	p=.02	O	O
30	and	O	O
31	current	O	O
32	p=.02	O	O
33	social	BI	O
34	impairment	II	O
35	and	O	O
36	higher	O	O
37	percentage	O	O
38	meeting	O	O
39	cut-off	O	O
40	score	O	O
41	for	O	O
42	autism	BI	O
43	p=.047	II	O
44	on	O	O
45	Autism	O	O
46	Diagnostic	O	O
47	Interview-Revised	O	O
48	.	O	O

0	Using	O	O
1	voxel-based	O	O
2	morphometry	O	O
3	and	O	O
4	multiple	O	O
5	regression	O	O
6	models	O	O
7	associations	O	O
8	between	O	O
9	limb	BI	O
10	apraxia	II	O
11	and	O	O
12	gray	O	O
13	matter	O	O
14	GM	O	O
15	volume	O	O
16	were	O	O
17	investigated	O	O
18	in	O	O
19	36	O	O
20	dementia	BI	O
21	patients	O	O
22	18	O	O
23	AD	O	O
24	18	O	O
25	bvFTD	BU	O
26	in	O	O
27	early	O	O
28	disease	O	O
29	stages	O	O
30	.	O	O

0	We	O	O
1	present	O	O
2	the	O	O
3	clinical	O	O
4	data	O	O
5	of	O	O
6	four	O	O
7	patients	O	O
8	aged	O	O
9	821	O	O
10	years	O	O
11	with	O	O
12	childhood-onset	O	O
13	neurogenetic	O	O
14	disorders	O	O
15	including	O	O
16	ataxia-telangiectasia	BI	O
17	Coffin-Lowry	BU	O
18	syndrome	IU	O
19	and	O	O
20	epileptic	O	O
21	encephalopathy	O	O
22	due	O	O
23	to	O	O
24	SCN1A	O	O
25	mutations	O	O
26	.	O	O

0	This	O	O
1	study	O	O
2	assessed	O	O
3	the	O	O
4	effects	O	O
5	of	O	O
6	atomoxetine	O	O
7	on	O	O
8	cognitive	O	O
9	functions	O	O
10	in	O	O
11	treatment	O	O
12	of	O	O
13	attention	BI	O
14	deficit	II	O
15	hyperactivity	BI	O
16	disorder	II	O
17	ADHD	O	O
18	symptoms	O	O
19	in	O	O
20	children	O	O
21	with	O	O
22	CH	BU	O
23	.	O	O

0	We	O	O
1	analyzed	O	O
2	temporal	O	O
3	and	O	O
4	stride	O	O
5	characteristics	O	O
6	in	O	O
7	patients	O	O
8	with	O	O
9	myotonic	BU	O
10	dystrophy	IU	O
11	type	IU	O
12	1	IU	O
13	DM1	O	O
14	and	O	O
15	type	O	O
16	2	O	O
17	DM2	O	O
18	while	O	O
19	performing	O	O
20	dual	O	O
21	mental	O	O
22	and	O	O
23	motor	O	O
24	tasks	O	O
25	and	O	O
26	investigated	O	O
27	correlations	O	O
28	between	O	O
29	gait	O	O
30	parameters	O	O
31	and	O	O
32	cognitive	BI	O
33	impairments	II	O
34	.	O	O

0	It	O	O
1	is	O	O
2	mainly	O	O
3	characterized	O	O
4	by	O	O
5	moderate-to-severe	BI	O
6	intellectual	II	O
7	disability	II	O
8	epilepsy	O	O
9	facial	O	O
10	dysmorphism	O	O
11	and	O	O
12	various	O	O
13	malformations	O	O
14	including	O	O
15	Hirschsprung	BU	O
16	disease	IU	O
17	and	O	O
18	corpus	O	O
19	callosum	O	O
20	anomalies	O	O
21	.	O	O

0	PURPOSE	O	O
1	To	O	O
2	describe	O	O
3	a	O	O
4	55-year-old	O	O
5	male	O	O
6	with	O	O
7	Erdheim-Chester	BU	O
8	disease	IU	O
9	with	O	O
10	bilateral	O	O
11	orbital	O	O
12	infiltration	O	O
13	and	O	O
14	visual	BI	O
15	loss	II	O
16	who	O	O
17	was	O	O
18	successfully	O	O
19	treated	O	O
20	with	O	O
21	interferon-alpha	O	O
22	.	O	O

0	Jervell	BU	O
1	and	IU	O
2	Lange-Nielsen	IU	O
3	syndrome	IU	O
4	is	O	O
5	important	O	O
6	because	O	O
7	of	O	O
8	its	O	O
9	potential	O	O
10	association	O	O
11	with	O	O
12	sudden	O	O
13	death	O	O
14	in	O	O
15	children	O	O
16	with	O	O
17	congenital	BI	O
18	sensorineural	II	O
19	deafness	II	O
20	.	O	O

0	Friedreich	BU	O
1	ataxia	IU	O
2	is	O	O
3	the	O	O
4	most	O	O
5	common	O	O
6	hereditary	BI	O
7	ataxia	II	O
8	with	O	O
9	a	O	O
10	reported	O	O
11	prevalence	O	O
12	of	O	O
13	120	O	O
14	000	O	O
15	-	O	O
16	150	O	O
17	000	O	O
18	in	O	O
19	Central	O	O
20	Europe	O	O
21	.	O	O

0	Wolfram	BU	O
1	syndrome	IU	O
2	is	O	O
3	a	O	O
4	rare	O	O
5	neurodegenerative	O	O
6	and	O	O
7	genetic	O	O
8	disorder	O	O
9	which	O	O
10	should	O	O
11	be	O	O
12	suspected	O	O
13	in	O	O
14	patients	O	O
15	with	O	O
16	young	O	O
17	onset	O	O
18	non-immune	O	O
19	insulin	O	O
20	dependent	O	O
21	diabetes	O	O
22	mellitus	O	O
23	and	O	O
24	optic	BI	O
25	atrophy	II	O
26	.	O	O

0	Smith-Magenis	BU	O
1	syndrome	IU	O
2	SMS	IU	O
3	is	O	O
4	a	O	O
5	multiple	O	O
6	congenital	O	O
7	anomalies	O	O
8	mental	BI	O
9	retardation	II	O
10	syndrome	II	O
11	characterized	O	O
12	by	O	O
13	an	O	O
14	interstitial	O	O
15	deletion	O	O
16	on	O	O
17	the	O	O
18	short	O	O
19	arm	O	O
20	of	O	O
21	chromosome	O	O
22	17	O	O
23	involving	O	O
24	the	O	O
25	band	O	O
26	p11.2	O	O
27	.	O	O

0	CONCLUSIONS	O	O
1	Intellectual	BI	O
2	disability	II	O
3	is	O	O
4	a	O	O
5	consistent	O	O
6	finding	O	O
7	in	O	O
8	patients	O	O
9	with	O	O
10	alpha-mannosidosis	BU	O
11	but	O	O
12	with	O	O
13	extensive	O	O
14	variation	O	O
15	.	O	O

0	Taken	O	O
1	together	O	O
2	with	O	O
3	previous	O	O
4	reports	O	O
5	this	O	O
6	case	O	O
7	suggests	O	O
8	that	O	O
9	4H	BU	O
10	syndrome	IU	O
11	can	O	O
12	be	O	O
13	regarded	O	O
14	as	O	O
15	a	O	O
16	spectrum	O	O
17	disorder	O	O
18	the	O	O
19	cardinal	O	O
20	signs	O	O
21	of	O	O
22	which	O	O
23	may	O	O
24	be	O	O
25	central	O	O
26	hypomyelination	O	O
27	ataxia	BI	O
28	hypogonadotropic	O	O
29	hypogonadism	O	O
30	and	O	O
31	hypodontia	O	O
32	.	O	O

0	Thus	O	O
1	Rsk2	O	O
2	loss-of-function	O	O
3	as	O	O
4	seen	O	O
5	in	O	O
6	CLS	BU	O
7	perturbs	O	O
8	the	O	O
9	differentiation	O	O
10	of	O	O
11	neural	O	O
12	precursors	O	O
13	into	O	O
14	neurons	O	O
15	and	O	O
16	maintains	O	O
17	them	O	O
18	instead	O	O
19	as	O	O
20	proliferating	O	O
21	radial	O	O
22	precursor	O	O
23	cells	O	O
24	a	O	O
25	defect	O	O
26	that	O	O
27	may	O	O
28	underlie	O	O
29	the	O	O
30	cognitive	BI	O
31	dysfunction	II	O
32	seen	O	O
33	in	O	O
34	CLS	BU	O
35	.	O	O

0	This	O	O
1	observation	O	O
2	reinforces	O	O
3	the	O	O
4	hypothesis	O	O
5	that	O	O
6	additional	BU	O
7	copies	IU	O
8	of	IU	O
9	proximal	IU	O
10	chromosome	IU	O
11	15q11	IU	O
12	segment	IU	O
13	may	O	O
14	be	O	O
15	causally	O	O
16	related	O	O
17	to	O	O
18	mental	BI	O
19	retardation	II	O
20	and	O	O
21	dysmorphic	O	O
22	features	O	O
23	.	O	O

0	In	O	O
1	addition	O	O
2	siblings	O	O
3	with	O	O
4	Alströms	BU	O
5	syndrome	IU	O
6	characterized	O	O
7	by	O	O
8	pigmentary	BI	O
9	retinal	II	O
10	degeneration	II	O
11	causing	O	O
12	blindness	BI	O
13	in	O	O
14	early	O	O
15	childhood	O	O
16	progressive	BI	O
17	sensorineural	II	O
18	hearing	II	O
19	loss	II	O
20	and	O	O
21	progressive	O	O
22	renal	O	O
23	failure	O	O
24	are	O	O
25	reported	O	O
26	.	O	O

0	No	O	O
1	association	O	O
2	between	O	O
3	AR	O	O
4	mental	BI	O
5	retardation	II	O
6	and	O	O
7	retinoblastoma	BU	O
8	has	O	O
9	been	O	O
10	described	O	O
11	.	O	O

0	To	O	O
1	determine	O	O
2	whether	O	O
3	these	O	O
4	phenotypes	O	O
5	are	O	O
6	recapitulated	O	O
7	in	O	O
8	humans	O	O
9	we	O	O
10	generated	O	O
11	induced	O	O
12	pluripotent	O	O
13	stem	O	O
14	iPS	O	O
15	cell	O	O
16	lines	O	O
17	from	O	O
18	patients	O	O
19	with	O	O
20	Costello	BU	O
21	syndrome	IU	O
22	CS	IU	O
23	a	O	O
24	developmental	O	O
25	disorder	O	O
26	caused	O	O
27	by	O	O
28	abnormal	O	O
29	Ras	O	O
30	signaling	O	O
31	and	O	O
32	characterized	O	O
33	by	O	O
34	neurodevelopmental	O	O
35	abnormalities	O	O
36	such	O	O
37	as	O	O
38	cognitive	BI	O
39	impairment	II	O
40	and	O	O
41	autism	BI	O
42	.	O	O

0	The	O	O
1	Plant	O	O
2	homeodomain	O	O
3	finger	O	O
4	gene	O	O
5	6	O	O
6	PHF6	O	O
7	was	O	O
8	identified	O	O
9	as	O	O
10	the	O	O
11	gene	O	O
12	mutated	O	O
13	in	O	O
14	patients	O	O
15	suffering	O	O
16	from	O	O
17	the	O	O
18	Borjeson-Forssman-Lehmann	BU	O
19	Syndrome	IU	O
20	BFLS	IU	O
21	an	O	O
22	X-linked	BI	O
23	mental	II	O
24	retardation	II	O
25	disorder	II	O
26	.	O	O

0	OBJECTIVES	O	O
1	The	O	O
2	purpose	O	O
3	of	O	O
4	this	O	O
5	article	O	O
6	is	O	O
7	to	O	O
8	analyze	O	O
9	the	O	O
10	association	O	O
11	of	O	O
12	epilepsy	O	O
13	in	O	O
14	children	O	O
15	with	O	O
16	DS	BU	O
17	-	O	O
18	frequency	O	O
19	and	O	O
20	type	O	O
21	of	O	O
22	seizures	O	O
23	treatment	O	O
24	outcome	O	O
25	and	O	O
26	to	O	O
27	compare	O	O
28	cognitive	BI	O
29	impairment	II	O
30	of	O	O
31	children	O	O
32	with	O	O
33	DS	BU	O
34	and	O	O
35	epilepsy	O	O
36	and	O	O
37	DS	BU	O
38	without	O	O
39	epilepsy	O	O
40	from	O	O
41	our	O	O
42	cohort	O	O
43	.	O	O

0	Here	O	O
1	we	O	O
2	describe	O	O
3	a	O	O
4	case	O	O
5	of	O	O
6	GS	BU	O
7	presenting	O	O
8	in	O	O
9	infancy	O	O
10	with	O	O
11	hypokalemia	O	O
12	and	O	O
13	psychomotor	BI	O
14	retardation	II	O
15	.	O	O

0	Electrocardiograms	O	O
1	ECG	O	O
2	of	O	O
3	503	O	O
4	children	O	O
5	with	O	O
6	congenital	BI	O
7	bilateral	II	O
8	profound	II	O
9	hearing	II	O
10	loss	II	O
11	which	O	O
12	were	O	O
13	cochlear	O	O
14	implanted	O	O
15	in	O	O
16	cochlear	O	O
17	implant	O	O
18	center	O	O
19	of	O	O
20	a	O	O
21	tertiary	O	O
22	hospital	O	O
23	were	O	O
24	evaluated	O	O
25	for	O	O
26	long	BU	O
27	QT	IU	O
28	syndrome	IU	O
29	.	O	O

0	Bilateral	BI	O
1	sensorineural	II	O
2	hearing	II	O
3	loss	II	O
4	is	O	O
5	a	O	O
6	characteristic	O	O
7	feature	O	O
8	of	O	O
9	Alport	BU	O
10	syndrome	IU	O
11	which	O	O
12	is	O	O
13	always	O	O
14	linked	O	O
15	to	O	O
16	renal	O	O
17	manifestations	O	O
18	so	O	O
19	they	O	O
20	have	O	O
21	a	O	O
22	parallel	O	O
23	evolution	O	O
24	and	O	O
25	prognosis	O	O
26	and	O	O
27	deafness	BI	O
28	helps	O	O
29	to	O	O
30	identify	O	O
31	the	O	O
32	renal	O	O
33	disease	O	O
34	.	O	O

0	It	O	O
1	is	O	O
2	usually	O	O
3	characterized	O	O
4	by	O	O
5	hypertrophic	BU	O
6	cardiomyopathy	IU	O
7	mental	BI	O
8	retardation	II	O
9	and	O	O
10	skeletal	O	O
11	myopathy	O	O
12	sometimes	O	O
13	also	O	O
14	with	O	O
15	atypical	O	O
16	features	O	O
17	.	O	O

0	we	O	O
1	submitted	O	O
2	5	O	O
3	children	O	O
4	affected	O	O
5	by	O	O
6	CHARGE	BU	O
7	syndrome	IU	O
8	with	O	O
9	profound	BI	O
10	bilateral	II	O
11	sensorineural	II	O
12	hearing	II	O
13	loss	II	O
14	to	O	O
15	CI	O	O
16	.	O	O

0	Muckle-Wells	BU	O
1	syndrome	IU	O
2	MWS	IU	O
3	is	O	O
4	an	O	O
5	autoinflammatory	O	O
6	disease	O	O
7	characterized	O	O
8	by	O	O
9	excessive	O	O
10	interleukin-1	O	O
11	IL-1	O	O
12	release	O	O
13	resulting	O	O
14	in	O	O
15	recurrent	O	O
16	fevers	O	O
17	sensorineural	BI	O
18	hearing	II	O
19	loss	II	O
20	and	O	O
21	amyloidosis	BU	O
22	.	O	O

0	Coffin-Lowry	BU	O
1	syndrome	IU	O
2	CLS	IU	O
3	is	O	O
4	a	O	O
5	rare	O	O
6	neurodevelopmental	O	O
7	condition	O	O
8	caused	O	O
9	by	O	O
10	heterogeneous	O	O
11	mutations	O	O
12	in	O	O
13	the	O	O
14	RPS6KA3	O	O
15	gene	O	O
16	on	O	O
17	the	O	O
18	X	O	O
19	chromosome	O	O
20	leading	O	O
21	to	O	O
22	severe	BI	O
23	intellectual	II	O
24	disability	II	O
25	and	O	O
26	dysmorphism	O	O
27	in	O	O
28	men	O	O
29	while	O	O
30	women	O	O
31	are	O	O
32	carriers	O	O
33	and	O	O
34	only	O	O
35	weakly	O	O
36	affected	O	O
37	.	O	O

0	Zellweger	BU	O
1	syndrome	IU	O
2	ZS	IU	O
3	is	O	O
4	the	O	O
5	most	O	O
6	severe	O	O
7	form	O	O
8	of	O	O
9	PBD	O	O
10	and	O	O
11	is	O	O
12	characterized	O	O
13	by	O	O
14	craniofacial	O	O
15	abnormalities	O	O
16	severe	O	O
17	hypotonia	O	O
18	neonatal	O	O
19	seizures	O	O
20	ocular	BI	O
21	abnormalities	II	O
22	psychomotor	BI	O
23	retardation	II	O
24	hepatomegaly	O	O
25	and	O	O
26	increased	O	O
27	levels	O	O
28	of	O	O
29	very	O	O
30	long	O	O
31	chain	O	O
32	fatty	O	O
33	acids	O	O
34	VLCFA	O	O
35	.	O	O

0	For	O	O
1	respiratory	O	O
2	management	O	O
3	it	O	O
4	is	O	O
5	important	O	O
6	to	O	O
7	regularly	O	O
8	evaluate	O	O
9	respiratory	O	O
10	function	O	O
11	in	O	O
12	FCMD	BU	O
13	patients	O	O
14	over	O	O
15	10years	O	O
16	of	O	O
17	age	O	O
18	since	O	O
19	intellectual	BI	O
20	impairment	II	O
21	and	O	O
22	insomnia	O	O
23	often	O	O
24	mask	O	O
25	the	O	O
26	signs	O	O
27	of	O	O
28	respiratory	O	O
29	dysfunction	O	O
30	.	O	O

0	One	O	O
1	patient	O	O
2	had	O	O
3	hearing	BI	O
4	loss	II	O
5	suggesting	O	O
6	Usher	BU	O
7	syndrome	IU	O
8	.	O	O

0	Our	O	O
1	data	O	O
2	enhance	O	O
3	the	O	O
4	importance	O	O
5	of	O	O
6	establish	O	O
7	a	O	O
8	differential	O	O
9	diagnosis	O	O
10	with	O	O
11	other	O	O
12	retinal	BI	O
13	dystrophies	II	O
14	supporting	O	O
15	the	O	O
16	idea	O	O
17	of	O	O
18	an	O	O
19	underestimated	O	O
20	prevalence	O	O
21	of	O	O
22	choroideremia	BU	O
23	.	O	O

0	Motor	BI	O
1	dysfunction	II	O
2	is	O	O
3	a	O	O
4	common	O	O
5	complication	O	O
6	of	O	O
7	classical	O	O
8	galactosemia	BU	O
9	with	O	O
10	tremor	O	O
11	and	O	O
12	dystonia	O	O
13	the	O	O
14	most	O	O
15	frequent	O	O
16	findings	O	O
17	.	O	O

0	Advances	O	O
1	in	O	O
2	clinical	O	O
3	imaging	O	O
4	and	O	O
5	molecular	O	O
6	characterisation	O	O
7	have	O	O
8	increased	O	O
9	the	O	O
10	accuracy	O	O
11	of	O	O
12	frontotemporal	BU	O
13	dementia	IU	O
14	diagnosis	O	O
15	thus	O	O
16	allowing	O	O
17	for	O	O
18	the	O	O
19	accurate	O	O
20	differentiation	O	O
21	of	O	O
22	these	O	O
23	syndromes	O	O
24	from	O	O
25	psychiatric	BI	O
26	disorders	II	O
27	.	O	O

0	We	O	O
1	assessed	O	O
2	the	O	O
3	nature	O	O
4	of	O	O
5	swallowing	BI	O
6	impairment	II	O
7	in	O	O
8	Kennedy	BU	O
9	disease	IU	O
10	by	O	O
11	undertaking	O	O
12	fiberoptic	O	O
13	endoscopic	O	O
14	evaluation	O	O
15	of	O	O
16	swallowing	O	O
17	examinations	O	O
18	of	O	O
19	10	O	O
20	genetically	O	O
21	confirmed	O	O
22	patients	O	O
23	with	O	O
24	Kennedy	O	O
25	disease	O	O
26	who	O	O
27	were	O	O
28	scored	O	O
29	according	O	O
30	to	O	O
31	an	O	O
32	ordinal	O	O
33	rating	O	O
34	scale	O	O
35	including	O	O
36	25	O	O
37	different	O	O
38	items	O	O
39	.	O	O

0	OBJECTIVE	O	O
1	To	O	O
2	assess	O	O
3	the	O	O
4	influence	O	O
5	of	O	O
6	the	O	O
7	apolipoprotein	O	O
8	E	O	O
9	APOE	O	O
10	and	O	O
11	C9ORF72	O	O
12	genotypes	O	O
13	on	O	O
14	cognitive	BI	O
15	impairment	II	O
16	in	O	O
17	a	O	O
18	population-based	O	O
19	series	O	O
20	of	O	O
21	Italian	O	O
22	patients	O	O
23	with	O	O
24	ALS	BU	O
25	.	O	O

0	Homocystinuria	O	O
1	HCU	O	O
2	due	O	O
3	to	O	O
4	deficiency	BU	O
5	of	IU	O
6	cystathionine	IU	O
7	beta-synthetase	IU	O
8	is	O	O
9	associated	O	O
10	with	O	O
11	increased	O	O
12	plasma	O	O
13	levels	O	O
14	of	O	O
15	homocysteine	O	O
16	and	O	O
17	methionine	O	O
18	and	O	O
19	is	O	O
20	characterized	O	O
21	by	O	O
22	developmental	BI	O
23	delay	II	O
24	intellectual	BI	O
25	impairment	II	O
26	ocular	BI	O
27	defects	II	O
28	thromboembolism	O	O
29	and	O	O
30	skeletal	O	O
31	abnormalities	O	O
32	.	O	O

0	This	O	O
1	included	O	O
2	cases	O	O
3	with	O	O
4	neurodegeneration	O	O
5	and	O	O
6	brain	O	O
7	iron	O	O
8	accumulation	O	O
9	corticobasal	O	O
10	degeneartion	O	O
11	progressive	BU	O
12	supranuclear	IU	O
13	palsy	IU	O
14	PSP	O	O
15	Parkinsons	O	O
16	disease	O	O
17	PD	O	O
18	multiple	O	O
19	system	O	O
20	atropy	O	O
21	giant	BU	O
22	axonal	IU	O
23	neuropathy	IU	O
24	GAN	IU	O
25	neuroaxonal	O	O
26	dystrophy	O	O
27	NAD	O	O
28	Guam	BI	O
29	dementia	II	O
30	and	O	O
31	HARP	O	O
32	syndrome	O	O
33	pallido-pyramidal	O	O
34	syndrome	O	O
35	and	O	O
36	hypoprebetalipoproteinemia	O	O
37	acanthocytosis	O	O
38	retinitis	BU	O
39	pigmentosa	IU	O
40	and	O	O
41	pallidal	O	O
42	degeneration	O	O
43	.	O	O

0	Based	O	O
1	on	O	O
2	the	O	O
3	present	O	O
4	data	O	O
5	we	O	O
6	propose	O	O
7	that	O	O
8	C4Orf48	O	O
9	probably	O	O
10	encodes	O	O
11	a	O	O
12	novel	O	O
13	neuropeptide	O	O
14	which	O	O
15	if	O	O
16	hemizygously	O	O
17	deleted	O	O
18	may	O	O
19	be	O	O
20	involved	O	O
21	in	O	O
22	the	O	O
23	observed	O	O
24	intellectual	BI	O
25	and	II	O
26	fine	II	O
27	motor	II	O
28	disabilities	II	O
29	and	O	O
30	thus	O	O
31	in	O	O
32	the	O	O
33	overall	O	O
34	neurological	O	O
35	aspects	O	O
36	of	O	O
37	Wolf-Hirschhorn	BU	O
38	syndrome	IU	O
39	.	O	O

0	SMS	BU	O
1	provides	O	O
2	a	O	O
3	demonstration	O	O
4	of	O	O
5	a	O	O
6	biological	O	O
7	basis	O	O
8	for	O	O
9	sleep	BI	O
10	disorder	II	O
11	in	O	O
12	a	O	O
13	genetic	O	O
14	disease	O	O
15	.	O	O

0	It	O	O
1	has	O	O
2	been	O	O
3	suggested	O	O
4	that	O	O
5	microarray	O	O
6	analysis	O	O
7	should	O	O
8	be	O	O
9	included	O	O
10	in	O	O
11	the	O	O
12	diagnostic	O	O
13	evaluation	O	O
14	of	O	O
15	patients	O	O
16	with	O	O
17	infantile	BU	O
18	spasms	IU	O
19	and	O	O
20	developmental	BI	O
21	delay	II	O
22	when	O	O
23	an	O	O
24	evaluation	O	O
25	for	O	O
26	structural	O	O
27	brain	O	O
28	lesions	O	O
29	and	O	O
30	metabolic	O	O
31	disorders	O	O
32	reveal	O	O
33	no	O	O
34	abnormal	O	O
35	findings	O	O
36	.	O	O

